Pathology of Renal Cancer by Akaza, H et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2010
Pathology of Renal Cancer
Akaza, H; Lopez-Beltran, A; Martignoni, G; Moch, H; Montironi, R; Reuter, V E
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-55932
Book Section
Published Version
Originally published at:
Akaza, H; Lopez-Beltran, A; Martignoni, G; Moch, H; Montironi, R; Reuter, V E (2010). Pathology of
Renal Cancer. In: Kirkali, Z; Mulders, P. 1st EAU-ICD International Consultation on Kidney Cancer.
Barcelona: ICUD, 47-72.
11st EAU-ICUD
International Consultation on Kidney Cancer  Barcelona-2010
EDITORS
Z. KIRKALI AND P. MULDERS
KIDNEY CANCER
 
 
Edition 2011 ICUD
2fo r  i n f o r m a t i o n  a n d  o r d e r s  :
D i s t r i b u t o r  : eD IT Ions 2 1
5  B ou leva rd F landrin -  7 5 0 16  Paris -  F R AN C E
F ax:  + 33 1 4 5  0 4  7 2 8 9  E- mail :  editions21@ w anadoo.f r
©  ICuD - eA u 2 0 1 1
A l l  r i ght s  r e s e r ve d. N o pa r t  of  t hi s  publ i c a t i on m a y be  r e pr oduc e d, s t or e d i n a  r e t r i e va l  s ys t e m , or  t r a ns m i t t e d i n
a n y f or m  or  by a ny m e a ns , e l e c t r oni c , m e c ha ni c a l , pho t oc opyi ng, r e c o r di ng, or  ot he r w i s e , w i t hout  pr i or  pe r m i s --
s i o n of  t he  publ i s he r .
A c c ur a t e  i ndi c a t i ons , a dve r s e  r e a c t i ons , a nd dos a ge  s c he dul e s  f or  dr ugs  a r e  pr ovi de d i n t hi s  book, but  i t  i s  pos s i bl e  
t h a t  t he y m a y c ha nge . T he  r e a de r  i s  ur ge d t o r e vi e w  t he  pa c ka ge  i nf or m a t i on da t a  of  t he  m a nuf a c t ur e r s
of  t he  m e di c a t i ons  m e nt i one d.
T h e  P ubl i s he r s  ha ve  m a de  e ve r y e f f or t  t o t r a c e  t he  c opyr i ght  hol de r s  f or  bor r ow e d m a t e r i a l . I f  t he y ha ve  i na dve r--
tently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.
T he  gr e a t  t r a ge dy of  s c i e nc e  :
T he  s l a yi ng of  a  be a ut i f ul  hypot he s i s  by a n ugl y f a c t
T hom a s  H uxl e y ( 1 8 25 - 1 895)
IsB n :  0-9546956- 9- 0
3ConT enT s
-  C ontents  3
-  Pref ace  4
-  F acu lty  6
- Classificatin of Kidney Cancer  9
- Evidence Based Medicine Overview  10
C ommittee 1 : Etiology and Epidemiology  15
B . lj u n g b e r g ,  S. C. Campbell , H. Choi, D. Jacqmin, L.A. Kiemeney, J. Lee, S. Weikert
C ommittee 2 : Basic Research in Kidney Cancer  31
e. oo s t e r w i j k ,  A. Belldegrun, A. R. Brannon, D. S. Finley, K. Junker, F. Pouliot,  
                         W. K. Rathmell, H. Uemura, 
C ommittee 3 :  Pathology  4 7
f. A l g a b a , H. Akaza, A. Lypez-Beltrin, G. Martignoni, H. Moch, R. Montironi, V. Reuter.
C ommittee 4  : Prognostic Factors of Renal Cell Carcinoma:
                        A Contemporary Review  7 3
P . I. K a r a k i e w i c z,  C. Cheng, V. Ficarra, M. Murai,  S. Oudard, A. J. Pantuck, S. F. Shariat, 
                              R. =igeuner
C ommittee 5   : Treatment of Localized Renal Cell Carcinoma  9 9
H . Va n  P o p p e l ,  F. Becker, J. Caddedu, I. Gill, G. Janetschek, M. Jewett, P. Laguna, 
                          M. Marberger, F. Montorsi, T. Polascik, O. Ukimura, G. =hu
C ommittee 6   : Locally Advanced Disease  15 3
C. G . W o o d ,  T. W. Chong, Y. Hirao, S. Joniau, M. Kuczyk, B. Leibovich, V. Margulis,  
                     V. Master, S. Rawal, M. Wirth
C ommittee 7  :  Treatment of Metastatic Disease  16 7
J .- J . P a t a r d ,  J . B e l l m u n t ,  A. B x, R. Bukowski, T. Choueiri, T. Eisen, B. Escudier,  
                                           R. Motzer, B. Rini, J. Roigas, C. Sternberg
4Preface to IcUD-eaU InternatIonal
consUltatIon on KIDney cancer 2010
Kidney cancer remains to be an important item in the agenda of medicine. Better understanding 
of the mechanisms of renal cancer development, advances in surgery, utilization of alternative 
therapies and development of effective targeted therapies make kidney cancer a hot topic. 
The International Consultation on Urological Diseases (ICUD) and European Association 
of Urology (EAU) with the support of European Organisation for Research and Treatment 
of Cancer (EORTC) Genitourinary Group organized the 2010 International Consultation on 
Kidney Cancer. Experts from all around the world gathered in Barcelona during the EAU 
Annu al M eeting  on April 16 , 20 10 . Actu ally this w as not a momentou s eve nt b u t a more 
than a year of planning and hard work of many people. Thanks to the hard work of everyone 
involved, only 11 months after the event, you are able to hold this excellent book and CD in 
yo u r hand.
New developments on this disease  makes it timely to have a presentation at the and a 
subsequent consensus report that finally will be presented as a booklet/CD-rom at the 2011 
EAU meeting in Vienna.
Usually, when there are many developments in a field during a relatively short period of time, 
it is not easy to come to a consensus. In this respect, the chairmen of the 7 committees did 
a tremendou s j ob  to set the scene, to create the f oru m f or discu ssing  the releva nt evi dence 
and to finalize the elements of the consensus in their respective committees. While the 
committees w ent throu g h a consensu s process, they f ollow ed the O xf ord g rading  syst em 
leve ls of  evi dence and u sed the f ou r g rades f rom the O xf ord syst em f or recommendations. 
This w as done b y a search f or papers throu g h the maj or datab ases cove ring  the last ye ars 
as M edline, Pu b med, Emb ase and C ochrane L ib rary . T hey searched in releva nt j ou rnals and 
ev alu ated all the papers. 
=. Kirkali P. M u lders
5The first committee chaired by Dr.LMungberg (Umea, Sweden) inve stig ated the ‘E ti o l o g y a n d  
ep i d emi o l o g y´ f renal cell carcinoma (RCC). By describing the risk factors and incidence 
trends, they ob tained the 20 10  vi ew point and stated consensu s. T he second committee 
was on ³Basic research in kidney cancer´ and chaired by Dr OosterwiMk from NiMmegen 
were relevant research results were summarized. The following committee was dealing with 
“P a th o l o g y” and chaired b y D r.Alg ab a f rom B arcelona, Spain. An ext ensive  description w as 
given on morphology images and cytopathological entities with the latest classification issues 
describ ed. C ommittee 4  g ave  one of  most ext ensive  ove rvi ew s of  “P r o g n o st i c f a ct o r s”  in renal 
cell carcinoma. Dr.Karakiewicz (Montreal, Canada) and his committee presented a literature-
based overview reaching meta-analysis status. In committee 5, Dr.Van Poppel from Leuven, 
B elg iu m and the g rou p g ave  one of  the most detailed ove rvi ew s of  the cu rrent literatu re on 
“T r ea tmen t o f  l o ca l i ze d  R C C´. With the use of many illustrations it became one of the best 
pu b lications on this su b j ect so f ar. “T r ea tmen t o f Lo ca l l y a d va n ce d  R C C ’:  w as inve stig ated b y 
committee 6 under the chairmanship of Dr.Wood (Houston, USA). This subMect was dealt with 
in a detailed manner and g ave  a va lu ab le state- of - the- art on this ve ry timely issu e. F inally the 
“ Tr ea tmen t o f  M eta st a ti c d i se a se”  w as handled b y committee 7  co- chaired b y D r.B ellmu nt 
(Barcelona, Spain) and Dr. Patard (Rennes, France). In a time of rapid changes in the systemic 
manag ement of  R C C , they w ere ab le to implement the latest resu lts in their consensu s.
The ICUD/EAU 2010 International Consultation on Kidney Cancer is the first-time ever 
consensus meeting on one of the most hot topics in urologic oncology, Kidney Cancer. The 
chairmen and the exp erts in their respective  committees have  done a w onderf u l j ob  to produ ce 
this state-of-the-art, evidence based knowledge and recommendations. We are grateful to the 
executive committees of ICUD and EAU respectively represented by Dr.Paul Abrams from 
Bristol, UK and Dr.Manfred Wirth from Dresden, Germany. Ms.Evelyn White and her team at 
EAU Central Office were extremely instrumental in logistics. Last but not least, this book could 
not be realized without the tireless work of Dr.Saad Khoury and his team.
We hope that you will enMoy reading this timely, up-to-date, evidence-based book and find the 
recommendations of the world-renown experts in kidney cancer useful in your practice.
ZI Y A KI R K AL I &  PET ER MU L D ER S
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InT RoD uCT Ion
The International Consultation on Urological Diseases (ICUD) 
is a non-governmental organization registered with the World 
Health Organisation (WHO). In the last ten years Consultations 
have been organised on BPH, Prostate Cancer, Urinary Stone 
Disease, Nosocomial Infections, Erectile Dysfunction and 
Urinary Incontinence. These consultations have looked at 
pu b lished ev idence and produ ced recommendations at f ou r 
lev els;  hig hly  recommended, recommended, optional and not 
recommended. This method has been useful but the ICUD 
b eliev es that there shou ld b e more ex plicit statements of  the 
lev els of  ev idence that g enerate the su b sequ ent g rades of  
recommendations.
T he Ag ency  f or H ealth C are Policy  and R esearch 
(AHCPR) have used specified evidence levels to Mustify 
recommendations f or the inv estig ation and treatment of  a 
v ariety  of  conditions. T he O x f ord C entre f or Ev idence B ased 
M edicine hav e produ ced a w idely  accepted adaptation of  the 
work of AHCPR. (June 5th 2001 http://minerva.minervation. 
com/cebm/docs/levels.html). The ICUD has examined the 
O x f ord g u idelines and discu ssed w ith the O x f ord g rou p 
their applicability to the Consultations organised by ICUD. It 
is hig hly  desirab le that the recommendations made b y  the 
C onsu ltations f ollow  an accepted g rading  sy stem su pported 
b y  ex plicit lev els of  ev idence.
The ICUD proposes that future consultations should use a 
modified version of the Oxford system which can be directly 
‘ mapped’  onto the O x f ord sy stem.
1 .  1s t Step: Define the specific questions or statements 
t h a t  t h e  r e c o m m e n d a t i o n s  a r e  s u p p o s e d  t o  a d d r e s s .
2 .  2n d st e p :  A n a l y s e  a n d  r a t e  ( l e v e l  o f  e v i d e n c e )  t h e  
r e l e v a n t  p a p e r s  p u b l i s h e d  i n  t h e  l i t e r a t u r e . 
T he analy sis of  the literatu re is an important step in preparing  
recommendations and their g u arantee of  qu ality .
2 . 1 W hat papers shoul d be incl uded in the anal ysis?
•   Papers pu b lished, or accepted f or pu b lication in the peer 
rev iew ed issu es of  j ou rnals.
•   T he committee shou ld do its b est to search f or papers 
accepted f or pu b lication b y  the peer rev iew ed j ou rnals in 
the  relevant field but not yet published.
•   Ab stracts pu b lished in peer rev iew  j ou rnals shou ld b e 
identified. If of sufficient interest the author(s) should 
be asked for full details of methodology and results. The 
relev ant committee memb ers can then ‘ peer rev iew ’  the 
data, and if the data confirms the details in the abstract, 
then that ab stract may  b e inclu ded, w ith an ex planatory  
f ootnote. T his is a complex  issu e –  it may  actu ally  increase 
pu b lication b ias as “ u ninteresting ”  ab stracts commonly  do 
not prog ress to f u ll pu b lication.
•   Papers pu b lished in non peer rev iew ed su pplements w ill 
not b e inclu ded.
An ex hau stiv e list shou ld b e ob tained throu g h:
I.  the m a j o r  d a t a b a s es covering the last ten years (e.g. 
M edline, Emb ase, C ochrane L ib rary , B iosis, Science 
Citation Index)
II.  the t a b l e  o f  c o n t e n t s f  the maj or j ou rnals of  u rolog y  and 
other relevant Mournals, for the last three months, to take 
into accou nt the possib le delay  in the index ation of  the 
pu b lished papers in the datab ases.
It is expected that the highly experienced and expert 
committee memb ers prov ide additional assu rance that no 
important stu dy  w ou ld b e missed u sing  this rev iew  process.
2 . 2  H ow  papers are anal ysed?
Papers pu b lished in peer rev iew ed j ou rnals hav e dif f ering  
qu ality  and lev el of  ev idence.
Each committee w ill rate the inclu ded papers according  to 
levels of evidence (see below).
The level (strength) of evidence provided by an individual 
stu dy  depends on the ab ility  of  the stu dy  desig n to minimise 
the possib ility  of  b ias and to max imise attrib u tion.
is inÀuenced by:
•  t h e  t y p e  o f  s t u d y
T he hierarchy  of  stu dy  ty pes are:
-  Sy stematic rev iew s and meta- analy sis of  randomised
controlled trials
-  R andomised controlled trials
-  N on- randomised cohort stu dies
-  C ase control stu dies
-  C ase series
-  Ex pert opinion
•  h o w  w e l l  t h e  s t u d y  w a s  d e s i g n e d  a n d  c a r r i e d  o u t
Failure to give due attention to key aspects of study 
methodology increase the risk of bias or confounding factors, 
and thu s redu ces the stu dy ’ s reliab ility .
T he u se of  s t a n d a r d  c h e c k  l i s t s is recommended to insu re 
that all relev ant aspects are considered and that a consistent 
approach is u sed in the methodolog ical assessment of  the 
ev idenc .
The obMective of the check list is to give a quality rating for 
indiv idu al stu dies.
•  h o w  w e l l  t h e  s t u d y  w a s  r e p o r t e d
The ICUD has adopted the CONSORT statement and its 
widely accepted check list. The CONSORT statement and 
the checklist are available at
http: //www.consort-statement.org
2 . 3  H ow  papers are rated?
Papers are rated f ollow ing  a « le v e l  o f  ev i d e n c e  s c a l e ».
ICUD has modified the Oxford Center for Evidence-Based 
M edicine lev els of  ev idence.
T he lev els of  ev idence scales v ary  b etw een ty pes of  stu dies 
(ie therapy, diagnosis, differential diagnosis/symptom 
prevalence study).
the Oxford Center for Evidence-Based Medicine Website: 
http://minerva.minervation.com/cebm/docs/ levels.html
3 .  3 rd Step: Synthesis of the ev idence
Af ter the selection of  the papers and the rating  of  the lev el 
of  ev idence of  each stu dy , the nex t step is to compile a 
su mmary  of  the indiv idu al stu dies and the ov erall direction of  
the ev idence in an ev i d e n c e  T a b l e.
4 .   4 th Step: Considered j udgment ( integration of 
indiv idual  cl inical  ex pertise)
H av ing  completed a rig orou s and ob j ectiv e sy nthesis of  the 
evidence base, the committee must then make a Mudgement 
as to the g rade of  the recommendation on the b asis of  this 
ev idence. T his requ ires the ex ercise of  j u dg ement b ased on 
clinical experience as well as knowledge of the evidence  and 
the methods u sed to g enerate it. Ev idence b ased medicine 
requ ires the integ ration of  indiv idu al clinical ex pertise w ith b est 
eV IDence –  B aseD M eDIcIne oV erV IeW  of tH e M aIn stePs for
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av ailab le ex ternal clinical ev idence f rom sy stematic research. 
Without the former, practice quickly becomes tyrannised 
b y  ev idence, f or ev en ex cellent ex ternal ev idence may  b e 
inapplicab le to, or inappropriate f or, an indiv idu al patient:  
without current bestevidence, practice quickly becomes 
ou t of  date. Althou g h it is not practical to lay  ou r “ ru les”  f or 
ex ercising  j u dg ement, g u ideline dev elopment g rou ps are 
asked to consider theevidence in terms of quantity, quality, 
and consistency ;  applicab ility ;  g eneralisab ility ;  and clinical 
impact.
5 . 5t h st e p :  fi n a l  G r a d i n g
The grading of the recommendation is intended to strike an 
appropriate b alance b etw een incorporating  the complex ity  of  
ty pe and qu ality  of  the ev idence and maintaining  clarity  f or 
g u ideline u sers.
T he recommendations f or g rading  f ollow  the O x f ord C entre 
f or Ev idence- B ased M edicine.
T he lev els of  ev idence show n b elow  hav e ag ain b een 
modified in the light of previous consultations. There are now 
4  lev els of  ev idence instead of  5 .
T he g rades of  recommendation hav e not b een redu ced and a 
“ no recommendation possib le”  g rade has b een added.
6 .  le v e l s  o f  ev i d e n c e  a n d  G r a d e s  o f  Re c o m m e n d a t i o n  
T h e r a p e u t i c  In t e r v e n t i o n s
All interv entions shou ld b e j u dg ed b y  the b ody  of  ev idence 
for their efficacy, tolerability, safety, clinical effectiveness and 
cost effectiveness. It is accepted that at present little data 
ex ists on cost ef f ectiv eness f or most interv entions.
6 . 1 L ev el s of E v idence
F irstly , it shou ld b e stated that any  lev el of  ev idence may  b e 
positive (the therapy works) or negative (the therapy doesn¶t 
work). A level of evidence is given to each individual study.
•   le v e l  1  evidence (incorporates Oxford 1a, 1b) usually 
involves meta-anaylsis of trials (RCTs) or a good quality 
randomised controlled trial, or ‘ all or none’  stu dies in w hich 
no treatment is not an option, f or ex ample in v esicov ag inal 
fistula.
•   le v e l  2 evidence (incorporates Oxford 2a, 2b and 2c) 
includes ³low´ quality RCT (e.g.  80 follow up) or 
metaanalysis (with homogeneity) of good quality prospective 
‘ cohort stu dies’ . T hese may  inclu de a sing le g rou p w hen 
indiv idu als w ho dev elop the condition are compared w ith 
others f rom w ithin the orig inal cohort g rou p. T here can b e 
parallel cohorts, where those with the condition in the first 
g rou p are compared w ith those in the second g rou p.
•   le v e l  3 evidence (incorporates Oxford 3a, 3b and 4) 
inclu des:
g o o d  q u a l i t y retrospectiv e ‘ case- control stu dies’  w here 
a g rou p of  patients w ho hav e a condition are matched 
appropriately (e.g. for age, sex etc) with control individuals 
w ho do not hav e the condition.
g o o d  q u a l i t y  ‘ case series’  w here a complete g rou p of  patients 
all, with the same condition/disease/therapeutic intervention, 
are describ ed, w ithou t a comparison control g rou p.
•   le v e l  4 evidence (incorporates Oxford 4) includes expert 
opinion w ere the pinion is b ased not on ev idence b u t on 
µfirst principles¶ (e.g. physiological or anatomical) or bench 
research. T he D elphi process can b e u sed to g iv e ‘ ex pert 
opinion¶ greater authority. In the Delphi process a series of 
qu estions are posed to a panel;  the answ ers are collected 
into a series of µoptions¶; the options are serially ranked; 
if a 75 agreement is reached then a Delphi consensus 
statement can b e made.
6 . 2  G rades of Recommendation
The ICUD will use the four grades from the Oxford system. 
As w ith lev els of  ev idence the g rades of  ev idence may  apply  
either positively (do the procedure) or negatively (don¶t do the 
procedure). Where there is disparity of evidence, for example 
if  there w ere three w ell condu cted R C T ’ s indicating  that D ru g  
A w as su perior to placeb o, b u t one R C T  w hose resu lts show  
no dif f erence, then there has to b e an indiv idu al j u dg ement 
as to the g rade of  recommendation g iv en and the rationale 
ex plained.
•   G r a d e  A r commendation u su ally  depends on consistent 
lev el 1 ev idence and of ten means that the recommenda--
tion is ef f ectiv ely  mandatory  and placed w ithin a clinical care 
pathw ay . H ow ev er, there w ill b e occasions w here ex cellent 
evidence (level 1) does not lead to a Grade A recommenda-
tion, f or ex ample, if  the therapy  is prohib itiv ely  ex pensiv e, 
dangerous or unethical. Grade A recommendation can 
follow from Level 2 evidence. However, a Grade A recom-
mendation needs a g reater b ody  of  ev idence if  b ased on 
any thing  ex cept L ev el 1 ev idence
•   G r a d e  B  r commendation u su ally  depends on consistent 
lev el 2 and or 3 stu dies, or ‘ maj ority  ev idence’  f rom R C T ’ s.
•   G r a d e  C recommendation u su ally  depends on lev el 4  stu d--
ies or µmaM rity evidence¶ from level 2/3 studies or Dephi 
processed ex pert opinion.
•   G r a d e  D “ N o recommendation possib le”  w ou ld b e u sed 
where the evidence is inadequate or conÀicting and when 
ex pert opinion is deliv ered w ithou t a f ormal analy tical pro--
cess, su ch as b y  D ephi.
7 . le v e l s  o f  ev i d e n c e  a n d  G r a d e s  o f  Re c o m m e n d a t i o n  
f o r  M e t h o d s  o f  A s s e s s m e n t  a n d  In v e s t i g a t i o n
F rom initial discu ssions w ith the O x f ord g rou p it is clear that 
application of levels of evidence/grades of recommendation 
f or diag nostic techniqu es is mu ch more complex  than f or 
interv entions.
The ICUD recommend, that, as a minimum, any test should 
b e su b j ected to three qu estions:
1.  does the test hav e g ood technical perf ormance, f or 
ex ample, do three aliqu ots of  the same u rine sample g iv e 
the same resu lt w hen su b j ected to ‘ stix ’  testing ?
2.  D oes the test hav e g ood diag nostic perf ormance, ideally  
ag ainst a “ g old standard”  measu re?
3.  D oes the test hav e g ood therapeu tic perf ormance, that is, 
does the u se of  the test alter clinical manag ement, does 
the u se of  the test improv e ou tcome?
For the third component (therapeutic performance) the same 
approach can b e u sed as f or section 6 .
8 .  le v e l s  o f  ev i d e n c e  a n d  G r a d e s  o f  Re c o m m e n d a t i o n  
f o r  B a s i c  sc i e n c e  a n d  ep i d e m i o l o g y  st u d i e s
The proposed ICUD system does not easily fit into these 
areas of  science. F u rther research needs to b e carried ou t, 
in order to dev elop ex plicit lev els of  ev idence that can lead 
to recommendations as to the sou ndness of  data in these 
important aspects of  medicine.
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R enal cell carcinoma (R C C ) is the most common 
renal tu mou r and accou nts f or approxi mately 9 0 %  
of  all renal malig nancies.[ 1]  D espite adva nces in 
diag nosis arou nd 20 - 30  %  of  the patients still have  
metastatic R C C  (mR C C ) at the time of  diag nosis[ 2] . 
Arou nd 20 – 30 %  of  patients u nderg oing  nephrectomy 
w ill exp erience relapse and deve lop metastasis.[ 1,3]  
F or these patients w ith mR C C , ou tcomes are 
g enerally poor and the incidence of  R C C  and mR C C  
imposes a seriou s w orldw ide epidemiolog ical b u rden 
(leve l of  evi dence 2)[ 2] . T he g eneral increase in 
incidence seems to have  peake d and decrease in 
incidence as w ell as in mortality has b een noticed 
in some cou ntries. L if estyl e f actors are the most 
important etiolog ical f actors. 
II. InCID enCe of RCC
W orldw ide, ki dney cancer is the 14 th most common 
malig nancy w ith approxi mately 20 0 ,0 0 0  new  cases 
diag nosed in 20 0 2.[ 4 ]  Althou g h R C C  is a g lob al 
prob lem, the incidence va ries g eog raphically[ 4 ] . 
R ates of  R C C  are hig h in Eu rope, N orth America, 
and Au stralia, w hereas rates are low  in I ndia, Japan, 
Af rica, and C hina. U ntil the last ye ars, w orldw ide 
incidence has increased b y ab ou t 2%  ye arly . (leve l 
of  evi dence:  3). 
1 . InCID enCe In euRoP eA n CounT RIes:
I n 20 0 6 , arou nd 6 4 ,0 0 0  new  cases of  ki dney cancer 
w ere estimated in the EU [ 5 ,6 ]  (10th most common 
cancer, fi g u r e  1) and 26 ,4 0 0  ki dney cancer- related 
deaths occu rred. I n the Eu ropean ob serv atory of  
cancer of  20 0 9 , estimated ag e- standardize d ki dney 
cancer incidence rates per 10 0 ,0 0 0  Eu ropeans w ere 
14 .5  (N = 4 0 .39 5 ) f or males and 6 .9  (N = 24 .6 5 6 ) f or 
f emales. C ze ch R epu b lic, L ithu ania, Estonia and 
I celand have  the hig hest R C C  rates in Eu rope  w hile 
in R omania, B u lg aria, and Sw itze rland the incidence 
w as ob serve d low est [ 4 ,6 ] .  D if f erences in estimated 
ki dney cancer incidence and mortality f rom ki dney 
cancer among  males in 27  Eu ropean cou ntries, are 
show n in t a b l e  1. Althou g h the w orldw ide incidence 
of  R C C  has increased, data f rom a Eu ropean stu dy , 
analyzi ng  ki dney cancer incidence b etw een19 8 0  and 
20 0 4 , indicate a shif t tow ards stab iliza tion or eve n a 
decrease in b oth sexe s in some cou ntries in w estern 
and northern Eu rope, exce pt f or Eng land, Scotland 
and I reland, w hereas incidence in Eastern Eu rope 
has increased [ 7 ] . (leve l of  evi dence:  3). ( fi g u r e  2 .)
2 . InCID enCe W oRlD W ID e :
I t is estimated that only in the U S there w ill b e ab ou t 
5 4 ,0 0 0  new  cases of  ki dney cancer and 13,0 0 0  ki dney 
cancer- related deaths in 20 0 8 .[ 8 ]  T he pattern of  
occu rrence as describ ed f or Eu rope is also ob serve d 
in the U .S. D ata f rom the Su rve illance, Epidemiolog y , 
and End R esu lts (SEER ) datab ase show  a g reater 
incidence increase of  R C C  diag nosed b etw een 
19 7 5  and 19 9 8  f or b lack patients ag ed 20 – 5 9  ye ars 
compared w ith w hite patients of  the same ag e and 
disease stag e (4 .5 %  vs 2.9 % , respective ly) [ 9 ,10 ] . 
Su rvi va l w as also low er among  b lack compared w ith 
w hite patients w ith R C C  [ 6 ] . A retrospective  stu dy of  
clinical trial popu lations f rom 19 9 2 to 20 0 2, su pports 
the finding that race is a predictor of overall survival in 
patients w ith mR C C .[ 11]  F rom the SEER  data, it w as 
also ob serve d that Asian Americans had ab ou t half  
the risk of  ki dney  cancer than the other racial/ ethnic 
g rou ps, w hich is consistent w ith low er incidence rates 
of  R C C  in Asian cou ntries.[ 9 ]  I n Japan also, ki dney 
cancer, is more f requ ent in males than in f emales, 
and show s an su b stantial g eog raphical dif f erence in 
total incidence w ithin the cou ntry [ 12,13]
I. InT RoD uCT Ion
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III. RCC M oRT A lITY  RAT es
K idney cancer accou nted f or 10 2,0 0 0  deaths and 
the rates w here ab ou t tw ice as hig h f or males as 
f or f emales. O ve rall mortality rates w ere hig hest in 
N orth America, Au stralia/ N ew  Z ealand and W estern, 
Eastern and N orthern Eu rope (fi g u r e  3). Af rica and 
Asia reported the low est mortality rates [ 14 ]  (leve l of  
ev idence:  1).
I n 20 0 6  in the Eu ropean U nion the estimated nu mb er 
of  ki dney cancer death w as 27 .326 , arou nd 2,2 %  
of  all cancer deaths (16 .7 9 8  males (rate 5 .8 ) and 
10 .5 28  f emales (rate 2.6 ). T he  ove rall mortality rates 
f or ki dney cancer in EU  cou ntries have  increased 
u ntil the late 19 8 0 s/ early 19 9 0 s, thereaf ter rates 
have  stab ilize d or declined.[ 7 ]  ( fi g u r e  2 .) I n total 
the mortality rates declined f rom 4 .8  per 10 0 ,0 0 0  
in 19 9 0 – 19 9 4  to 4 .1 in 20 0 0 – 20 0 4  in men, and 
declined f rom 2.1 to 1.8  per 10 0 ,0 0 0  in w omen.[ 4 ]  
(leve l of  evi dence:  3). T he chang ing  mortality rates 
in the EU  va ry among  the dif f erent cou ntries. I n 
Scandinavi a, a decrease in mortality is ob serve d 
since the 8 0 s, w hereas a decrease since the early 
19 9 0 s is seen in F rance, G ermany , I taly , Au stria, 
and T he N etherlands. T he decreases w ere g enerally 
g reater in men than in w omen. Some Eu ropean 
cou ntries do not show  decreased mortality rates and 
an increased rate has b een ob serve d in some of  the 
eastern Eu ropean cou ntries [ 7 ] . T his f avo u rab le trend 
in mortality w ithin the EU , mig ht in part b e accou nted 
f or b y improve ments in diag nosis and treatment, and 
b y the rising  incidence of  small renal masses, b u t it 
can not b e f u lly exp lained.[ 15 ,16 ]  (leve l of  evi dence:  
3).
I n the U S, ove rall mortality rates of  patients w ith 
ki dney cancer have  increased f rom 1.5  per 10 0 ,0 0 0  
in 19 8 3 to 6 .5  per 10 0 ,0 0 0  in 20 0 2.[ 17 ]  T his increase 
mig ht b e at least partly b e exp lained b y the f act that 
small tu mors are more su ccessf u lly treated and 
5 - ye ar relative  su rvi va l rates have  improve d ove r 
time f or patients w ith R C C  f rom 5 6 .4 %  (diag nosed 
19 8 3– 19 8 7 ) to 6 8 .9 %  (diag nosed 19 9 8 – 20 0 2). [ 16 ]  
Af ter the b eg inning  of  20 0 0 s the rates have  b een 
leve ling  of f  and slig htly declined u ntil 20 0 6 , a similar 
trend as is present in Eu rope w here the rates have  
b een declining  in most cou ntries.[ 7 ,18 ,19 ]   (leve l of  
evi dence:  3).
ReCoM M enD A T Ions: N one
IV. eT IoloG ICA l fACT oRs
1 . seX :
Ag e- standardize d incidence rates of  R C C  have  
g enerally b een reported to b e hig her among  men 
than w omen [ 1] . T his pattern is consistently ob serve d 
throu g hou t the w orld w ith the exce ption of  W estern 
Af rica w ere reported incidence rates seemed to b e 
hig her among  w omen. I ncidence data, in particu lar 
f rom more deve loped reg ions of  the w orld, su g g est 
that men are at an increased risk of  deve loping  R C C  
(leve l of  evi dence:  3).
2 . RA Ce:
R eported ag e- standardize d incidence rates of  R C C  
are hig hest in Eu rope and N orthern America [ 1] . 
T he incidence rates seem to b e su b stantially low er 
among  Asians b oth in most Asian cou ntries and in 
the U S [ 1- 3] . T hese ob serva tions su g g est a hig her 
risk of  R C C  among  w hites compared to Asians (leve l 
of  evi dence:  3). T he low est incidence rates have  
b en reported f rom Af rican cou ntries [ 1] , b u t on 
T abl e 1.  E stimated incidence and mortal ity rates 
from k idney cancer in men in 2 7  E uropean countries 
in 2 0 0 6 ;  age standardize d rate per 10 0 , 0 0 0  [ 6 ] .
Co u n t r y In c i d e n c e  M o r t a l i t y  
C ze ch R epu b lic 28 .9 14 .5 6
L ithu ania 27 .0 9 9 .9 5
Estonia 24 .26 11.25
L atvi a 21.7 6  10 .8 4
I celand 20 .7 4 10 .19
Poland 20 .0 4 8 .7 3
F rance 18 .8 5 .37
H u ng ary 17 .7 9 7 .7 5
Au stria 17 .7 8 5 .4 5
I reland 17 .5 7 7 .0 2
B elg iu m 16 .4 7 6 .7 4
G ermany 16 .4 3 5 .6 3
Slova ki a 15 .8 3 9 .0 3
Slove nia 15 .5 6 7 .9 9
L u xe mb ou rg 15 .4 5 9 .5 3
Eu ropean U nion 14 .5 4 5 .8 3
F inland 14 .16 6 .7 8
I taly 14 .11 4 .6 6
N orw ay 13.0 4 5 .2
G reece 11.7 9 4 .33
D enmark 10 .9 1 6 .4 2
U nited K ing dom, 10 .8 4 5 .8 8
T he N etherlands 10 .8 3 5 .9 4
C yp ru s 10 .7 4 5 .6 6
M alta 10 .0 6 7 .5 2
Sw eden 9 .9 2 6 .12
B u lg aria 9 .6 9 4 .12
Spain 9 .29 4 .38
Sw itze rland 8 .24 3.6
Portu g al 6 .9 3.32
R omania 5 .7 3 3.9 3
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Figure 2 .  T rends in ov eral l  age- adj usted incidence and mortal ity from RCC per 10 0 0 0  men in 11 E uropean 
countries betw een 19 8 0  and 2 0 0 4 .  From L ev i F,  et al .  B J U  I nt.  2 0 0 8 ; 10 1( 8 ) :9 4 9 - 5 8 .  
Figure 1.  E stimated number of cancer cases and deaths in 4 0  E uropean countries 2 0 0 8 .  B ased on an 
il l ustration in Farl ey J  et al ,  E U RO P E A N  J O U RN A L  O F CA N CE R 2 0 10 ;  4 6 ,  7 6 5  – 7 8 1.
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the contrary the incidence rates are hig hest among  
Af rican Americans in the U S [ 2, 3] . R acial disparities 
in incidence rates may b e attrib u tab le to dif f erences 
in f requ ency of  diag nostic imag ing , access to health 
care, and preva lence of  other risk f actors. At present, 
ev idence on an independent association b etw een 
race and R C C  risk is inconclu sive .
3 . A G e:
D ata f rom the “ C ancer I ncidence in F ive  C ontinents”  
datab ase at I AR C  and the U .S. the Su rve illance, 
Epidemiolog y , and End R esu lts (SEER ) prog ram 
indicate that incidence rates in Eu rope and U SA 
increase consistently w ith ag e, w ith a plateau  
reached arou nd the ag e g rou p of  7 0 - 7 5  ye ars and 
ab ove  [ 2, 4 ] . T he latter ef f ect may b e du e to less 
f requ ent diag nostic testing  in this ag e g rou p. 
4 . CIG A ReT T e sM oK InG :  
C ig arette smoki ng  has b een estab lished as a risk 
f actor f or R C C  b y a larg e nu mb er of  stu dies. A meta-
analysi s [ 5 ]  inclu ding  19  case- control and 5  cohort 
studies confirmed that ever smoking increases the 
risk of  R C C  compared to neve r smoki ng  (leve l of  
evi dence:  2). T he increases in risk related to eve r 
smoki ng  w ere estimated to b e 5 4 %  f or men and 22%  
f or w omen. T he association b etw een smoki ng  and 
R C C  is relative ly  w eak,  b u t a clear dose- response 
relationship is evi dent w ith hig her risk  estimates w ith 
heavi er smoki ng  [ 5 ]  (leve l of  evi dence:  2). 
T here is only limited evi dence to su g g est that 
smoki ng  cessation may redu ce the risk of  R C C  in 
eve r smoki ng  men af ter 10  ye ars or long er of  non-
smoki ng  [ 5 - 7 ]  (leve l of  evi dence:  3). L imited data 
Figure 3 .  A ge- standardize d mortal ity rates for k idney cancer by gender in different continents ( G l obal  Cancer 
Statistics,  2 0 0 2  [ 14 ] )
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f rom f ew  case- control stu dies su g g est a potential 
association b etw een passive  smoki ng  and R C C  [ 7 -
9 ]  (leve l of  evi dence:  3). 
5 . oVeRWeIG H T / oB esITY :
Ex cess b ody w eig ht has b een estab lished as a risk 
f actor f or R C C  in seve ral case- control and cohort 
stu dies. M ost stu dies inve stig ated b ody mass index 
(B M I ) u sing  self - reported b ody w eig ht and heig ht. A 
meta- analysi s [ 10 ]  of  prospective  stu dies provi ded 
ev idence f or an association b etw een B M I  and risk 
of  R C C  w ith su mmary risk estimates (per 5  kg / m2 
increase in B M I ) of  1.24  in men and 1.34  in w omen 
(leve l of  evi dence:  2). T he resu lts su g g ested a 
somew hat strong er association in w omen than in 
men, b u t this dif f erence w as not rob u st and mainly 
drive n b y one larg e N orw eg ian cohort stu dy [ 11] . A 
qu antitative  revi ew  of  earlier stu dies f ou nd equ ally 
strong  associations among  men and w omen. 
Overall, evidence on sex-specific differences in 
the association b etw een B M I  and R C C  risk is not 
conclu sive . Stu dies inve stig ating  b ody f at distrib u tion 
su g g ested an increased risk of  R C C  w ith increasing  
w aist- to- hip ratio [ 12- 15 ]  (leve l of  evi dence:  3), b u t 
ev idence is too limited to conclu de that ab dominal 
ob esity is a risk f actor of  R C C  independently of  B M I . 
L imited data su g g est an increased risk of  R C C  w ith 
weight gain or weight Àuctuations [12, 13, 16] (level 
of  evi dence:  3).
6 . B looD  P RessuRe,  H Y P eRT ensIon A nD  
use of A nT IH Y P eRT ensIVe M eD ICA T Ions:
H y pertension or its treatment has b een associated 
w ith the risk of  R C C  in seve ral prospective  cohort 
stu dies [ 14 ,16 - 24 ]  (leve l of  evi dence:  2). T hree 
cohort [ 16 , 23, 24 ]  and one case- control stu dy 
[ 25 ]  measu red b lood pressu re and ob serve d an 
increased risk of  R C C  w ith eleva ted b lood pressu re, 
w ith a clear dose- response relationship reported 
in tw o cohort stu dies [ 16 , 24 ]  (leve l of  evi dence:  
2). T w o other prospective  cohort stu dies ob serve d 
an increased risk of  R C C  mortality w ith eleva ted 
b lood pressu re in men (fi g u r e  4. 26 , 27 ). T he 
independent contrib u tion of  b lood pressu re leve l and 
antihyp ertensive  medication u se have  g enerally b een 
difficult to distinguish, as most studies are based on 
a diag nosis of  hyp ertension that is inevi tab ly linke d 
to treatment w ith antihyp ertensive  dru g s. D ata f rom 
one case- control stu dy and one adequ ately pow ered 
cohort stu dy indicate that hig h b lood pressu re, 
rather than the u se of  antihyp ertensive  medication 
increases R C C  risk [ 24 , 25 ]  (leve l of  evi dence:  3). 
O ther stu dies did not consider b lood pressu re and 
medication u se independently of  each other. D ata 
f rom tw o cohort stu dies su g g est that b etter control 
of  b lood pressu re may low er R C C  risk [ 16 , 24 ]  (leve l 
of  evi dence:  3), w hereas u se of  antihyp ertensive  
medications inclu ding  diu retics is prob ab ly not a 
cau sal risk f actor [ 17 , 19 , 24 , 25 ]  (leve l of  evi dence:  
3). T he association ob serve d b etw een u se of  
diu retics and other antihyp ertensive  dru g s may thu s 
b e du e to conf ou nding  b y a history of  hyp ertension, 
b u t data on this issu e remain inconclu sive . 
7 . ConClusIons:
C ig arette smoki ng , exce ss b ody w eig ht according  
to increases in B M I , and hyp ertension are the most 
prevalent modifiable risk factors of RCC increasing 
the risk independently of  each other in b oth sexe s.
L ong - term smoki ng  cessation may redu ce R C C  risk 
in men, while its inÀuence in women is unclear.
B ody f at distrib u tion may impact R C C  risk 
independently of  B M I , b u t f u rther stu dies are 
necessary .
Eleva ted b lood pressu re increases R C C  risk,  w hile 
u se of  antihyp ertensive  medications per se may 
not b e a risk f actor as long  as b lood pressu re is 
ef f ective ly controlled.
8 . ReCoM M enD A T Ions:
R edu ctions in the preva lence of  cig arette 
smoki ng , exce ss b ody w eig ht, and u ncontrolled 
b lood pressu re are recommended as preve ntive  
strateg ies f or R C C  (G rade B  recommendation). 
Smoki ng  cessation can possib ly decrease R C C  
risk in ex- smoke rs af ter 10  ye ars or long er (G rade 
C  recommendation). Ef f ective  control of  b lood 
pressu re may decrease R C C  risk in indivi du als 
w ith hyp ertension (G rade C  recommendation).
V. G eneT IC fA CT oRs
1 . fA MIlIA l A nD  HeReD ITA RY  RenA l 
CA nCeR sY nD RoM es
O ve rall, approxi mately 2- 3%  of  R C C  are f amilial, i.e. 
primarily du e to inherited g enetic def ects (See tab le 
2) [ 4 7 ,4 8 ] . Each of  the common histolog ic su b typ es 
of  R C C  has a corresponding  f amilial syn drome, 
and each of  these is cau sed b y a distinct g enetic 
alteration [ 4 9 ] .  All of  these syn dromes are relative ly 
rare, su ch as V H L  w hich appears to b e the most 
common, althou g h f ou nd in only 1/ 36 ,0 0 0  b irths. 
T hese syn dromes shou ld b e considered in patients 
w ith early onset and/ or mu ltif ocal/ b ilateral disease. 
Some are du e to mu tated or inactiva ted tu mor 
su ppressor g enes and others to activa ted oncog enes, 
ye t all are transmitted in an au tosomal dominant 
manner.  G enetic cou nseling  and g ene sequ encing  
shou ld b e considered, and appropriate screening  f or 
the other manif estations of  the syn dromes shou ld 
b e perf ormed [ 5 0 ] .  F amily memb ers at risk shou ld 
also b e cou nseled to consider releva nt clinical and 
g enetic testing . M ost of  these syn dromes can b e 
ma ag ed conserva tive ly;  at least u ntil tu mor size  
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reaches 3.0  cm, b ecau se the risk of  metastasis 
remains relative ly low  u ntil this threshold is reached. 
N ephron- sparing  approaches are pref erred in an 
ef f ort to delay or preclu de the need f or dialysi s [ 5 1] . 
O ne exce ptional syn drome is f amilial leiomyo matosis 
R C C  in w hich the tu mors are of ten hig hly ag g ressive  
–  a more proactiv e approach is of ten indicated in this 
sy ndrome. 
2 . VH l sY nD RoM e
T he f amilial syn drome f or clear cell R C C  is V H L  in 
w hich patients can also deve lop hemang iob lastomas 
of  the central nervo u s syn drome, retinal ang iomas, 
and pheochromocyt omas.  B enig n tu mors in the inner 
ear, pancreas, and epididym is are also common [ 5 2] . 
Penetrance f or each of  these manif estations is f ar 
f rom complete, e.g . R C C  is only f ou nd in ab ou t 4 0 -
5 0 %  of  patients. T he V H L  g ene is located at 3p25 - 26  
and produ ces a protein that normally targ ets hyp oxi a 
indu cib le f actors (H I F s) f or u b iqu itin- mediated 
deg radation. L oss of  f u nction leads to accu mu lation 
of  H I F s and su b sequ ent u preg u lation of  V EG F  and 
other f actors that promote ang iog enesis and tu mor 
g row th [ 5 3] . T u mors in this syn drome thu s tend to 
b e hig hly va scu lar contrib u ting  to their potential 
morb idity . N ephron- sparing  approaches are pref erred 
b u t V H L  ki dney tu mors can b e lethal, and R C C  is the 
most common cau se of  death in this syn drome [ 5 0 ] . 
ReCoM M enD A T Ion: Active  screening  f or R C C  
in patients w ith this syn drome can allow  f or early 
detection and improve d clinical ou tcomes.  (G rade 
C  recommendation)
3 . H eReD IT A RY  P A P IllA RY  RCC
H ereditary papillary R C C  is cau sed b y activa tion of  
the c- met proto- oncog ene on chromosome 7 q31, 
w hich encodes a g row th f actor receptor.  M u tations 
lead to constitu tive  activa tion of  the receptor, w hich 
promotes tu mor g row th.  T yp e 1 papillary R C C  is 
excl u sive ly ob serve d in this syn drome, w hich is 
u niqu e in that it does not present w ith manif estations 
in other org an syn dromes [ 4 8 ] .
4 . fA M IlIA l leIoM Y oM A T osIs RCC
F amilial leiomyo matosis R C C  can present w ith 
cu taneou s leiomyo mas and w omen of ten have  a 
history of  hyst erectomy f or u terine leiomyo mas 
at an early ag e.  T yp e I I  papillary R C C  w ith a 
tendency tow ards ag g ressive  tu mor b iolog y is 
characteristic [ 4 8 , 5 3] .  T he f u marate hyd ratase 
g ene on chromosome 1q4 2 has b een correlated w ith 
this syn drome, althou g h research to link this K reb s 
cycl e enzym e to malig nant transf ormation is still in 
prog ress.
5 . B IRT - H oG G - D uB É  sY nD RoM e
B irt- H og g - D u b é  (B H D ) syn drome, in w hich patients 
develop cutaneous fibrofolliculomas, lung cysts, 
spontaneou s pneu mothoraces, and a va riety of  renal 
tu mors primarily derive d f rom the distal nephron, is 
the final familial RCC syndrome characterized as of 
20 10 .  R enal tu mors typ ically inclu de chromophob e 
R C C , oncocyt omas, and hyb rid or transitional tu mors 
that exh ib it f eatu res of  b oth of  these entities [ 4 9 ] . 
H ow eve r, other f orms of  R C C , inclu ding  clear cell 
R C C , have  also b een ob serve d in this syn drome, 
w hich is u niqu e in the dive rsity of  tu mor typ es that 
have  b een reported.  O ve rall penetrance f or renal 
tu mors is ab ou t 20 - 4 0 % .  M ost renal tu mors in B H D  
have  limited b iolog ical ag g ressive ness, althou g h 
metastatic b ehavi or and lethality have  b een reported. 
T his syn drome has b een correlated to mu tations in 
the f ollicu lin tu mor su ppressor g ene on chromosome 
17 p11.2 [ 5 0 ] .  
Figure 4 .  Rel ativ e risk  functions of RCC according to systol ic ( A )  and diastol ic ( B )  bl ood pressure in a 
popul ation based prospectiv e cohort study ( E P I C) .  From W eik ert et al ,  A m J  E pidemiol  2 0 0 7 .
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VI. eT IoloG Y  of oT H eR D IseA ses
1 . A CQ uIReD  RenA l CY sT IC D IseA se
Acqu ired renal cyst ic disease (AR C D ) consists of  
mu ltiple hyp erplastic renal cyst s on each ki dney . I t 
happens in patients w ith end stag e renal disease 
(ESR D ) and most of ten seen in patients on long -
term hemodialysi s.[ 5 4 - 5 6 ]  AR C D  is also f requ ently 
associated w ith adenomas and can prog ress to 
R C C .[ 5 7 ]  
T he incidence of  R C C  in AR C D  is mu ch hig her than 
g eneral popu lation Stu dies in the U S reported a 
three to six time hig her incidence.[ 5 8 ,5 9 ]  I n Japan, 
R C C  dev elops seve ral to tw enty times hig her in 
dialysi s patients than in the g eneral popu lation.[ 6 0 ]  
Therefore ARCD is a definite high risk factor of RCC. 
(leve l of  evi dence:  2b ). Also an association of  R C C  
w ith a period of  dialysi s w as inve stig ated. T he stu dy 
reported that patients w ho had 10  y ears of  dialy sis 
dev eloped no sig ns of  R C C  ev en 15  y ears f orw ards. 
I t is controve rsial that renal hyp erplastic cyst s and 
adenomas u nderg o malig nant transf ormation. B retan 
[ 6 2]  et al insisted that there mig ht b e a prog ression 
f rom b enig n renal cyst  to epithelial hyp erplasia and to 
RCC based on the findings of renal tumors occurring 
in hyp erplastic epitheliu m of  some complicated cyst s. 
B u t no other stu dies va lidated the theory . 
Syndrome G enetic E l ement M aj or Cl inical  M anifestations
vo n H ippel– L indau VHL g ene C lear cell R C C
  (chromosome 3p25 - 26 ) H emang iob lastomas
  of  the central nervo u s syst em
R etinal ang iomas
Pheochromocyt oma
H ereditary c-met proto- oncog ene T yp e 1 papillary R C C
  papillary R C C   (chromosome 7 q31)
F amilial leiomyo matosis 
and R C C
F u marate hyd ratase T yp e 2 papillary R C C
  (chromosome 1q4 2) C u taneou s leiomyo mas
U terine leiomyo mas
B irt- H og g - D u b é F ollicu lin C hromophob e R C C
  (chromosome 17 p11.2) O ncocyt oma
T ransitional tu mors*
O ccasional clear cell R C C
Cutaneous fibrofolliculomas
L u ng  cyst s
Spontaneou s pneu mothorax
* A l so k now n as hybrid oncocytic tumors and containing features of both chromophobe RCC and 
oncocytoma.
A dapted from Campbel l  SC,  L ane B R: M al ignant Renal  T umors.  Campbel l - W al sh U rol ogy,  10h edition.   E dited 
by W ein A J ,  K av oussi L R,  N ov ick  A C,  P artin A W ,  P eters CA ,  E l sev ier,  P hil adel phia,  P A ,  Chapter 4 9 ,  in 
press,  A ugust,  2 0 0 9 .
T abl e 2 .  Famil ial  Renal  Cel l  Carcinoma Syndromes.  [ 4 9 , 5 2 ]  A dapted from Campbel l  SC,  L ane B R: M al ignant 
Renal  T umors.  Campbel l - W al sh U rol ogy,  10h edition.   E dited by W ein A J ,  K av oussi L R,  N ov ick  A C,  P artin A W ,  
P eters CA ,  E l sev ier,  P hil adel phia,  P A ,  Chapter 4 9 ,  in press,  A ugust,  2 0 0 9 .
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R C C  occu rring  in ESR D  has a f ew  characteristics 
dif f erent f rom classic R C C . T he ag e w hen R C C  is 
diag nosed is yo u ng er in patients w ith ESR D  than in 
the g eneral popu lation. T he incidence ratio of  male 
to f emale is hig her in patients w ith ESR D  than in the 
g eneral popu lation. (7 : 1 vs 2: 1, respective ly)  [ 6 3]
Some inve stig ators reported that the cyst s 
in the patients w ith AR C D  redu ce af ter renal 
transplantation.[ 6 4 ]  H ow eve r, the risk of  R C C  af ter 
renal transplantation may not decrease. L evi ne[ 6 5 ]  
et al. and H einz[ 6 6 ]  et al. reported R C C  deve loping  
af ter transplantation.
2 . D IA B eT es
D iab etes mellitu s (D M ) is kn ow n to b e associated 
w ith an increased risk of  seve ral cancers. H ow eve r, 
D M  is a controve rsial risk f actor in R C C .[ 6 7 - 7 1]  
Two cohort studies reported significantly increased 
risks of  R C C  in patients w ith D M  w ith relative  risks 
of  1.3 in men and 1.7  in w omen,[ 6 8 ,6 9 ]  b u t most 
of  other stu dies f ailed to prove  a relation b etw een 
D M  and risk of  R C C .[ 7 1- 7 3]  T w o international renal-
cell- cancer stu dies ob serve d b orderline or no direct 
association.[ 7 0 ,7 4 ]
A recent epidemiologic study did not find significant 
O R s b etw een D M  and R C C . T he au thors conclu ded 
that ove rw eig ht and ob esity are w eakl y associated 
w ith R C C  b u t attrib u ting  D M  as a risk f actor is 
controve rsial.[ 7 5 ]  (leve l of  evi dence:  3)
3 . uRInA RY  T RA CT  InfeCT Ion
C ohort stu dies reg arding  U T I  history as an 
independent risk f actor f or R C C  are limited. C how  
et al.[ 7 6 ]  inve stig ated the incidence and risk of  U T I  
in a popu lation- b ased cohort of  6 1,14 4  patients 
hospitalize d f or u rinary stones in Sw eden f rom 19 6 5  
to 19 8 3. Af ter 25  ye ars of  f ollow - u p, C how  et al. 
reported on no increase in the incidence of  R C C  f or 
the su b set of  cohort patients w ho had a history of  
U T I . 
I n 5  case control stu dies M cL au g hlin et al.[7 7 ], H iatt 
et al.[ 7 8 ] , and Parke r et al.[ 7 9 ]  reported an increased 
risk of  R C C  associated w ith a history of  U T I  w hile 
Schlehof er et al.[ 8 0 ]  and M cC redie et al.[ 8 1]  reported 
no association. These conÀicting results indicate that 
U T I  is not an independent risk  f actor f or R C C . (lev el of  
ev idence:  3)
4 . ConClusIons:
ARCD is definitely a risk factor of RCC and patients 
w ith ESR D  shou ld b e reg u larly screened. I t is u nclear 
w hether transplantation redu ces the risk of  R C C . 
D iab etes and u rinary tract inf ection are controve rsial 
as independent risk f actors of  R C C .
5 . ReCoM M enD A T Ions:
I n AR C D , reg u lar screening  of  the ki dney (G rade 
B  recommendation) is recommended f or early 
diag nosis f or R C C .
VII. nuT RIT IonA l fA CT oRs,  D IeT  
A nD  RenA l Cell CA nCeR ( RCC)
T here is more than a 10 - f old dif f erence in incidence 
of  ki dney cancer b etw een hig h- income cou ntries 
and middle/ low - income cou ntries [ 8 2] . I ncidence 
has increased more than 9 0 %  in less than 20  ye ars 
in Eastern Asia [ 8 3,8 4 ] , coinciding  w ith dramatic 
chang es in f ood su pply and dietary patterns. 
T og ether these data su g g est that lif estyl e, inclu ding  
diet, plays a role in R C C  deve lopment. 
1 . nuT RIenT s
a)  P rotein and Fat
An ecolog ic stu dy has reported that the per capita 
daily intake s of  f at and protein are positive ly 
correlated w ith the incidence of  ki dney cancer in 
b oth men and w omen [ 8 5 ]  (leve l of  evi dence:  3).
H ig h protein consu mption has b een hyp othesize d 
to increase R C C  risk b ecau se of  the potential 
u nf avo rab le ef f ect on the ki dney of  nitrog en w aste 
produ ts. M ost case- control stu dies have  reported 
non-significant or significant positive associations 
b etw een intake s of  total or animal protein and the 
risk of  R C C  [ 8 6 - 8 8 ]  (leve l of  evi dence:  3). H ow eve r, 
prospective  stu dies, w hich avo id selection and recall 
b ias b ecau se participants start to b e f ollow ed f rom 
the b eg inning  of  the stu dy , and dietary inf ormation 
is collected prior to diag nosis of  R C C , have  b een 
less su pportive . A pooled analysi s of  13 prospective  
cohort stu dies in the U S, C anada, and Eu rope 
[ 8 9 ]  and a larg e Eu ropean collab orative  stu dy [ 9 0 ]  
ob serve d no association b etw een total, animal, or 
plant protein and R C C  risk (leve l of  evi dence:  2). 
R esu lts of  case- control stu dies on total f at or 
va riou s typ es of  f at intake  (ve g etab le, animal, dairy , 
satu rated, monou nsatu rated, polyu nsatu rated, 
trans f at, and cholesterol) and R C C  risk have  b een 
inconsistent [ 8 7 ,8 8 ,9 0 - 9 2] , and no association w as 
f ou nd in a collab orative  analysi s of  13 prospective  
cohort stu dies [ 8 9 ]  (leve l of  evi dence:  2). 
b)  V itamins
Prospective  stu dies of  mu ltivi tamin u se and risk 
of  R C C  have  f ou nd no association [ 9 3,9 4 ]  (leve l 
of  evi dence:  2). O ther su pplemental u se or intake  
of  vi tamins (f rom b oth f oods and su pplements), 
inclu ding  f olate and vi tamins A, C , D , and E, have  
not show n consistent resu lts [ 8 7 ,9 3,9 5 - 10 1] . O ne 
recent larg e case- control stu dy that exa mined 
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g enetic polym orphisms of  vi tamin D  receptor g enes 
su g g ested that vi tamin D  cou ld play a role in R C C  
[ 10 2]  (leve l of  evi dence:  3), b u t this possib ility needs 
f u rther stu dy .
c)  O ther nutrients
Among  stu dies that have  exa mined associations 
b etw een R C C  and nu trients ab u ndant in f ru its 
and vegetables, such as dietary fiber [87,90,91], 
indivi du al carotenoids [ 8 7 ,8 8 ,9 5 ,9 8 ,10 1,10 3] , and 
Àavonoids [97,104,105], many case-control studies 
and a pooled analysi s of  cohort stu dies f ou nd an 
inve rse association f or some of  these nu trients 
[ 9 5 ,10 3,10 6 ,10 7 ]  (leve l of  evi dence:  2). H ow eve r, this 
may b e partly exp lained b y the inve rse association 
f or intake  of  f ru its and ve g etab les noted in the same 
popu lations [ 9 5 ,10 3,10 6 ,10 7 ] . B ecau se stu dies on 
total carb ohyd rate [ 8 7 ,9 0 ,9 1]  or minerals [ 8 7 ,9 6 ,10 7 ]  
are sparse, their findings cannot be considered 
conclu sive . 
2 . fooD  G RouP s
a)  Fruits and v egetabl es
Althou g h the resu lts f or f ru its and v eg etab les f rom 
case- control stu dies of  R C C  have  b een inconsistent 
[ 8 6 ,8 7 ,10 6 - 110 ] , the larg est su ch stu dies (each 
w ith more than 5 0 0  R C C  cases) have  show n more 
consistent inve rse associations f or total f ru it [ 8 7 ] , 
total ve g etab les [ 8 7 ,10 6 ,10 9 ] , and su b g rou ps of  
ve g etab les [ 8 7 ,9 5 ,10 7 ,10 9 ]  (leve l of  evi dence:  3).
I n a prospective  stu dy , a pooled analysi s of  13 cohort 
stu dies f ou nd that f ru it and ve g etab le consu mption 
w as associated w ith a low er risk of  R C C  [22] (leve l 
of  evi dence:  2) w hereas stu dies of  a larg e Eu ropean 
[ 111]  and a U S [112] cohort did not find an inverse 
association (leve l of  evi dence:  2). 
b)  M eat and Fish
T he consu mption of  red or processed meat w as 
associated w ith increased risk of  R C C  in a meta-
analysi s of  case- control stu dies [ 113]  and in other 
case- control stu dies [ 10 9 ,110 ,114 ]  (leve l of  evi dence 
2).  H ow eve r, a pooled analysi s of  cohort stu dies 
f ou nd no increase in risk f or either red meat or 
processed meat [ 8 9 ]  (leve l of  evi dence:  2). T he data 
on pou ltry intake  w ere not consistent [ 8 9 ,10 9 ,110 ] .
Total fish intake was not associated with RCC risk 
in case- control stu dies [ 10 9 ,114 ]  or in a pooled 
analysi s of  13 cohort stu dies [ 8 9 ]  (leve l of  evi dence:  
2). Althou g h one Sw edish cohort stu dy su g g ested a 
lower risk of RCC among women with high fatty fish 
consu mption [ 115 ]  (leve l of  evi dence:  2), stu dies on 
specific type of fish consumption are few. 
c)  A l cohol ,  coffee,  and other bev erages
T he main f u nctions of  the ki dneys are to reg u late 
w ater and inorg anic- ion b alance and to excr ete 
w aste produ cts and f oreig n chemicals [ 116 ] . B ecau se 
complicated chemical exch ang es take  place in renal 
tissu es, the risk of  R C C  may b e af f ected b y the 
qu antity and typ e of  b eve rag es consu med.
Stu dies on intake  of  alcohol or alcoholic b eve rag e 
show ed su g g estive  inve rse or no associations 
[ 8 7 ,8 8 ,9 5 ,117 ]. H ow eve r, recent case- control [ 118 -
120 ]  and cohort stu dies [ 121- 123] show ed that 
moderate alcohol consumption was significantly 
inve rsely associated w ith risk of  R C C  (leve l of  
evidence: 2). Total Àuid intake was not associated with 
R C C  risk [ 124 ]  (leve l of  evi dence:  2), su g g esting  that 
the du ration that carcinog enic solu tes are in contact 
w ith R C C  may b e u nrelated to the mechanism b y 
w hich alcohol preve nts R C C  risk.
C of f ee intake  w as not associated w ith R C C  risk in 
most case- control stu dies [ 8 8 ,9 2,9 5 ,125 ,126 ] , b u t 
a pooled analysi s of  cohort stu dies f ou nd a low er 
risk of  R C C  w ith cof f ee consu mption [ 127 ]  (leve l of  
evi dence:  2). 
F inding s on other b eve rag es inclu ding  sof t drinks,  
j u ice, milk,  and tea w ere inconsistent in prospective  
stu dies [ 127 ,128 ]  and in case- control stu dies [ 8 6 -
8 8 ,10 6 ,10 9 ,110 ,117 ,125 ,129 ,130 ] . 
3 . oT H eR fooD  G RouP s
R esu lts w ere inconsistent f or cereals, g rain 
prod ct , g lyce mic index/ g lyce mic load 
[ 8 7 ,8 8 ,10 7 ,110 ,131- 133] , and dairy produ cts other 
than milk,  inclu ding  eg g s, yo g u rt, ice cream, cheese 
[ 8 7 ,8 8 ,9 7 ,10 6 ,10 7 ,10 9 ] .
VIII. oCCuP AT Ion 
W orldw ide, ki dney cancer occu rs ab ou t tw ice as 
f requ ent among  males as among  f emales. B ecau se 
of  this male/ f emale ratio and the w idespread interest 
in health ef f ects related to occu pational exp osu res, 
seve ral stu dies inve stig ated associations b etw een 
occu pation and ki dney cancer. 
Q u ite a f ew  stu dies presented clearly increased risks 
of  ki dney cancer related to seve ral occu pations, 
possib ly b ecau se of  historical hig h exp osu re leve ls. 
A larg e international case- control stu dy f ou nd 
significant associations with employment in the blast-
f u rnace or the coke - ove n indu stry (R R  1.7 ), the iron 
and steel indu stry (R R  1.6 ) and exp osu re to asb estos 
(R R  1.4 ), cadmiu m (R R  2.0 ), dry- cleaning  solve nts 
(R R  1.4 ), g asoline (R R  1.6 ) and other petroleu m 
produ cts (R R  1.6 ) (leve l of  evi dence:  3).[ 134 ]  Similar 
associations w ere f ou nd in a mu lticenter stu dy f rom 
G ermany .[ 135 ] T hese stu dies w ere condu cted in the 
nineties w ith qu estionnaires ab ou t exp osu res in the 
decades b ef ore that. N ow adays,  in g eneral, strong ly 
increased risks are not f ou nd anym ore, althou g h 
a recent stu dy condu cted in C entral and Eastern 
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Eu rope, the area w ith the hig hest rates of  ki dney 
cancer w orldw ide, su g g ested an association b etw een 
ki dney cancer and ag ricu ltu ral w ork,  particu larly 
among  f emale w orke rs (leve l of  evi dence:  3).[ 136 ]
A commonly reported toxi c mineral w ith su g g ested 
nephrocarcinog enicity is asb estos.[ 1] A more recent 
meta- analysi s of  asb estos- exp osed cohort stu dies 
conclu ded, how eve r, that there is u nconvi ncing  
ev idence of  an increased association, althou g h hig h 
asb estos exp osu re mig ht cau se a small increase in 
risk (leve l of  evi dence:  2).[ 137 ]
W orke rs exp osed to hig h leve ls of  polycycl ic aromatic 
hy drocarb ons, like  coke  and coal ove n w orke rs, 
w ere reported to have  an increased risk of  ki dney 
cancer (leve l of  evi dence:  3).[ 134  1]  T he resu lts 
of two cohort studies showed a highly significant 
ex cess of  mortality among  steelw orke rs as coke  
ov en w orke rs, b u t af ter a f ollow - u p of  30  ye ars no 
increased mortality risk w as f ou nd anym ore (leve l of  
ev idence:  2).[ 138 ] Also, a stu dy of  Eu ropean asphalt 
w orke rs did not show  an increased ki dney cancer 
risk. [ 139 ]
F inding s indicate that there is no association 
between oil refinery workers, who are highly exposed 
to g asoline, and risk of  ki dney cancer. A popu lation-
b ased case- control stu dy of  occu pational exp osu re 
condu cted in the 19 8 0 s in C anada f ou nd an O R  of  
1.0  f or b oth g asoline and other exp osu re to lead and 
ki dney cancer.[ 14 0 ]  T he same w as tru e in a stu dy 
f rom Sw eden w here occu pational diesel exp osu re 
w as not f ou nd to b e related to ki dney cancer (leve l of  
ev idence:  3).[ 14 1]
Perchloroethyl ene is a primary solv ent in the dry-
cleaning  indu stry  w hich may b e carcinog enic to 
hu mans.[ 14 2]  A revi ew  of  occu pational exp osu re to 
perchloroethyl ene and cancer  did not su pport this 
su g g estion and reported that apart f rom limitations 
and inconsistencies in the pu b lished literatu re, a 
relationship b etw een PC E and ki dney cancer is 
u nlike ly (leve l of  evi dence:  3).[ 14 3] T richloroethyl ene 
(T C E), a solve nt u sed as va por deg reaser f or 
the cleaning  of  metal parts, w as linke d  to ki dney 
cancer b ecau se of  evi dence of  carcinog enicity 
in exp erimental animals, and some reg ions in 
G ermany have  a hig h T C E exp osu re[ 14 4 ]  B u t these 
findings are not supported by the results of other 
inve stig ations that conclu ded that the carcinog enicity 
of  trichloroethyl ene in hu mans remains a matter of  
controve rsy (leve l of  evi dence:  3).[ 14 5 ]  
R ecently a case- control stu dy of  pesticides exp osu re 
and kidney cancer showed a significantly increased 
risk[146], but more studies are needed to confirm 
these findings (level of evidence: 3). 
ConClusIon: B ased on the literatu re, ove rall, 
ki dney cancer is not considered to b e a typ ical 
occu pation- related tu mor.[ 14 7 ]  
ReCoM M enD A T Ion: I t is g enerally 
recommended to decrease or preve nt exp osu re 
to occu pational carcinog ens (e.g ., asb estos, 
polycycl ic aromatic hyd rocarb ons, dry- cleaning  
solvents, cadmium) by means of modifications of 
produ ction processes or protective  interve ntions. 
Su ch policies may also low er the risk of  renal 
cell cancer, b u t presu mab ly to a small ext ent only 
(G rade C  R ecommendation).  
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H.  UE M U R A,
C ancer of  the ki dney is exp ected to af f ect almost 
10 0 .0 0 0  patients in the U nited States and Eu ropean 
U nion in 20 10  [ 1; 2] . R enal cell carcinomas (R C C ) ref er 
to cortically derive d tu mors of  the renal parenchym a 
and encompass a heterog eneou s g rou p of  cancers 
[3]. Advances in basic research aimed at defining 
pivo tal molecu lar eve nts in the deve lopment of  these 
dif f erent entities has show n that renal cancers can 
be subdivided based on genetic profiles. Moreover, 
kn ow ledg e of  u nderlyi ng  molecu lar characteristics 
identified the vascular endothelial growth factor 
(V EG F ) and the mammalian targ et of  rapamyci n 
(mT O R ) pathw ay s as f u ndamental to the b iolog y 
of  clear cell R C C . T his b iolog ic insig ht provi ded a 
rationale f or targ eting  these g row th f actor sig naling  
pathw ays in R C C . 
B asic science in R C C  is a va st area theref ore w e 
w ill f ocu s on f ou r areas of  research that w ere f elt 
most releva nt f or renal cancer and are not discu ssed 
in- depth in other chapters:  the molecu lar b asis of  
renal cancer, targeted therapies, renal cancer and 
immunity, and genetic factors and RCC. Finally, it is 
important to note that g reat maj ority of  b asic research 
in R C C  is f ocu sed on clear cell R C C  g ive n the hig h 
prevalence of this histological subtype. Additionally, 
w hile the va st maj ority of  stu dies have  b een 
performed on material from primary lesions, future 
stu dies shou ld consider exa mination of  metastatic 
lesions as w ell. 
II. T H e M oleCulA R B A sIs of 
RenA l CA nCeR
Historically, four main histological renal cancers were 
recognized in the Heidelberg classification: clear 
cell Renal Cell Cancer (ccRCC, 60-80), papillary 
RCC (10-15), chromophobe RCC (a5) and renal 
oncocytoma (a5) [3;4] Recently, translocation 
linked[5;6], mucinous tubular and spindle type RCC 
[7] and tubulocystic carcinoma[8] (all comprising 1 
of  cases) have  b een added to this list. I t is now  clear 
that these morpholog ical su b typ es represent hig hly 
dissimilar diseases in b oth g enetics and clinical 
behavior, and thus may or may not be variants of 
a common cancer or common cell of  orig in ( fi g u r e  
1 ).
T he b iolog y of  the vo n H ippel- L indau  (V H L ) g ene 
product, pVHL, and its regulation of the hypoxia 
indu cib le f actor (H I F ) f amily of  hyp oxi a- reg u lated 
transcription factors, is tightly linked to ccRCC 
biology. The discovery of the VHL gene, and its 
association w ith the V H L  syn drome of  central nervo u s 
system hemangioblastomas, pheochromocytoma/ 
paraganglioma, and ccRCC, in 1993[9] quickly led 
to the discove ry that V H L  mu tation is also tig htly 
associated with sporadic ccRCC, detected in up to 
90 of tumors [10-13]. The loss of VHL leads to 
the loss of regulation of HIF family members HIF1α, 
HIF2α [14-18], and HIF3α [19], which is further 
composed of  sev eral splice va riants. X enog raf t 
stu dies have  demonstrated that restoration of  pV H L  
expression or suppression of deregulated HIF2α 
impairs the g row th of  these tu mors [ 20 ; 21] . 
Papillary RCC, chromophobe RCC and renal 
oncocyt oma are less dominated b y mu tations in a 
sing le g ene. M u tations in c- met have  b een associated 
with familial papillary type 1 RCC, but only in a subset 
of sporadic papillary RCC, and is thus less dominant 
than VHL is for ccRCC [22]. A more rare, but also 
hig hly ag g ressive  typ e of  papillary  typ e I I  renal cell 
carcinoma has b een associated w ith mu tations 
in the fumarate hydratase gene [23], although the 
releva nce of  this mu tation in sporadic disease is 
u nkn ow n. H eterozyg ou s kn ock- ou t of  the g ene 
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implicated in the B irt- H ig g - D u b é  (B H D ) syn drome in 
mice leads to the deve lopment of  renal cyst s and 
three different histological types of renal tumors, 
similar to hu man B H D  w hich is closely associated 
with familial chromophobe RCC, but predisposes to 
other histologies as well [24]. 
I n spite of  the tig ht correlation of  ccR C C  w ith 
inactivation of VHL, the effect on HIF deregulation is 
not u nif orm:  va riant mu tations in V H L  may contrib u te 
to imbalances of HIF1α and HIF2α deregulation, 
leading  to distinct ef f ects on cell g row th [ 25 ; 26 ] . I n 
a strateg y to determine w hether tu mors cou ld b e 
defined based upon the most studied and understood 
pathway in RCC, gene expression profiles were 
linke d w ith V H L  mu tation analysi s and exp ression 
characteristics of the HIFs [27]. In this study, 160 
ccRCCs were classified as VHL mutant or wild 
ty pe and according  to H I F  protein exp ression. V H L  
mutant, HIF1 and HIF2 expressing tumors (H1H2) 
overexpressed the Akt/mTOR pathway, while VHL 
mu tant tu mors exp ressing  solely H I F 2 (H 2 tu mors) 
replicated more rapidly, marked by overexpression of 
Ki-67, which other groups have identified as a poor-
risk marker [28]. ccRCC can thus be characterized 
as H1H2 or H2, with dramatically differing effects on 
tu mor cell prolif eration and C - myc reg u lation [ 27 ] . 
R ecent evi dence su g g ests that the H 2 tu mors may 
be derived from H1H2 tumors that lose HIF1α in a 
subset of tumors, suggesting a potentially selective 
pressure to lose the HIF1α gene during tumor 
progression [29].  These insights potentially narrow 
the key tumorigenic events within the VHL/HIF axis.
Besides VHL loss and HIF activation, maMor efforts 
have ye t to identif y a simple linear prog ression 
of  g enetic lesions accou nting  f or the g ains in 
aggressiveness in RCC [30-34]. Two recent ccRCC 
cyt og enetic stu dies lend clu es to u nderstanding  
this prog ression. O ne stu dy perf ormed b oth sing le 
nu cleotide polym orphism (SN P) analysi s and 
g ene ex pression analysi s on sporadic ccR C C  
and tu mors f rom patients w ith V H L  disease [ 30 ] . 
Importantly, this study demonstrated that tumors 
f rom sporadic and V H L - disease ccR C C  tu mors 
have overall similar profiles, but sporadic tumors are 
more heterog enou s and contain a hig her nu mb er 
of genetic events per tumor, but they cannot be 
Figure 1: Schematic representation of the nephron and the different subtypes of RCC according to the 
‘Heidelberg’ classification in relation to their positions within the nephron and collecting tubule. Genetic 
changes that are characteristic for the different RCC subtypes are indicated.
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disting u ished u sing  u nsu pervi sed analysi s of  g ene 
expression data.  In a prospective analysis of 282 
ccRCC patients with up to 108 months of follow-up 
using traditional cytogenetic karyotyping techniques 
[ 32]  chromosomal loss at 3p (the g enomic home 
of the VHL gene) was significantly associated with 
improved disease-specific survival, while losses of 
4p, 9p and 14q were significantly associated with 
reduced disease-specific survival, but the specific 
g enes in these reg ions implicated in cau sing  the 
poor prog nosis remain to b e characterize d. 
The first whole sequencing study in ccRCC confirmed 
that considerab le g enetic heterog eneity exi sts in 
ccRCC [29] emphasizing that even though the vast 
maj ority of  ccR C C  contain mu tated V H L  most like ly 
every tumor has a unique gene signature. This study 
also substantiated findings in multiple mouse knock-
out studies and a zebrafish study which demonstrated 
that VHL mutations/knock out alone is insufficient to 
produ ce ccR C C  and that additional g enetic eve nts 
are required [35;36]. 
Although unable to cause sporadic ccRCC alone, the 
presence and typ e of  V H L  mu tations in tu mors have  
b een consistently considered as possib le b iomarke rs. 
Cowey, et al, recently reviewed its potential in 
prog nosis and prediction [ 37 ] . F u rther research 
is still required to establish VHL¶s efficacy as a 
biomarker, but given the frequency of its inactivation, 
more opportu nities to u nderstand the heterog eneity 
of  this disease may lie in exp loration of  dow nstream 
f actors.  W hen V H L  is inactiva ted and H I F  exp ression 
constitutively stabilized, a host of other genes 
w hich make  u p va riou s components of  the hyp oxi a 
response are transcriptionally u preg u lated (revi ew ed 
in [38]).  It remains to be determined which of these 
factors or pathways most significantly contributes to 
the formation or maintenance of ccRCC¶s malignant 
phenotype.  One HIF target, the vascular endothelial 
growth factor (VEGF), has been found to be 
significantly upregulated in kidney tumors compared 
to its eleva ted exp ression in many other cancers. As 
a prognostic biomarker, VEGF has not been proven 
to be valuable, but may be predictive of response to 
VEGF targeted therapy, as described below.
I n order to identif y more ef f ective  b iomarke rs and 
further understand the underlying biology, several 
dif f erent g rou ps perf ormed g ene ex pression analyse s 
on ccR C C  tu mor samples. T a b l e  1 g ive s an ove rvi ew  
of these studies. One of the initial expression profiling 
studies examined 29 ccRCC tumors, identifying 51 
g enes that cou ld classif y tu mors b ased on 5  ye ar 
disease-specific survival [39]. This study verified the 
possibility that gene expression profiles could be 
used to predict outcome in ccRCC, but remains to 
be validated or defined by biological parameters that 
may accou nt f or this dif f erence in disease activi ty . 
One study of 51 tumor samples identified vascular 
cell adhesion molecule-1, VCAM-1, as a prognostic 
biomarker [40], which has subsequently undergone 
retrospective validation [41;42]. Importantly, high 
exp ression of  this molecu le predicted f or b etter 
ove rall su rvi va l in b oth clear cell and papillary 
tumors, suggesting that VCAM-1 expression may 
g enerally indicate tu mor cells w ith low er metastatic 
potential.  T he f u rther implications f or sensitivi ty to 
antiang iog enic therapy are not ye t kn ow n.
Several gene signatures for RCC progression, for 
example three genes (caveolin 1, lysyl oxidase, and 
annexin A4) have been identified as associated with 
RCC aggression and/or survival [43] [44]. Similarly, 
su rvi vi n w as show n to independently predict clear 
cell progression and risk of death [45] [46]. Finally, 
the largest study, analyzing 177 clear cell tumors, 
identified 340 transcripts (including VCAM-1) 
significant in multivariate analysis with stage, grade 
and performance status [47] [48]. 
W hile the ab ove  stu dies f ocu sed on clinical endpoints 
in their analyses, many started with an unsupervised 
analysi s to g et a g eneral u nderstanding  of  the data. 
The study that identified VCAM-1 as a prognostic 
b iomarke r saw  the presence of  potentially tw o 
ubgroups within the stage IV tumors, with survival 
differences [40]. This suggests that molecular 
f eatu res b eyo nd clinical stag ing  cou ld provi de 
inf ormative  data in u nderstanding  eve n metastatic 
tumor behavior.  The group of =hao, et al. examined 
their 177 tumors using 3,674 genes also observed 
two larger groups of ccRCC, with significant survival 
dif f ere ces as w ell as predicted b iolog ical pathw ay 
distinctions [47]. These studies helped to set the 
stag e f or f u rther delineation of  su b g rou ps w ithin 
ccR C C .
T w o other stu dies stand ou t as b eing  predominantly 
g eared tow ard identif yi ng  the inherent su b g rou ps 
and u nderlyi ng  b iolog ical dif f erences of  ccR C C . 
One group first looked at 16 ccRCC tumors and saw 
that there seemed to be two types of clear cell, one 
that more hig hly ove rexp ressed metab olic g enes 
and the other extracellular matrix/cell adhesion 
genes[49]. Most recently, a bioinformatic technique 
called u nsu pervi sed consensu s clu stering  w as u sed 
on 48 tumors to identify two subtypes of ccRCC, 
ccA and ccB,  distinguished by fewer than 120 
probes[50]. Validating these results in the =hao, et 
al., data set of 177 tumors, patients with ccA tumors 
have  a marke d su rvi va l adva ntag e ove r those w ith 
ccB tumors. Additionally, this dataset validates the 
characteristics that ccA tumors display a profile of 
altered metabolism, whereas ccB tumors display 
characteristics of  w ou nd healing  and epithelial to 
mesenchym al transition. 
Finally, one study focused entirely on metastases 
[51], finding that late occurring metastases more 
highly expressed genes involved in angiogenesis, 
cell migration and adhesion. Additionally, genes 
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related to cell divi sion and cell cycl e w ere 
ov erexp ressed in samples f rom patients w ith 
multiple metastases, indicating that the presence of 
more metastases mig ht b e cau sed b y an increased 
g row th potential.
All of  the potential b iomarke rs emerg ing  f rom the g ene 
expression studies require removal and processing 
of  at least part of  the tu mor. Plasma seru m proteins 
have traditionally been studied to find non-invasive 
diag nostic marke rs f or the presence of  ccR C C  as 
compared to normal or benign renal tissue. Currently, 
there are no circu lating  tu mor marke rs ava ilab le 
f or clinical u se in manag ement of  R C C . Seve ral 
molecu les have  b een stu died as candidates f or 
diag nosis of  R C C :  I n clear cell R C C  the resu lts w ith 
VEGF and VEGFR have been contradictory[52;53], 
and these marke rs mig ht b e more su itab le as 
predictive  than as diag nostic marke rs. R ecent 
stu dies have  show n eleva ted C AI X  leve ls in ccR C C  
patients [54], with a significant association between 
C AI X  seru m leve ls and occu rrence of  metastases 
[55]. Furthermore, in patients with localized disease 
an eleva ted C AI X  leve l predicts the recu rrence and 
is correlated with a shorter PFS. Again, there is not 
a complete concordance w ith tissu e resu lts. O ther 
markers related to tumor biology like MMP-7, CD95, 
bFGF, hepcidin-25, Il-10 or IL-6 showed promising 
results as possible biomarkers for RCC [56-60], 
b u t these marke rs need to b e va lidated in separate 
stu dies. 
B ecau se of  the complexi ty of  the tu mor deve lopment 
and progression, identification of complex protein 
sig natu res is more promising . H ig h throu g hpu t 
technolog ies like  M AL D I  (M atrix- assisted laser 
desorption/ionization) or SELDI (Surface Enhanced 
Laser Desorption/Ionisation) allow the analysis of 
the w hole proteome of  many samples in a short 
time w ith hig h sensitivi ty . SEL D I - T O F - M S (T ime of  
F lig ht M ass Spectrometry)  has especially b een u sed 
to define prognosis related profiles. Unique protein 
sig natu res of  tu mor patients compared to normal 
controls with high sensitivity (70-87) and specificity 
(89.9-92) have been described [56-63]. One of 
the candidate proteins, SAA1, was identified by 3 
groups[61;64;65]. In all published studies, elevated 
SAA1 concentration correlated with metastasis, 
poor prognosis and shorter survival [61;64-66], 
ev en thou g h dif f erent cu t- of f  va lu es w ere u sed. 
I ndependent stu dies are needed to su b stantiate the 
va lu e of  SAA1. 
Finally, an 831 tumor tissue microarray study analyzed 
15  proteins that are associated w ith  the pV H L  
and phosphatase and tensin homolog u e (PT EN ) 
pathways [67]. Surprisingly, while pVHL and phospho-
mT O R  staining  correlated inve rsely w ith tu mor stag e 
and grade, neither protein correlated with survival. 
Within the intermediate stage tumors (pT2 and pT3), 
tu mors w ith p27  and C AI X  exp ression associated 
w ith improve d ou tcome. T his stu dy su g g ests that 
the dysr eg u lation of  seve ral independent pathw ays 
are crucial for tumor progression, corroborating the 
sequencing study by Dalglish, et al. [29]. 
MicroRNA, 21-23 nucleotide segments of single-
stranded non-coding RNA, have now been 
implicated in tumorigenesis of many cancers, even 
being identified as potential prognostic biomarkers 
in several of these (reviewed in [68]). The aberrant 
exp ression of  these non- coding  R N As can provi de 
a powerful method of epigenetic tumor regulation, 
as an indivi du al microR N A can alter the exp ression 
of many target genes. In RCC, various studies have 
identified various individual or panels of microRNAs 
that are dif f erentially exp ressed b etw een normal 
renal tissu e and tu mor or b etw een histolog ical 
subtypes [69-76]. The identification of relevant 
targ ets of  these tu mor associated microR N As are 
Must becoming realized [74]. MicroRNAs can be 
easily extracted from formalin fixation, paraffin 
embedded tissue, and blood. The ability to easily 
u e non- inva sive  measu res to identif y a stab le targ et 
make s microR N As a ve ry attractive  b iomarke r f or 
diagnostic, prognostic, and predictive purposes. 
A larg e nu mb er of  potential b iomarke rs have  
emerg ed f rom all these g ene exp ression stu dies. 
Encouragingly, trends are beginning to emerge 
b etw een stu dies. T he next  important step w ill b e 
b ring ing  these potential b iomarke rs and b iomarke r 
profiles to the clinical arena.
III. T ARG eT eD  T H eRA P Ies In RCC 
T he increased u nderstanding  of  the f u ndamental 
disease b iolog y of  R C C  has b een translated into 
the deve lopment of  therapies w ith inhib itory activi ty 
against the implicated pathways, particularly the 
V EG F  and mT O R  pathw ays.  A nu mb er of  tyr osine 
ki nase inhib itors (T K I ) have  now  b een reg istered 
for treatment of metastatic RCC (mRCC) (sunitinib, 
sorafenib, pazopanib) and more TKI (e.g. axitinib, 
tivo za nib ) are b eing  deve loped. T he rapid and 
simu ltaneou s emerg ence of  seve ral active  
compou nds has f ar ou tpaced the ab ility to critically 
u nderstand precise mechanisms of  response and 
resistance [ 7 7 ] ( fi g u r e  2 ). 
Surprisingly, the TKI were clinically implemented 
w ith ve ry f ew  preceding  pre- clinical stu dies. F or 
example, the cross-reactivity of TKI with non-target 
(non-VEGF-receptor) TK [78] was established after 
clinical implementation and preclinical stu dies in 
va riou s animal models demonstrated stab iliza tion 
or reg ression of  xe nog raf ted tu mors (mostly in 
non- R C C  models). T he rationale to stu dy this new  
categ ory of  dru g s in R C C  patients w as b ased on 
theoretical considerations that these T K I  attacke d 
pathways essential in RCC biology and, therefore, 
mig ht b e appropriate new  dru g s f or R C C  therapy . 
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Indeed, the effects of TKI in RCC patients are 
impressive, with obMective response rates as high as 
45 (reviewed by e.g., Rini et al.  [79]), but treatment 
is often accompanied by many side effects requiring 
dose redu ction or cessation of  treatment. 
T K I  treatment of  R C C  patients leads to a massive  
destru ction of  the tu mor va scu latu re w ith concomitant 
tu mor necrosis. W hether R C C  cells themselve s are 
targeted remains uncertain [80]. At pharmacological 
releva nt doses no ef f ect on tu mor cells w as 
observed[80] and there is evidence that tumor co-
option occurs, i.e., tumor growth along larger mature 
vessels, permitting tumors to escape TKI treatment. 
Additionally, resistance to existing VEGF blocking 
agents may include upregulation of HIF- and/or non-
HIF-mediated angiogenic proteins or inadequate 
targ et inhib ition. mT O R  therapy resistance may 
invo lve  a compensatory increase in u pstream 
elements leading  to H I F  produ ction [ 7 7 ] . 
Obviously, predictive biomarkers for response to 
TKI in mRCC patients are urgently needed, and 
some have  b een describ ed. Seru m f rom patients 
w ith clinical response or prog ression w as screened 
b y cyt oki ne arrays to discove r that T N F - alpha and 
MMP-9 levels remained low in responders [81]. 
Additionally, high levels of these proteins in the serum 
correlated w ith decreased ove rall su rvi va l. I n another 
study, low serum levels of sVEGFR-3 and VEGF-C 
corresponded w ith long er prog ression f ree su rvi va l 
(PF S) and ob j ective  response rate in b eva cizu mab -
Figure 2:  In conditions of normoxia and normal von Hippel Lindau (VHL) gene function, VHL protein is 
the substrate recognition component of an E3 ubiquitin ligase complex that targets hypoxia-inducible 
factor alpha (HIFα) for proteolysis. In cellular hypoxia or with an inactivated VHL gene, the VHL protein-HIF 
interaction is disrupted, leading to stabilization/accumulation of HIF transcription factors. HIF accumulation 
can also result from activation of mammalian target of rapamycin (mTOR) downstream of cellular stimuli 
and the PI3-K/Akt pathway. mTOR phosphorylates and activates p70S6K leading to enhanced translation 
of certain proteins including HIF. Activated HIF translocates into the nucleus and leads to transcription 
of a large repertoire of hypoxia-inducible genes including vascular endothelial growth factor (VEGF) and 
platelet derived growth factor (PDGF). These ligands bind to their cognate receptors present on the surface 
of endothelial cells, leading to cell migration, proliferation and permeability. Sites of action of targeted 
therapies are illustrated. Temsirolimus and everolimus bind to FK506-binding protein (FKBP), and the 
resultant protein–drug complex inhibits the kinase activity of the mTOR complex 1 (mTORC1). Bevacizumab 
is a VEGF ligand-binding antibody. Sunitinib, sorafenib, axitinib and pazopanib are small molecule inhibitors 
of multiple tyrosine kinase receptors including VEGF-R and PDGFR (Reprinted with permission. © 2008 
American Society of Clinical Oncology. Rini BI: Metastatic renal cell carcinoma: many treatment options, one 
patient. J Clin Oncol 2009;27:3225-34.) 
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refractory mRCC [82]. A third study suggested that 
large changes in serum VEGF, sVEGFR-2 and 
sV EG F R - 3 leve ls corresponded w ith tu mor response 
[83], and a fourth study found a correlation between 
fold-increase of serum VEGF and clinical benefit 
[84]. All of these potential predictive biomarkers 
require external validation in larger sample sizes, 
b u t su g g est that seru m may prove  to contain cog ent 
marke rs of  su rvi va l and response.
IV. RCC A nD  T H e IM M une sY sT eM
T here is increasing  evi dence that T K I  treatment leads 
to alterations of  the immu ne statu s of  R C C  patients 
[85;86]. Sunitinib can reverse myeloid-derived 
suppressor cell induced immune suppression, but 
other stu dies indicate that Su nitinib  can inhib it the 
prolif eration of  primary hu man T  cells f rom normal 
healthy vo lu nteers as w ell as f rom R C C  patients 
[87]. Moreover, sunitinib treatment appears to 
reve rse T h1 su ppression and impairs N K  f u nction. 
Similarly, sorafenib treatment impairs NK activity 
and cytotoxicity at pharmacological levels [85]. 
Also, sorafenib treatment leads to a decrease of 
T reg  in primary lesions and T reg  leve ls decrease to 
normal leve ls af ter soraf enib  treatment. W hether the 
immu ne component is important and mig ht b e u sed 
to ou r adva ntag e in desig ning  comb ination therapies 
is an uncharted field [86].
I t is important to realize  that R C C  tu mors deve lop in 
immu ne competent hosts and that these tu mors have  
escaped f rom immu ne su rve illance and immu ne 
editing  leading  to tu mor cells that are resistant to 
immu ne- syst em mediated destru ction ( fi g u r e  3 )  
[88]. Nevertheless, to date, immunotherapy is the 
only treatment that can consistently indu ce du rab le 
complete clinical responses in mRCC [89].
Seve ral stu dies have  demonstrated the ab ility of  
tumor infiltrating lymphocytes (TIL) to induce tumor 
response in mR C C  w ith ob j ective  response rates 
between 0 and 25 , with concomitant infusion of IL-2 
[90-95]. At UCLA, patients with largely advanced and 
metastatic disease received a combination of TIL/
CD8 and IL-2. Overall, 9.1  of patients achieved 
CR while 25.5 had a PR showing the potential 
of TIL in mRCC [94]. Taken together these studies 
demonstrated the need of  u sing  hig hly selective  
and specific activation methods of effector cells in 
order to achieve  a meaning f u l antitu mor immu ne 
response. Unlike melanoma, where specific T-cell 
clones against well-defined tumor epitopes can be 
frequently generated, T-cell clones that specifically 
recog nize  ki dney cancer tu mor antig ens are hard 
to g enerate. T he proof  of  concept of  isolating  these 
clones and su ccessf u lly treat patients w ith mR C C  
has how eve r b een w ell estab lished. O n the other 
hand, given the in vitro work needed to isolate TIL, 
this approach still needs to prove  that it indu ces 
b ett r clinical responses than H D - I L 2 alone. 
Side stu dies of  clinical trials w ith dendritic cells 
loaded with cell lysates, peptides, or RNA or Treg 
depletion have demonstrated the induction of specific 
T cell responses, but no clear correlation between 
clinical benefit and the occurrence of a immune 
reaction was found [96;97]. There is evidence that 
va riou s f actor hamper an anti- tu mor response:  
defective CD8 signaling, a Th2-bias, and elevated 
leve ls of  g ang liosides f rom T  cells are associated 
with T cell dysfunction[98;99]. Basic research aimed 
at u nderstanding  the relation b etw een R C C  and 
immu ne cells have  reve aled an increasing ly complex 
pictu re w ith many playe rs. C ross- talk b etw een R C C  
and dendritic cells (DC), Treg, CD4, CD8, NK-
cells, ȖįT cells, NK-like T cells, and Myeloid Derived 
Suppressor Cells, have been described[100]. 
T he plasticity of  cells f rom the immu ne syst em is 
ext raordinary and the tu mor milieu  plays a pivo tal 
role and can greatly inÀuence the outcome. 
In recent studies, efforts were poised at gene-
modified T-cells [101] and multimodality immune-
based strategies [102]. Gene-modified T cells in 
melanoma has show n interesting  resu lts w ith tw o 
CR  [103]. For RCC, infusion of gene-modified T cells 
with CAI; specificity lead to liver toxicity, probably 
du e to destru ction of  b ile epithelial cells that also 
exp ress C AI X  [ 10 1] . Althou g h this demonstrated that 
the gene-modified did exert the desired specificity, 
the ob serve d toxi city also hig hlig hts the potential 
prob lems of  this approach:  ext raordinary tu mor 
specificity appears to be of utmost importance. 
I n the mu lti- modality immu ne- b ased strateg y 
the CA9 and GMCSF genes were inserted in an 
adenovi ru s g enome to inf ect D C  w hich allow ed the 
expression of the GMCSF/CA9 fusion protein [102]. 
O ve rexp ression of  the f u sion protein in D C  throu g h 
adenoviral infection CA9 specific T cells could be 
generated with toxicity against RCC. Hence, this 
new  strateg y comb ines many immu notherapy 
approaches:  1) the immu nostimu latory ef f ects of  
cyt oki nes;  2) the va ccine capab ilities of  D C  and;  3) 
the specific antitumor activity generated by tumor 
antigen gene delivery in APC. Indeed, the CA9-
GMCSF/DC based vaccine is an example of the 
new  mu ltimodality immu ne- b ased strateg ies that 
may enhance the w ell- estab lished potentials of  
immu notherapy in R C C .
T he ef f ective ness of  tu mor va ccines has b een show n 
in many animal models. However, translation to the 
clinic has proven difficult, possibly because in these 
model syst ems natu rally occu rring  tu mors have  not 
been studied, thereby avoiding tumor surveillance and 
tumor editing. Thus, the concept is tested in immune 
competent hosts that are va ccinated w ith peptides 
or tu mor homog enates and challeng ed w ith vi ab le 
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tumor cells or, alternatively, vaccination strategies 
are tested in animals w ith estab lished tu mors. I nitial 
tu mor va ccines w ere b ased on total tu mor cell 
lys ates that w ere inj ected to the patients (au tolog ou s 
tumor cell vaccines). However, new strategies using 
genetically modified tumor cells, antigen presenting 
cells (APC) or tumor specific peptides have been 
developed to increase the specificity of the response. 
T w o phase- I I I  clinical trials that have  u sed au tolog ou s 
cell lysa te or peptides to preve nt recu rrence in hig h-
risk RCC patients have been published [104;105]. 
Jocham et al. have reported a statistically significant 
increase in 5-year PFS (77.4 vs 67.8, p 0.0204) 
f or the v accine g rou p in hig h- risk non- metastatic 
RCC patients. More recently, Wood et al. published 
a similar stu dy in hig h- risk non- metastatic patients 
u sing  heat shock protein derive d peptide va ccines 
and did not ob serve  a statistical dif f erence in PF S 
(p 0.51). However, secondary analysis did show 
an almost statistically significant PFS survival when 
only stage I and II patients where included (p 0.056). 
Therefore, vaccine approaches show great promise 
in preve nting  recu rrence af ter nephrectomy b u t the 
subgroups of patients that would beneficiate from 
su ch therapy still need to b e determined. Animal 
models in w hich the natu ral history of  hu man R C C  
can b e replicated w ill b e of  g reat va lu e to test this 
concept more rig orou sly .  
V. G eneT IC fACT oRs A nD  RCC
Epidemiological studies have conclusively identified 
three risk f actors f or the deve lopment of  R C C :  
hypertension, obesity and smoking [106-108]. 
Furthermore, there is evidence that genetic factors 
inÀuence susceptibility to RCC; for instance, the 
lif e- time risk increases approxi mately tw o- f old f or 
those with a first-degree relative with RCC [109]. 
Thus far, candidate gene studies have not yielded 
notab le candidate g enes. I n a recent g enome- w ide 
association stu dy (G W AS) of  R C C  three su sceptib ility 
Figure 3: Extrinsic tumor suppression by the immune system. Transformed cells (in this example kidney 
cells with mutated VHL) escaping intrinsic control are subjected to extrinsic tumor suppressor mechanisms 
that detect and eliminate developing tumors before they become clinically apparent. This is known as the 
elimination phase of a broader process that has been termed cancer immunoediting. Cancer immunoediting is 
now considered a process composed of 3 phases: elimination, or cancer immune surveillance; equilibrium, a 
phase of tumor dormancy where tumor cells and immunity enter into a dynamic equilibrium that keeps tumor 
expansion in check; and escape, where tumor cells emerge that either display reduced immunogenicities 
or engage a large number of possible immunosuppressive mechanisms to attenuate antitumor immune 
responses leading to the appearance of progressively growing tumors (Figure adapted from Swann JB, 
Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46. Reprinted with permission).
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loci on chromosomes 2p21 (EPAS1), 11q13.3 and 
12q24.31 (SCARB1) were identified (Purdue et al, 
submitted). The findings from the GWAS provided 
further evidence that EPAS1 (HIF2α) is a key gene 
in RCC development, but additional studies are 
needed to identify the functionally relevant common 
variants associated with increased risk.
Up to now little attention has been paid to inter-ethnic 
variability or individual differences, whereas this is 
an important aspect in the current TKI era. Patients 
of afro-american descent have higher incidence 
rates and lower survival rates compared to all other 
races, also when diagnosed with localized disease. 
In contrast, Asian/Pacific Islander patients have 
lower incidence rates and higher survival rates than 
all the other ethnicities [110]. Furthermore, response 
to treatment and frequency of severe toxicity is 
related to ethnic origin, most likely due to different 
pharmacokinetics and not the genetic nature of the 
disease. Sunitinib, sorafenib and pazopanib have 
been associated with significant toxicity profiles 
which vary widely. Higher toxicities during cytotoxic 
chemotherapy have been reported in patients 
enrolled Japanese trials compared to patients in 
American or European trials [111]. Ethnic differences 
in hematological toxicity have been attributed to the 
varying activities of drug –metabolizing enzymes 
and transporters that are mainly associated with 
polymorphisms in the promoter and coding regions 
of these enzymes [111]. In a phase II study assessing 
the efficacy and safety of sunitinib in Japanese 
patients, the incidence of hematological adverse 
events was numerically higher than those previously 
reported in western trials, however the AUC values 
for sunitinib were similar in both groups [112].
In the only pharmacogenetic study published until 
now, 31 single nucleotide polymorphisms in 12 can-
didate genes, together with several non-genetic vari-
ants, were analyzed for a possible association with 
toxicity [113]. Encouragingly, particular haplotypes 
(most notably by polymorphisms in CYP1A1) could 
be correlated to sunitinib-related toxicity. Because 
race-related differences in the frequency distribution 
of four genetic polymorphisms in the CYP1A1 P450 
enzyme genes have been identified between Japa-
nese and Caucasian populations, this may partly ex-
plain the inter-ethnic differences observed [114].
 VI. ConClusIons
In the last decade, great strides have been made 
in the understanding of molecular mechanisms 
underlying renal cell carcinoma patients. The 
state-of-the-art has clearly led this field to the 
enviable position of having a range of molecularly 
targeted therapies. Nevertheless, despite the 
clear improvement in the therapeutic options for 
mRCC patients, therapies targeting the tumor cells 
themselves are highly desirable. Better models, 
closer resembling the natural course of renal cancer 
are needed. It is foreseen that through integration 
of various high-throughput platforms personalized 
cancer treatment for renal cell carcinoma patients is 
possible. There are further improvements expected 
on the horizon: recent effort have made progress 
toward using formalin-fixed paraffin-embedded 
tissues for molecular analyses (including DNA 
and RNA recovery), which will permit studies on 
enormous archives of existing specimens [115] 
including metastatic lesions, a hitherto understudied 
area; mature profiles of protein and nucleic acid 
biomarkers will help us to define the spectrum of 
tumors that lie under the umbrella of ccRCC; and 
a future unmapped territory of genetic mutations to 
explore that may provide more tools and answers 
to the questions we ask. There is great hope for the 
future of renal cell carcinoma treatment, and it will be 
exciting to see what new advances will be made in 
the decade to come. 
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I. H IsT oRICA l B A CK G RounD
T he microscopic characterisation of  R enal C ell 
C arcinoma (R C C ) started in the mid- 19th centu ry w ith 
the controve rsy arou sed b y G raw itz’ s hyp othesis. 
I n 18 8 3 G raw itz stated that “ a l ve o l a r ” (clear cell) 
tu mou rs, previ ou sly considered lipomas, w ere 
orig inated in the neoplastic transf ormation of  adrenal 
cortical residu es into renal cortical. O ne ye ar later he 
confirmed his theory when he found ectopic adrenal 
cortex in the renal cortex [ 1] , T his theory w as readily 
opposed b y Su dek,  w ho considered the renal tu b u lar 
orig in [ 2] . T he controve rsy b etw een su pporters 
and detractors of  the G raw itz theory w ent on f or 
decades. T he term Hyp er n ep h r o ma w as introdu ced 
in 19 0 9 , and made ref erence to its adrenal orig in [ 3] . 
Ev en thou g h the su pport to the su pposedly adrenal 
origin started to grow weaker, and finally Oberling et 
al.’ s u ltrastru ctu ral stu dies [ 4 ]  pu t a f u ll stop to the 
arg u ment w hen they demonstrated the tu b u lar orig in 
of  renal carcinoma.
At this moment the international classifications 
unified all histological types under the common 
denomination of  renal adenocarcinoma;  this cou ld 
b e a clear cell or a g ranu lar cell carcinoma, its 
architectu re cou ld b e tu b u lar, papillary or cyst ic, and 
its appearance w as rarely sarcomatoid [ 5 ] .
O ne of  the maj or adva nces w as T hoenes et 
al.’ s description of  the ch r o mo p h o b e r en a l  ce l l  
ca r ci n o ma [ 6 ] , morpholog ically dif f erent f rom the 
clear cell carcinoma and prob ab ly orig inated in the 
intercalated cells of  the distal nephron [ 7 ] . F rom this 
description (initially not accepted b y the international 
classifications), the possibility of determining 
dif f erent orig ins of  the histolog ical su b typ es started 
to b e searched w ith monoclonal antib odies [ 8 ] ;  
u nf ortu nately , f or the ove rlapping  of  the marke rs it 
w as not possib le to dif f erentiate g rou ps, so no ki nd 
of modification of the established classification was 
finally determined.
I t w as only w hen K ova cs’  initial chromosome stu dies 
[9], subsequently redefined by the Heidelberg 
classification [10], were introduced that the renal 
cancer microscopic su b typ es w ere take n into accou nt 
again, as a correspondence was confirmed between 
g enetic ab normalities and microscopic phenotyp e.
II. fRoM  T H e ClA ssICA l T o 2 0 0 4  
W H o RCC ClA ssIfICA T Ion
The classifications can be different depending on 
their ob j ective  and the dif f erent w ays of  thinki ng  
thou g ht the time. T he mechanical model of  disease 
and the limited therapeu tic modalities (practically 
only surgery) gave for a long time a classification with 
a f ew  histolog ical su b typ es. W ith the introdu ction of  
the new  therapies and the stu dy of  the f amilial R C C  
[ 11]  some molecu lar pathw ays are incorporate to the 
R C C . F or all of  these considerations emerg es the 
latest WHO¶s 2004 classification [12] that combines 
the morpholog ical and g enetic characteristics and 
starts to recog nise some va riations w ith evi dences 
of  dif f erent immu nophenotyp e or molecu lar chang es 
w ith clinical implications.
The WHO¶s 2004 classification ( T a b l e 1 ) make s a 
clear distinction b etw een certain tu mou r su b typ es 
avi ng  b etter prog nosis, and others that do not. T he 
dif f erences reg arding  prog nosis of  the most u su al 
forms is statistically significant at the univariant 
stu dies [ 13, 14 ] , b u t it has no independent statistical 
significance in some other studies [15]. In spite of 
this, some cell su b typ es do seem to b e related to 
dif f erent carcinog enesis [ 16 ] , and their response to 
f u u re therapies may b e dif f erent too [ 17 ] . 
50
III. H eReD IT ARY  A nD  fAM IlIA l RCC
Each tu mou r typ e presents a special histolog ical 
spectru m of  phenotyp es w hich is accompanied b y 
the exp ression of  a certain spectru m of  antig ens 
that can b e detected immu nohistolog ically (among  
others f or dif f erential diag nostic pu rposes). 
N early each renal cell tu mou r typ e occu rs in a 
sporadic or in a hereditary f orm [ 18 ] . A su rprising  
nu mb er of  hereditary syn dromes predisposes to 
the deve lopment of  renal cell carcinoma. W ithin 
the last ye ars 7  renal cancer syn dromes have  b een 
characterize d. F ive  of  the predisposing  g enes have  
meanwhile been identified: VHL, MET, FH, BHD, 
and HRPT2 ( T a b l e  2 ). 
VHL disease is the most frequent familial renal 
cancer syn drome and is associated w ith clear cell 
renal carcinoma and mu lti- org an neoplasia, escorted 
by mutations in the VHL gene and loss of the wild-
type VHL-allele. The von Hippel-Lindau syndrome is 
estimated to occur at rates of 1:36.000 to 1:45.500 
population. The typical renal manifestation of VHL are 
kidney cysts and renal clear cell carcinomas. Multiple 
ki dney tu mors of  other histolog ical typ es ru le ou t the 
diagnosis of VHL syndrome. Histological examination 
of macroscopical inconspicous renal tissue from VHL-
patients may reve al seve ral hu ndred independent 
tu mors and cyst s. T he mean ag e of  manif estation is 
37  ye ars ve rsu s 6 1 ye ars f or sporadic clear cell renal 
carcinomas, w ith an onset ag e of  16  to 6 7  ye ars. 
Metastatic RCC is the leading cause of death from 
VHL. The median life expectancy of VHL-patients 
was 49 years. In order to detect VHL-associated 
tu mors in time, analysi s of  g erm line mu tations of  the 
VHL-gene have been recommended in every patient 
w ith retinal or C N S hemang iob lastoma, particu larly 
of  those in yo u ng er ag e and w ith mu ltiple lesions. 
Germ line mutations of the VHL-gene are spread 
all over the 3 exons. Missense-mutations are most 
common, b u t nonsense- mu tations microdeletions/
insertions, splice mu tations and larg e deletions 
also occu r. T he spectru m of  clinical manif estations 
of VHL reÀects the type of germ line mutations. 
Phenotyp es are b ased on the ab sence (typ e 1) or 
presence (type 2) of pheochromocytoma. VHL type 
2 is u su ally associated w ith missense- mu tations and 
su b divi ded on the presence (typ e 2a) or ab sence 
(2b ) of  renal cell carcinoma. I n contrast to loss 
of functions variance in VHL type 1, mutations 
predisposing to pheochromocytoma (VHL type 1) 
are mainly of  the missance typ e predicted to g ive  
rise to conformationally change of pVHL. In addition, 
VHL type 2c has been used for patients with only 
pheochromocyt oma;  how eve r seve ral ye ars 
later some of these cases developed other VHL 
manif estations. 
Patients w ith hereditary papillary renal carcinoma 
(HPRC) have a germline-activating mutation in the 
MET-proto-oncogene which can cause renal cancers 
w ith papillary typ e- 1 histolog y . Papillary typ e- 2 renal 
carcinomas and u terine smooth- mu scle tu mors are 
associated w ith hereditary leiomyo matosis and renal 
cell cancer syndromes (HLRCC), which is caused by 
g ermline loss- of - f u nction mu tations in the F u marate-
Hydratase (FH) gene. The hyperparathyreoidism-
Maw tumor (HPT-JT) syndrome is associated with 
parathyroid adenomas, fibro-myalgious tumors 
of  the j aw  and renal tu mors. T his syn drome is 
caused by germline mutations in the HRPT2. The 
Birt-Hogg-Dubp syndrome (BHD) is associated 
w ith an increased risk f or renal cancers of  va riou s 
histolog ical typ es, su ch as chromophob e R C C  and 
oncocyt ic hyb rid tu mors. 
With respect to these findings the cytogenetic 
b ackg rou nd of  renal carcinog enesis b ecame more 
important as qu estions of  an adenoma /  carcinoma 
sequ ence and initiation steps and tu mou r prog ression 
w ere analyze d. I t shou ld b e noted that this research 
is still g oing  on and is completed b y new  molecu lar 
g enetic resu lts.
B ased on the kn ow ledg e of  these dif f erent cyt og enetic 
pathw ays there w as an intensive  research f or 
molecu lar chang es that w ere associated w ith these 
chromosomal aberrations. This finally led to some 
important tu mou r su ppressor g enes like  the vo n 
Hippel-Lindau gene in clear cell carcinoma etc and 
oncog enes that are invo lve d in cell cycl e reg u lation 
and dif f erentiation. 
Between 24-45 of VHL patients develop clear 
cell renal cell carcinoma (ccR C C ). I nactiva ting  
germline mutations of the VHL gene represents the 
g enetic hallmark of  this syn drome and have  b een 
demonstrated in almost all VHL patients. Sporadic 
clear cell R C C  (the most f requ ent su b typ e of  sporadic 
renal cancer [ 18 ]  is characterize d b y inactiva tion of  
the VHL gene by deletion, mutation or promoter 
hyp ermethyl ation in ab ou t 7 0 %  of  the tu mors. 
The functions of the VHL protein (pVHL) have been 
extensively studied in the last 15 years. The VHL 
protein (pVHL) is implicated in cell-cycle control 
and g ene reg u lation, and requ ires transcription-
dependent nuclear-cytoplasmic trafficking for its 
T abl e 1: W H O  H I ST O L O G I CA L  CL A SSI FI CA T I O N  O F 
RCC
C lear cell renal cell carcinoma
Multilocular clear cell renal cell carcinoma
Papillary renal cell carcinoma
C hromophob e renal cell carcinoma
C arcinoma of  the collecting  du cts of  B ellini
R enal medu llary carcinoma
X p11 translocation carcinomas
C arcinoma associated w ith neu rob lastoma
Mucinous tubular and spindle cell carcinoma
Renal cell carcinoma, unclassified
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function. There are two biologically active VHL 
protein isoforms: pVHL[30] and pVHL[19]. The 
distribution of VHL protein isoforms varies in the 
nu clear and cyt oplasmic compartments of  renal 
tumors and alteration of subcellular pVHL trafficking 
is of  potential releva nce f or the b iolog ical b ehavi or of  
clear- cell R C C  [ 19 , 20 ] .
The pVHL functions as a recognition subunit in a 
E3 u b iqu itin protein lig ase complex , targ eting  the 
h y p o xi a - i n d u ci b l e tr a n scr i p ti o n  f a ct o r  a (HIF-a) for 
u b iqu itin mediated deg radation in the presence of  
oxyg en [ 21] . U nder normoxi c conditions, hyp oxi a-
inducible factor-1 (HIF-1) is hydroxylated (-OH) on 
tw o conserve d proline residu es b y a f amily of  prolyl  
hyd roxyl ases at its oxyg en- dependent deg radation 
domain. T his hyd roxyl ation provi des a su b strate-
recognition site for the von Hippel–Lindau (VHL) E3 
u b iqu itin lig ase complex,  w hich contains elong ins C  
and B, cullin-2 (CUL2) and RB;1. Polyubiquitylation 
of HIF1- by the VHL complex leads to its proteasomal 
degradation by the 26S proteasome. Hypoxic 
conditions block hydroxylation, allowing HIF-1 
s y n d r o m e c h r . g e n e p r o t e i n t u m o u r  t y p ee x t r a r e n a l  m a n i f e s t a t i o n s
D e r m i s ot h e r
o r g a n s
von Hippel-
Lindau
3p25 V H L pVHL mu ltiple, b ilateral
clearcell R C C ,
renal cys ts
-
hemang iob lastoma of
retina /  cns;
phaeochromocyt oma;
pancreatic- / renal cyst s;  
neu roendocrine tu mou rs;
epidyd imal /  parametrial 
cyst s;  
tu mou rs of  the inner ear
h e r e d i t a r y  
papillary
R C C
7 p31 c- M E THGF-R mu ltiple, b ilateral
papillary R C C   
( typ e 1 )
- -
HLRC 1q4 2 F H FH papillary R C C
( non typ e 1 )
leiomyo ma u terine leiomyo ma /
leiomyo sarcoma
f amilial
papillary thyr oid
carcinoma
1q21 ? ? papillary R C C ,
oncocyt omas
       
     
         -
papillary thyr oid
carcinoma
hyp erpara-
thyroidism –
j aw  tu mou r
( HP-JT ) 
1q25 HR P T 2 epithelial-
stromal 
mixe d tu mou rs, 
papillary R C C
    
         -   
tu mou rs of  the parathyr oi--
dea;
fibro-osseous Maw tumours 
Birt-Hogg-Dubp 17 p11 B HD F ollicu linmu ltiple chromo-
phob e R C C , onco-
cyt ic adenoma,
papillary R C C
Facial fibrofolli-
cu loma
pu lmonal cyst s;
spontaneou s
pneu mothorax
tu b erou s
sclerosis
  9 q34
16 p13
T S C  1
T S C  2
Hamartin
T u b erin
mu ltiple, b ilateral
ang iomyo lipomas,
lym phang ioleio-
myo matosis;
rare clear cell R C C
ang io-
fibroma;
peau  chag rin;
su b u ng u al
fibroma
cardiac rhab domyo ma;
adenomatou s small
intestine polyp s;
pu lmonal /  renal cyst s;
cortical tu b er;  su b epen--
dym al g iant cell astrocy--
tomas
constitu -
tional
transloca- tion 
chr. 3
3p13-
14
? ? mu ltiple, b ilateral
clear cell R C C -
-
T abl e 2 :  H ereditary renal  cel l  tumours 
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su b u nits to accu mu late and activa te transcription 
of  hyp oxi a- responsive  g enes. VHL inactiva tion 
—  as occu rs in renal cells f rom patients w ith a 
g ermline VHL mu tation and loss of  the w ild- typ e 
allele — mimics the hyp oxi c response b y preve nting  
degradation of HIF-1 subunits. Loss of VHL function 
causes accumulation of HIF-1 subunits in the 
cy toplasm and their translocation to the nu cleu s. 
HIF-1 dimerizes with HIF-1 and is coactivated by 
CBP/p300. HIF binds to hypoxia response elements 
(HRE) in gene promotors, thereby activating 
transcription of  g enes u preg u lated in clear- cell 
renal tu mou rs, inclu ding  va scu lar endothelial g row th 
factor (VEGF), erythropoietin and platelet-derived 
g row th f actor. C lear cell R C C  is characterize d b y 
rich neo- va scu lariza tion and an of ten prominent 
va scu lar netw ork arou nd tu mor cells, su g g esting  
the elab oration of  tu mor ang iog enesis f actors b y 
neoplastic cells. I t has b een demonstrated that 
strong  va scu lariza tion in ccR C C  is correlated w ith 
VEGF expression, suggesting that this growth factor 
plays a role in the va scu lar b iolog y  of  ccR C C  tu mors 
as a consequence of VHL inactivation [22]. VEGF 
stimu lates endothelial cell prolif eration i n  vi tr o and 
has also an ang iog enic activi ty i n  vi vo .  
Recently, it was shown that loss of VHL function 
results in strongly enhanced transcription of HIF-
a indu cib le g enes, especially in u p- reg u lation of  
C X C R 4  [ 23] . T heref ore, the vo n  Hi p p el - Li n d a u 
(VHL) tumor suppressor gene product is one of 
the maj or reg u lators of  C X C R 4  exp ression and 
increased C X C R 4  exp ression leve ls are most like ly 
a consequence of impaired VHL function in ccRCC. 
Strong  C X C R 4  exp ression is associated w ith poor 
prog nosis of  R C C . T hu s, b y exp ressing  C X C R 4 , 
tu mors ob vi ou sly  aqu ire properties, w hich enab le 
them to inva de tissu e b arriers, mig rate to secondary 
org ans, and f orm metastases. Althou g h C X C R 4 /
C;CL12 expression patterns may explain selection 
of specific organs for the formation of metastasis, 
the exa ct molecu lar mechanisms b y w hich the 
C;CR4/C;CL12 axis promotes tumor invasion are 
still u nclear.
Other pVHL functions include fibronectin matrix 
assemb ly , p5 3 stab iliza tion and transactiva tion 
[24, 25].  In addition, pVHL has the ability to bind 
and stab ilize  microtu b u les b y protecting  them f rom 
depolym eriza tion, w hich is a prerequ isite f or ciliu m 
f ormation [ 26 ] . I n f act, tw o previ ou s i n  vi tr o stu dies 
showed that by re-expressing pVHL in VHL null 
ccRCC cell lines pVHL regulates the formation of 
primary cilia [ 27 , 28 ] .  T hese ob serva tions strong ly 
suggest that loss of VHL function in renal epithelial 
cells leads to deg eneration of  primary cilia, w hich 
represents a critical step tow ards cyst  f ormation and 
ccRCC development in VHL patients. Interestingly, 
renal cyst s are also present in ab ou t 6 0 %  of  
individuals suffering from the von Hippel-Lindau 
(VHL) disease. One might hypothesize that cyst 
f rmation is one of the first visible renal alterations in 
VHL-caused tumor formation. 
The elucidation of the different pVHL functions is 
the b asis f or u nderstanding  the nove l therapeu tic 
strategies for RCC patients [29]. Targeting the VHL 
pathw ay f or therapeu tic interve ntion can theoretically 
occur at many sites. VHL protein function could be 
replaced, restoring  b inding  to hyp oxi a- indu cib le 
factor-1 (HIF-1) and allowing its proteasomal 
degradation. Further, the activity of HIF-1 could be a 
targ et f or inhib ition. F inally , molecu les u preg u lated b y 
HIF-1 (e.g. C;CR4) also provide specific targets for 
potential downstream inhibition of the VHL pathway. 
IV. CleA R Cell RenA l Cell 
CA RCInoM A
T u mou rs are u su ally sing le in the sporadic cases, w ith 
4 %  mu ltiplicity and 3%  b ilaterality . T he tu mou r is w ell 
delimited by pseudocapsule of fibrous tissue that is 
the consequ ence of  compression of  the su rrou nding  
tissues. Due to cytoplasm lipids accumulation the 
section surface is yellow. Haemorrhagic areas are 
f requ ent f or the larg e va scu lar stroma. O ccasionally 
there are scar areas and some of  them eve n inclu de 
calcification. Necrosis is associated with more 
ag g ressive  neoplasias.
T he cyst ic appearance it sometimes adopts may b e 
du e to necrosis and liqu ef action (pseu do- cyst s) or 
b ecau se it is f ormed b y g enu ine neoplastic cyst s .
Among  the cyst ic renal cell carcinomas there are 
cases of  clear cell renal cell carcinomas w ith a 
w ide cyst ic transf ormation, as w ell as cases w ith 
complete cyst ic appearance that lack  a solid tu moral 
component.
T he latter su b typ e has b een called m u l t i l o c u l a r  
c y s t i c  r e n a l  c e l l  c r c i n o m a  [ 30 ].  T he cyst s’  
w all exh ib it isolated malig nant cells ( fi g . 1 ). 
Macroscopically their appearance may be similar 
to that of  a mu ltilocu lar cyst  (cyst ic nephroma). T he 
exce llent prog nosis in a recent mu lti- institu tional 
stu dy su g g ests the possib ility of  considering  it a low -
malig nant- potential carcinoma [ 31] .
1 . M ICRosCoP Y  
As su g g ested b y its name, this neoplasia consists 
of  clear cyt oplasm cells;  they are clear du e to their 
hig h content of  g lyco g en and lipids that dissolve  in 
the cou rse of  the histolog ic processing . C ells w ith 
a hig her mitochondrial content may b e seen  to 
acqu ire an eosinophilic or g ranu lar appearance ( fi g . 
2 ). T he predominance of  this cell typ e is exce ptional. 
R ou nded or irreg u lar eosinophilic cyt oplasm 
inclu sions are rarely f ou nd. T he nu clei are rou nded 
and their characteristics depend u pon their deg ree of  
dif f erentiation. T he most f requ ent arrang ement f orms 
53
a solid pattern. T u b u lar and occasionally microcyst ic 
patterns can also b e present. Papillary areas are 
ve ry rarely ob serv ed  [ 32] . F ive  percent of  cases are 
of  the spindle cell (sarcomatoid) typ e [ 33] .
2 . IM M unoP H enoT Y P e 
T he cells exp ress more f requ ently low  molecu lar 
weight cytokeratins (CAM 5.2 around 60) than 
hig h molecu lar w eig ht cyt oke ratins (C K 14  in 3.7 % ) 
[34]. Vimentin is expressed in 82.6 [35], CD10 
in 9 4 %  ( fi g . 4 ) and R C C  antib ody in 8 5 %  [ 36 ] . 
Epithelial membrane antigen (EMA) (MUC-1) in 85 
[ 37 ] . G lu tathione S- transf erase α (G ST -α) in 8 2%  
[ 38 ] . F rom adhesion molecu les there is only 5 %  of  
E-cadherin [37] and Kidney-specific cadherin (Ksp-
cadherin) is neg ative  [ 39 ] . Parva lb u min is exp ressed 
in 26 %  and β-Defensin-1 in 13 [35]. Other markers 
su ch as c- ki t, R O N  proto- oncog ene and p5 0 4 S 
– alpha-methylacyl-CoA racemase (AMACR) are 
vi rtu ally neg ative  [ 4 0 , 4 1, 4 2] .
3 . G eneT IC CH A nG es
3p deletion (LOH 3p) is the most typical genetic 
ab normality of  this carcinoma, present in 7 5 .8 %  of  
cases [ 4 3] ,  b u t not excl u sive  to it [ 4 4 ] . T hree g enes 
have  b een located on the short arm of  chromosome 
3 that are prob ab ly invo lve d in renal carcinoma. T he 
su ppressor g ene in 3p25 - 26  (VHL) w hich coincides 
with von Hippel-Lindau disease but is expressed 
in 34 - 5 6 %  of  sporadic carcinomas [ 4 5 ] , and those 
located on 3p14 .2 (potential g ene F HI T ) and on 
3p.12, w hose deletion is more f requ ent that of  the 
f ormer. O ther pu tative  tu mou r su ppressor g enes at 
3p as R A S S F 1 A  and N R C - 1  at 3p12 are reported 
[ 4 6 , 4 7 ] .
LOH 3p interferes with the hypoxia-inducible pathway 
that activates VEGF and PDGF, both of which play 
an essential role in ang iog enesis, g lu cose transport, 
glycolysis, pH control, epithelial proliferation, cell 
mig ration and apoptosis, and can help the hyp oxi c 
adaptation of  the clear cell carcinoma [ 4 8 ] . T heref ore, 
a therapeu tic mu lti- targ eted approach that selective ly 
and simu ltaneou sly b locks these g row th f actors 
represents an attractive  w ay of  treatment [ 4 9 , 5 0 ] .
Fig.  1A  . -  Cystic neopl asms w ith cl ear cel l  in the 
w al l
Fig.  1B . -  Fibrous w al l  w ith cl ear cel l s.
Fig.  2 A . -  Cl ear cel l  renal  cel l  carcinoma Fig.  2 B . -  E osinophil ic cel l s ( high grade)  in cl ear cel l  
renal  cel l  carcinoma
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V. PA P IllARY  RenA l Cell 
CA RCInoM A  M oRP H oloG Y  
CRIT eRIA  foR P A T H oloG ICA l 
D IA G nosIs.
T u mors w ith a diameter u p to 5  millimeters are 
considered adenomas [ 12] . T hey are of ten incidental 
findings and occur in up to 23 of autopsy patients. 
T he larg er tu mors are vi ew ed as carcinomas, 
comprises the 15 %  of  all of  su rg ically remove d 
renal cell neoplasms and its male to f emale ratio is 
2:1[12].
Papillary renal cell neoplasms are g rossly 
characterize d b y a spherical b ou ndary and a b eig e 
to w hite colou r. T hey can exh ib it central necrosis 
resu lting  f rom a poor va scu lar su pply and f requ ent 
hemorrhag es. I n some cases this f eatu re can b e 
so ext ensive  to mimic a cyst  b oth radiolog ically and 
g rossly [ 5 1] .
Papillary renal cell neoplasms are characterize d 
b y  papillary or tu b u lo- papillary architectu re. T he 
epithelial neoplastic cells line a delicate fibrovascular 
core in w hich ag g reg ates of  f oamy macrophag es 
can b e f ou nd. T he core can b e exp anded b y edema. 
I n carcinomas cholesterol cryst als, necrosis and 
haemorrhag e are f requ ently seen and haemosiderin 
g ranu les may b e present in macrophag es, stroma and 
tu mou r cell cyt oplasm. Sarcomatoid dedif f erentiation 
is seen in approxi mately 5 %  of  papillary renal cell 
carcinomas [ 5 1]  
1 . P A T H oloG ICA l suB T Y P es
T w o w ell recog nize d morpholog ical typ es of  papillary 
renal cell carcinomas have been described [52]: 
T yp e 1  tu mou rs have  papillae cove red b y small cells 
w ith scanty cyt oplasm, arrang ed in a sing le laye r on 
the papillary b asement memb rane w ith low  nu clear 
g rade ( fi g . 3 );  T yp e 2  tu mou rs are composed 
b y  cells w ith hig her nu clear g rade, eosinophilic 
cytoplasm and pseudostratified nuclei on papillary 
cores ( fi g . 4 ). T yp e 1 tu mou rs are more f requ ently 
multifocal. Psammoma bodies are common. Longer 
su rvi va ls have  b een describ ed f or typ e 1 papillary 
renal cell carcinoma w hen compared w ith typ e 
2 [ 5 4 ] .  Papillary renal cell carcinomas entirely 
composed b y oncocyt es has b een describ ed  [ 5 4 , 
5 5 , 5 6 , 5 7 , 5 8 ] . T his su b set of  papillary tu mors 
show s clinico- patholog ic f eatu res dif f erent f rom typ e 
1 and typ e 2 papillary renal cell carcinomas and has 
b een proposed to b e ref erred as a third g rou p, b eing  
the ou tcome intermediate b etw een typ e 1 and typ e 2 
[ 5 4 , 5 5 , 5 6 , 5 7 , 5 8 ] .
T here are emerg ing  g rou ps of  papillary renal 
carcinoma show ing  at a cyt olog ic leve l a w ider 
spectru m than that already recog nize d. O ncocyt ic 
papillary renal cell carcinoma are composed of  
papillary structures with delicate fibrovascular stalks 
containing , occasionally , crow ded lipid- laden f oamy 
macrophag es T he papillae are lined b y sing le or, more 
rarely, pseudostratified layers of cells with granular, 
deeply typ ical eosinophilic cyt oplasm w ith distinctive  
cell b order. T he nu clei w ere rou nd w ith f requ ently 
prominent nu cleoli conf orming  to a nu clear g rade 3. 
Solid areas w ith morpholog ical f eatu res ove rlapping  
typ ical renal oncocyt oma are of ten ob serve d [ 5 4 , 5 5 , 
5 6 , 5 7 , 5 8 ] .
Papillary renal cell carcinoma w ith clear cell chang es 
is a neoplasm composed of  papillary stru ctu res 
cove red b y mediu m- size d cells w ith clear cyt oplasm 
made u p 20 %  to 9 0 %  of  the total neoplastic area T he 
tu mor cells show  va riab le deg rees of  cyt oplasmic 
clarity;  of ten, the cyt oplasm has a microve sicu lar or 
finely granular appearance similar to the cytoplasm 
of  f oamy macrophag es that w ere f requ ently present 
w ithin papillary cores and in spaces b etw een the 
papillae. U su ally , the nu clei are positioned centrally 
or b asally , and nu clear g rade is qu ite homog eneou s 
throu g hou t the neoplasms [ 32, 5 9 , 6 0 ] .
Spindle cell areas in papillary renal cell carcinoma 
g enerally sig nif y sarcomatoid chang e and are hig h 
g rade. I t has b een reported that low - g rade spindle 
cell f oci, closely  mimicki ng  mu cinou s tu b u lar 
spindle cell carcinoma can occu r. T hese tu mors are 
predominantly solid, f eatu ring  compact areas of  low -
g rade spindle cells lining  thin, ang u lated tu b u les. 
Mucinous stroma was not appreciated in any case 
[ 6 1] .
2 . IM M unoH IsT oCH eM ICA l feA T uRes
R eaction f or cyt ok eratin 7  w as strong  or moderate in 
4 8  of  6 1 T yp e 1 tu mors, and reaction w as nu ll in 24  
of  30  T yp e 2 orig inally describ ed tu mors [ 5 2] . 
T he neoplastic oncocyt ic cells of  oncocyt ic papillary 
renal cell carcinoma in all cases describ ed, 
exh ib ited strong , dif f u se, and g ranu lar positivi ty f or 
antimitochondrial antigen reaction and for AMACR 
( fi g . 5 ). T u moral cells demonstrated va riab le 
positivi ty f or cyt oke ratins, AE1/ AE3, C K 8 - 18 , C K 7 , 
CK19, EMA and CD10 was positive in 10 cases. 
T here w as dif f u se positivi ty f or vi mentin and some 
cases w ere positive  f or parva lb u min [ 5 4 ] . 
Papillary renal cell carcinoma w ith clear cell chang es 
showed strong immunoreactivity for AMACR, of 
w hich a su b set also exp ress cyt oke ratin 7  su ch as all 
cases of  spindle cell papillary renal cell carcinomas 
reported [ 5 9 ] .
3 . M oleCulA R/ G eneT IC feA T uRes
Papillary renal cell carcinoma is characterize d 
b y trisomy of  chromosomes 3q, 7 , 8 , 12, 16 , 17  
and 20  and loss of  the Y  chromosome [ 6 2] ;  these 
most consistent g enetic ab normalities are present 
in b oth solitary and mu ltif ocal papillary renal cell 
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carcinomas and they occu r early in the evo lu tion of  
this neoplasm[ 6 2]  Some au thors have  su g g ested 
g enetic dif f erences b etw een typ e 1 and typ e 2;  typ e 
1 papillary renal cell carcinoma cases seem to have  
a significantly higher frequency of  allelic imb alance 
on 17 q than typ e 2 cases and typ e 2 cases an hig her 
f requ ency of allelic imb alance on 9 p than typ e 1 
cases [63, 64]. The c-Met proto-oncogene mutation 
on chromosome 7  characterize s hereditary and a 
su b set of  sporadic papillary renal cell carcinomas 
[ 6 5 ] . Patients w ith the hereditary leiomyo matosis and 
renal- cell cancer syn drome are at risk f or cu taneou s 
and u terine leiomyo mas and solitary papillary renal-
cell carcinoma w ith typ e 2 histolog ic f eatu res [ 6 6 ] . 
F u marate hyd ratase g ene, the g ene that cau ses  this 
au tosomal dominant syn drome, encodes f u marate 
hyd ratase, a K reb s- cycl e enzym e [ 6 7 ] .
Among  oncocyt ic papillary R C C s, three or more 
signals were frequently observed in the tumor cells: 
chromosomes 7  (rang e, 3% - 7 4 % ;  30 %  in 7  of  12) 
and 17  (rang e, 6 % - 6 9 % ;  z3 0 %  in 7  of  12). I n 5  
cases, three or more sig nals f or b oth chromosomes 
w ere f ou nd. N o sig nal f or Y  w as ob serve d in 8 0 %  to 
9 0 %  of  nu clei in 3 tu mors of  the 10  males [ 5 4 ] .
Among  14  papillary renal cell carcinoma w ith clear 
cell chang es, most neoplasms exh ib ited g ains of  
chromosome 7 ;  nine show ed g ains of  chromosome 
17  and 4  neoplasms f rom 6  male patients show ed 
loss of  chromosome Y .10 C hromosome 3p deletion 
was detected in 4 cases. FISH analysis from areas 
of  papillary renal cell carcinoma and f rom areas w ith 
clear cell morpholog y in the same tu mor show ed 
similar resu lts [ 5 9 ]
All spindle cell papillary renal carcinomas reported 
show ed trisomy of  chromosome 7 , and 3 of  5  show ed 
trisomy of  chromosome 17  [ 6 1] .
4 . D IffeRenT IA l D IA G nosIs
Papillary renal cell carcinoma is the tu mou r that most 
f requ ently may exh ib it ove rlapping  characters w ith 
other su b typ es of  renal cell carcinoma. C lear cell 
renal carcinoma, w hich is the most f requ ent renal cell 
neoplasms, may show  pseu do- papillary stru ctu res;  
in this context the immunoprofiling characterized by 
the immunoreactivities for AMACR and cytokeratin 
7  and the g ains of  chromosomes 7  and 17  are 
u su ally mandatory to classif y the neoplasms as to b e 
papillary su b typ e. T he solid va riant of  papillary renal 
cell carcinoma may show  ove rlapping  f eatu res w ith 
seve ral neoplasms in particu lar w ith the metanephric 
adenoma w hereas the oncocyt ic v ariant encou nters 
in the dif f erential diag nosis the renal oncocyt oma;  
ag ain the g ains of  b oth chromosomes 7  and 17  are 
present in this papillary su b typ e. 
T he g rou p of  papillary renal cell carcinoma is 
ext remely heterog eneou s in particu lar in the su b set 
of neoplasms classifiable as type 2 probably 
inclu ding  cases of  clear cell renal cell carcinoma w ith 
pseu dopapillary tu b u lo- g landu lar architectu re and 
hig h nu clear g rade, cases of  translocation carcinoma 
and B ellini du ct carcinoma.  
Fig.  3 . -  P apil l ary renal  cel l  carcinoma type I ,  
basophil ic cel l s
Fig.  4 . -  P apil l ary renal  cel l  carcinoma type I I ,  
eosinophil ic cel l s w ith high grade
Fig.  5 . -  A M A CR ex pression in papil l ary renal  cel l  
carcinoma.
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VI.  CH RoM oP H oB e RenA l Cell 
CA RCInoM A
C romophob e renal cell carcinoma (C R C C ), a 
renal cell carcinoma of  low  malig nant potential 
characterize d b y hu g e pale cells w ith prominent cell 
memb ranes, w as initially describ e in nitrosamine-
induced renal tumours in rats. The first cases of 
C R C C  in hu mans w ere reported in 19 8 5 . C R C C  
accou nt f or approxi mately 5  per cent of  su rg ically 
remove d renal epithelial tu mors [ 7 1]  T he median/
mean ag e of  incidence is in the sixt h decade, w ith 
a rang e in ag e of  27  to 8 6  ye ars, and the nu mb er of  
men and women is roughly equal. Mortality is less 
than 10  % . Sporadic and hereditary f orms do exi st.
1 . M A CRosCoP IC AP P eA RA nCe
Depending on size, chromophobe renal cell tumors 
consist of  one or more solid tu mor nodu les w ith a 
slightly lobulated surface. In unfixed conditions 
the cu t su rf ace appears homog eneou sly orang e 
turning beige or sandy after formalin fixation. The 
u nif orm pale cu t su rf ace interspersed w ith a f ew  
hemorrhag es is a ve ry characteristic g ross f eatu re, 
w hile a slig ht b row n colored cu t su rf ace is u su ally 
seldom.
2 . H IsT oP A T H oloG Y
T he b asic chromophob e cell typ e is characterize d 
b y larg e polyg onal cells w ith a transparent slig htly 
reticu lated cyt oplasm f or  nu merou s sometimes inva-
g inated ve sicles, 15 0 - 30 0  nm in diameter resem--
b ling  those of  the intercalated cells typ e b  of  the cor--
tical collecting  du ct,  w ith prominent cell memb rane 
leading  to a plant cell like  appearance ( fi g . 6 ). T he 
periva scu lar cells are of ten enlarg ed. An eosinophilic 
va riant does exi st ( fi g . 7 ), it is pu rely composed of  
intensive ly g ranu lar larg e and small cells w ith promi--
nent cell memb ranes [ 7 0 ] . Sarcomatoid/ spindle cell 
transf ormation does occu r ( fi g . 8 )[ 7 2] . Another di--
ag nostic hallmark is the lack of   cyt oplasmic coloring  
w ith rou tine dye s b u t a dif f u se cyt oplasmic staining  
reaction with HaleCs iron colloid stain ( fi g . 9 ). C hro--
mophob e cells u su ally show  condensed and hyp er--
chromatic sometimes b inu cleated nu clei. I n g eneral, 
the g row th pattern is solid/ compact, sometimes crib--
riform associated with focal calcifications and broad 
fibrotic septae. The so called hybrid tumors share 
histopatholog ical characteristics of  chromophob e 
carcinoma and oncocyt ic adenoma as b oth cell typ es 
are interming led. F u hramn g rading  seems not to b e 
appropiated to g rade chromophob e R C C .
3 . IM M unoP RofIle
I mmu nohistolog y presents the f ollow ing  antig en 
profile: Pan-Cytoceratin , Vimentin  -, EMA  
(diffuse), lectins , Parvalbumin , RCC-antigen -/, 
CD 10 –. CRCC presents significant hypodiploid cell 
clones with Àow cytometry and quantitative image 
analysis of DNA ploidy.
4 .  CY T oG eneT ICs A nD  M oleCulA R 
A lT eRA T Ions
R enal cell carcinomas of  the chromophob e typ e 
are cyt og enetically characterize d b y  a massive  loss 
of  chromosomes, i.e. - 1,- Y ,- 2,- 10 ,- 6 ,- 21,- 13,and -
17. These data are confirmed by FISH- and CGH 
analysi s [ 6 8 , 6 9 ] .
Fig.  6 . -  Chromophobe renal  cel l  carcinoma,  cl ear 
cel l  type
Fig.  7 . -  Chromophobe renal  cel l  carcinoma,  
eosinophil ic type.
Fig.  8 . -  Chromophobe renal  cel l  carcinoma of high 
grade w ith sarcomatoid component.
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C y tog enetic and molecu lar g enetic data on 
chromophob e renal cell carcinoma (R C C ) is limited, 
possib ly du e to their g eneral tendency to g row  
ve ry slow ly in vi tro compared to all other typ e of  
renal tumors. Karyotyping, Àuorescence in situ 
hy b ridiza tion, comparative  g enomic hyb ridiza tion, 
and microsatellite analyse s have  reve aled that 
mu ltiple and nonrandom chromosomal losses, i.e. 
monosomies of  chro mosomes 1, 2, 6 , 10 , 13, 17 , 
21, and the Y  or X  chromosome are pathog nomonic 
f or chromophob e R C C . Additional stru ctu ral 
chromosomal ab errations have  b een describ ed, b u t 
no (partial) loss of  the short arm of  chromosome 3. T he 
massive  chromosomal losses lead to a hyp odiploid 
DNA index (low modal number of chromosomes). 
Endoredu plication/ polyp loidiza tion of  the hyp odiploid 
cells has b een ob serve d. T elomeric associations 
and telomere shortening  hav e also b een ob serv ed. 
F u rthermore, molecu lar analy sis of  this su b ty pe 
has rev ealed g ross alterations of  the mitochondrial 
DNA. Nagy et al. found somatic mitochondrial DNA 
mu tations, althou g h there ex act role remains to b e 
elu cidated.
At the molecu lar leve l, C ontractor et al. show ed an 
association b etw een loss of  chromosome 17  and 
mu tation of  T P 5 3 tu mor su ppressor g ene in 27 %  of  
the chromophob e R C C s. Sü kö sd et al. demonstrated 
loss of heterozygosity (LOH) around the P T E N g ene 
at the 10q23.3 chromosomal region. However, 
deletional or mu tational inactiva tion of  the P T E N /
M M A C 1 g ene cou ld b e excl u ded.
The finding of mito chon drial DNA changes and 
the loss of  Y / X  and chromosome 1 in b oth renal 
oncocyt oma and chromophob e carcinoma mig ht 
indicate prog ression f rom renal oncocyt oma to 
chromophob e renal cell carcinomas the malig nant 
cou nter part of  renal oncocyt oma throu g h additional 
chromosome losses, also exp laining  the occasionally 
malig nant b ehavi or of  renal oncocyt omas. W ith 
respect to hereditary R C C , no f amilies have  b een 
reported w ith memb ers af f ected w ith chromophob e 
renal carcinomas.
F amilial clu stering  is u nkn ow n. T here is an inherited 
cancer syndrome called Bird-Hogg-Dube-Syndrom 
(BHD), which is an autosomal dominant disease 
characterize d b y trichof ollicu lomas, trichodisko mas 
and lung cysts. The BHD-gene is localized on the 
short arm of  chromosome 17 . 
B ru nelli et al stu died a larg e nu mb er of  classic 
and eosinophilic chromophob e R C C s and show ed 
that the eosinophilic va riant of  chromophob e renal 
cell carcinoma and classic chromophob e renal 
cell carcinoma have  similar f requ ency of  losses of  
chromosomes 1, 2, 6 , 10 , and 17 , consistent w ith 
the notion that these tu mors are simply morpholog ic 
va riants of  the same neoplasm.
T he mechanisms of  the ka ryo typ ic chang es du ring  
the deve lopment of  chromophob e R C C  is u nkn ow n, 
b u t the characteristic chromosomal losses are helpf u l 
in estab lishing  an accu rate diag nosis.
5 . M A J oR D IffeRenT IA l D IA G nosIs
•	 R en a l  o n co cyt o ma .  C hromophob e renal cell 
carcinomas, especially the eosinophilic va riant, 
are frequently difficult to distinguish from renal 
oncocyt omas on hematoxyl in and eosin stained 
histolog ic sections. T he distinction is important, as 
chromophob e renal cell carcinoma is a malig nant 
tu mor w hile oncocyt oma is considered to b e a 
b enig n lesion. R eports of  “ malig nant”  or “ metastatic”  
oncocyt omas are postu lated to actu ally represent 
misdiag nosed chromophob e renal cell carcinomas. 
The Hale¶s colloidal iron stain shows a diffuse 
and strong  reticu lar pattern in almost 10 0 %  of  
chromophob e R C C . C hromophob e renal cell 
carcinomas f requ ently show  loss of  chromosomes 
1 (7 0 %  of  classic, 6 7 %  of  eosinophilic), 2 (9 0 %  
classic, 5 6 %  eosinophilic), 6  (8 0 %  classic, 5 6 %  
eosinophilic), 10  (6 0 %  classic, 4 4 %  eosinophilic), 
and 17  (9 0 %  classic, 7 8 %  eosinophilic). 4 4 %  of  
eosinophilic chromophob e renal cell carcinomas 
exhibit loss of all five of these chromosomes. 
G enetic alterations of  oncocyt oma have  not ye t b een 
well characterized. However, renal oncocytomas 
have  b een reported to b ear either rearrang ements 
or translocations invo lvi ng  chromosome 11q13[ 8 6 ]  
or partial or complete losses of  chromosomes 1, 14 , 
and/ or a sex chromosome (Y  or X ). Seve ral g rou ps 
of  inve stig ators have  reported that chromosome 
3p loss is not detectab le in oncocyt oma. B ecau se 
of  the f requ ent association b etw een oncocyt omas 
and chromosome 1p alterations, the loss of  a 
tu mor su ppressor g ene residing  on chromosome 
1p has b een proposed as the earliest g enetic 
eve nt associated w ith the deve lopment of  renal 
oncocyt oma. O ncocyt omas have  also b een show n 
to exh ib it microsatellite instab ilities. Alterations in 
mitochondrial DNA have also been implicated in 
th  deve lopment of  oncocyt omas. I t is notew orthy 
that there are no apparent ove rlapping  g enetic 
alterations shared b y eosinophilic chromophob e 
Fig.  9 . -  H al e’ s iron staining in chromophobe renal  
cel l  carcinoma.
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renal cell carcinoma and oncocyt oma, despite their 
morpholog ical similarities. I t has b een postu lated 
that eosinophilic chromophob e R C C  orig inates f rom 
renal oncocyt oma, and represents the malig nant 
f orm of  this tu mor.
•	 R en a l  o n co cyt o si s.  R enal oncocyt osis is 
characterize d b y the presence of  mu ltiple tu mors 
w ith oncocyt ic f eatu res, of ten associated w ith small 
clu sters of  tu b u le- like  stru ctu res w ith oncocyt ic 
chang e. C ossu - R occa et al stu died 11 tu mors f rom 
the ki dneys of  one su ch patient. F lu orescence in 
situ  hyb ridiza tion w as perf ormed w ith centromeric 
prob es f or chromosomes 1, 2, 6 , 10 , and 17  in each 
of  the 11 tu mors. All 11 tu mors f rom this patient 
w ith renal oncocyt osis show ed no loss of  any of  the 
chromosomes 1, 2, 6 , 10 , or 17 , a pattern identical 
to that f ou nd in normal control tissu es. T heref ore 
the chromosomal profile may be the diagnostic 
procedu re of  choice f or disting u ishing  b etw een 
chromophob e R C C  and renal oncocyt osis.
6 . P RoG nosIs
T he larg e maj ority  of  C C R C s are stag e T 1 and T 2 
(8 6 % ) w hereas only 10 %  show  ext ension throu g h 
the renal capsu le into su rrou nding  adipose tissu e, 
only 4 %  show  invo lve ment of  the renal ve in (T 3b ). 
A f ew  cases of  w ell- docu mented distant metastasis 
(lu ng , live r and pancreas) have  b een describ ed . N o 
lym ph node metastases have  b een reported ye t. 
Spindle cell phenotyp e is associated w ith ag g ressive  
tu mou r g row th/ metastasis. G enetic predictive  f actors 
are not kn ow n.
VII.  ColleCT InG  D uCT  
CA RCInoM A ,  RenA l M eD ullARY  
CA RCInoM A
R enal collecting  du ct, or B ellini’ s du ct, carcinoma 
(CDC) is a relatively rare subtype of renal cell 
carcinoma (R C C ), accou nting  f or 0 .4 %  to 1.8 %  [ 7 3, 
74] of all RCCs in Western counties. In Japan, the 
Japanese Society of Renal Cancer reported that a 
Nationwide survey of CDC from 2001 to 2003 [75]. 
I n this su rve y that w as the larg est case series to 
consider ou tcome to date, 8 1 cases w ere cou nted 
from 281 institutions throughout Japan.  The 
incidence of CDC in Japan was considered as less 
than 1.5 % , b ecau se each institu tion exp erienced 
more than 10  patients w ith R C C  per ye ar.  Seve ral 
stu dies have  show n a male predominance and a 
tendency f or this disease to occu r more f requ ently 
in relatively younger adults. Japanese survey 
show ed that the median ag e w as 5 8 .2 ye ars and 
males comprised 7 1.6 %  of  the patient popu lation. 
According to Japanese survey, regional lymph node 
metastases w ere present in 4 4 %  of  the patients at 
diag nosis, w hereas distant metastases w ere seen 
in 32. The 1-, 3-, and 10-year disease-specific 
su rvi va ls w ere 6 9 % , 4 5 % , and 14 % , respective ly .
Renal medullary carcinoma (RMC) is a relatively 
new  su b typ e of  R C C  that is thou g ht to arise f rom 
the calyceal epithelium.  It has been first seen and 
is still detected almost excl u sive ly in indivi du als w ith 
sickl e cell trait or anemia.  T his tu mor shares many 
histologic features with CDC, and some consider it a 
subtype of CDC or at least a closely related tumor. 
Althou g h relationship b etw een these tw o entities 
still remains controversial, most recently RMC is 
considered to differentiate from CDC  [74, 76].
1 .  M oRP H oloG ICA l CRIT eRIA  foR 
P AT H oloG ICA l D IA G nosIs
CDCs are derived from the medulla, but many are 
infiltrative and extension into the cortex is common. 
Typically CDCs are white to gray and have a firm 
consistency on sectioning. Histologically, CDC is 
characterize d b y a tu b u lopapillary architectu re, 
w hich consists of  an admixt u re of  dilated tu b u les 
and papillary stru ctu res typ ically lined b y a sing le 
laye r of  cu b oidal cells, of ten creating  a cob b lestone 
appearance and associating  w ith desmoplastic 
stromal reaction ( fi g . 1 0 ).  O n the other hand, it 
has b een reported that most common histolog ic 
appearance of RMC is cribriforming glands 
surrounding by a desmoplastic reaction.  Both CDC 
and RMC are considered to be somewhat similar to 
poorly dif f erentiated u rothelial carcinoma. 
2 . M oleCulA R/ G eneT IC feA T uRes
In CDCs, trisomy for chromosomes 4, 7, 8, 17 and 
20  and loss of  chromosomes 14 , 18  and 22 w ere 
reported [ 7 7 ] .  Another analyse s show ed monosomy 
of chromosomes 1, 6, 14, 15 and 22 [78].  Loss of 
heterozyg osity of  8 p and 13q has b een reported 
in f u rther stu dies [ 7 9 ] .  T he most constant chang e 
w ou ld b e 1q32 deletion 8 0 , 8 1).  T he molecu lar 
pathogenesis of CDC is not known.  Although 
loss of chromosome 3p, including VHL gene was 
not common in CDC [79], some literatures have 
described that activation of VEGF signaling, which 
Fig.  10 . -  Col l ecting duct carcinoma w ith desmopl astic 
reaction
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is analog ou s to the clear cell R C C  hyp oxi a pathw ay 
may be related to RMC carcinogenesis [76, 82].
3 . IM M unoH IsT oCH eM ICA l feA T uRes
O n immu nohistochemistry , the characteristics f eatu re 
is co- exp ression of  low -  and hig h- molecu lar w eig ht 
cy toke ratines (cyt oke ratin 34 b E12) and positive  
reaction to lectins su ch as U l ex eu r o p ea u s ag g lu tinin-
1 (U EA- 1) [ 7 3, 7 7 , 8 3] .  K ob aya shi N , et al. [ 8 4 ] . 
have described that CDC expresses E-cadherin, c-
K I T  in addition to U EA- 1 and cyt ok eraitnes.  T here is 
a variable expression of Leu M1 and EMA, whereas 
marke rs of  proxi mal renal tu b u les are almost alw ays 
negative.  Some studies reported that RMC strongly 
ex presses ke ratin 19  and T opo I I  alpha [ 8 5 ] .
4 . D IffeRenT IA l D IA G nosIs
CDC is frequently difficult to distinguish from RMC, 
pelvi c u rothelial carcinoma (U C ) w ith marke d 
renal parenchy mal inva sion and hig h- g rade 
papillary RCC.  To differentiate CDC from RMC, 
immu nohistochemical and molecu lar approaches 
may be useful.  The difference between CDC and 
RMA was found in expression pattern of UEA-
1, hig h- molecu lar w eig ht cyt oke ratin, c- K I T , E-
cadherin, VEGF, EMA, Her-2neu, and karyotype of 
chromosomes [ 7 4 ] . I mmu nohistochemical approach 
is u sef u l f or the dif f erential diag nosis of  these renal 
tu mors.  Sw artz,  et al. [ 7 6 ]  have  reported ab ou t 
differential diagnosis between CDC and RMC that 
characteristic immunohistochemical profile for 
CDC is positivity for cytokeratin 34bE12 and UEA-
1.  T he cyt oke ratin 34 b E12 marke r w as neg ative  in 
RMCs and UEA-1 was present only a minority of 
RMCs in a focal, patchy distribution.  It has been 
also reported that U EA- 1, E- cadherin, and c- K I T  
are frequently positive in CDC in comparison with 
papillary R C C , w hich u su ally exp resses marke rs f or 
proximal renal tubules, such as CD10, RCC antigen 
and AMACR [74, 84].  Although invasive UC has 
similar immunohistochemical features with CDC, it 
has b een also show n that hig h-  and low - molecu lar-
w eig ht cy toke ratin are positive  at a low  f requ ency 
compared w ith inva sive  U C  [ 8 4 ] . 
 
VIII.  M uCInous T uB ulA R A nD  
sP InD le Cell CA RCInoM A
1 .  M oRP H oloG ICA l CRIT eRIA  foR 
P AT H oloG ICA l D IA G nosIs
This entity, included by the first time in the current 
WHO classification, [12] is a low-grade carcinoma 
composed of  tig htly packe d tu b u les separated b y 
pale mu cinou s stroma and a spindle cell component 
( fi g . 1 1  a n d  1 2 ) [ 12, 6 1-  9 8 ] .  I t seems to derive  f rom 
the distal nephron b u t some au thors b elieve  it cou ld 
b e a va riant of  papillary R C C  w ith proxi mal tu b u le 
orig in[ 6 1, 8 6 , 8 7 ]  T here is a f emale predominance 
and the mean ag e is 5 3 ye ars at diag nosis.[ 12, 
6 1-  9 8 ] . I t presents as circu mscrib ed asym ptomatic 
mass on u ltrasou nd exa mination.[ 1]  Some patients 
may deve lop metastases on f ollow - u p. R are cases 
show ing  tru e, w ell docu mented, sarcomatoid chang e 
h ve  b een recently reported. [ 8 8 ] . T w o of  these cases 
occu rred in a 7 1- ye ar- old w oman and an 8 0 - ye ar-
old man w ho b oth u nderw ent a radical nephrectomy 
procedu re. [ 8 8 ] . I n addition to the classic mu cinou s 
tubular and spindle cell carcinoma (MTSRCC) 
morpholog y , b oth cases had a sarcomatoid 
component characterize d b y predominantly hig h-
g rade spindle cells, solid pleomorphic epithelioid 
cells, and malignant fibrous histiocytoma-like 
storif orm patterns [ 8 8 ] . Sarcomatoid chang e 
comprised 6 0 %  and 20 %  of  the tu mors, respective ly;  
one patient died w ith w idespread metastasis.5 I t is 
currently considered a poorly defined entity.
2 . M oleCulA R/ G eneT IC feA T uRes
T his tu mor has va riab le g enetic f eatu res and show s 
a comb ination of  losses invo lvi ng  chromosomes 1, 
4 , 6 , 8 , 13, 14  and 15  and g ains of  chromosomes 
Fig.  11. -  M ucinous tubul ar and spindl e cel l  
carcinoma.  T ubul ar and spindl e components.
Fig.  12 . -  M ucinous tubul ar and spindl e cel l  
carcinoma.  M ucinous component.
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2, 5 , 7 , 9 , 10 , 11, 12, 16 , 17 , 19 , 20 , 22, and X  [ 6 1, 
8 6 - 9 8 ]  C ossu - R occa et al [ 8 9 ]  stu died 10  mu cinou s 
tubular and spindle cell carcinoma with FISH for 
chromosomes 7 , 17  and Y . T hey  f ou nd that renal 
MTSRCC lacks the gains of chromosomes 7 and 
17  and losses of  chromosome Y  that are typ ically 
f ou nd in papillary renal cell carcinoma. R ako zy et al 
[90] studied 6 tumors from five patients with CGH 
and f ou nd mu ltiple g enetic ab normalities inclu ded 
consistent losses of  chromosomes 1, 4 , 6 , 8 , 9 , 13, 
14, 15 and 22 in all cases. CGH study by Ferlicot et 
al [91] identified the loss of chromosomes 1, 4, 6, 8, 
13, 14, 15 and 18 in a group of MTSRCC.
3 . IM M unoH IsT oCH eM ICA l feA T uRes
A recent immu nohistochemical analysi s f ou nd a 
significant immunophenotypic overlap with papillary 
R C C , and some au thors b elieve  this is a va riant of  
papillary R C C  w ith spindle cell dif f erentiation [ 8 6 , 
9 2]  Exp ression of  alpha- methyl acyl - C oA racemase 
(89), cytokeratin 7 (82), Vimentin (80), EMA 
(7 8 % ), 34 ß E12 (4 5 % ) and E- C adherin (28 % ), and 
negativity for CK 14, CD 10, Villin, RCC antigen, c-
ki t and U l ex  E u r o p a eu s ag g lu tinin are characteristic 
of MTSRCC [12, 61- 98]The proliferative rate in 
MTSRCC is low (1). Some cases of MTSRCC 
may exp ress neu roendocrine marke rs, su ch as N SE 
and CD57 [93].
4 . D IffeRenT IA l D IA G nosIs
MaMor histologic differential diagnosis is type I 
papillary R C C  and papillary R C C  w ith solid g row th. 
[ 12, 6 1-  9 8 ] . A prob lem f u rther compou nded w ith the 
description of  papillary R C C  w ith low - g rade spindle 
cell f oci as a mimic of  mu cinou s tu b u lar and spindle 
cell carcinoma [ 6 1]  All cases in this categ ory w ere 
dif f u sely immu noreactive  f or cyt oke ratin 7 , and 
focally CD10 positive. [61] Also, all 5  cases show ed 
trisomy of  chromosome 7 , and 3 of  5  show ed trisomy 
of chromosome 17 by FISH, supporting classification 
as papillary RCC [61]. Rare cases of MTSRCC 
may present true sarcomatoid change a finding of 
importance in terms of  dif f erential diag nosis [ 8 8 ] . 
MTSRCC may be ³mucin-poor´ and show a marked 
predominance of  either of  its principal morpholog ic 
components, w hich cou pled w ith the presence 
of  other u nu su al f eatu res su ch as clear cells, 
papillations, f oamy macrophag es, and necrosis, 
may mimic other f orms of  renal cell carcinoma 
[ 9 4 ] . Patholog ists mu st b e aw are of  the spectru m 
of histologic findings within MTSRCC to ensure 
their accurate diagnosis [94-98]. Mucinous tubular 
and spindle cell renal carcinomas are u ncommon 
neoplasms w ith distinctive  morpholog ic f eatu res. 
Since MTSRCC shares several morphological 
characteristics w ith typ e I  papillary renal cell 
carcinoma and its morpholog ic va riants, kn ow ledg e 
of their molecular and immunohistochemical profiles 
can b e important in disting u ishing  b etw een them [ 12, 
6 1-  9 8 ] .
IX . RenA l CA RCInoM A s 
A ssoCIA T eD  W IT H  X P 1 1 .2  
T RA nsloCA T Ions/ T fe3  G ene 
fusIons
These carcinomas are defined by several different 
translocations invo lvi ng  chromosome X p11.2, 
all resu lting  in g ene f u sions invo lvi ng  the T F E 3 
gene. The first reported translocation was the 
t(X ; 1)(p11.2; q21), w hich resu lts in f u sion of  the 
P R C C and T F E 3 g enes. Another chromosome 
translocation is the t(X ; 17 )(p11.2; q25 ), w hich resu lts 
in f u sion of  the A S P L (a.k. a. R C C 1 7 or A S P S C R 1) 
and T F E 3  g enes. O f  note, the identical A S P L-
T F E 3 g ene f u sion is also characteristic of  alve olar 
sof t part sarcoma (ASPS), w here it w as orig inally 
identified. Other reported translocations include a 
t(X ; 1)(p11.2; p34 ), resu lting  in f u sion of  the P S Fand 
T F E 3 g enes, and an inv( X )(p11; q12), resu lting  in 
f u sion of  the N o n O (p 5 4n r b) and T F E 3 g enes. T hese 
carcinomas predominantly af f ect children and yo u ng  
adu lts, thou g h rare adu lt cases have  b een reported. 
T he A S P L- T F E 3 carcinomas characteristically 
present at adva nced stag e;  almost all cases have  
b een associated w ith lym ph node metastases at 
diag nosis, eve n w ith small primaries [ 9 9 - 10 6 ] .
1 . M A CRosCoP IC AP P eA RA nCe
R enal carcinomas associated w ith X p11.2 
translocations resemb le conve ntional (clear cell) 
renal carcinomas on g ross exa mination, most 
commonly b eing  tan- ye llow , and of ten necrotic and 
hemorrhag ic. 
2 . H IsT oP A T H oloG Y
T he most distinctive  histopatholog ical appearance 
is that of  a papillary carcinoma comprised of  clear 
cells;  how eve r, these tu mors f requ ently have  a more 
nested architectu re, and of ten f eatu re cells w ith 
g ranu lar eosinophilic cyt oplasm. T he morpholog ic 
appearance of carcinomas associated with specific 
chromosome translocation b reakp oints dif f ers. T he 
A S P L- T F E 3 renal carcinomas are characterize d b y 
cells w ith vo lu minou s clear to eosinophilic cyt oplasm, 
discrete cell b orders, ve sicu lar chromatin and 
prominent nu cleoli. Psammoma b odies are constant 
and sometimes ext ensive , of ten arising  w ithin 
characteristic hya line nodu les. T he P R C C - T F E 3 
renal carcinomas g enerally f eatu re less ab u ndant 
cyt oplasm, f ew er psammoma b odies, f ew er hya line 
nodu les, and a more nested, compact architectu re. 
T oo f ew  P S F - T F E 3 and N o n O - T F E 3 renal tu mors 
have  so f ar b een stu died to comment on their 
distinctive  histopatholog ical f eatu res, if  any . 
3 . IM M unoP RofIle
O nly ab ou t 5 0 %  of  renal carcinomas w ith X p11.2-
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associated translocations exp ress epithelial 
markers such as cytokeratin and EMA by 
immu nohistochemistry , and the lab eling  is of ten 
focal. Vimentin immunoreactivity is also often focal, 
w hich contrasts w ith conve ntional renal carcinomas. 
S-100 protein, desmin, and HMB45 are consistently 
neg ative . T he tu mors consistently lab el f or the 
Renal Cell Carcinoma Marker antigen and CD10, 
similar to conve ntional renal carcinomas. T he most 
distinctive  immu nohistochemical f eatu re of  these 
tu mors is nu clear immu noreactivi ty f or T F E3 protein, 
w hich is a common f eatu re in all X p11.2- associated 
carcinomas and ASPS.
4 . eleCT RonM ICRosCoP Y
U ltrastru ctu rally , X p11.2- associated carcinomas most 
closely resemb le conve ntional renal carcinomas 
b ecau se they f eatu re cell j u nctions, microvi lli, 
intracytoplasmic fat and glycogen. However, a 
significant number of cases demonstrate distinctive 
ultrastructural features. Most of the A S P L- T F E 3 
renal carcinomas demonstrate memb rane- b ou nd 
cy toplasmic g ranu les and a f ew  contain memb rane-
b ou nd rhomb oidal cryst als identical to those seen 
in sof t tissu e ASPS O ccasional P R C C - T F E 3 
renal carcinomas have  demonstrated distinctive  
intracisternal microtu b u les identical to those seen in 
ex traske letal myxo id chondrosarcoma.
5 . M A J oR D IffeRenT IA l D IA G nosIs
•	 P a p i l l a r y r en a l  ce l l  ca r ci n o ma .  T ranslocation 
renal cell carcinomas sometimes of ten show  w ell 
developed papillary structures. However, they lack 
the cyt og enetic ab normalities that are typ ical of  
classic papillary R C C  -  trisomy of  7  and 17 , and loss 
of  chromosome Y . 
•	 C l ea r  ce l l  R C C .  Some translocation renal cell 
carcinomas exh ib it the presence of  clear cells f orming  
nested architecture, and are difficult to distinguish 
f rom classic clear cell R C C ;  how eve r, translocation 
renal cell carcinoma lacks the chromosome 3p 
deletion typ ical of  clear cell R C C . 
6 .  CY T oG eneT ICs A nD  M oleCulA R 
A lT eRA T Ions
As mentioned above, these tumors are defined by 
X p11.2 translocations and resu lting  T F E 3 g ene 
f u sions. T F E3 is a memb er of  the b asic- helix- loop-
helix f amily of  transcription f actors, w hile P S F and 
N o n O  encode splicing  f actors. P R C C and A S P L 
encode nove l proteins f or w hich a f u nction has not 
ye t b een discove red, b u t the f ormer may also b e 
involved in splicing. Both the PRCC-TFE3 and ASPL-
TFE3 fusion proteins retain the TFE3 DNA binding 
domain, localize  to the nu cleu s, and can act as 
ab errant transcription f actors. T hrou g h interactions 
w ith other proteins, PR C C - T F E3 may also interf ere 
w ith splicing  and mitotic checkp oint control. T he 
ex pression leve ls of  T F E3 f u sion proteins appear 
ab errantly hig h compared to native  T F E3, perhaps 
b ecau se the f u sion partners of  T F E 3 are u b iqu itou sly 
exp ressed and contrib u te their promoters to the 
f u sion proteins. I n terms of  stru ctu ral heterog eneity , 
tw o alternative  typ es of  A S P L- T F E 3 f u sion transcripts 
and f ou r typ es of  P R C C - T F E 3 transcripts have  b een 
describ ed, b u t there are no apparent morpholog ic 
or clinical correlates of  this g enetic va riab ility . 
I nteresting ly , w hile b oth the t(X ; 17 ) renal carcinomas 
and the sof t tissu e ASPS contain identical A S P L-
T F E 3 f u sion transcripts, the t(X ; 17 ) translocation is 
consistently b alanced (reciprocal) in the f ormer b u t 
u su ally u nb alanced in the latter (i.e. the deriva tive  X  
chromosome is not seen in ASPS). 
7 . P RoG nosIs
Very little is known about the clinical behavior of these 
carcinomas. W hile the A S P L- T F E 3 renal carcinomas 
u su ally present at adva nced stag e, their clinical 
cou rse thu s f ar appears to b e indolent.  Seve ral 
P R C C - T F E 3 renal carcinomas have  recu rred late, 
u p to 20  or 30  ye ars af ter initial diag nosis. 
X . RenA l Cell CA RCInoM A  
unClA ssIfIeD
1 .  M oRP H oloG ICA l CRIT eRIA  foR 
P AT H oloG ICA l D IA G nosIs
I n su rg ical series, it represents 4 - 7 %  of  renal tu mors 
[ 12, 10 7 ] , and at presentation most are of  hig h g rade 
and stag e at diag nosis w ith poor su rvi va l [ 12, 9 6 , 
9 7 , 9 8 , 10 7 , 10 8 , 10 9 , 110 ,111, 112]  T he proportion 
of unclassified RCC carcinoma did not change with 
increasing  decade of  lif e in one stu dy [ 10 8 ]  F eatu res 
w hich mig ht place a carcinoma in this categ ory are 
defined by the current WHO classification of kidney 
cancer [12]. Limited reported data suggests that it is 
an ag g ressive  f orm of  R C C , mainly b ecau se most 
cases are at adva nced stag e at presentation [ 12, 
10 7 - 110 ]  R esu lts b ased on tw o relative ly larg e series 
su pport this su g g estion. Z isman et al [ 10 9 ]  reported 
31 patients with unclassified RCC and compared the 
prog nostic ou tcome w ith 317  matched patients w ith 
clear cell RCC. The incidence of unclassified RCC 
in his series w as 2.9 %  [ 10 9 ]  At initial diag nosis 29  
patients (94) with unclassified and 264 (83) with 
clear cell R C C  had metastatic disease (p =  0 .14 3). 
Compared with the clear cell variety unclassified 
disease w as associated w ith larg er tu mors (p =  
0 .0 0 5 ), increased risk of  adrenal g land invo lve ment 
(25 %  of  cases, p =  0 .0 0 0 1), direct inva sion to 
adj acent org ans (4 2% , p =  0 .0 0 0 0 1), b one (5 2% , 
p =  0 .0 22), reg ional (5 2% , p =  0 .0 0 4 2) and non-
reg ional lym ph node (4 1% , p =  0 .0 3) metastases 
[109]. Unclassified histology was a significant 
indicator f or poor prog nosis on mu ltiva riate analysi s 
(p 0.0001) [109]. Median survival in patients with 
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unclassified renal cell carcinoma was 4.3 months 
[ 10 9 ] . Most recently, Karakiewicz et al [110] revi ew ed 
85 cases of unclassified RCC to compare cancer-
specific mortality in patients with unclassified 
R C C  vs.  clear cell R C C  af ter nephrectomy . O f  
patients with unclassified RCC, 80 had Fuhrman 
grades III or IV vs. 37.8 for clear cell RCC [110]. 
Moreover, 36.5 of patients with unclassified RCC 
had pathologically confirmed nodal metastases vs. 
8 .6 %  w ith clear cell R C C . F inally , 5 4 .1%  of  patients 
with unclassified RCC had distant metastases 
at the time of  nephrectomy vs.  16 .8 %  w ith clear 
cell RCC. Despite these differences in the overall 
analyse s, af ter matching  f or tu mor characteristics, 
the unclassified RCC -specific mortality rate was 1.6 
times hig her (P =  0 .0 4 ) in matched analyse s and 1.7  
times hig her (P =  0 .0 0 1) in mu ltiva riate analyse s.5  
B oth, Z isman et al [ 10 9 ]  and K araki ew icz et al [ 110 ]  
concluded that unclassified RCC is associated with 
distinct and hig hly ag g ressive  b iolog ical b ehavi or, 
and poor clinical ou tcome. 
2 .  ReCoM M enD eD P AT H oloG ICA l 
G uID elInes In T H ese CA ses
According to the current WHO classification of kidney 
cancer [12, 96] the features to define unclassified 
RCC include: i) composites of recognized types, ii) 
pu re sarcomatoid morpholog y w ithou t recog niza b le 
epithelial elements, iii) mu cin produ ction, iv)  rare 
mixt u res of  epithelial and stromal elements, and v)  
u nrecog niza b le cell typ es. 
Pathologic studies on unclassified RCC are very 
limited w ith most reporting  on small cases series 
[ 12, 9 6 , 9 7 , 9 8 , 10 7 , 10 8 , 10 9 , 110 ,111, 112] . 
Reuter [107], following the WHO criteria suggests 
that unclassified RCC represents a histologically 
and clinically heterog eneou s categ ory of  tu mors 
that does not fit neatly into any of the other well-
defined categories. Bakshi et al [111] reported that 
RCC antigen is expressed by 85 of unclassified 
R C C  in their series. B ru der et al [ 112]  reported 13 
cases of unclassified RCC in a series of 41 renal cell 
carcinomas of  patients yo u ng er than 22 ye ars. T hese 
tumors could not be assigned to types specified 
by the current WHO classification; of these, 10 
cases were grouped as unclassified not otherwise 
specified, including a unique renal cell carcinoma 
w ith prominently  va cu olated cyt oplasm and W T 1 
expression. Three additional unclassified RCC 
occu rred in comb ination w ith nephrob lastoma. T he 
stu dy b y  B ru der et al [ 112]  adds new  morpholog ic 
features which together with the WHO criteria might 
place a carcinoma in the category of unclassified 
R C C . Patholog ists mu st b e aw are of  the spectru m of  
histologic findings within unclassified RCC to ensure 
their accu rate diag nosis [ 12, 9 6 , 9 7 , 9 8 , 10 7 , 10 8 , 
10 9 , 110 ,111, 112] .
X I. non 2 0 0 4  W H o RCC suB T Y P es 
ConsID eReD
1 . T uB uloCY sT IC CA RCInoM A
T hese tu mou rs are composed b y  packe d tu b u les 
and cyst s lined b y cu b oidal or hob nail cells w ith 
ab u ndant eosinophilic cyt oplasm and larg e nu clei 
show ing  prominent nu cleoli.
a)  Cl inical  features
T u b u locyst ic carcinoma has b een in part describ ed 
as a su b set of  the g rou p of  the B ellini’ s tu mou r or 
as low - g rade collecting  du ct carcinoma.[ 113]  I t has 
b een reported most in adu lts and w ith a male/ f emale 
ratio 7:1. Radiologically, it has a broad radiological 
differential diagnosis and can be classified as a 
Bosniak type II, III and IV.  The great maMority of 
these tu mors b ehave  in an indolent f ashion, b u t a 
f ew  have  metastatize d. [ 114 - 117 ] .
b)  M acroscopy
T his tu mou r is u su ally a solitary u nencapsu lated 
tu mor w ith a w hite or g ray spong y cu t su rf ace. T hey 
can b e va riab le in size , althou g h most of  them are 
pT1 tumors . Multifocal cases have been reported 
and association w ith papillary neoplasms have  b een 
provi ded.[ 114 - 117 ] .
c)  H istopathol ogy
I t is composed of  packe d tu b u les and cyst s separated 
by bland fibrous stroma. The lining cells are cuboidal 
to colu mnar and hob nail cells are commonly 
seen. T he cells have  an ab u ndant eosinophilic or 
amphophilic cyt oplasm and the nu clei are larg e and 
have  prominent nu cleoli ( fi g . 1 3 ). O ccasional cells 
w ith a low - g rade nu clear chang es may b e seen.[ 114 -
117 ] . 
T he dif f erential diag nosis inclu de a va riou s spectru m 
of  tu mou rs namely , mu ltilocu lated clear cell renal cell 
carcinoma, cyst ic nephroma, mixe d epithelial and 
stromal tu mor and cyst ic oncocyt oma. 
d) Immunoprofile
A w ide rang e of  marke r positivi ty w ith cyt oke ratins 
(CK8, CK18, CK19) are consistently positive. CD10 
and P5 0 4 S (racemase) are positive  in g reater than 
9 0 %  of  tu mors. C K 7  is va riab le exp ressed, althou g h 
that pattern may b e w eak and f ocal. Staining  f or 
kidney-specific cadherin and Pax-2 may also be 
s en. High molecular weight cytokeratin (34BE12) is 
nearly alw ays neg ative .[ 114 - 117 ]
e)  Somatic genetics
Gene expression profiling  and Àuorescence in 
situ  hyb ridiza tion stu dies indicate that tu b u locyst ic 
carcinoma has a molecu lar sig natu re consisting  in 
g ains of  chromosomes 7  and 17 .[ 114 - 117 ]
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f)  D iscussion
T he histog enesis of  tu b u locyst ic carcinoma is 
u nclear. T he association w ith mu ltiple papillary 
neoplasms prompted the arg u e that tu b u locyst ic 
carcinoma may represent a su b set of  papillary 
renal cell carcinoma su ch as mu ltilocu lated clear 
cell renal cell carcinoma is considered a va riant of  
clear cell renal cell carcinoma. Due to unique clinico-
patholog ical and g enetic characters, this typ e of  
renal cell carcinoma merit a f ormal recog nition in a 
renewed future classification.
2 .  T H Y RoID - lIK e ( follICulA R)  RenA l 
CA RCInoM A  
T his tu mou r is a renal carcinoma w ith a f ollicu lar 
architectu re resemb ling  f ollicu lar carcinoma of  the 
thyr oid and composed b y cells show ing  low - g rade 
pleomorphism w ith amphophilic to eosinophilic 
cy toplasm.
a)  Cl inical  features
T he seve n tu mors reported to date w ere f rom f ou r 
f emale patients and three male adu lt patients. All 
tumors were incidental findings and two patients had 
a past history of  u nrelated malig nancies. T he tu mors 
w ere tan colored and show  a va riab le size  and low  
pT . F ollow - u p data w ere ava ilab le f or all seve n cases 
and all patients remained tumor free after 6–84 
months.[ 118 , 119 ] .
b)  M icroscopy
T he tu mors contain a pseu docapsu le and are 
composed of  cells show ing  low - g rade pleomorphism 
w ith amphophilic to eosinophilic cyt oplasm. T he 
cells ag g reg ate into micro and macrof ollicles. 
Colloid-like proteinaceous Àuid may be revealed. 
Pseu doinclu sions and nu clear g roove s may b e 
present. 
T he main dif f erential diag nosis f or these tu mors is 
metastases f rom either a primary thyr oid f ollicu lar 
carcinoma or thyr oid carcinoma arising  in a teratoma. 
T he eva lu ation of  T T F 1 exp ression shou ld alw ays 
b e u ndertake n in tu mors show ing  this morpholog y to 
excl u de metastatic disease.[ 118 , 119 ] .
c) Immunoprofile
Variable expression of cytokeratin 7 and CD10 have 
b een reported. Six of  the cases w ere neg ative  f or 
RCC, WT1, vimentin, Ksp-cadherin, Pax 2, AMACR, 
CD56 and CD57, whereas all cases were negative 
f or T T F 1.[ 118 , 119 ] .
d)  Somatic genetics
O ne case show ed g ains of  chromosome 8 q24 , 12 
and 16 , and loss of  1p36 .3 and 9 q21.33,10 3 w hereas 
gene expression profiling showed widespread 
u nderexp ression or ove rexp ression, particu larly 
invo lvi ng  chromosomes 1, 2, 3, 5 , 6 , 10 , 11, 16  and 
17 .[ 118 , 119 ] .
e)  D iscussion
T his tu mor cannot b e considered an entity b ecau se 
of  the f ew  cases stu died and reported.
3 .  A CQ uIReD  CY sT IC D IseA se-
A ssoCIA T eD  RenA l Cell CA RCInoMA  
A nD  CleA R Cell P A P IllARY RCC 
T hese tu mors are associated w ith end renal disease. 
T he f ormer are composed b y larg e eosinophilic cells 
w ith a rou nded nu cleu s and larg e nu cleolu s arrang ed 
in va riety of  architectu ral patterns and characterize d 
b y the presence of  oxa late cryst als;  the second b y 
cells w ith clear cyt oplasm and  low - g rade nu clear 
pleomorphism org anize d in solid, tu b u lar and 
microcyst ic areas and f requ ently w ith a pronou nced 
cyst ic component.
a)  Cl inical  features
Stu dies indicate an increased preva lence of  
carcinoma in patients w ith end stag e renal disease. 
Most of the cases present more than one tumor in a 
ing le ki dney . I n a detailed stu dy of  6 6  tu mor- b earing  
ki dneys f rom patients w ith end- stag e renal disease, 
a w ide spectru m of  renal neoplasia w as noted.[ 120 , 
121] .
Fig.  13 B . -  T ubul o- cystic carcinoma.  Fig.  13 A . -  T ubul o- cystic carcinoma.
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Acqu ired cyst ic disease- associated renal cell 
carcinoma are present in 4 6 %  of  ki dneys w ith 
acqu ired cyst ic disease and clear cell papillary 
R C C  is the second tu mou r describ ed. T he last can 
occu r in ki dneys b oth w ith or w ithou t acqu ired cyst ic 
disease.[ 120 , 121] .
O u tcome data f or acqu ired cyst ic disease- associated 
renal cell carcinoma are limited, w ith one death f rom 
metastatic disease 34  months f ollow ing  diag nosis, 
b eing  reported. I n tw o other cases reg ional lym ph 
node metastases w ere seen.[ 120 , 121] .
N o deaths f rom clear cell papillary renal cell 
carcinoma associated in patients w ith and w ithou t 
end- stag e renal disease have  b een reported.[ 120 , 
121] .
b)  M acroscopy
Acqu ired cyst ic disease- associated renal cell 
carcinoma are u su ally w ell- circu mscrib ed, larg e w ith 
dystrophic calcification. Clear cell papillary RCC 
f requ ently contain a prominent pseu docapsu le and 
cy stic f eatu re.
c)  M icroscopy
Acqu ired cyst ic disease- associated renal cell 
carcinoma displaye d a va riety of  architectu ral 
patterns w ith solid, acinar, cys tic and papillary 
patterns b eing  present. I rreg u lar lu mina may g ive  
the tumor a cribriform appearance. Most of reported 
cases the tu mor appeared to arise in a cyst . T he 
tu mor cells contain eosinophilic cyt oplasm w ith 
a rou nded nu cleu s and larg e nu cleolu s. O xa late 
cryst als are present in the maj ority of  tu mors and 
also calciu m ag g reg ates.[ 122]
C lear cell papillary R C C  show  in 5 0 %  of  cases a 
pronou nced cyst ic component;  solid, tu b u lar and 
microcyst ic areas are also present. T he tu mor cells 
show  a clear cy toplasm and a low - g rade nu clear 
pleomorphism w ith nu clei situ ated tow ards the 
su rf ace of  the papillary tu f ts.[ 120 , 121] .
d) Immunoprofile
Acqu ired cyst ic disease- R C C s are positive  f or vi ncu lin 
and AMACR on immunohistochemical examination, 
and in a proportion of  cases show  va riab le f ocal 
staining  f or cyt oke ratin 7  and parva lb u min, discordant 
positive  immu noexp ression f or cyt ok eratin AE1/ AE3 
and CD10, and variable expression for vimentin 
CAM 5.2. [123, 124].
C lear cell papillary R C C  show  positive  staining  f or 
cytokeratin 7 and are negative for AMACR and 
parva lb u min.[ 123] . 
e)  Somatic genetics
I n a ki dney show ing  acqu ired cyst ic disease, 
g enetic analysi s show ed g ains of  chromosomes 7  
and 17. In acquired cystic disease-RCCs FISH and 
CGH  analyses showed multiple gains of numerous 
chromosomes inclu ding  chromosomes1, 2 , 6 , 10 , 
3, 7, 17 and Y. Mutations of the VHL gene have 
not yet been identified in these tumors. Clear cell 
papillary R C C  did not show  neither 3p nor trisomies 
of  chromosomes 7  and 17 .[ 121, 124 ] . 
f)  D iscussion
Discrete clinico-pathological informations are present 
in reg ard to acqu ired cyst ic disease- R C C s w hereas 
more data are needed f or the clear cell papillary 
R C C  and its possib le relationship w ith other.
4 .  leIoM Y oM A T ous RenA l Cell 
CA RCInoM A s 
T hey are tu mors composed of  tu b u lar ag g reg ates 
of  neoplastic clear cell intermixe d in a prominent 
leiomyo matou s prolif eration.
a)  Cl inical  features
Among  12 reported cases, eig ht f emale and f ou r 
male patients rang ed in adu lt ag es. T w o of  the 
patients had co- exi sting  cancer (b reast carcinoma 
and papillary renal cell carcinoma) and one patient 
had tuberous sclerosis. Most tumors were incidental 
findings, although three patients presented with 
hematu ria. O u tcome stu dies f or leiomyo matou s 
renal cell carcinoma are limited. N o evi dence of  
recu rrence or metastases w as seen in these and 
tw o other cases f ollow ed f rom 6  months to 5  ye ars 
(mean 3 ye ars). [ 7 4 , 125 , 126 ] .
b)  M acroscopy
Grossly the tumors measured 1.8–14 cm (mean 4.6 
cm) and w ere va riou sly describ ed as tan, b row n, 
ye llow  or w hite w ith the f requ ent presence of  a 
thick inve sting  capsu le. O f  cases f or w hich details 
are ava ilab le, f ou r w ere pT 1a and one pT 1b  at 
diag nosis.
c)  M icroscopy
T he tu mors are composed of  nests, cords and sheets 
of  epithelial cells f requ ently f orming  solid areas, 
tu b u les or papillary stru ctu res. T here is slig ht nu clear 
pleomorphism w ith ab u ndant clear cyt oplasm. T he 
stroma is composed b y matu re smooth mu scle 
w hich is of ten more pronou nced at the periphery and 
in some cases appears to ext end into adj acent renal 
tissu e or into perirenal f at.
T he dif f erential diag nosis f or these tu mors is clear 
cell renal cell carcinoma, ang iomyo lipoma and 
sarcomatoid renal cell carcinoma. [ 7 4 , 125 , 126 ] .
d) Immunoprofile
T he epithelial component of  the tu mor show ed 
positive  immu noexp ression of  cyt ok eratins AE1/ AE 
and CAM 5.2, CD-10, S-100 protein (focal), EMA and 
vi mentin. T here w as va riab le exp ression of  34 b E12, 
whereas smooth muscle actin and HMB45 was 
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neg ative . T he stroma component w as positive  f or a 
smooth mu scle actin, caldesmon, desmin, vi mentin 
and negative for HMB45, CD117, cytokeratins, EMA, 
ER  and PR .[ 7 4 ] .
e)  Somatic genetics
G enetic stu dies on these tu mors are contradictory . 
In three cases FISH showed loss of VHL and FHIT, 
w ith loss of  chromosome 3 in one case and 3p in 
another. I n a separate stu dy there w as no evi dence 
of  3p deletion in the three cases exa mined.[ 7 4 ] .
T here is still a deb ate among  the relationship b etw een 
the renal adematou s tu mou r (R AT ) recently describ ed 
[ 127 ] , clear cell papillary and leiomyo matou s renal 
cell carcinoma. Microscopically, examination reveals 
a leiomyo matou s stroma su rrou nding  and encasing  
a distinctive  and characteristic epithelial component. 
T his latter is represented b y adenomatou s stru ctu res 
composed of  cells w ith small deeply b asophilic 
nu clei alienated along  the b asal memb rane. Along  
these characters, clear cell papillary renal carcinoma 
may also show  ove rlapping  morpholog ical f eatu res.
F inally all these neoplasms are constanly positive  
for CK7. Due to aforementioned morphological 
contrasting findings, a formal classification is early.
X II. CRIT ICA l ReVIeW  of G RA D InG
At first the Fuhrman¶s grade was applied only to 
the clear cell renal cell carcinomas. N ow adays the 
g rading  of  all cell su b typ es is recommended . B u t 
in non clear cell typ es some criticism appears in the 
u se of  this syst em, f or this reason w e w ill consider 
the g rading  in dif f erent  histolog ical su b typ es.
1 . CleA R Cell RenA l Cell CA RCInoMA  
Despite criticisms to the reproducibility of the 
F u hrman’ s nu clear g rade (b ased on the size  and 
shape of  the nu cleu s and also on the presence 
or ab sence of  nu cleoli) [ 128 ]   it is the most w idely 
method u sed internationally .
I t is a g ood prog nostic marke r w ith, a 5 - ye ar cancer 
specific survival rate of 89, 65 and 46 for 
g rades 1, 2 and 3- 4 , respective ly [ 129 ] . T he present 
trend is to su b divi de the f ou r F u hrman’ s g rades into 
low  g rade (g rade 1 and 2) and hig h g rade (g rade 3 
and 4 ) [ 130 ] . W ith this approach the interob serve r 
and intraob serve r va riab ility is improve d w ithou t loss 
of  ou tcome discrimination [ 131] .
T he w ider u se of  u ltrasou nd f avo u rs the detection 
of  asym ptomatic renal tu mou rs [ 132]  w ith a hig her 
incidence of organ-confined carcinomas. In this 
situ ation the F u hrman’ s g rading  can also b e of  
help. N u clear g rade g reater than 2 correlates w ith 
significantly shorter survival (p   0.018) in Stage I 
tu mou rs [ 133] .
2 . P A P IllARY RenA l Cell CA RCInoM A
T he stu dy of  the dif f erent criteria of  F u hrman’ s 
syst em only f ocal nu cleolar g rade w as associated 
w ith su rvi va l, on u niva riate and mu ltiva riate analysi s 
in papillary R C C  [ 134 ] , T hat means that the nu cleolar 
size  is, prob ab ly , most important that the su b typ e.
3 . CH RoM oP H oB e RCC
I rreg u lar nu clei and prominent nu cleoli are 
typ ically seen. T heref ore, F u hrman’ s g rade is of ten 
reported w orse eve n in patients w ith f avo u rab le 
ou tcomes. Some au thors propose an adaptation 
of the classification for this RCC subtype with 
redefinition of three grades for chromophobe RCC: 
Grade 1: cells with wide nuclear range without 
nuclear crowding or anaplasia. Grade2: presence 
of  nu clear pleomorphism and nu clear crow ding . 
Grade 3: nuclear anaplasia including giant cells 
and sarcomatoid transf ormation. T his new  syst em 
accepts the more pleomorphic nu clear aspect in low  
g rades that correlates b etter w ith the pT  categ ory 
and predicts the clinical ou tcome independently 
[ 135 ]  T his new  approach shou ld how eve r b e 
va lidated b y other series b ef ore its introdu ction in 
clinical practice. 
F inally , the M u ci n o u s tu b u l a r  a n d  sp i n d l e ce l l  
ca r ci n o ma , a new subtype in the WHO 2004 
classification, is not graded. Likewise, the 
O n co cyt o ma, as a b enig n tu mor, is not g raded.
X III. G uID elInes foR 
P AT H oloG ICA l sT A G InG  
eVA luA T Ion
T he qu ality of  any patholog ical eva lu ation depends 
on a caref u l macroscopic exa mination of  the su rg ical 
specimens [136]. Basic for an efficacious pathological 
study are: identification of the anatomical structures, 
preserva tion of  the complete specimens (i.e. no 
cu ts), and appropriate handling  b y u rolog ists. 
T he specimens shou ld b e manipu lated w hen f resh. 
Avo id stripping  the capsu le b ef ore sectioning  the 
specimen, and identif y the renal ve in, the renal artery , 
and the u reter. C aref u l ext ernal inspection is b asic 
f or eva lu ating  the radicality of  the nephrectomy . T he 
areas w here su ch radicality is du b iou s shou ld b e 
inke d w ith I ndian ink b ef ore sectioning .
T he specimen shou ld b e sectioned eve ry 10  
mm inclu ding  the perinephric f at tissu e. Eve ry 
tu moral nodu le and anatomical stru ctu re shou ld b e 
identified and the specimen should be fixed and left 
ove rnig ht.
Samples f or microscopy stu dy shou ld b e selected 
and identified by means of identification labels, and 
they should include: i) One tumour section per every 
centimetre of  tu mou r diameter. ii) Section of  the 
tu mou r- f at tissu e interf ace. iii) Accu rate stu dy of  the 
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sinu s f at tissu e close to the tu mou r, w ith a sag ittal 
section of  this area [ 137 ]  i n va si o n  o f  th e si n u s f a t 
ti s su e seems to entail g reater ag g ressive ness (5  
years specific survival 25.9) than perinephric fat 
tissue invasion (5 years specific survival 50.9) 
[ 138 ] , prob ab ly b ecau se it contains a nu mb er of  
larg e thin- w alled ve ins and lym phatics, and it is not 
separated from the renal cortex by a fibrous capsule 
[ 139 ]   iv)  
Section of  the renal ve in, eve n if  normal. v)  T w o 
or three samples of  normal ki dney , close to the 
tu mou r and also distal to it. O ne of  the ob j ective s 
of this sampling is finding microvascular invasion. 
vi ) Adrenal g land section, eve n if  the tu mou r is f ar 
f rom it. vi i) C omplete dissection inclu ding  lym ph 
nodes. T he nu mb er of  lym ph nodes to b e dissected 
depends on the patholog ist’ s motiva tion and the 
u rolog ists´ s ski lls. G enerally the lym ph nodes are 
rarely identifiable unless specifically dissected by 
the su rg eon. I n this case inclu sion of  the complete 
hiliar f at tissu e is recommended [ 137 ]
Margins are of the utmost importance. Positive 
marg ins are ve ry rarely f ou nd in specimens f rom 
a radical procedu re. I f  positive  marg ins w ere 
f ou nd, their location and their ext ension shou ld b e 
reported.
T he marg ins of  a nephron- sparing  nephrectomy are 
the renal parenchym a marg in and the perinephric f at 
marg in. I t is advi sab le to ink the exci sion marg ins 
b ef ore dissection. T he u rinary tract w all shou ld b e 
considered a marg in if  the tu mou r ext ends into the 
calyce al syst em [ 14 0 ] .
X IV. M oleCulA R B A sIs of RenA l 
CA nCeR  T ReA T M enT
T he kn ow ledg e of  the molecu lar b asis of  R C C  
has been improved with the introduction of DNA 
ex pression analysi s. Array b ased exp ression 
profiling allows for a molecular classification of 
tumours. The first gene expression profiling study in 
R C C  w as pu b lished in 20 0 1 b y Y ou ng  et a l .  [ 14 1] . 
T hey analyse d a total of  seve n samples consisting  of  
clear cell R C C , chromophob e R C C  and oncocyt oma 
w ith matching  normal renal tissu e and f ou nd distinct 
dif f erences in g enes exp ression b etw een these 
entities. C lear cell R C C  cou ld b e disting u ished f rom 
chromophob e R C C / oncocyt oma b y exp ression 
of Vimentin, whereas galectin-3 expression was 
more preva lent in oncocyt oma/ chromophob e R C C . 
T aka hashi et a l . pu b lished a correlation of  R C C  
expression profiles with clinical follow up data and 
defined a group of transcripts, which predicted 
patient risk of  prog ression more accu rately than 
conve ntional tu mou r stag ing  in a small tu mou r 
cohort (n= 29 )[ 14 2] . C andidate diag nostic marke rs 
were identified by the same group in a larger 
s udy (n 70): glutathione S-transferase was highly 
expressed in clear cell RCC, α-methylacyl racemase 
(AMACR) was typical of papillary RCC and carbonic 
anhyd rase I I  w as f ou nd in chromophob e R C C  [ 14 3] . 
The studies of Vasselli et a l . (58 tumors) and Jones 
et a l . (4 9  R C C s) f ocu sed on a clu ster or sig natu re 
b ased prediction of  patient prog nosis [ 14 4 , 14 5 ] . 
Our refined understanding of the molecular pathways 
invo lve d in renal carcinog enesis has provi ded a 
rationale for novel therapeutics which specifically 
targ et molecu les of  ab errantly activa ted pathw ays.  
The Von Hippel-Lindau (VHL) tumour suppressor 
g ene is epig enetically silenced or mu tated in the 
maj ority of  sporadic clear cell renal carcinoma (see 
above). The decreased pVHL expression leads to 
a stabilisation of the hypoxia induced factor (HIF)-
α and consequently to the transcription of HIF-α 
targ et g enes, many of  w hich are invo lve d in tu mou r 
promoting  processes as prolif eration, ang iog enesis 
and cell motility [ 14 8 ] . T arg eting  the transcription 
factor HIF directly is difficult, but a variety of agents 
have been identified that downregulate HIF-α levels 
indirectly , e.g ., inhib itors targ eting  the mammalian 
target of rapamycin (mTOR) [149, 159] or Heat 
shock protein 90 (HSP90) [149, 150]. Another 
approach is to target HIF-α regulated genes directly. 
HIF-α responsive genes of maMor importance in 
tumour biology are VEGF, PDGF, TGFα, EGFR and 
C a I X . VeG f is ove rexp ressed in R C C  and has 
prog nostic properties [ 15 1] . P D G f (Platelet- derive d 
g row th f actor) correlates to hig her F u hrman g rades 
and appears to b e a prog nostic marke r in R C C  
[ 15 2] . T Gf ( T r a n s f o r m i n g  g r o w t h  f a c t o r ) . TGF-α 
is ove rexp ressed in R C C  and is indu ced b y hyp oxi a 
[153]. TGF-ȕ is overexpressed in various malignant 
tu mors inclu ding  R C C  [ 15 4 ] . eG fR (ep i d e r m a l  
g r o w t h  f a c t o r  r e c e p t o r ,  er b B - 1 ) is ove rexp ressed 
in the maj ority of  R C C  [ 15 5 , 15 6 ] . CA IX  ( Ca r b o n i c  
a n h y d r a s e  IX ) is ove rexp ressed in >  9 0 %  of  clear 
cell R C C , b u t is u su ally not f ou nd in normal tu b u lu s 
epitheliu m. I nteresting ly , in R C C  it has b een f ou nd 
as a neg ative  marke r of  prog nosis and is discu ssed 
as a predictive marker of IL-2 therapy response 
[ 15 7 , 15 8 ] .  O ther targ et g enes not associated w ith 
HIF-α are KIT, CO;-2 and Matrix Metalloproteinases 
(MMP). K IT is a typ e I I I  tyr osine ki nase receptor 
that is ove rexp ressed in chromophob e R C C  and 
oncocyt oma, b u t rarely in clear cell R C C  [ 16 0 ] . 
CoX - 2 is u preg u lated in many malig nant tu mou rs 
inclu ding  R C C . Possib ly , C O X - 2 is a predictive  
marke r f or therapy response to C O X - inhib itors in 
R C C  [ 16 1] . M a t r i x  M e t a l l o p r o t e i n a s e s  ( M M P ) have  
b een associated w ith a poor prog nosis in R C C  [ 16 2] . 
A su mmary of  releva nt b iomarke rs in R C C  has b een 
recently pu b lished b y Eichelb erg  et al. (Eichelb erg  
C, Junker K, LMungberg B, Moch H. Diagnostic 
and prog nostic molecu lar marke rs f or renal cell 
carcinoma: a critical appraisal of the current state of 
research and clinical applicab ility . [ 16 4 ] .
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P r o g n o s t i c  fa c t o r s  o f  Re n a l  Ce l l  
Ca r c i n o m a :
A  c o n t e m p o r a r y  Re v i e w
M . SU N,  S .  F .  SHA R IA T,
 C .  CHE N G, V.  FI C A R R A, M .  MU R A I,
S .  OU D A R D, A .  J.  PA N T U C K,
R .  ZI G E U N E R, P .  I .  KA R A K I E W I C Z ,
T he natu ral history of  renal cell carcinoma (R C C ) 
may b e u npredictab le. F or exa mple, b etw een 4 .2 
and 7 .1%  of  patients w ith tu mors <4  centimeters 
that are u su ally indolent in natu re, harb or metastatic 
disease at presentation and are at an eleva ted risk 
of disease-specific mortality. [1] Conversely, as many 
as 4 0 %  of  patients w ith lym ph node metastases 
diagnosed at nephrectomy are alive at five years 
after surgery. [2] Several approaches have been 
proposed to help predicting  the natu ral history of  
treated R C C  and to disting u ish b etw een poor and 
f avo rab le risk patients. I n the cu rrent manu script, 
we will brieÀy address the history of prognostics. We 
w ill revi ew  the exi sting  prog nostic f actors, as w ell 
as f actors predicting  response to targ eted therapy 
and complete the revi ew  w ith estab lished prog nostic 
models.
II. H IsT oRY  of P RoG nosT ICs In 
RCC
I n 19 8 8 , Elson et al. pioneered the approach to 
multivariable modeling in prediction of cancer-specific 
mortality ( T a b l e  1 ). [3] In 1999, Motzer et al. (n 670) 
identified five predictors (Karnofsky Performance 
Statu s) (K PS), lactate dehyd rog enase, hemog lob in, 
corrected calciu m, and presence/ ab sence of  
nephrectomy) of metastatic RCC mortality. [4] The 
developed Motzer score stratified patients between 
f avo rab le (0  risk f actors), intermediate (1- 2 risk 
f actors), and poor risk (>3 risk factors). [4] In 2002, 
an update of the Motzer score (n 463) replaced 
nephrectomy statu s w ith time f rom diag nosis to 
start of interferon. [5] In 2004, a second update 
(n 251) reduced the score to three predictors (KPS, 
hemoglobin, and corrected calcium). [6]
In 2005, Mekhail et al. suggested several modifi-
cations to the 20 0 2 M otze r score va riab les (K PS, 
lactate dehyd rog enase, hemog lob in, corrected calci--
um, and time from diagnosis to start of interferon) [5] 
su ch as addition of  previ ou s exp osu re to radiother--
apy and va riab les indicating  the presence of  nodal, 
hepatic, and/or lung metastases (n 353; T a b l e  1). [7]
I n 20 0 7 , Escu dier et al. also su g g ested the replace--
ment of  K PS w ith the nu mb er of  metastatic sites. 
[8]Unfortunately, none of the original Motzer models 
w ere f ormally va lidated. I n consequ ence, their ac--
cu racy , perf ormance characteristics and impact on 
clinical decision- maki ng  remain u nkn ow n. 
A report f rom the G r o u p e F r a n ça i s d ’ I mmu n o th é r a p i e 
su g g ested a dif f erent prog nostic model, w hich 
identified four variables that were statistically 
significantly associated with progression in patients 
receivi ng  immu notherapy ( T a b l e  1 ). T hese consisted 
of  time f rom R C C  diag nosis to metastases, nu mb er 
of  metastatic sites, presence of  hepatic metastases, 
and of theneutrophil count. [9] Recently, Heng et al. 
[10] devised and internally validated a model that 
replicates the M otze r methodolog y and relies on 
four of five Motzer criteria (hemoglobin, corrected 
calciu m, K PS and time f rom diag nosis to treatment), 
in addition to neu trophil and platelet cou nts. O f  all 
models, the Heng et al.[10] model was the only one 
su b j ected to internal (b ootstrap) va lidation, w hich 
show ed 7 3%  accu racy in predictionof  mortality 
af ter therapy w ith va scu lar endothelial g row th f actor 
(V EG F ) therapy . I t aw aits its ext ernal va lidation.
T he M otze r, M ikh ail, G r o u p e F r a n ça i s d ’ I mmu -
n o th é r a p i e nd H eng  models excl u sive ly apply to 
patients w ith metastatic R C C . O ther models have  
b een deve loped f or patients w ith all stag es or non-
metastatic R C C . F or exa mple, inve stig ators f rom 
U nive rsity of  C alif ornia L os Ang eles (U C L A) devi sed 
an integ rated stag ing  syst em (U I SS) f or prediction 
of  su rvi va l in patients w ith all stag es of  R C C 
I. InT RoD uCT Ion
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T abl e 1.  P rediction of ov eral l  surv iv al  and/ or progression- free surv iv al  in metastatic renal  cel l  carcinoma
M o d e l sa m p l e
s i ze
T a r g e t  p o p u l a t i o nP r e d i c t o r s c - i n d e x
Elson et al. [3] 6 10 mR C C - EC O G - PS 
-  time f rom initial diag nosis 
-  N u mb er of  metastatic sites 
-  prior cyt oxi c chemotherapy  
-  w eig ht loss
n.r.
Motzer et al. [4] 6 7 0 mR C C  treated w ith N T -  lactate dehyd rog enase > U L N  
-  hemog lob in > U L N  
-  K PS 
-  corrected seru m calciu m > U L N  
-  ab sence of  N T
n.r.
Motzer et al. [5] 4 6 3 mR C C  treated w ith N T / I N F -  K PS 
-  lactate dehyd rog enase < U L N  
-  hemog lob in > U L N  
-  corrected seru m calciu m > U L N  
-  time f rom diag nosis to I F N
n.r.
Motzer et al. [6] 25 1 mR C C  treated w ith N T / I N F -  K PS 
-  hemog lob in > U L N  
-  corrected seru m calciu m > U L N
n.r.
Negrier et al. [147] 7 8 2 mR C C  treated w ith cyt oki ne -  presence of  b iolog ical sig ns of  
inÀammation 
-  short time interva l f rom renal tu mor 
to mR C C  
-  eleva ted neu trophil cou nt 
-  live r metastases 
-  b one metastases 
-  perf ormance statu s 
-  nu mb er of  metastatic sites 
-  alka line phosphotase 
-  hemog lob in
n.r. (O S)
Negrier et al. [147] 7 8 2 mR C C  treated w ith cyt oki ne-  presence of  hepatic metastases 
-  short interva l f rom renal tu mor to 
metastases 
-  > 1 metastatic site 
-  eleva ted neu trophil cou nt
n.r. (PF S)
L eib ovi ch et al. 
[152]
17 3 mR C C  treated w ith N T / I L - 2- N classification 
-  constitu tional sym ptoms 
-  location of  metastatic sites 
-  histolog ical su b typ e 
-  sarcomatoid f eatu res 
-  thyr oid stimu lating  hormone leve ls
n.r.
L eib ovi ch et al. 
[126]
7 27 metastatic clear cell R C C  
treated w ith N T
-  ag e 
-  g ender 
-  sym ptoms at N T  
-  time f rom N T  to mR C C  
-  location/ su rg ical treatment of  
metastases 
-  presence/ leve l of  tu mor thromb u s 
-  histolog ical su b typ e 
-  T N M  (20 0 2) 
-  tu mor size  
-  perinephritic f at inva sion 
-  lym ph node inva sion 
-  nu clear g rade 
-  tu mor necrosis 
-  sarcomatoid dif f erentiation
6 7 .0 %
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Negrier et al. [9] 7 8 2 mR C C  patients treated w ith 
cyt oki ne
-  > 1 metastatic site 
-  havi ng  receive d comb ination of  
therapies
n.r. 
(efficacy)
Mekhail et al. [7] 35 3 mR C C -  mu ltif ocality  
-  time f rom diag nosis to stu dy entry  
-  lactate dehyd rog enase > U L N  
-  corrected seru m calciu m > U L N  
-  previ ou s radiotherapy  
-  presence of  hepatic/ pu lmonary/  
retroperitoneal/ lym ph node 
metastases
n.r.
D onsko v et al. 
[184]
120 mR C C  patients treated w ith 
I L - 2
-  lactate dehyd rog enase 
-  lym ph node metastases 
-  hemog lob in 
-  K PS 
-  b one metastases 
-  hig h b lood neu trophil cou nt 
-  presence of  intratu moral neu trophils 
-  low  intratu moral C D 5 7 +  natu ral ki ller 
cell cou nt
n.r.
C hou eiri et al. 
[183]
120 mR C C  patients treated w ith 
V EG F  ag ents
-  corrected seru m calciu m > U L N  
-  neu trophil cou nt > U L N  
-  platelet cou nt > U L N  
-  EC O G - PS 
-  time f rom diag nosis to stu dy start
n.r.
Escudier et al. [8] 30 0 mR C C  patients w ho f ailed 
immu notherapy
-  alka line phosphatase > U L N  
-  corrected seru m calciu m > U L N  
-  lactate dehyd rog enase > U L N  
-  nu mb er of  metastatic sites 
-  time f rom diag nosis to metastatic 
diag nosis
n.r.
Motzer et al. [185] 37 5 mR C C  patients treated w ith 
su nitinib
-  corrected seru m calciu m 
-  nu mb er of  metastatic sites 
-  hemog lob in > U L N  
-  prior N T  
-  lu ng  metastases 
-  live r metastases 
-  EC O G - PS 
-  thromb ocyt osis 
-  time f rom diag nosis to treatment 
-  alka line phosphotase 
-  lactate dehyd rog enase
6 3.0 %
Heng et al. [10] 6 4 5 mR C C  patients treated w ith 
V EG F  ag ents
-  K PS 
-  time f rom diag nosis to treatment 
-  hemog lob in > U L N  
-  corrected seru m calciu m > U L N  
-  neu trophil > U L N  
-  platelet > U L N
7 3.0 %
T abl e 1.  P rediction of ov eral l  surv iv al  and/ or progression- free surv iv al  in metastatic renal  cel l  carcinoma 
( continued)
L egend: mR C C :  meta st a ti c r en a l  ce l l  ca r ci n o ma ;  E C O G - P S :  E a st er n  C o o p er a ti ve  O n co l o g y G r o u p  P er f o r ma n ce  
S ta tu s;  N T :  n ep h r ect o my;  U LN :  u p p er  l i mi t n o r ma l ;  K P S :  K a r n o f sky p er f o r ma n ce  st a tu s;  I N F :  i n ter f er o n ;  O S :  o ve r a l l  
su r vi va l ;  P F S :  p r o g r essi o n - f r ee su r vi va l ;  I L2- :  i n ter l eu ki n2- ;  VE G F :  va scu l a r  en d o th el i a l  g r o w th  f a ct o r ;  n . r . :  n o t 
r ep o r ted
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( T a b l e  2 ). [11, 12] This model relies on the TNM stage, 
F u hrman g rade, and EC O G - PS and has b een w idely 
tested and validated (c-indices: 58-86). [13-19] A 
mu lti- institu tional collab orative  g rou p of  Eu ropean 
and N orth American inve stig ators deve loped tw o 
prognostic models that address RCC-specific 
mortality b ased on va riab les that can b e ob tained 
either prior ( T a b l e  3 ) to or af ter nephrectomy ( T a b l e  
4 ). T hese tw o models can predict the natu ral history 
of  R C C  af ter nephrectomy . H ow eve r, they are 
not desig ned to accou nt f or the ef f ect of  targ eted 
therapies in patients with metastatic RCC. [20, 21] 
T he accu racy of  the pre- nephrectomy model f or 
prediction of cancer-specific mortality at 5 yearsis 
8 6 .7 %  vs.  8 6 .8 %  f or the post- nephrectomy model 
( T a b l e  2 ). Similar models w ere deve loped b y  other 
inve stig ators and allow  estimation of  recu rrence-
free survival [22, 23] or metastatic progression 
after nephrectomy,[24] with accuracy rates between 
6 5  and 8 0 % .  M u ltiva riab le models su ch as the 
UISS[11], the Kattan postoperative nomogram[25], 
BioScore[26], and SSIGN score (tumor stage, size, 
grade, necrosis) [27] have better prognostic ability 
than anatomical stag ing  alone ( T a b l e  4 ).  D espite their 
Table 2. Postoperative assessment of cancer-specific mortality
M o d e l sa m p l e
s i ze
T a r g e t  p o p u l a t i o nP r e d i c t o r s c - i n d e x
=isman et al. [11] 6 6 1 R C C  of  all stag es -  AJC C 
-  F u hrman g rade 
-  EC O G - PS
8 2.0 - 8 6 .0 %
=isman et al. [12] 8 14 R C C  of  all stag es -  T N M  (19 9 7 ) 
+  EC O G - PS
7 3.0 %  
7 9 .0 - 8 6 .0 %
Frank et al. [27] 18 0 1 L ocalize d clear cell R C C-  T N M  (19 9 7 ) 
-  tu mor size  
-  nu clear g rade 
-  tu mor necrosis
8 5 .0 %  (int.) 
8 1.0 - 8 2.0 %  (va l.)
Kim et al. [97] 318 R C C  of  all stag es -  M  stag e 
-  metastatic C AI X  
-  p5 3 
-  vi mentin 
-  g elsolin
7 9 .0 %
Kim et al. [182] 15 0 M etastatic clear cell R C C-  T  stag e 
-  EC O G - PS 
-  C AI X  
-  vi mentin 
-  p5 3 
-  PT EN
6 8 .0 %
T hompson et al. 
[187]
15 6 0 L ocalize d clear cell R C C-  T N M  (19 9 7 ) 
-  tu mor size  
-  nu clear g rade 
-  tu mor necrosis
n.r.
K araki ew icz et 
al. [20]
25 30  (dev .) 
14 22 (va l.)
C lear cell, papillary , 
chromophob e R C C
-  pT  stag e 
-  pN  stag e 
-  M  stag e 
-  tu mor size  
-  F u hrman g rade 
- Symptoms classification
8 7 .8 - 8 9 .2%  (va l.)
K araki ew icz et al. 
[188]
25 30  (dev .) 
35 6 0  (va l.)
R C C  of  all stag es -  pT  stag e 
-  pN  stag e 
-  M  stag e 
-  tu mor size  
-  F u hrman g rade 
- Symptoms classification
8 7 .0 - 9 1.0 %  (va l.)
Parker et al. [26] 8 18 C lear cell R C C -  B 7 - H 1 
-  su rvi vi n 
-  K i- 6 7
7 3.3%
L egend: R C C : r en a l  ce l l  ca r ci n o ma ;  E C O G - P S :  E a st er n  C o o p er a ti ve  O n co l o g y G r o u p  P er f o r ma n ce  S ta tu s;  i n t. :  
i n ter n a l ;  va l . :  va l i d a ti o n ;  d ev . :  d eve l o p men t
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T abl e 3 .  P reoperativ e assessment of prognosis
M o d e l sa m p l e  s i ze ou t c o m e c - i n d e x
Yaycioglu et al. [23] 29 6 R ecu rrence af ter nephrectomy 6 5 .1%
Cindolo et al. [22] 6 6 0 R ecu rrence af ter nephrectomy 6 7 .2%
RaM et al. [187] 29 0  (dev .) 9 4  (va l.) C lear cell R C C 8 2%  (dev .) 7 6 %  (v al.)
Lane et al. [188] 8 5 1 B enig n vs.  malig nant 
I ndolent vs.  ag g ressive
6 4 .4 %  
5 5 .7 %
Hollingsworth et al. [189] 26 6 18 C SM  and O S n.r.
Hutterer et al. [190] 25 22 (dev .) 2136  (v al.)L ym ph node metastases at 
nephrectomy
7 8 .4 %
RaM et al. [24] 25 17 M etastatic recu rrence af ter 
nephrectomy
8 0 .0 %
Karakiewicz et al. [21] 24 7 4  (dev .) 19 7 2 (v al.)C SM 8 4 - 8 8 %
Hutterer et al. [191] 26 6 0  (dev .) 27 16  (v al.)D istant metastases at nephrectomy 8 5 .0 %
Kutikov et al. [192] 30 8 0 1 C SM , O C M , N C M n.r.
L egend: dev.: development; val.: validation; n.r.: not reported; CSM: cancer-specific mortality; OCM: other-cancer 
mo r ta l i ty;  N C M :  n o n - ca n ce r  r el a ted  mo r ta l i ty;  O S :  o ve r a l l  su r vi va l ;  R C C :  r en a l  ce l l  ca r ci n o ma
T abl e 4 .  P ostoperativ e assessment of recurrence
M o d e l sa m p l e  
s i ze
T a r g e t  p o p u l a t i o nP r e d i c t o r s c - i n d e x
Kattan et al. [25] 6 0 1 L ocalize d R C C - symptom classification 
-  histolog ical su b typ e 
-  tu mor size  
-  pT  stag e
7 4 .0 %  (ove rall 
rec.)
Frank et al. [193] 18 6 4 L ocalize d clear cell R C C -  ag e 
-  g ender 
- symptom classification 
-  T N M  (19 9 7 ) 
-  nu clear g rade 
-  tu mor necrosis 
-  sarcomatoid f eatu re 
-  cyst ic architectu re 
-  mu ltif ocality  
-  su rg ical marg in statu s 
-  nephrectomy typ e
8 0 .5 %  
(ab dominal rec.) 
8 2.6 %  (thoracic 
rec.) 
8 0 .0 %  (b one 
rec.)
Sorbellini et al. [194] 7 0 1 L ocalize d clear cell R C C- symptom classification 
-  tu mor size  
-  pT  stag e 
-  F u hrman g rade 
-  tu mor necrosis 
-  va scu lar inva sion
8 2.0 %  (ove rall 
rec.)
Lam et al. [195] 5 5 9 L ocalize d/ locally adva nced 
R C C
-  T N M  (19 9 7 ) 
-  nu clear g rade 
-  EC O G - PS
n.r. (solitary rec.,  
chest rec.,  
ab dominal rec., 
b one rec., 
b rain rec.)
L egend: R C C :  r en a l  ce l l  ca r ci n o ma ;  r ec. :  r ecu r r en ce ;  E C O G - P S :  E a st er n  C o o p er a ti ve  O n co l o g y G r o u p  
P er f o r ma n ce  S ta tu s;  n . r . :  n o t r ep o r ted
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adequ ate prog nostic ab ility , none of  these models 
is 10 0 %  accu rate.  I n consequ ence, the search 
f or more accu rate marke rs continu es.M olecu lar 
ev ents that can u nve il the b iolog ical heterog eneity 
u nderlyi ng  the va ried clinical b ehavi or of  R C C  may 
help in improvi ng  indivi du alize d prog nostication and 
risk-stratified clinical decision-making.  The hope and 
interest lies in the identification of accurate markers 
that w ill predict the responses to the exi sting  ef f ective  
but toxic systemic therapies[28-32].
O ve r the past tw o decades, the molecu lar dissection 
of  cancer has increased ou r u nderstanding  of  the 
pathw ays that are altered in neoplastic cells.W hile 
some b iomarke rs w ere show n to b e associated 
w ith other estab lished clinical and/ or patholog ical 
characteristics of  R C C ( T a b l e  5 ), others demonstrated 
a meaning f u l ef f ect w ith prog ression- f ree su rvi va l, 
overall survival, cancer-specific mortality, prognosis, 
and eve n added va lu e w hen incorporated w ith 
ex isting  prog nostic models ( T a b l e  6 ). T he f ollow ing  
parag raphs w ill ou tline the exi sting  b iomarke rs, 
w hich demonstrated a potential f or improvi ng  the 
predictive  and/ or prog nostic ab ility of  clinical and 
patholog ic va riab les. 
III. RCC B IoM A RK eRs
1 . T Issue- B A seD  B IoM A RK eRs
a)  V on- H ippel L indau ( V H L )  gene
T he V H L  g ene w as orig inally describ ed, isolated, 
and identified as a tumor suppressor gene on 
chromosome 3p resulting in deficient protein 
isof orms pV H L 19  and pV H L 30  ( fi g . 1 ). I ts 
ab sence in the V H L  f amilial tu mor syn drome 
predisposes to retinal ang iomas, central nervo u s 
sy stem hemang iob lastomas, pancreatic tu mors, 
pheochromocyt omas and mu ltiple b ilateral clear cell 
RCC lesions. [33] VHL is inactivated in almost all 
patients w ith V H L  syn drome and approxi mately 7 0 %  
of sporadic clear cell RCC. [34] Alteration in the VHL 
proteins resu lts in impaired deg radation of  hyp oxi a 
induced factor 1-alpha (HIF-1α), which accumulates 
ev en u nder normal (non- hyp oxi c) conditions.  O ther 
V H L  g ene ef f ects inclu de reg u lation of  the cell- cycl e 
arrest vi a p5 3 and deposition of  ext racellu lar matrix.
Presence of  V H L  alterations (mu tation or 
hy permethyl ation) predicts long er prog ression- f ree 
su rvi va l and low er mortality f or stag e I - I I I  clear cell 
RCC (p 0.024 and 0.023, respectively). [34] However, 
the su rvi va l rate of  patients w ith V H L  mu tations w as 
not dif f erent f rom patients w ithou t V H L  mu tations in 
other analyses. [35] The investigators postulated that 
reg u lation of  ang iog enesis and prolif eration of  R C C  
is not directly inÀuenced by VHL mutations, but that 
³loss-of-function´ VHL mutations directly inÀuence 
the prog ression of  R C C . 
R ini et al. show ed that 6 0 %  of  metastatic R C C  
patients had V H L  mu tations and that 4 8 %  of  those 
p tients achieve d an ob j ective  response to targ eted 
therapy vs.  35 %  f or patients w ith no V H L  mu tation 
or ethylation. [36]The independent prognostic 
ef f ect of  V H L  mu tation w as also reported eve n af ter 
adj u sting  f or EC O G - PS, hemog lob in, corrected 
calciu m, lactate dehyd rog enase, radiation exp osu re, 
previous therapy and number of metastatic sites. [37] 
In pazopanib-treated patients, a 76 clinical benefit 
rate (partial response+ stab le disease) w as achieve d 
in patients w ith V H L  g ene va riation vs.  6 3%  in those 
without. [38]Similar findings were recorded, where 
loss- of - f u nction V H L  mu tation conf erred a 5 2%  
response rate (partial response+ complete response) 
to targ eted therapies vs.  31%  f or w ild- typ e V H L  
(p 0.04). [39] Additional studies are clearly needed to 
b etter elu cidate the role of  V H L  mu tations in sporadic 
R C C , especially in the context  of  targ eted therapies. 
However, added data quantifying the added benefit 
and ext ernally va lidated accu racy resu lts of  models 
that integ rate V H L  are not ye t ava ilab le.
b) Hypoxia Inducible Factor (HIF-α)
HIF-α accumulates either in hypoxic cell conditions 
or when pVHL is deficient ( fi g . 1 ). I ncreased 
expression of HIF-α was recorded in 75 (24/32) 
of  clear cell R C C  and only 38 %  (3/ 8 ) of  non- clear 
cell RCC cases. [40] None of the HIF-1α-negative 
clear cell R C C  patients show ed a mu tation of  the 
VHL gene. The level of HIF-α appeared to correlate 
w ith the presence of  V H L  mu tation. L idg ren et al. 
showed that clear cell RCC variant had significantly 
higher HIF-1α expression compared to papillary 
or chromophobe RCC variants. [41]Prognostic 
significance of HIF-α levels was recorded only in 
patients with clear cell RCC (p 0.02; Fig. 2A), but 
not in patients with papillary RCC (p 0.2). [41]
T he same au thors reported no su rvi va l dif f erence 
between patients with high and low HIF-1α expression 
in either clear cell or papillary R C C  va riants (all p> 0 .1). 
[42] Conversely, Klatte et al. showed worse survival 
(13.5 vs. 24.4 months, p 0.005) with elevated HIF-
1α tumor tissue levels( fi g . 2B ). M ethodolog ical and 
analyt ical dif f erences may accou nt f or the dif f erent 
findings. [43]
I n patients exp osed to su nitinib , hig h leve ls of  H I F -
1α (p 0.003) or of HIF-2α (p 0.001) confer more 
favorable response (defined as complete or partial 
response) to therapy. [44] Clearly, standardized 
methodolog y and more stu dies are needed to b etter 
u nderstand the prog nostic and predictive  role of  
HIF-α. Added value and external validity data are 
aw aited.
Va s c u l a r  e n d o t h e l i a l  g r o w t h  f a c t o r  ( VeG f)
V EG F , a dimeric g lyco protein and a memb er of  
the platelet- derive d g row th f actor, af f ects tu mor 
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T abl e 5 .  M ol ecul ar mark er and its association w ith other establ ished cl inical  and/ or pathol ogical  characteristics 
of renal  cel l  carcinoma ( RCC) .
M a r k e r H i s t o l o g y T u m o r  
s t a g e
T u m o r  
s i ze
T u m o r  
n e c r o s i s
T u m o r  
g r a d e
M e t a s t a t i c
d i s e a s e /
p r o g r e s s i o n
ot h e r
N eu trophil
C - reactive  
protein
+
V H L +
HIF-α + (clear cell)
T issue- based
V EG F + / ns (papillary) + + + + Predictor of  
microve ssel 
inva sion
C AI X ns ns +
mT O R
pS6 +
PT EN +
pAkt + +
O ther
C ave olin- 1 +  (clear cell)
p5 3 +  (papillary) +
K i- 6 7
Su rvi vi n +  (all H S) + Predictor of  
ag g ressive  disease
B 7 - H 1 +
V imentin +  (clear cell/
papillary)
F ascin +  (sarcomatoid) + + +
M M P +  (non clear cell) + Predictor of  
ag g ressive  disease
I M P3 +  (sarcomatoid) + + + Predictor of  lym ph 
node invo lve ment
B l ood- based
V EG F
C AI X +  (clear cell) + / ns + ns
N G AL
SAA +
I G F - I
N M P- 22 Predictor of  R C C  
diag nosis
L egend: +: associated with; ns: not significant
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Table 6. Molecular marker and its association with progression-free survival (PFS), overall survival (OS), 
cancer-specific mortality (CSM), prognosis, treatment efficacy and its added value in established risk 
stratification for renal cell carcinoma (RCC).
M a r k e r P r o g n o s i s P fs osCsM T r e a t m e n t  
eIficac\
A d d e d  
v a l u e  i n  
p r o g n o s t i c  
m o d e l s
N eu trophil + +  (in I L - 2 patients) + ns (low  response rate 
in I L - 2 patients)
+  
(L eib ovi ch)
C - reactive  
protein
+ +
V H L + / ns + / ns + +  (predicts response to 
targ eted therapy)
+
HIF-α + +  (predicts response to 
su nitinib )
T issue- based
V EG F + +
C AI X + +
mT O R
pS6 + +  (predicts response to 
temsirolimu s)
PT EN + +  (predicts response 
to mT O R  inhib itors)/
ns (low  response in 
temsirolimu s)
pAkt +  (f or 
localize d and 
metastatic 
R C C )
+ +  (predicts response to 
temsirolimu s)
O ther
C ave olin- 1 + / ns (coexp ression 
w ith Akt / mT O R )
p5 3 ns
K i- 6 7 + + +  
(coexp ression 
w ith C AI X )
Su rvi vi n + +
B 7 - H 1 + +
V imentin +
F ascin
M M P +
I M P3 + + +  (SSI G N )
B l ood- based
V EG F + / ns + / ns (in metastatic 
R C C )/ +  (in 
soraf enib  patients)
+  (predicts response 
rate in su nitinib )/ ns 
(does not predict 
response rate in 
soraf enib )
C AI X + +
N G AL +
SAA +
I G F - I +
N M P- 22
L egend: +: association; ns: not significant
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ang iog enesis in b oth normal and patholog ic conditions 
( fi g . 1 ) . I n tu mors, ang iog enesis is indu ced b y 
V EG F . I n clear cell R C C , the u preg u lation of  V EG F  
mR N A is exp ected du e to the dysr eg u lation of  H I F -
1α as a result of the loss of VHL protein in addition 
to the hyp oxi c envi ronment.  L arg er tu mors have  
inadequ ate b lood su pply and exa cerb ate hyp oxi a 
cau sing  f u rther u preg u lation of  V EG F  exp ression. 
Enhanced V EG F  concentration correlates w ith 
VHL gene inactivation. [45, 46] Increased VEGF 
produ ction occu rs in R C C  patients w ith V H L  g ene 
alterations (p< 0 .0 0 1) and adva nced g rade (p< 0 .0 0 1). 
[47] Elevated VEGF expression was reported in 29 
of  patients w ith clear cell R C C  and u nexp ectedly in 
67 of patients with papillary RCC (p 0.02) [48], but 
could not be confirmed in other studies [49]. In clear 
cell R C C , V EG F  exp ression correlates w ith tu mor 
size (p 0.05) [48], Fuhrman grade (p 0.002), tumor 
necrosis (p 0.001), tumor stage (p 0.006)[50], 
microvessel invasion (p 0.01)[51], RCC progression 
rate (p 0.01)[50], and RCC-specific survival( fi g . 3 ). 
[48-50] Further confirmatory studies are needed to 
assess V EG F  pathw ay w ith dow nstream molecu les 
su ch as phospho- ext racelu llar sig nal- reg u lated 
ki nase (pER K ) possib ly servi ng  as b iomarke r 
f or therapy response. D espite its promising  
characteristics, VEGF awaits confirmation of its 
added va lu e and ext ernal va lidity . 
c) Carbonic Anhydrase I; (CAI;)
CAI; is a HIF-1α regulated transmembrane protein 
associated w ith neoplastic g row th, ag g ressive  tu mor 
phenotyp e, and poor prog nosis in a larg e spectru m 
of  hu man tu mors ( fi g . 1 ). [52-55] CAI; is thought to 
assist in reg u lating  intra- cellu lar and ext racellu lar pH  
lev ls i  response to tu moral hyp oxi a and su b sequ ent 
anaerob ic metab olism.  I n R C C , especially clear 
cell R C C , C AI X  can estab lish the diag nosis as it is 
exp ress d in ove r 8 0 %  of  R C C  samples and 9 0 %  of  
clear cell R C C  specimens. I nteresting ly , hig h C AI X  
exp ression is associated w ith b etter prog nosis in 
localized RCC and metastatic RCC. [56-60]
F or exa mple, C AI X  staining  leve ls have  b een 
show n to b e inve rsely related to metastatic spread 
(p 0.036) and high CAI; expression predicted 
b etter su rvi va l ( fi g . 4 ), eve n af ter adj u sting  f or the 
ef f ects of  T  stag e, F u hrman g rade, nodal statu s, and 
perf ormance statu s (all p<0.005). [57] Moreover, low 
C AI X  staining  (<8 5 % ) predicted w orse ou tcome in 
patients with metastatic RCC (HR: 3.10, p0.001) [57] 
nd eve n af ter adj u stment f or the ef f ects of  clinical 
and patholog ic characteristics (H R :  4 .7 6 , p< 0 .0 0 1) 
[56]. Similar findings were reported in patients 
who received interleukin-2 therapy (p 0.04). [60] 
H ow eve r, low  C AI X  exp ression w as not associated 
Figure 1. Biological pathways and markers in renal cell carcinoma.
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w ith R C C  death af ter adj u sting  f or the ef f ect of  tu mor 
grade (p 0.3) or coagulative tumor necrosis (p 0.1). 
[61] Data from ongoing trials will hopefully provide 
better insight in this highly promising marker. [62, 
63] Besides prognostic value, the tumor-specific and 
hig h prev alence of  C AI X  in R C C  make s it a g reat 
targ et f or imag ing  and therapy u sing  monoclonal 
antib odies su ch as G 25 0 .
d) Mammalian target of rapamycin (mTOR)
T he mT O R  pathw ay reg u lates cell g row th and its 
u p- reg u lation in tu mors contrib u tes to many critical 
cell lar f u nctions su ch as protein deg radation and 
ang iog enesis ( fi g . 1 ). [64] The prognostic role of 
mT O R  as a b iomarke r is sparse and non- conclu sive . 
However, mTOR inhibitors (temsirolimus[31], 
everolimus[32]) have come to represent agents 
of  choice f or metastatic R C C . T he prog nostic and 
predictive  releva nce of  mT O R  and its u pstream (i.e., 
PT EN ) and dow nstream (i.e., phosphoryl ated S6  
rib osomal protein-  see b elow ) molecu les are b eing  
critically eva lu ated to identif y responders to these 
ag ents.
Figure 2. Kaplan-Meier survival curves stratified according to high vs. low HIF-1α levels in patients with clear 
cell renal cell carcinoma [41, 43]
Figure 3. Kaplan-Meier survival curves stratified according to VEGF negative vs. VEGF positive tumors (A) 
[48] and prognostic factors associated with survival in multivariable analyses (B) [48]
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e) Ribosomal protein S6
R ib osomal protein S6  (pS6 ), a dow nstream 
mTOR target, has S6 kinase activity [65] and 
the phosphoryl ated S6  (pS6 ) protein af f ects its 
dow nstream targ ets, altering  mR N A translation 
( fi g . 1) .[66]pS6 is differentially overexpressed 
in metastatic clear cell R C C  and appears to b e 
associated w ith activa tion of  the mT O R  pathw ay . 
[67]pS6 is a predictor of survival in both localized 
(HR: 3.14, p 0.002) and metastatic RCC (HR: 1.55, 
p 0.04). [67] Indeed high expression of S6 kinase 
(p 0.02) predicted response to temsirolimus in 20 
patients [68]and may prove to be useful in predicting 
optimal b iolog ic doses of  mT O R  inhib itors (i.e. 
everolimus) [69].
f) Protein Kinase B (pAkt)
pAkt , also called protein ki nase B , reg u lates b oth 
g row th and su rvi va l mechanisms b y phophoryl ating  
a w ide spectru m of  su b strates in the cyt oplasm 
and the nu cleu s ( fi g . 1 ). [70] In univariable, 
b u t not mu ltiva riab le, analyse s, eleva ted  pAkt  
immu nostaining  w as associated w ith hig her g rade 
(p 0.04), higher rate of metastatic disease (p 0.004) 
and poorer RCC-specific survival (p 0.01). [71] 
O thers reported a f avo rab le prog nosis in localize d 
RCC with high pAkt expression (HR: 0.66, p 0.3, Fig. 
5A). [67] Conversely, poor prognosis was reported 
w ith hig h cyt oplasmic pAkt  exp ression in metastatic 
RCC (HR: 1.31, p 0.2, Fig. 5B). [67] It is noteworthy 
that nu clear pAkt  exp ression w as hig her in localize d 
RCC tissue than in metastatic RCC tissue. [67] As 
su ch, the localiza tion of  pAkt  may b e releva nt f or 
determination of  its ef f ect on tu mor b ehavi or and 
resu lting  prog nostic va lu e. 
Tumor samples from a subset of patients (n 19) 
w ithin a randomize d phase I I  trial of  temsirolimu s 
in metastatic RCC were studied. [68]High pAkt 
ex pression may predict response to temsirolimu s 
treated patients with advanced RCC (p 0.07). 
O b j ective  tu mor response w as ob serve d only in 
patients with high expression of pAkt. Confirmation 
of these findings is necessary before conclusions 
can b e made.
g) PTE1
PT EN  is a tu mor su ppressor protein that is encoded b y 
the tu mor su ppressor g ene P T E N ( fi g . 1 ). U pstream 
to mT O R , the phosphatase PT EN  reg u lates the 
mT O R  pathw ay b y inhib iting  Akt  phosphryl ation 
through PI3K. [72, 73] While PTEN mutation may be a 
rare eve nt, P T E N loss occu rs du ring  carcinog enesis 
and is associated w ith adve rse prog nosis in R C C . 
[72, 73] PTEN expression is higher in tumors with 
low er T  stag e, non- clear cell R C C , and localize d 
stag e. H ig h PT EN  exp ression improve s su rvi va l 
(HR: 0.74, p 0.3). [67]mTOR inhibitors may be most 
beneficial in patients with low PTEN expression. 
H ow eve r, recently no correlation b etw een b aseline 
PTEN and temsirolimus efficacy was found in poor-
risk metastatic R C C  patients( fi g . 6). [74]
h)  A l ternativ e biomark ers
su r v i v i n
D ereg u lation of  apoptosis is a hallmark in hu man 
carcinog enesis, f acilitating  the acqu isition of  
deleteriou s cancer traits, inclu ding  loss of  tu mor 
su ppressor g enes, ang iog enic chang es and 
immortaliza tion ( fi g . 1 ).  Su rvi vi n is a memb er of  the 
inhib itor of  apoptosis (I AP) g ene f amily that has b een 
f ou nd to control mitotic prog ression and indu ces 
chang es in g ene exp ression that are associated w ith 
tu mor cell inva sive ness.  Su rvi vi n mR N A is selective ly 
exp ressed du ring  emb ryo nic and f etal deve lopment, 
b ecomes u ndetectab le or exp ressed at low  leve ls in 
most dif f erentiated normal adu lt tissu es, and is ove r-
expressed in humans cancers, [75-79] including 
RCC [80]. Survivin is expressed in all RCC variants. 
[81]High survivin expression( fi g . 7 ) is associated 
w ith poor dif f erentiation, more ag g ressive  b ehavi or 
Figure 4. Kaplan-Meier survival curves stratified according to high levels of CAI; vs. low levels of CAI; 
in patients with clear cell renal cell carcinoma (A) [56] and survival curves stratified according to CAI; 
expression and metastatic status (B) [57]
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(all p0.05) [81], and lower survival in clear cell RCC 
(eve n af ter adj u sting  f or the ef f ects of  EC O G - PS, 
TNM and grade(HR: 2.4, p0.001) [82]. In localized 
R C C , hig h su rvi vi n exp ression predicted disease 
progression (HR: 1.9, p 0.02). [82]
B 7 - H 1
B 7 - H 1 is a cell- su rf ace g lyco protein w ithin the B 7  
family of T-cell costimulatory molecules. [83] B7-H1 
expression inhibits tumor-specific T-cell-mediated 
immu nity throu g h indu ction of  T - cell apoptosis, 
impairs cyt oki ne produ ction, and diminishes the 
cytotoxicity of activated T cells. [84-88] High B7-
H 1 exp ression w as associated w ith hig her R C C -
specific (HR: 3.92, p0.001) and all-cause mortality 
(H R :  2.37 , p< 0 .0 0 1) in 30 6  patients treated w ith 
nephrectomy for clear cell RCC. [89-91] In localized 
disease, tu mors w ith hig h B 7 - H 1 exp ression w ere 
more like ly to metastasize  (H R :  4 .13, p< 0 .0 0 1) eve n 
af ter adj u sting  f or the ef f ects of  T  stag e, g rade, 
and performance status (HR: 1.78, p 0.04). [89] In 
localized clear cell RCC (HR: 3.32, p 0.002), as well 
as in all R C C  stag es (H R :  3.25 , p< 0 .0 0 1), hig h B 7 - H 1 
ex pression in comb ination w ith su rv ivi n exp ression 
predicted hig her mortality af ter adj u sting  f or the 
ef f ects of  T N M  stag e, tu mor g rade, and EC O G - PS 
(n 298, fi g . 8). [92]
p 5 3
p5 3 protein is a D N A b inding  molecu le invo lve d in the 
reg u lation of  transcription ( fi g . 1 ). [93] p53 has an 
important role in reg u lating  cell g row th and prolif eration 
b y stopping  cell cycl e and indu cting  apoptosis w hen 
DNA damage occurs. [94] p53 mutations allow 
detection throu g h immu nohistochemical staining  
due to its extended half-life. [95] p53 overexpression 
in papillary , chromophob e and clear cell R C C  w as 
recorded in 7 0 , 27 , and 12%  of  tu mors,respective ly . 
[96] p53 overexpression was an independent 
predictor of  metastasis- f ree su rvi va l in patients w ith 
localized clear cell RCC (p 0.01). [96] The prognostic 
role of  p5 3 in R C C  remains controve rsial w ith stu dies 
f ailing  to show  any independent prog nostic va lu e f or 
survival (HR: 1.75, p 0.07). [97] In other studies, its 
prognostic significance was limited to patients with 
localized disease only (p 0.002). [98]
Figure 6. Correlation between baseline PTE1 and temsirolimus efficacy in patients with poor-risk metastatic 
renal cell carcinoma [74]
Figure 5. Kaplan-Meier survival curves stratified according to protein expression of cytoplasmic pAkt in 
metastatic renal cell carcinoma (A) [67] and stratified according to protein expression of nuclear pAkt in 
localized renal cell carcinoma (B) [67]
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Figure 8. Illustration of proposed survivin and B7-H1 interaction [92]
Figure 7. Kaplan-Meier survival curves stratified according to low expression (score 1) vs. high expression 
(score 2–4) of survivin of patients with clear cell renal cell carcinoma [81]
88
M a t r i x  m e t a l l o p r o t e i n a s e s
T he matrix metalloproteinase (M M P) f amily of  
enzym es is comprised of  critically important 
ex tracellu lar matrix remodeling  proteases w hose 
activi ty has b een implicated in a nu mb er of  ke y 
normal and patholog ic processes ( fi g . 1 ). T he latter 
inclu de tu mor g row th, prog ression, and metastasis 
as w ell as the dysr eg u lated ang iog enesis that is 
associated w ith these eve nts. As a resu lt, these 
proteases have  come to represent important 
therapeu tic and diag nostic targ ets f or the treatment 
and detection of  hu man cancers.  I n R C C , M M P2 
and M M P9  w ere f ou nd to b e ove rexp ressed in 6 7 –
76 and 43 of tumors, respectively. [99-101] In 
addition, ove rexp ression of  M M P2 and M M P9  w as 
more common in non- clear cell R C C  tu mors.M M P2 
and M M P9  ove rexp ression w ere associated w ith 
aggressive behavior, tumor grade, and survival.[99-
101] These associations are important, as there are 
seve ral syn thetic (i.e. b atimastat, marimastat) and 
natu ral (i.e. b ryo statins) matrix metalloproteinase 
inhib itors that cou ld help preve nt and/ or treat M M P 
overexpressing cancers.[102]
In s u l i n - l i k e  g r o w t h  f a c t o r  II m RnA - b i n d i n g  
p r o t e i n  3  ( IM P 3 )
I M P3 is an oncof etal R N A- b inding  protein that 
reg u lates transcription of  insu lin- like  g row th f actor I I  
mR N A. I M P3 is exp ressed in deve loping  epitheliu m, 
mu scle, and placenta du ring  early stag es of  hu man 
and mou se emb ryo g enesis, b u t it is exp ressed 
at low  or u ndetectab le leve ls in adu lt tissu es. 
I M P3 exp ression has b een associated w ith cell 
prolif eration and inva sion in va riou s cancers. I n 
R C C , I M P3 is associated w ith hig her R C C  stag e, 
g rade, sarcomatoid dif f erentiation and cancer-
specific mortality. In a cohort of 371 patients with 
localize d clear cell, papillary , chromophob e, and 
unclassified RCC, Jiang et al. reported that tumor 
cell IMP3 expression was significantly associated 
w ith prog ression to distant metastases and death, 
ev en af ter mu ltiva riab le adj u stment f or the ef f ects 
of  patient ag e, sex,  tu mor size , stag e, g rade, and 
histolog ical su b typ e ( fi g . 9 )  .[103] The prognostic 
va lu e of  I M P3 w as ext ernally va lidated in 7 16  clear 
cell R C C  tu mors show ing  that I M P3 exp ression w as 
significantly associated with advanced T stage and 
g rade, increased reg ional lym ph node invo lve ment, 
and distant metastases, as w ell as an increased 
lik elihood f or coexi stent coag u lative  tu mor necrosis 
and sarcomatoid differentiation.[104]In addition, 
ev en af ter mu ltiv ariab le adj u stment f or prog nostic 
f eatu res comprising  the SSI G N  score, positive  
I M P3 exp ression w as independently associated w ith 
an increased risk of  death f rom R C C . I n a recent 
article, Jiang  et al. have  show n that addition of  I M P3 
ex pression to tu mor stag e improve s its prediction 
of metastasis.[105]IMP3 expression is a predictor 
of  metastatic prog ression and death f rom R C C  and 
assessment of  I M P3 exp ression may prove  u sef u l 
to identify at risk patients who might benefit from 
ag g ressive  adj u nctive  therapy af ter primary tu mor 
resection. U ltimately , I M P3 and the I G F  pathw ay 
may provi de u sef u l targ ets to improve  clear cell R C C  
therapy; however, further studies will be warranted 
before any definitive conclusions can be made.
K i - 6 7
Ki-67 is a cell proliferation marker [106] that is 
associated w ith an ag g ressive  phenotyp e in clear 
cell RCC.  [107-110] High Ki-67 expression predicts 
h gher recurrence rates (HR: 1.05, p 0.02) [111] 
and worse survival (HR: 1.95, p0.001) [26, 112-
114]. Interestingly, the combination of Ki-67 and 
C AI X  (H R :  1.7 6 , p< 0 .0 0 1) su rpassed the prog nostic 
abili y of nuclear grade in cancer-specific mortality 
analyses. [110]
Ca v e o l i n - 1
C ave olin- 1 is a stru ctu ral component of  ca ve o l a e. 
T hese are plasma memb rane microdomains invo lve d 
in the intracellu lar sig naling  pathw ays that reg u late 
cell adhesion, growth and survival. [115] Increased 
cave olin- 1 exp ression has b een associated w ith 
a poor clinical ou tcome in seve ral cancers su ch 
as prostate, lu ng , and esophag eal malig nancies. 
[116-123] Membranous caveolin-1 is expressed in 
8 6 .4 %  of  clear cell R C C s and less than 5 %  of  each 
chromophob e or papillary R C C s. C ave olin- 1 co-
xp ression w ith Akt / mT O R  pathw ay components 
portended worse survival (HR: 2.13, p0.001). [124] 
Others could, however, not confirm these findings 
(HR: 1.35, p 0.9). [125]
T u m o r  n e c r o s i s
C ontrove rsy exi sts reg arding  the importance of  
tu mor necrosis in R C C  prog nostics. T u mor necrosis 
represents one of  the components of  the L eib ovi ch 
scoring algorithm. [126] Previous evaluation of tumor 
necrosis as a potential marke r f or R C C  mortality and 
recu rrence reve aled that it conf ers no added va lu e 
w hen standard clinical and/ or patholog ic tu mor 
characteristics w ere considered ( fi g . 1 0 A). [107, 
127-129] Tumor necrosis improved prediction of 
survival in patients with localized RCC (p 0.03) but 
not in patients with metastatic RCC (p 0.4). [107] To 
improve  its prog nostic ab ility , K latte et al. su g g ested 
qu antif yi ng  the ex tent of  tu mor necrosis, instead of  
dichotomizi ng  b etw een its presence vs.  its ab sence 
( fi g . 1 0B - C). [129] Added value and external 
accu racy remain to b e prove n.
C- r e a c t i v e  p r o t e i n
Seve ral inve stig ators exa mined the prog nostic 
significance of C-reactive protein. For example, C-
reactive  protein w as a strong  predictor of  metastasis 
(p< 0 .0 0 1) and ove rall mortality (p< 0 .0 0 1) af ter 
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Figure 9. Kaplan-Meier metastasis-free survival (A) and overall survival (B) curves stratified according to 
IMP3 status [103]
Figure 10. Predictive accuracy estimates of the Karakiewicz nomogram and the SSIG1 score with and without 
integration of tumor necrosis (A) [127] Kaplan-Meier survival curves stratified according to presence and 
absence of tumor necrosis (B) [129] and according to the extent of tumor necrosis (20 vs. !20) (C) [129]
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nephrectomy f or localize d R C C  in 130  patients. 
[130] C-reactive protein increased the predictive 
accu racy of  seve ral estab lished clinical and 
pathologic predictors by 3.7 (p0.001). [131]A 
g ain of  10 %  (7 6 .6  vs.  8 6 .5 % ) w as reported b y 
Iimura et al. in a different cohort (n 539) within an 
ex ternal v alidation( fi g . 1 1 ). [ 32] In consequence, 
this inexp ensive  and w idely ava ilab le b iomarke r is 
hig hly promising . I ts capab ility to predict response 
to targ eted therapy as a predictive  marke rs remains 
to b e prove n.
Vi m e n t i n
Vimentin a cytoplasmic intermediate filament, is 
not u su ally exp ressed in epithelial cells ( fi g . 1 ). 
V imentin exp ression is common in clear cell (26 -
51) and papillary RCC (61). [133-137] Others 
f ou nd low  f requ ency of  vi mentin staining  in clear cell 
RCC. [138] Vimentin overexpression (30 to 53) 
predicted poor prog nosis (p< 0 .0 0 7 ), independent of  
the effect of T stage and grade. [137]
fa s c i n
F ascin is a g lob u lar actin cross- linki ng  protein 
invo lve d in cell adhesion and motility ( fi g . 1 ). 
H ig h f ascin exp ression (p< 0 .0 0 1) correlated w ith 
sarcomatoid transf ormation, hig h tu mor stag e 
(p 0.008), high tumor grade (p 0.002), and larger 
tumor size (p0.001). [139] Moreover, fascin 
ex pression predicted metastatic prog ression (H R :  
7.2, p0.001). Other investigators confirmed these 
findings.[140]
2 . B looD - B A seD  B IoM A RK eRs
a) Thrombocytosis
T he prog nostic potential of  thromb ocyt osis w as 
reported in five studies. [141-145] However, the 
qu estion of  w hether a b iomarke r can improve  the 
ab ility of  estab lished predictors of  cancer ou tcome 
requ ires more than the conve ntional u niva riab le and 
mu ltiva riab le analyse s, w ith associated haza rd rates 
and p- va lu es. I n order f or a b iomarke r to b e clinically 
u sef u l, it mu st add u niqu e predictive  inf ormation, 
thu s improvi ng  the perf ormance of  a predictive  
model constru cted w ithou t the new  b iomarke r b y a 
significant margin. Thrombocytosis did not add any 
meaning f u l va lu e (+ 0 .3% ) to a model that comprised 
T N M  stag e, ag e, tu mor size , F u hrman g rade, 
histolog ical su b typ e, and preoperative  hemog lob in 
(n 1828). [141] In consequence, the prognostic 
va lu e of  thromb ocyt osis remains to b e prove n. 
b) 1eutrophils
Seve ral inve stig ators demonstrated independent 
predictor statu s f or peripheral b lood and intratu moral 
neu trophils, w hen mortality w as considered as an 
endpoint. [146-150] In a phase II study, Donskov et 
al. eva lu ated 6 3 metastatic R C C  patients treated w ith 
interleukin-2 or interleukin-2histamine. [148] High 
peripheral b lood neu trophil cou nts predicted ve ry 
poor su rvi va l and lack of  response to interleu ki n- 2 
alone or interleu ki n- 2+ histamine. Seru m neu trophils 
w ere also inclu ded among  six most inf ormative  
predictors in the Heng et al.[10] survival model. In 
addition, the presence of  intratu moral neu trophils 
also independently predicted shorter recu rrence-
free survival (hazard ratio [HR]: 3.0, p0.001), higher 
R C C  mortality (H R :  3.5 , p< 0 .0 0 1), and poor ove rall 
su rvi va l (H R :  3.1, p< 0 .0 0 1) in 121 patients w ith 
localized RCC. [151] Finally, intratumoral neutrophil 
cou nts improve d the predictive  accu racy of  the 
Leibovich scoring algorithm [152] from 74 to 80. 
Despite those promising results, the confirmation 
of  added va lu e w hen intratu moral neu trophils w as 
considered was not confirmed. This variable awaits 
its ext ernal va lidation.
c) VEGF
Plasma V EG F  lev els correlate strong ly w ith tissu e 
VEGF expression (p 0.01). [50] Similarly, serum 
leve ls of  V EG F  correlate w ith clinical stag e and 
tumor grade of RCC, [50, 153, 154] vascular invasion 
(p 0.03), tumor size (p 0.01), [154] and survival. [153-
155] For example, in 302 metastatic RCC patients, 
b aseline seru m V EG F  leve ls predicted prog ression-
f ree su rvi va l (H R :  1.19 , p< 0 .0 0 1) and ove rall su rvi va l 
(HR: 1.39, p0.001) after treatment. [155] However, 
seru m V EG F  f ailed to achieve  independent predictor 
status in other studies. [153-157]This may be due 
to an lyt ical prob lems in some of  the stu dies. I t has 
Figure 11. Predictive accuracy estimates of two models with and without integration of CRP [131, 132]
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b een previ ou sly f ou nd that V EG F  leve ls are hig her 
w hen measu red in seru m than w hen measu red in 
plasma.[158] Since VEGF is present in platelet 
g ranu les and is released u pon platelet activa tion, 
the hig her leve ls of  V EG F  in seru m w ere like ly du e, 
at least in part, to those released f rom damag ed 
platelets, making the quantification of non-platelet 
derive d V EG F  less accu rate. Af ter su nitinib  exp osu re, 
low er V EG F  plasma leve ls predicted response to 
therapy (p0.05) [159] and decreased risk of disease 
progression (HR: 1.96, 95 confidence interval: 
1.47 – 2.45) [160]. Low baseline soluble VEGF 
leve ls also predicted response to su nitinib  af ter 
bevacizumab failure. [161] Conversely, VEGF levels 
f ailed to predict response to soraf enib  according  to 
RECIST criteria (p 0.6), but was associated with 
overall survival in these patients (p 0.01). [162]The 
va lidation of  V EG F  leve ls as a prog nostic f actor in 
targ eted therapies is cu rrently b eing  eva lu ated in 
tw o separate trials (N C T 0 0 5 38 7 7 2, N C T 0 0 9 30 34 5 ).
d) Serum amyloid A
H u man seru m Amyl oid A (SAA) is an H D L -
associated lipoprotein kn ow n to play a maj or role as 
a modulator of inÀammation and in the metabolism 
and transport of  cholesterol. SAA is a potentially 
u sef u l b iomarke r to monitor patients harb oring  
hu man tu mors su ch as g astric, nasopharyn g eal, 
and lu ng  cancer. I n R C C , SAA concentrations w ere 
hig her in metastatic patients and SAA leve ls w ere an 
independent predictor of all-cause survival.[163]A 
protein pattern, including SAA identified by surface 
enhanced laser desorption/ionization time-of-Àight 
mass spectrometry (SEL D I - T O F - M S) analysi s of  
seru m samples of  5 0  clear cell R C C  patients and 
5 0  v olu nteers w as ab le to discriminate the tw o 
groups with a sensitivity of 70–78 and a specificity 
of 82–92, respectively.[164] One maMor problem 
w ith the u se of  SAA, an acu te phase reactant, as a 
potential seru m marke r in hu man cancer patients, is 
the f act that its eleva tion in the seru m of  patients is 
su g g ested to b e of  live r orig in rather than a tu mor- cell 
produ ct. I ndeed, SAA leve l in the b lood may eleva te 
u p to 10 0 0 - f old in response of  the b ody to va riou s 
inMuries including trauma and various inÀammations 
in addition to neoplasia.
e) CAI;
R ecently , an assay f or detecting  low  leve ls of  C AI X  
in blood was developed. [165] Higher serum CAI; 
leve ls correlated w ith clear cell R C C  va riant (8 6 % , 
p 0.001), but not with tumor stage or grade. [166] 
O thers f ou nd a correlation of  hig her seru m C AI X  
levels with tumor size and disease stage (p 0.004), 
[167, 168] as well as disease recurrence (p 0.001) 
[168] and mortality (p 0.048) [169]. An ongoing trial 
w ill determine the prog nostic va lu e of  seru m C AI X  
as a va lid b iolog ical marke r of  treatment response to 
immu notherapy and/ or targ eted therapy in patients 
w ith metastatic R C C  (N C T 0 0 9 4 20 5 8 ).
f) 1eutrophil gelatinase-associated
lipocalin (1GAL)
N G AL  is a protein u preg u lated in ‘ distressed’  cells, 
su ch as the case w hen in the presence of  a tu mor. 
[170] It demonstrated high correlation with matrix 
metalloproteinase- 9 , a protein invo lve d in the 
deg radation of  the ext racellu lar matrix,  w hich relates 
to tumor invasion and metastases. [171] NGAL has a 
protective effect against acute ischemic inMury [172], 
and is high in several human cancers. [173] Above-
threshold leve l of  N G AL  resu lted in decreased 
prog ression- f ree su rvi va l relative  to those w ith 
b elow - threshold leve l of  N G AL  in patients treated 
with sunitinib (3.4 vs. 8.2 months, p 0.03). [174]
g) Insulin-like growth factor-1
W hile there are many va ried roles of  insu lin- like  
g row th f actor I  (I G F - I ), and it exi sts in dif f erent b io-
compartments, there is abundant scientific evidence 
demonstrating  that I G F - I  is an important metab olic 
b iomarke r associated w ith a va riety of  health-  and 
exe rcise- related ou tcomes. I n most cases (mu scle, 
b one, tendon, b ody composition, and cog nitive  
f u nction), eleva ted I G F - I  concentrations are 
considered beneficial; however, cancer remains a 
notab le exce ption. I n a series of  25 6  R C C  patients, 
seru m I G F - 1 leve ls w ere associated w ith all- cau se 
su rvi va l af ter adj u sting  f or the ef f ects of  tu mor stag e. 
[175] While interesting, the prognostic role of IGF 
axi s in R C C  is only in its inf ancy .
3 . uRIne M A RK eRs
T he u rinary nu clear matrix protein 22 (N M P- 22) 
is a F ederal D ru g  Administration (F D A) approve d 
b iomarke r f or b ladder cancer screening  and 
monitoring. [176-178] It has also been examined as 
a diag nostic marke r f or R C C . T hree stu dies have  
show n that u rinary N M P- 22 leve ls w ere hig her in 
R C C  patients compared to those in control su b j ects 
(all p<0.005).[179-181] Well-done, large-scale 
stu dies are needed to estab lish the u tility of  N M P- 22 
in R C C  diag nosis and potentially prog nosis. 
IV. use of B IoM A RK eRs In 
P RoG nosT IC M oD els
A prog nostic model f or prediction of  su rvi va l in R C C  
u sing  primarily molecu lar marke rs as predictors 
(p5 3, C AI X , g elsolin, vi mentin, and metastatic 
status) was 79 accurate (n 318; T a b l e  2 ,  fi g . 
1 2 ). [97] Subsequently, the same group of authors 
eva lu ated a slig htly dif f erent model of  molecu lar 
marke rs (C AI X , PT EN , vi mentin, p5 3) and w as 6 4 %  
accurate(n 150). Adding ECOG-PS and tumor stage 
increased predictive  accu racy b y 4 % . Predictive  
accu racy relyi ng  on clinical and molecu lar marke rs 
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(68) was statistically significantly higher (p 0.003) 
than that of the UISS system alone (62). [182] The 
integration of the BioScore[26] (tumor expression 
leve ls of  B 7 - H 1, su rvi vi n, ki - 6 7 ) in clear cell R C C  
patients (n 634) to the UISS and the SSIGN models 
g ained respective ly 4 .5  and 1.6 %  accu racy ( T a b l e  
4 ). 
O thers eva lu ated the prog nostic va lu e of  b iomarke rs 
w ith clinical and/ or patholog ical characteristics in 
patients w ith adva nced R C C  treated w ith V EG F -  or 
mTOR-targeted therapies or immunotherapy. [8, 146, 
183-185] Recently, factors associated with longer 
ov erall su rvi va l w ithin su nitinib - treated patients 
inclu ded time f rom diag nosis to treatment of  more 
than a ye ar, EC O G - PS, corrected calciu m, ab sence 
of  b one metastases, low  L D H , and hig h hemog lob in. 
[186] Factors associated with longer overall survival 
w ithin interf eron- alpha treated patients inclu ded:  male 
g ender, ab sence of  b one or lym ph node metastases, 
low er L D H , hig her hemog lob in, corrected calciu m, 
hig her neu trophil cou nt, and interva l f rom diag nosis 
to treatment of more than a year. [186]
I n anti- V EG F  therapy- naï ve  metastatic R C C , 
hemog lob in (p< 0 .0 0 1), corrected calciu m (p< 0 .0 0 1), 
K PS (p< 0 .0 0 1), time f rom diag nosis to treatment 
(p 0.01), neutrophils (p0.001) and platelets 
(p 0.01) were adverse prognostic factors for overall 
survival (accuracy: 73, n 645). [10]
V. ConClusIons
T he search f or predictive  and prog nostic marke rs 
stems f rom the u npredictab le natu re of  R C C  in its 
localize d, locally adva nced and metastatic stag es. A 
nu mb er of  su ch marke rs emerg ed. O f  those, many 
show  promise b y vi rtu e of  stratif yi ng  the su rvi va l 
cu rve s or discriminating  b etw een stag e distrib u tions 
(eg . C AI X , V EG F ). O ther marke rs achieve d 
independent predictor statu s (e.g . ki - 6 7 , seru m 
C AI X ) w hen their contrib u tion to the prediction of  the 
endpoint of  interest w as exa mined. F inally , the most 
va lu ab le ones (C - reactive  protein, B ioScore (su rvi vi n, 
B 7 - H 1, ki - 6 7 )) demonstrated an added va lu e w hen 
combined accuracy was quantified without and 
with their contribution. Independent confirmation of 
their va lu e, w ithin ext ernal va lidation stu dies and 
u sing  standardize d measu rements, represents an 
u nconditional requ irement prior to their integ ration 
into rou tine clinical practice. V alidation of  inf ormative  
marke rs of  response to targ eted ag ents represents a 
priority consideration. 
T he va lu e of  nove l marke rs is requ ired w ithin the 
f ramew ork of  exi sting  marke rs and models. F or 
exa mple, a recent model that relies on clinical and 
radiolog ical inf ormation can predict the prob ab ility of  
mortality from one to ten years after nephrectomy.[21] 
I t relies on clinical and radiolog ical va riab les and 
resu lts in 8 4 - 8 8 %  accu racy . A similar model that 
integ rated patholog ical characteristics resu lted in 
8 8 - 8 9 %  accu racy f or predictions of  mortality f rom 
one to ten years after nephrectomy.[20] Neither of 
the models relied on b iomarke r data. T he hig hly 
accu rate natu re of  these models raises the b ar f or 
novel biomarkers, as it is relatively difficult to improve 
accu racy b eyo nd the 9 0 %  mark.  C onve rsely , the 
dearth of  models capab le of  accu rately predicting  
the prob ab ility of  response to targ eted therapies 
represents an important unmet need in the field of 
R C C  prog nostics.
Figure 12. Prognostic model for prediction of 2- and 40-year overall survival relying on metastatic status, 
metastatic CAI;, p53, vimentin and gelsolin in the format of a nomogram [97]
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I. InT RoD uCT Ion 
D u e to the increased u se of  diag nostic imag ing  
more ki dney tu mou rs are b eing  detected incidentally , 
leading  to an increased incidence of  asym ptomatic 
organ-confined small renal masses (SRMs) 
[1]. SRMs account for 48 to 66 of renal cell 
carcinoma (RCC) diagnoses [2]. This has resulted 
in an increased incidence of RCC over the last 
three decades. There is controversy on the mortality 
rates of RCC. Some authors mention that mortality 
rates are rising. Cancer statistics are showing 
the opposite (38 in 1997 vs. 25 in 2007) [3,4]. 
Current treatment should be reassessed [1]. Today, 
the standard of care for clinically localized RCC 
is su rg ery predominantly in the f orm of  nephron-
sparing surgery (NSS) because of the durable 
oncolog ic ou tcome and ove rall su rvi va l. Active  
surveillance (AS) and minimally invasive ablative 
technolog ies have  emerg ed as potential alternative s 
to surgery in selected patients. In this chapter, we 
critically review the recent data on the management 
of localized RCC with the obMective of arriving at a 
g eneral consensu s.
II. M eT H oD s
A comprehensive review of the Medline literature 
f rom Janu ary 1, 20 0 4  to April 11, 20 10  reg arding  
the treatment of localized RCC was conducted. The 
combination of the following words was used: renal 
cell carcinoma, nephrectomy (MeSH maMor topic), 
surgical procedures, minimally invasive (MeSH 
maMor topic), nephron-sparing surgery, cryoablation, 
radiofrequency ablation, surveillance and watchful 
waiting. Search was limited to English papers. 
Further references were identified from the reference 
list of retrieved articles. As few randomised stu dies 
were available the maMority of the conclusions 
were drawn from case series or comparative 
cohort stu dies, b oth prospective  and retrospective . 
A preliminary draft was composed by the chairman 
of  the g rou p and circu lated throu g hou t the memb ers 
for modifications. After considering all modifications 
a definite draft was composed, reviewed and 
su pported b y all memb ers of  the g rou p. I n case of  
statement disagreement consensus was reached by 
maMority. 
 
III. A CT IVe suRVeIllA nCe foR 
loCA lIZ eD  RCC
1 . InT RoD uCT Ion
SRMs are not uncommonly detected in elderly 
patients or those with significant co-morbidities. 
These patients have a higher risk of perioperative 
mortality and morb idity af ter treatment and a limited 
lif e exp ectance that of ten appears to exce ed the 
risk of cancer progression. Moreover, a significant 
proportion (up to 20) of these SRMs is benign 
when biopsied or removed [5-9]. Even when those 
SRMs are confirmed to be RCC, most have slow 
growth rates and infrequently metastasize during the 
first few years after diagnosis [10]. These issues are 
important arg u ments to su pport an initial su rve illance 
period f or selected patients and reserve  treatment 
for progression. Active surveillance (AS) of SRMs 
is now increasingly performed in carefully selected 
patients with an emerging experience to support this 
treatment option [ 2,7 ,11- 29 ] . 
2 .  sMA ll RenA l MA sses A nD  T H eIR 
nA T uRA l H IsT oRY
Most AS studies of SRMs have relatively few subMects 
and are retrospective with limited follow-up and 
pathological confirmation of malignancy. Therefore 
Chawla et al performed a meta-analysis of several 
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small AS series and their own institutional cohort 
[2,12-14,16-18,20,21]. A total of 234 untreated SRMs 
had a mean follow-up of 34 months. The maMority of 
the lesions (mean size of 2.60 cm, range 1.73 to 
4.08 cm) demonstrated a slow growth rate (mean 
rate 0 .28  per ye ar, rang e 0 .0 9  cm to 0 .8 6  cm per 
year). Metastasis was reported in 1 of the cases 
during AS. In total, 86 of the lesions were smaller 
than 4  cm in maxi mal diameter at presentation. 
Initial tumour size did not predict overall growth rate 
(P 0.46). An absolute cut-off for selecting patients 
f or a su rve illance strateg y does not exi st since at 
present, the metastatic potential of  ob serve d tu mou rs 
cannot b e predicted. ( fi g . 1 ) There are several 
important considerations in interpreting  the resu lts 
of the Chawla meta-analysis. Many tumours were 
not biopsied and may have been benign. Only 46 
of  the patients had patholog ical eva lu ation and the 
pathological analysis was incomplete in many cases. 
Tumours with rapid growth often underwent surgery 
b ecau se of  concern f or prog ression to metastasis. 
A rapid growing mass is arbitrarily defined as one 
that doubles it volume within 1 year [2]. Some 
deg ree of  selection b ias may have  b een present b y 
inadvertently selecting patients with slower growth 
rates during an initial period of AS. Finally, the series 
had short durations of follow-up (mean 30 months) 
which may not reÀect the intermediate and long-
term growth potential of these tumours. Overall, the 
f avo u rab le results in patients undergoing AS should 
b e interpreted as preliminary as these issu es cou ld 
bias the findings [21]. 
Similar findings supporting the absence of baseline 
predictive factors are found in two recent series from 
Cleveland and New York.  There were no reported 
dif f erences in patient’ s or tu mou r characteristics 
between those tumours that locally progress and 
those that remain stable [28,29].  Crispen et al 
reported the radiographic growth kinetics of renal 
tumours during a period of AS. Smaller tumours 
seem d to exhibit significantly faster volumetric 
growth than larger tumours. The authors found that 
39 (68 of 173) of patients on AS crossed over to 
treatment within 2 years of follow-up for a variety of 
reasons inclu ding  patient and physi cian pref erence. 
AS is associated with a low rate of progression to 
metastatic disease (1.3) (2 of 154). However, the 
actu al prog ression rate may b e hig her than reported 
b ecau se of  seve ral f actors inclu ding  the relative  
short duration of follow-up, inclusion of benign 
disease in some series, selective  interve ntion f or 
tumours demonstrating accelerated growth kinetics, 
and the selection b ias inherent to retrospective  data 
sets [ 29 ] . 
3 . P RoG nosT IC fACT oRs foR 
P RoG RessIon
a)  T umour size  
The favourable results of the Chawla et al analysis are 
consistent with data about biological aggressiveness 
of SRMs. Up to 20 of renal masses are actually 
benign [5-9]. Only about 20 to 25 demonstrate 
potentially aggressive characteristics [5,7,30].
Smaller renal tumours are more likely to be benign 
or to be of lower grade than larger tumours [31] with 
several studies showing increased growth potential 
of SRMs with a diameter ! 3 cm [5,7,32]. Kunkle et 
al reported  that the risk of  b iopsy prove n metastasis 
goes up 22 with each one centimeter increase in 
tumour size [24].  However, Remzi et al could not 
find a clear correlation between tumour size and 
b enig n histolog y in an analysi s of  histopatholog ical 
parameters in 287 tumours  4 cm in diameter 
[7]. They found that Fuhrman grades G3 and G4, 
higher pathological stage (pT3a or greater) and 
metastatic disease were seen significantly more 
frequently in tumours ! 3 cm in diameter. This 
difference was however not observed when masses 
 2 cm in diameter were compared with those 
measuring 2.1 – 3.0 cm. Taking into account that 
measuring tumour diameters is difficult, is subMect 
to ob serve r va riab ility , and is f requ ently b ased on 
different imaging modalities, some believe that AS 
strategies should be limited to patients with tumours 
 3 cm [7]. In general however,  4 cm is used to 
conform to stage T1a for RCC. Not all SRMs can 
b e deemed harmless and eve n ve ry  small tu mou rs 
may progress to metastatic disease. Three recent 
larg e sing le- center stu dies indicate that among st 
renal cancers 3-4 cm in size, 14-26 are high grade 
(grade 3 or 4) and 12-36 locally invade peri-renal 
fat (stage pT3a) [7,8,32]. These 3 series report that 
small 3- 4  cm cancers have  a hig her metastatic 
Fig.  1: CT  show ing atrophic right k idney and l eft 
sided smal l  renal  mass of uncertain pathol ogy
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risk approaching 6-8 [7,8,32]. The changes in 
morpholog ical characteristics of  the tu mou r ab ove  3 
cm reported by Remzi et al were more extreme than 
in other series. K latte et al reported their exp erience 
with 1.208 patients who underwent nephrectomy 
for small solid renal tumours. They found that the 
incidence of  metastatic disease in tu mou r rang es of  
0 .1 to 1.0 , 1.1 to 2.0 , 2.1 to 3.0  and 3.1 to 4 .0  cm 
was 7, 6, 5 and 8, respectively (P   0.322) 
[8]. Nguyen and Gill analyzed the national 1998-
2003 Surveillance, Epidemiology, and End Results 
(SEER) data-set and documented a 5.2 prevalence 
of metastasis at presentation in 8.792 patients with a 
small ( 4 cm) pathologically-confirmed renal cancer 
[33]. For size sub-categories  1, 1.1-2, 2.1-3, and 
3.1-4 cm, prevalence of metastasis at diagnosis was 
1.4, 2.5, 4.7 and 7.4, with 5-year cancer-
specific mortality of 4.2, 4.3, 5.5 and 7.9, 
respectively. For small renal cancers  4 cm, 5-
year cancer-specific mortality for all patients, and 
those without and with metastases at presentation 
was 6.2, 2.9 and 74.3 respectively. For each 
cm increase in primary cancer size , the calcu lated 
prevalence of metastases increased by 3.5 [33]. In 
all these reports, patients presenting with metastases 
and those with symptomatic primary tumours were 
u ndou b tedly inclu ded so the conclu sions shou ld b e 
applied to the u su al asym ptomatic properly stag ed 
SRM patient on AS with caution as the AS series 
report metastases in up to 2.3 [34]. However, 
when considering AS, tumour size alone may not be 
a reliable indication or trigger for treatment of SRMs 
[5,7-9].
b)  G row th rate
Chawla et al could not identify a significant correlation 
between initial tumour size and growth rate in their 
analysis of 157 post incidentally detected tumours 
from 5 observational series (P   0.46) [2,12-
14,18,21). This has been confirmed by Crispen et al 
[29]. Therefore, at this time, initial tumour size may 
not predict subsequent growth rate.  Most authors 
report the mean tumour growth rate to be between 
0.06 cm/yr and 0.21 cm/yr for tumours  4.0 cm in 
size [2,17,25,26,35]. Growth appeared to be slow 
even in those patients diagnosed with larger masses 
[ 19 ] . F or exa mple, the mean lesion size  in the series 
of Lamb et al was 7.2 cm (range 3.5 – 20.0) with a 
mean growth rate of 0.39 cm per year [19]. A recent 
study from the Memorial Sloan-Kettering Cancer 
Centre has shown that small renal tumours ( 3.5 cm) 
were similar to larger tumours in subtype and growth 
rate. Faster-growing tumours were more likely to 
be RCCs of higher grade. No significant correlation 
was found between the reciprocal of doubling time 
and initial tu mou r vo lu me, histolog ical su b typ e, or 
F u hrman g rade [ 36 ] . O ne mu st realize  that a su b set 
of patients may have small rapidly growing renal 
tumours with aggressive behaviour while under AS. 
Volpe et al reported that eight renal masses [25) 
doubled their volume within 12 months, and one 
patient prog ressed to metastatic disease [ 2] .  I n the 
study by Siu et al, a 3-cm mass that had not changed 
in size  f or 6  ye ars dou b led in size  ove r 6  months, 
and metastatic disease developed [37]. The value of 
volume doubling time is still uncertain. Nevertheless, 
L ee et al su g g ested that more accu rate assessment 
of tumour growth rate and volume doubling time 
may b e u sef u l f or u nderstanding  the natu ral history 
of  renal tu mou rs [ 38 ] .
c)  H istol ogy
A SRM has been reported to be more malignant 
if growth is observed. However in the Canadian 
prospective, multicenter study with needle biopsy, 
there was no difference in growth rate between 
benign and malignant tumours [39]. However, it 
remains difficult to predict biological behaviour of 
SRMs, even if they do not show growth. L ack of  
growth on serial CT scanning is not a reliable predictor 
of benign histology as even RCCs with zero growth 
rates have  demonstrated prog ression. K u nkl e et al 
revealed that 26 to 33 of renal tumours followed 
by AS do not grow at 29 months median follow-up. 
Importantly, these tumours with zero growth rates 
had similar rates of malignancy compared to growing 
lesions (83 and 89; respectively; P   0.56) [22]. 
The authors concluded that growth rate does not 
correlate with prognosis [22]. These observations 
and those of the Canadian study raise questions 
about the biology of SRMs that need to be better 
understood to define better prognostic factors.
d)  A ge
A meta- analysi s of  pu b lished ob serva tional series 
[ 2,11,16 - 18 ,21]  demonstrated an inve rse correlation 
between increasing age and tumour growth rate. 
Kouba et al found a more rapid growth in younger 
patients ( 60 years) (0.77 cm versus 0.26 cm per 
year) [40]. Therefore surveillance is currently not 
recommended in fit and young patients [10].
e)  P rogression to metastatic disease 
There is no published report of metastasis occurring 
in the absence of tumour growth but the Canadian 
series has reported 2 patients who were found 
to have  metastases at 4  and 12 months af ter 
enrolment while their SRMs were about 2 cm in 
diameter and there had been minimal or no growth 
(average  0.5 mm/yr, P   0.41) [39]. The low rate 
of metastatic progression in most AS series may 
be inÀuenced by the short follow-up as well as, the 
b enig n histolog y of  a nu mb er of  solid renal masses, 
the small tu mou r size  and the retrospective  natu re 
of the studies. Youssif et al reported a surveillance 
study with a mean of 47.6 months follow up. Two 
patients developed metastatic disease (5.7; 2 of 
35) after 29 and 40 months, respectively, in a group 
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of tumours  4 cm in diameter. The renal masses in 
these 2 patients had a growth rate of 0.95 cm/year 
and 0.9 cm/year, which is a faster growth rate than 
the mean of 0.15 cm/year observed in the 17 patients 
who were still being followed actively at the time of 
last follow-up. Until we have more information on 
this important prognostic factor, faster growth during 
the su rve illance period shou ld alert physi cians to the 
potential risk f or prog ression to metastatic disease 
and b e considered as a trig g er point f or a treatment 
recommendation [ 26 ] .
f)  I maging
I mag ing  characteristics do not provi de a reliab le 
prog nostic f actor f or prog ression at this time [ 9 ] . 
No parameter was able to predict progression or 
overall prognosis [21,30,32,37,41]. No difference 
was noted in tumour size at presentation or tumour 
growth rate between oncocytomas and RCCs 
in the meta-analysis by Chawla et al [21]. When 
comparing  independent compu terize d tomog raphy 
(CT) measurements of tumour size, differences less 
than 3.1 mm f or inter- ob serve r and less than 2.3 mm 
for intra-observer evaluations are situated within the 
rang e of  measu rement va riab ility and shou ld not 
be attributed to tumour growth. As tumour volume 
is exp onentially related to tu mou r diameter, the 
accu racy of  measu ring  tu mou r vo lu me is associated 
with a greater error (inter-and intra-observer 
variability for tumour volume: 2.515 mm3 and 
2.075 mm3, respectively) [42]. Ficarra et al recently 
proposed The Preoperative Aspects and Dimensions 
Used for an Anatomical (PADUA) classification of 
renal tumours that takes into consideration five 
anatomical aspects of  the tu mou r plu s its maxi mal 
diameter. The study demonstrated that the PADUA 
score is ab le to predict the risk of  su rg ical and 
medical perioperative complications in patients who 
underwent OPN [43]. This classification differs from 
the R.E.N.A.L nephrometry scoring system recently 
proposed b y K u tik ov et al to qu antif y the anatomical 
characteristics of renal masses (size, location and 
depth) on computerized tomography (CT)/magnetic 
resonance imaging (MRI) [44]. The main differences 
are the definition of the sinus lines and the 
evaluation of the anatomical relationship between 
the tu mou r and the u rinary collecting  syst em or renal 
sinus [43]. Furthermore, SRMs are not necessarily 
spheroidal which increases the error in measuring 
tumour volume. Therefore, neither tumour size nor 
tumour volume are reliable parameters for defining 
management of SRMs [45]. 
Two papers addressed the histological diagnosis 
of SRMs on CT. One study showed that the 
enhancement pattern of double-phase helical CT 
was different among the subtypes of RCC, but 
did not differentiate between RCC and other solid 
tumours. All clear cell RCCs (n 29) showed a peak 
attenuation in the corticomedullary phase (CMP) 
of ! 100 HU (type A). All chromophobe cell RCCs 
(n 2) showed a peak attenuation value in CMP of 
 100 HU (type B) and all papillary RCCs (n 5) 
showed a gradual enhancement with the attenuation 
value in the CMP of  100 HU (type C).  However 
oncocytomas (n 2) and metanephric adenomas (n 
  2) also showed patterns similar to these subtypes 
of RCC. Therefore the diagnosis of oncocytoma and 
metanephric adenoma is u nreliab le on the b asis 
of enhancement [46]. A more recent study showed 
that when using a multi-detector CT (MDCT) and 
thin overlapping reconstructions (3 mm section 
thickness, 50 overlap), renal cysts as small as 
5 mm can be diagnosed with more certainty than 
is possible with standard reconstructions (5 mm 
thickness and no overlap). Of 45 masses between 
5 and 10 mm, 38 (84) could be characterized as 
cysts with the experimental protocol, compared with 
only 13 (29) with the standard protocol. The overall 
number of indeterminate renal masses was reduced 
using the experimental protocol (86 of 161 lesions; 
53), compared with the standard protocol (101 
of 146 lesions; 69). Despite technical progress 
in technique, at this time, the maMority of detected 
renal masses are smaller than 5 mm and cannot be 
characterize d [ 4 7 ] . 
4 . RenA l T uM ouR B IoP sY
A retrospective study by Remzi et al reported that 
81.9 of all renal masses were RCC and only 17 
were correctly defined as benign on preoperative 
CT. In total 42 of renal masses underwent surgery 
for benign lesions not correctly identified as benign 
on preoperative CT. Surgery could potentially 
have been avoided in these patients [9]. Thus, a 
more refined preoperative diagnostic evaluation, 
in particular needle biopsy is needed for defining 
management of SRMs  [9] and can help in selecting 
patients suitable for AS [45]. Due to advances in 
b iopsy and imag ing  techniqu es the resu lts of  needle 
biopsies have improved significantly [48]. The overall 
complication rate in these studies was low (5) 
and maMor complications were rare ( 1). The 
most frequent complication was hemorrhage, which 
is almost always self-limiting.  Renal tumour biopsy 
has theref ore b ecome a saf e and accu rate techniqu e 
(45,49,50) that provides useful material for diagnosis 
in ! 90 of cases in centres with expertise [49].
Several issues have prevented widespread adoption 
of  pretreatment b iopsy . B iopsy accu racy remains 
a concern although the first order question of 
malignant vs. benign is approximately 80 accurate 
when tissue is obtained. There remains up to 20 of 
b iopsies that are non- diag nostic du e to tu mou r misses 
and this rate varies with experience and tumour size 
[51]. Three prospective studies have evaluated CT-
guided SRM biopsy. In these studies, ranges of 
b iopsy accu racy f or detecting  b enig n and malig nant 
tissue, histologic subtype, and Fuhrman grade were 
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89-96, 70-76, and 78-92, respectively [52-54]. 
In the study of Schmidbauer et al, 42 of the renal 
masses were larger than 4 cm. While the authors 
report excellent results of core biopsy, we do not know 
what is the accuracy of CT guided biopsy in SRMs 
[54]. In the study of Lechevallier et al, results are 
not stratified by size; the median size of the masses 
evaluated is 4 cm, but there are masses of 15 cm in 
this series [52]. Furthermore, accuracy is based on 
those biopsies that were diagnostic. In the study of 
Neuzillet et al 9 of biopsies were non diagnostic. 
In the studies of Schmidbauer and Lechevallier only 
3 and 21 of the biopsies failed, respectively. The 
corresponding figure was 37 in the 30 SRMs of  
3 cm. In view of those results grade and histological 
subtype accuracy remains controversial in SRMs 
[52-54]. As well, pathological confirmation in the 
study of Neuzillet was obtained only in 70.4 of 
the cases and in the study of Lechevallier in 50 of 
those patients with non metastatic lesions (surgery 
in 27 out of 52 patients) [52,53]. Most of the studies 
on biopsy exclusively in SRM are retrospective in 
nature and subMect to the same limitations above 
exposed. The subMect is reviewed in a recent paper 
of Laguna et al [55].
Several other issues include the difficulty with the 
diag nosis of  oncocyt oma ve rsu s hyb rid chromophob e 
RCC. Waldert et al have recently shown that up to 17 
of  oncocy toma actu ally  harb ou r hyb rid chromophob e 
RCC [56]. The diagnosis of oncocytoma on biopsy 
cannot b e relied on f or b eing  proof  of  a b enig n lesion 
and an u ncritical su rve illance approach. As ab ou t 
45 of benign renal tumours are oncocytoma, this is 
a maMor problem for the diagnostic accuracy of renal 
b iopsies [ 9 ] .
The use of preoperative biopsy is likely to reduce 
u nnecessary treatment if  b enig n lesions are initially 
observed. Multiple tumours probably need to undergo 
mu ltiple b iopsies b ecau se if  one of  the tu mou rs is 
RCC that does not mean that the other is RCC as well. 
Several new immunohistochemical and molecular 
f actors are b eing  eva lu ated as determinants of  the 
aggressiveness of RCC and molecular profiling of 
SRMs is now possible [57,58]. Unfortunately, the 
av ailab le data on molecu lar marke rs are not ye t 
valid enough for routine, clinical application [58]. 
Renal mass biopsy enhanced by molecular profiling 
will further help in decision making about AS. Further 
research will be required to define the utility and 
limitations of  this approach [ 4 1] .
5 . suRVeIllA nCe sT RA T eG Y
An absolute cut-off for tumour size and growth rate 
that shou ld prompt interve ntion du ring  su rve illance 
has not been well defined [25]. A working hypothesis 
has emerg ed that tu mou rs b eyo nd a diameter of  3 
or 4  cm or those that dou b le in vo lu me in less than 
12 months are at risk of  prog ression and shou ld 
b e treated [ 2,7 ,8 ,4 8 ] . A larg e mu lticentre series of  
incidental renal tu mou rs reve aled that a su rve illance 
strategy should not be advised in patients with a 
renal tumour !4 cm, if biopsy confirms high Fuhrman 
grade regardless of the size, or if CT findings suggest 
advanced T stage [59]. AS with regular radiographic 
follow-up should be a primary consideration for 
SRMs in elderly and/or infirm patients with multiple 
comorbidities that would make them high risk for 
intervention and in those with limited life expectancy 
[25,28] [60]. Delayed intervention of more than 1 
ye ar af ter diag nosis does not seem to exa cerb ate 
the prognosis for later metastatic RCC [25,40,61].
Before enrolling a patient in an AS protocol an 
adequ ate renal tu mou r mass b iopsy shou ld b e 
considered.  In some cases a benign tumour will be 
shown while mostly the biopsy will confirm malignancy 
and this will be helpful to further define follow-up [48]. 
The patient should be cou nselled ab ou t the small b u t 
non- neg lig ib le risk of  tu mou r prog ression du ring  the 
AS period, possible loss of opportunity for NSS, lack 
of  cu rative  salva g e therapies if  metastatic disease 
were to develop, limitations of renal mass biopsy, 
lack of long-term data on surveillance, close follow-
u p imag ing  and requ ired compliance.
For follow-up during the surveillance period, Rendon 
et al suggested CT or MRI every 3 months in the first 
year, every 6 months in the next two years and every 
year thereafter [23]. This high number of CTs was 
considered necessary to assu re a saf e su rve illance 
strategy. However, in this regard, the recognized risk 
of radiation exposure due to multiple CT scans should 
be kept in mind. The optimum protocol and imaging 
modality is unknown at present but ultrasound, with 
or without contrast, may provide adequate images 
f or measu rement.
6 . ConClusIons 
Not all SRMs are RCC. If untreated, the maMority 
grows slowly and have low rate of progression 
to metastasis, at least in the initial ye ars. A t this 
time,  an initial  period of A S w ith regul ar imaging 
fol l ow - up shoul d onl y be considered for patients 
with SRMs  4 cm who are considered unfit 
for interv ention or hav e l imited l ife ex pectancy 
or refuse treatment [ 6 2 ]  ( G rade C) . D el ayed 
interv ention shoul d be undertak en in tumours 
that show  fast grow th during A S and therefore 
may hav e a higher risk  of progression to 
metastatic disease ( G rade C) .  At this time, the 
whole body of literature is insufficient to recommend 
or disregard biopsy for SRMs. The identification of 
clinical, imag ing  and molecu lar marke rs of  disease 
progression, as well as further research on the role of 
b iopsy is needed to improve  the selection of  patients 
for AS. Until reliable prognostic parameters are 
formally identified, one must recognize that there is a 
small b u t non- neg lig ib le risk of  deve loping  metastatic 
disease in patients with SRMs followed expectantly. 
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Surveillance requires excellent patient compliance 
and rigorous follow-up with contrast enhanced CT or 
MRI. Finally, the long-term results of prospective AS 
studies such as the ongoing multicentre Canadian 
trial are eagerly awaited to more precisely identify 
the role of AS in the treatment of localized renal 
RCC. Molecular studies of prognostic factors for 
prog ression are in prog ress [ 39 ] .
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IV. RA D ICA l neP H ReCT oMY  foR 
loCA lIZ eD  RCC
1 . InT RoD uCT Ion
Radical nephrectomy (RN) includes the removal 
of  the tu mou r- b earing  ki dney and has b een the 
traditional approach for treating localized RCC 
in patients with a normal contralateral kidney [1]. 
Nowadays it is still the treatment of choice with 
excellent oncologic efficacy when the tumour is 
not amenable to NSS. Adrenalectomy and regional 
lym phadenectomy may b e perf ormed at the time 
of RN, but their benefit in absence of radiological 
signs of tumour invasion or in growth has not been 
prove n in prospective  randomised stu dies and 
consequ ently no hard recommendation can b e made 
to this respect. According  to a recent syst ematic 
review adrenalectomy should only be considered 
in select cases in which there are risk factors for 
adrenal invo lve ment su ch as increased size  and 
T stage, multifocality, upper pole location and 
ve nou s thromb osis [ 2] . L ym phadenectomy is only 
desirab le in the presence of  enlarg ed lym ph nodes 
on preoperative  imag ing  and can increase su rvi va l 
when combined with adMuvant immunotherapy [3,4]. 
The randomised EORTC trial 30881 including 732 
patients with preoperatively staged N0M0 tumours 
does show that lymph-node dissection combined 
with RN does not increase morbidity or mortality, but 
a su rvi va l adva ntag e cou ld not b e demonstrated. 
This is mainly due to the low incidence of lymph-node 
metastases (4) detected by lymphadenectomy. If 
RN is truly indicated, for instance for patients with 
locally adva nced disease, a limited reg ional lym ph 
node dissection still seems reasonable. There are 
reports that the remova l of  lym ph nodes containing  
microscopic metastases may be beneficial to some 
patients [ 3]  
2 .  fA CT oRs T H A T A ffeCT  T H e sT A T us of 
Rn A s G olD  sT A nD A RD  foR T ReA T InG  
RCC
During the last decade, the status of RN has been 
called into qu estion b ecau se of  seve ral f actors 
including: a) equal oncologic efficacy as partial 
nephrectomy (PN) for renal tumours  4 cm [5,6] 
and tumours between 4 and 7 cm [7,8), b) increased 
incidental detection of small ( 4 cm) renal masses 
with a significant proportion of benign tumours (up to 
20) (9-14), c) possibility of late recurrence of RCC 
in the contralateral kidney, d) a higher risk of chronic 
kidney disease (CKD) following RN [5,15,16].
Preserva tion of  renal f u nction is increasing ly 
prioritize d in the manag ement of  small renal masses 
and u nderscores the u se of  nephron- sparing  
modalities whenever feasible. Compared to patients 
undergoing PN, patients undergoing RN were more 
likely to have proteinura and CKD (defined by a 
serum creatinine level ! 2.0 mg/dl) during follow-
up [5,15]. This finding was later confirmed by the 
glomerular filtration rate (eGFR) estimated with the 
abbreviated Modification of Diet in Renal Disease 
Study equation (16-18). Of the patients with SRMs 
26 had pre-existing CKD (GFR  60 mL/min per 
1.7 3 m2) before surgery. After surgery, the 3-year 
probability of freedom from new-onset CKD (GRF 
 60 mL/min per 1.73 m2) was 80 after PN and 
35 after RN.  Corresponding values for the 3-year 
probability of freedom of moderate CKD (GFR  45 
mL / min per 1.7 3 m2) were 95 after PN and only 
64 after RN. RN remained a significant risk f actor 
for the development of new-onset CKD even after 
controlling  f or potential conf ou nding  f actors su ch as 
hypertension and diabetes. RN might no longer be 
reg arded as the g old standard treatment f or small 
renal tumours and should be reserved for patients with 
massive renal tumours in whom PN is not an option 
[ 16 ,17 ,19 ] . I n a recently pu b lished prospective  stu dy 
by Clark et al the postoperative change in creatinine 
clearance was significantly less (P   0.0001) in the 
PN group (-0.09mL/s, -6.1) compared to the RN 
group (-0.56mL/s, -31.6). The authors state that 
the b est method f or eva lu ating  g lob al renal f u nction 
is the 24 - hou rs creatinine clearance [ 20 ] .
RN is now recognized as a risk factor for the 
development of CKD, which is known to increase the 
risk of  cardiova scu lar eve nts and all- cau se mortality 
[21]. This is an important issue as renal tumour 
patients often are elderly patients with multiple 
comorb idities su ch as hyp ertension, diab etes, 
and peripheral va scu lar disease that mig ht lead to 
deterioration of baseline renal function. Therefore 
RCC patients undergoing nephrectomy cannot be 
compared to a healthy ki dney donor popu lation 
where the occurrence of CKD is exceptional [16,22-
24]. Thompson et al compared overall survival (OS) 
in patients with localized RCC of 4 cm or less and 
normal contralateral kidney who were treated with 
RN and PN. Compared with PN, RN was associated 
with decreased OS in young patients ( 65 years) 
with SRMs [25].
Relative to PN, RN is associated with an increase in 
ove rall mortality and non- cancer- related death rate 
in patients with T1a RCC. Therefore, PN should be 
performed whenever technically feasible [26].
3 . oP en RA D ICA l neP H ReCT oM Y
Open radical nephrectomy (ORN) can be performed 
b y a transperitoneal or ext raperitoneal approach. 
The choice of the surgical access depends on the 
size  and position of  the tu mou r, the patient’ s hab itu s 
and the su rg eon’ s pref erences. ( fi g . 2 ,  3 )
Indications for ORN include locally advanced renal 
tumours with invasion in the perirenal fat and 
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adrenal gland (T3a), invasion in the vena renalis 
or vena cava (T3b and c), tumours that extend in 
the adMacent organs (T4) and probably also those 
tumours that will undergo an extensive large lymph 
node dissection [ 27 ] . ( fi g . 4 )
In a prospective randomised EORTC phase III 
stu dy , V an Poppel et al f ou nd a perioperative  b lood 
loss  0.5 l (P  0.001) and severe hemorrhage (! 
1 l) in 96.0 and 1.2 of patients with small renal 
tumours ( 5 cm) treated with ORN. Pleural damage 
and spleen damage were respectively seen in 9.3 
and 0.4 of ORN patients [11]. Blom et al reported 
that lym ph- node dissection had no impact on the 
complication rate. The most common adverse events 
in patients treated with ORN without and with lymph-
node dissection, respectively were bleeding (6.5 
vs. 9.4), pleural damage (5.1 vs. 4.4) and 
infection (5.7 vs. 5.2). Less common adverse 
events were bowel damage, embolism and lymph 
Àuid drainage [3].
I n recent long - term retrospective  comparisons 
between ORN, laparoscopic radical nephrectomy 
(LRN) and hand-assisted LRN (HALRN) for T1 and 
T2 renal tumours, the 5-year disease-free survival, 
CSS and OS for ORN were similar at 90, 93 
and 87, respectively (28-32). Laparoscopic 
approaches have shown similarly favourable results. 
The postoperative complication rate for ORN was 
Fig.  2 a: L eft hemi- chev ron incision for radical  
nephrectomy
Fig.  2 b: Chev ron ex posure of the upper abdomen
Fig.  3 : P l anning of a thoraco- phreno- l aparotomy 
for l arger upper pol e tumors
Fig.  4 a: V iew  after l eft radical  nephrectomy and 
ex tended l ymphadenectomy
Fig.  4 b: E x tended l ymphadenectomy for rightsided 
RCC,  comprising the pericav al ,  inter- aorto- cav al  
and pre- aortic nodes
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acceptably low (9.8) [28-32]. The most common 
immediate complication is secondary hemorrhag e 
[ 33] .
4 .  lA P A RosCoP IC RA D ICA l 
neP H ReCT oM Y
a)  I ntroduction
Many still consider LRN the gold standard for the 
surgical management of T1 and T2 tumours as 
saf ety , su rvi va l rate and non- recu rrence rate are 
not significantly different from those associated with 
ORN.  Today, however the maMority of T1a and some 
T1b tumours are more properly treated with nephron-
sparing  techniqu es [ 32] .
b)  I ndications
Currently, LRN is best indicated for the surgical 
management of T1-2N0M0 tumours that warrant 
complete removal of the kidney [32]. However, 
when performed in advanced laparoscopic centres 
by significantly experienced surgeons, this can 
b e b roadened to inclu de more ext ensive  masses 
[28,34-36].  Mattar et al summarized the expanding 
indications for LRN, including very large tumours, 
locally adva nced disease, renal- ve in thromb i and 
cy toredu ctive  su rg ery [ 37 ] .
c)  O ncol ogic outcome
H emal et al eva lu ated the oncolog ic ou tcome of  
132 cases of LRN with intact specimen removal for 
T1-2N0M0 RCC.   The 5-year CSS in patients with 
a pT1a, pT1b and pT2 tumour was 97.2, 86.3 and 
82.2, respectively (significantly lower in pT2 than 
pT1a, P  0.008). The 5-year recurrence-free survival 
in patients with a pT1a, pT1b and pT2 tumour was 
97.2, 84.3 and 82.2, respectively (significantly 
lower in pT2 than pT1a, P   0.02) [38]. Another 
study demonstrated that the efficacy and oncological 
outcome of LRN in elderly patients ( 70 years) was 
as promising  as those in their yo u ng er cou nterparts 
( 70 years) [39]. More recently in 2009, Berger et 
al presented long-term, mean 11.2 years follow-up, 
in 73 patients undergoing LRN for pathologically-
confirmed RCC prior to 1999. All patients had 
completed a minimum of 10-year follow-up since 
surgery (range, 10-15 years). Actual 10-year overall, 
cancer-specific and recurrence-free survival rates 
were 65, 92, 86, respectively. Twelve-year 
overall, cancer-specific and recurrence-free survival 
rates were 35, 78, 77, respectively. At a mean 
67 months, 10 patients (14) developed metastatic 
disease, of whom 8 (11) died. The authors 
conclu ded that long - term oncolog ical ou tcomes af ter 
LRN for RCC are excellent and appear comparable 
to open su rg ery [ 4 0 ] .
d)  Compl ications
The incidence of complications associated with LRN 
ranges from approximately 10 to 20, and does not 
significantly differ from that associated with open 
surgery [36,41]. Compared with the open approach, 
LRN is associated with significantly less blood 
loss [41,42], significantly lower dose of analgesic 
ag ents du ring  the postoperative  cou rse [ 36 ,4 2]  and 
significantly shorter hospital stay [41,42]. A recent 
retrospective  chart analysi s b y Permpong ko sol 
including 549 patients reported total and maMor 
complication rates after LRN of 20 and 7.3, 
respective ly .  I ntra-  and postoperative  complication 
rates were 6.6 and 13.8, respectively. The most 
common complications were related to inMury of the 
adMacent organs (2.37) or the diaphragm (0.73). 
The second most commonly identified complications 
were vascular complications (2.2) [43]. One of the 
most important steps during LRN is the control of the 
hilum [44]. Open conversions occurred in 2.9 of 
cases [ 4 3] .
Gong et al compared LRN in patients with T1 (n 98) 
and T2 renal tumours (n 43). Transfusion rates (8 vs. 
23) and open conversions (1 vs. 12) were higher 
for T2 lesions while postoperative complication rates 
(25 vs. 21) and hospital stay (2 vs. 2.4 days) were 
similar between both groups. Complication rates 
were higher than in other series, which may have 
b een du e to the patient popu lation and the cau tiou s 
reporting [45]. The incidence of maMor complications 
unique to LRN and number of conversions decreases 
with surgeon¶s experience.  Some authors report a 
minimum experience of 50 procedures is necessary 
for reducing the risk of maMor complications [46,47]. 
Mentoring the surgeon is an effective approach for 
saf ely introdu cing  minimally inva siv e su rg ery su ch 
as LRN into practice [46,48,49]. 
e)  Comparison of different approaches
Two prospective randomized studies comparing 
transperitoneal LRN and retroperitoneal LRN found 
a shorter operative  time f or the retroperitoneal 
method. B oth approaches are similar in terms of  
other patient outcomes and complications [50,51]. 
In a retrospective study no significant differences in 
the two approaches were found [52]. Berglund et al 
f ou nd a  trend f avo u ring  the retroperitoneal approach 
for LRN in the morbidly obese patient [53).
f)  L RN  v ersus O RN
Portis et al compared LRN and ORN for localized 
RCC and reported no significant differences in 
oncologic outcome between the two procedures 
[54]. Recently, Burgess et al performed the first 
randomized controlled trial comparing LRN and ORN. 
Maximum tumour size was 8 cm and groups were 
well matched between the 45 patients. No significant 
differences were observed in blood loss, mortality 
rate, operation-room time and hospital stay. The 
only significantly differences were less postoperative 
pain and faster return to normal activities in the LRN 
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group [55]. A long-term prospective comparison of 
LRN and ORN  for T2 tumours showed that there 
was no difference in 5-year survival and that patients 
treated with LRN experienced significantly less 
b lood loss, had a decreased analg esic requ irement, 
shorter hospital stay and more rapid conva lescence 
[28]. A comparison of the 5- and 10-year disease-
free survival, CSS and OS of patients with T1 and 
T2 renal tumours treated with transperitoneal LRN or 
ORN revealed no significant differences [56].
g)   P urel y L RN  v ersus hand- assisted L RN  
( H A L RN )  v ersus O RN  
Matin et al retrospectively reviewed 271 patients that 
underwent HALRN or transperitoneal purely LRN. 
The operative time was shorter for HALRN than 
for LRN but HALRN was associated with greater 
use of analgesia and longer hospitalization [57]. 
Montgomery et al  found that wound infections and 
port-site hernias occurred less frequently with HALRN 
than with ORN, but more often than with LRN [58]. 
F ive  recent long - term retrospective  stu dies inclu ding  
647 patients with a mean follow-up of almost 4 years 
for the laparoscopic cohort compared LRN (pure 
LRN or HALRN) with ORN for T1-2 lesions. The rate 
of postoperative complications for LRN and ORN 
was similar and low. LRN was superior to ORN in 
terms of hospital stay and convalescence time. The 
oncologic outcome was similar for both treatment 
groups [28-32]. Local recurrence rates were low 
and most stu dies had none, particu larly in patients 
with less than T3 disease. Furthermore, there were 
no port-site metastases [32,59] [28-31]. A recent 
study analyzing 255 LRN showed that approach 
(standard vs.  hand assisted) and specimen handling 
(morcellation vs. intact extraction) has no discernible 
impact on oncolog ical perioperative  and long - term 
outcomes after LRN [60]. 
We can conclude that several comparisons support 
the superiority of LRN over ORN for the maMority of 
renal tu mou rs.  O ncolog ic control is similar, morb idity 
is low and does not significantly differ from open 
su rg ery , and conv alescence time is shorter af ter 
LRN.
5 . RoB oT IC RA D ICA l neP H ReCT oM Y
H emal et al prospective ly compared the f easib ility 
and safety of LRN and robotic RN for localized renal 
tumours (T1-2N0M0). Both groups had comparable 
oncological and operative outcomes. Robotic RN was 
associated with longer operative time and increased 
cost. There were no remarkable advantages of 
robotic RN observed over LRN [61].
6 .  folloW - uP  A fT eR RA D ICA l 
neP H ReCT oMY  
Skolarikos et al published a comprehensive review 
of the evidence supporting the necessity for follow-
up strategies for RCC after nephrectomy [62]. 
The rationale for postoperative surveillance of 
patients with RCC is to monitor for post-operative 
complications, renal f u nction, local recu rrence, 
recu rrence in the contralateral ki dney and metastatic 
disease in order to allow for appropriate treatment. 
No consensus currently exists on surveillance 
guidelines after surgical extirpation of RCC. 
Pu b lications on postoperative  su rve illance are 
based on retrospective studies. The intensity and 
typ e of  su rve illance shou ld b e estab lished according  
to the risk of  recu rrence and metastasis. L eib ovi ch 
et al deve loped as scoring  syst em b ased on tu mou r 
stag e, reg ional lym ph node statu s, tu mou r size , 
nu clear g rade, and histolog ic tu mou r necrosis to 
predict disease progression after RN for patients 
with clinically localized clear cell RCC [63]. Recently, 
Kassouf et al published Canadian guidelines for 
su rve illance af ter nephrectomy f or non metastatic 
RCC, based on pathological stage [64]. Grades of 
recommendations are provided using the modified 
Oxford Centre for Evidence-based Medicine scheme. 
Recommended surveillance after RN of pT1 tumours 
inclu des medical history and physi cal exa mination, 
blood biochemical tests, and chest-;-ray every year. 
Abdominal CT is recommended at 24 and 60 months 
(Grade C). Recommended surveillance after RN of 
pT2 tumours includes medical history and physical 
examination, blood biochemical tests, and chest-;-
ray eve ry 6  months f or 3 ye ars then ye arly . Ab dominal 
CT is recommended at 12, 36, 60, 84 and 108 months 
(Grade C) [64]. Most contemporary surveillance 
protocols have  b een b ased on stag e alone [ 6 4 ] . 
Recently, Siddiqui et al presented a subtype-specific 
mu ltif actorial su rve illance protocol b ased on va riou s 
pathological features that have a significant effect 
on recurrence. This surveillance protocol seems to 
b e b etter than those b ased on tu mou r stag e alone 
and can be used to efficiently adapt postoperative 
imaging to the individual patient [65]. The addition 
of  molecu lar predictors may identif y  those patients 
at high risk of progression in which the follow-up 
protocol will be more intensive [66].
7 . ConClusIons
RN is no longer the gold standard treatment for small 
renal tumours. RN as management for clinically 
localized RCC should be limited to those cases 
where the tumour is not amenable to nephron-sparing 
su rg ery . Routine ex tended l ymph node dissection 
in patients w ith detectabl e l ymph nodes does not 
improv e surv iv al  and can be restricted to staging 
purposes ( G rade A ) .  A drenal ectomy shoul d onl y 
be considered in sel ected cases in w hich there 
are risk  factors for adrenal  inv ol v ement ( G rade 
B ) . The choice of the transperitoneal or peritoneal 
approach has no impact on the efficiency and safety 
of the LRN procedure. LRN is reserved for stage T1 
and T2 tumours without strict limitations for tumour 
size. Complications are mainly vascular of type and 
are low in the hands of an experienced surgeon. 
There are no significant differences in oncological 
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outcome between LRN and ORN. H ow ev er,  L RN  
has benefits over OR1 in terms of morbidity. 
T herefore,  L RN  shoul d be the standard of care for 
T 1 and T 2  tumours,  prov ided that it is performed 
in an adv anced l aparoscopic centre by an 
ex perienced surgeon and N SS is not appl icabl e 
( G rade B ) . No consensus currently exists on 
su rve illance g u idelines af ter su rg ical ext irpation of  
RCC.  The maMority of follow-up strategies after RN 
is cu rrently b ased on tu mou r stag e alone, b u t tends 
to inclu de more histolog ical prog nostic f actors in the 
f u tu re to tailor su rve illance to the indivi du al patient.
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V. P A RT IA l neP H ReCT oM Y
1 . InT RoD uCT Ion 
Partial nephrectomy (PN) includes the complete 
removal of a localized renal tumour while maintaining 
as mu ch normal renal parenchy ma as possib le. 
Advantages of PN are the preservation of renal 
function, the prevention of Chronic Kidney Disease 
(CKD) and the avoidance of overtreatment of benign 
renal masses. PN in solitary kidneys with limited 
ischemia time resu lts in minimal chang es in long -
term renal function [1]. Moreover, some studies show 
a better quality of life after PN than after RN [2,3]. 
2 . ConCeRns W IT H  T H e use of P A RT IA l 
neP H ReCT oMY  
a)  Risk  of recurrence –  positiv e surgical  
margins
Significant concern with the use of PN for treating 
RCC is the risk of local recurrence in the ipsilateral 
kidney due to incomplete resection.  This concern 
may be tempered by the low rates of recurrence 
following PN in the literature (0 to 10) and even 
lower recurrence rates (1 to 3) when performing 
PN for  tumours  4 cm [4].  Moreover many ³local 
recu rrences”  are not du e to incomplete remova l 
b u t are rather de novo  tu mou rs, su ch as mu ltif ocal 
papillary RCC.
Analysi s of  the ava ilab le literatu re reve als that 
frozen sections or final pathologic examination of 
the margins have minimal clinical significance and 
that a normal tissue margin of Must 1 mm may be 
sufficient to prevent local recurrence and disease 
progression from RCC. Margin status is more 
important than marg in size  thou g h a positive  su rg ical 
margin does not always result in local recurrence 
and/or disease progression. Therefore surgeons 
should be aware that not all patients with positive 
surgical margins on final pathology need to undergo 
second surgery immediately. These patients can be 
Mudiciously followed with periodic ultrasound and CT 
scan to monitor their hig her risk of  local recu rrence 
(and disease progression) [5]. There are three 
recent reports f rom one centre on pu re enu cleation, 
meaning that the margin size was 0.00 mm. Simple 
enu cleation of  the tu mou r relyi ng  on the presence 
of an intact tumoural pseudocapsule was shown 
to b e saf e. O nly 2 of  the 10 7  patients deve loped 
a local recurrence (1.9) after simple enucleation 
of the tumour, one locally and one associated with 
distant metastasis [ 6 ] . O ne ye ar later the same 
g rou p f ou nd no local recu rrence at the leve l of  the 
enu cleation site and three had a k idney recu rrence 
elsewhere in the kidney after pure enucleation of the 
tumour in 232 patients. Kidney recurrence was most 
like ly attrib u tab le to mu ltif ocality [ 7 ] . Another stu dy 
reported two local recurrences with simultaneous 
metastatic prog ression and one ki dney recu rrence 
elsewhere in the kidney after simple enucleation for 
pT1b tumours [8]. A recent histopathological study 
showed that if there is pseudocapsula invasion into 
normal parenchym a, the presence of  a thin laye r of  
tissue can Mustify the presence of negative surgical 
marg ins eve n if  a simple tu mou r enu cleation is 
perf ormed [ 9 ] .
A survey on the use of LPN in 17 centres (n  855 
cases) in the United States and Europe revealed that 
21 (2.4) cases had positive surgical margins [10]. 
Permpongkosol et al identified a positive margin in 9 
of the 511 patients (1.8) undergoing LPN [11]. Frank 
et al f ou nd a similar su rg ical marg in rate in patients 
that underwent a LPN for central and peripheral 
tumours [12]. Positive margin rate was 6.7 in 
solitary ki dneys [ 13] .  L am et al recently reported that 
the rates of positive margins in PN specimen could be 
reduced with an optimal visualization of the tumour 
and the tumour margins. This could be achieved by 
intraoperative  u se of  u ltrasou nd f or deeper tu mou rs, 
cold- scissor parenchym al transection, emb oliza tion, 
and hilar clamping [14]. Currently, there is controversy 
on the optimal manag ement of  a positive  su rg ical 
margin.  For a large (³extensive´) positive margin 
it seems log ical that additional su rg ery shou ld b e 
advised, either repeat PN (primary or secondary, 
open or laparoscopic), or in the appropriate patient, 
an RN [11,15]. However, recent data indicate that 
positive  su rg ical marg ins af ter a completely deemed 
resection at the time of PN were not associated with 
an increased risk of  local recu rrence or metastatic 
disease. Therefore it has been suggested that select 
patients with microscopic (³focal´) positive margins 
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can b e saf ely of f ered close long - term su rve illance 
without compromising oncologic control [15,16]. 
While these data demonstrate that patients with a 
patholog ically positive  marg in may  b e ob serve d 
negative surgical margins should always be the 
goal in any oncologic procedure, including PN. Very 
recently, Bernhard et al identified three independent 
predictive factors for ipsilateral recurrence following 
NSS in RCC: tumour size ! 4 cm, tumour bilaterality 
(synchronous or asynchronous) and positive 
surgical margins status (hazard ratios were 6.31, 
4.57 and 1.15, respectively). Among the 809 NSS 
procedures with a medium follow-up of 27 months 
(1-252 months) 25 ipsilateral recurrences (3.2) 
occurred at a medium time of 27 (14.5 – 38.2) 
months. Positive  su rg ical marg ins occu rred in only 
1.5 of the patients. The authors concluded that 
a prolonged follow-up should be recommended in 
patients presenting one or more of the three identified 
factors. The main limitation of the study was its 
retrospective nature and a short follow-up (median 
FU, 27 months) [17]. A previous retrospective study 
inclu ding  data f rom 26  institu tions in Eu rope and the 
United States analyzed the outcome of 111 patients 
with positive surgical margins following NSS. Positive 
su rg ical marg ins statu s occu rred more f requ ently 
in the imperative group and is associated with an 
increased risk of  recu rrence, b u t marg in statu s 
was not an independent predictor of both cancer-
specific and overall survival [18]. These data taken 
together suggest that identified predictive factors for 
local recurrence after NSS do not necessarily affect 
survival and should not prohibit NSS in that setting. A 
recent study that reviewed the clinical records of 114 
NSS procedures found a positive surgical margin 
rate of 1.75. No disease progression or RCC 
attributable deaths were associated with positive 
surgical margins. These findings suggest that total 
nephrectomy shou ld b e avo ided as a response to 
positive  su rg ical marg ins [ 19 ] .
b)  H il ar cl amping -  w arm and col d ischemia 
time –  renal  function –  hemostatic agents
D u ring  the deve lopment phase there have  b een 
initial concerns with the use of LPN as related to a 
somewhat longer warm ischemia time and increased 
risk of maMor postoperative complications such as 
urinary leakage and hemorrhage [20]. Therefore the 
decision to perform an OPN or LPN depends on the 
ex perience of  the indivi du al laparoscopic su rg eon. 
OPN is most often done through a lumbotomy, 
after exposure of the kidney and the tumour with its 
ov erlyi ng  f at. ( fi g . 5 , 6 ) With increasing experience, 
LPN is now being performed at a growing number of 
tertiary centres worldwide. The technical challenge 
is to completely resect the tu mou r in a b loodless 
field followed by hemostatic renorraphy within a 
limited warm ischemia time. Factors associated with 
superior outcomes of LPN are routine hilar clamping, 
adMunctive use of hemostatic agents and renal 
parenchym al closu re b y su tu re lig ation [ 21] .
Hilar clamping minimizes blood loss and allows 
precise tu mou r ex cision and renal reconstru ction in a 
nearly bloodless field.  Today, there is no consensus 
about the clamping technique to be employed (artery 
only versus artery 	 vein) [22]. 
V ery recently , H u b er et al eva lu ated b leeding  
complications after open NSS in 196 patients at 
their institution (from 2005 to 2008). Median tumour 
diameter was 2.7 cm (range 0.5 – 11.8 cm). Bleeding 
required conservative (six), interventional (six) 
or surgical (three) therapy in 15 of the 196 cases 
(8). The authors identified multifocality (P 0.039) 
and imperative indications (P 0.043) as risk factors 
for hemorrhage after NSS. The management of 
bleeding was very successful, relying on transarterial 
embolization (TAE) as an effective and safe 
treatment. I n rare cases of  seve re b leeding  su rg ical 
exploration is unavoidable, with a lower chance of 
ki dney preserva tion [ 23] .
A recent well-designed but small prospective study 
has investigated separate renal function with 
effective renal plasma Àow and renal parenchymal 
volume measured from CT scan. The authors could 
demonstrate that 25 min of warm ischemia time 
(WIT) is a cut-off for irreversible renal damage [24]. 
A recent larg e mu lti- institu tional stu dy has eva lu ated 
Fig.  5 : I nstal l ation for l umbotomy
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the renal effects of ischemia in patients with solitary 
kidneys undergoing open NSS. The authors 
concluded that when vascular clamping during 
open NSS is necessary efforts should be made to 
limit WIT to 20 minutes and cold ischemia to 35 
minu tes in order to avo id an increased risk of  chronic 
renal insufficiency and acute renal failure [25]. The 
currently recommended WIT is 20 minutes or less, 
reg ardless of  su rg ical approach. I f  a long er ischemia 
time is anticipated, cold ischemia shou ld b e institu ted 
up front at the start of PN. Cold ischemia with ice 
slu sh [ 26 ]  shou ld b e ke pt as short as possib le, 
ideally within 35 min [27]. After surface cooling of the 
ki dney b y ice slu sh f or ab ou t 10  minu tes, the ki dney 
can b e clamped, and a saf e cold ischemia time f or a 
maximum of 35 min has been described in several 
studies [13,25,28,29]. Other methods to induce cold 
ischemia are arterial and u reteral perf u sion [ 30 - 33] . 
Recently, an early unclamping technique has been 
suggested by which only the initial parenchymal 
suturing is performed with the hilum clamped while 
su tu red renorrhaphy is perf ormed in the u nclamped, 
revascularized kidney. This resulted in a reduction of 
WIT by more than 50 (13.9 vs. 31 min, p  0.0001). 
Postoperative  hemorrhag e and reinterve ntion also 
tended to be lower but was not statistically significant. 
The current mean WIT  14 minutes is lower than 
or similar to that in contemporary OPN series [34]. 
Other authors have confirmed these findings [35-
37]. Nevertheless, the safe maximum duration of 
WIT remains in debate.  
A recent study evaluated the impact of WIT on renal 
function in 101 LPN patients using the Modification 
of Diet in Renal Disease (MDRD) equation to 
determine eGFR. The study results indicated that 
clinically significant risk for postoperative renal 
function impairment is evident only at a WIT of ! 40 
minutes. Incidence of renal function impairment was 
more than 2-fold higher in patients with WIT ! 40 
minutes than in the other groups (p  0.077). Larger 
studies in populations with normal preoperative 
renal function and with various degrees of CKD are 
requ ired to clarif y the risk f actors f or postoperative  
renal function impairment, including WIT. In the 
meantime eve ry attempt shou ld b e made to redu ce 
WIT [ 38 ] . 
Another stu dy reve aled that g reater tu mou r size , 
central tu mou r location and hig her b ody mass 
index are associated with longer WIT. By including 
these 3 factors into a nomogram prolonged WIT (! 
30 minutes) may be predicted before surgery [39]. 
However, the exp erience of  the su rg eon may b e the 
most critical parameter.
Fig.  6 a: E x posure of the k idney in a l umbotomy 
after compl ete hil ar dissection
Fig.  6 b: Compl ete mobil iza tion of the tumor 
bearing k idney on its artery,  v ein and ureter
Fig.  6 c: Freeing the k idney and the tumor,  cov ered 
by peri- renal  fat
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Very recently, Chan et al retrospectively evaluated 
in 65 patients (35 OPN and 30 LPN) which clinical 
parameters, alone or Mointly, accurately predicted 
unilateral renal function after OPN and LPN. In the 
u niva riate reg ression analysi s, intraoperative  vi su ally 
estimated preserved renal parenchyma (P0.001), 
tumour size (radiologic, P 0.017; pathologic, 
P 0.041) and procedure type (laparoscopic vs. 
open) (P 0.021) were the only factors found to 
be significantly correlated with postoperative 
scintigraphic differential renal function. Tumour depth 
(P 0.050) was borderline significantly correlated with 
postoperative  scintig raphic dif f erential renal f u nction. 
I ntraoperative  vi su al estimation of  preserve d renal 
parenchyma volume was the most accurate predictor 
of  actu al postoperative  u nilateral renal f u nction and 
should be routinely documented during OPN and 
LPN [40]. 
The use of hemostatic agents and glues during 
LPN in 18 centres (n  1347 cases) in the United 
States and Europe was shown to be routine in most 
centres performing LPN (in 77.4). The rates of 
postoperative  hemorrhag e requ iring  transf u sion and 
urine leakage rates were low in this survey (2.7 
and 1.9, respectively) [41].
c)  L ong- term oncol ogic data –  risk  of 
compl ications
A randomised prospective phase III trial was 
conducted (EORTC 30904) comparing OPN and 
ORN in 541 patients with tumours  5 cm and a normal 
contralateral ki dney . V an Poppel et al conclu ded that 
the complication rate with OPN is slightly higher than 
with ORN [42]. The long-term oncological results are 
not ye t ava ilab le. 
Porpiglia et al retrospectively analyzed 90 LPN 
procedures. The only variable that was found 
to correlate with a significantly higher rate of 
complications was a corticomedullar tumour growth 
pattern as opposed to a cortical growth pattern (P 
  0.02). It has to be noted that this finding is based 
on univariate analysis (no multivariate analysis was 
performed). To reduce the risk of complications 
associated with LPN the authors recommended 
selection of patients with cortical renal lesions 
only [43]. More recently, Turna et al retrospectively 
analyzed 507 LPN procedures. Presence of a solitary 
kidney, prolonged WIT and increased intraoperative 
blood loss were found to be independent risk factors 
on mu ltiva riate analysi s f or the deve lopment of  
postoperative complications after LPN [44].  Probably 
the new categorization as proposed by Ficarra et 
al and Kutikov et al will be helpful in defining risk 
factors [45,46]. 
3 . oP en P A RT IA l neP H ReCT oM Y
a)  I ntroduction
Open partial nephrectomy (OPN) is the nephron-
sparing modality with the largest clinical experience 
and the longest follow-up. OPN continues to be the 
treatment of  choice f or the manag ement of  localize d 
RCC given its wide application over the last two 
decades and the most su b stantial su pporting  b ody 
of  operative  and oncolog ic data. I mportantly , u nlike  
ablative treatment options OPN allows definitive 
pathological identification (i.e. stage, grade and 
histology) and proof of complete resection. Essential 
su rg ical principles inclu de exce llent exp osu re, 
control of  the renal va scu latu re, caref u l exci sion of  
the tumour with a negative surgical margin and repair 
of  the parenchym al def ect and collecting  syst em to 
minimize  the risk of  postoperative  hemorrhag e or 
urinary fistula. ( fi g . 7 , 8 )
b)  I ndications
The standard indications for NSS according to 
the EAU guidelines are divided in the following 
categ ories:  
ņ absolute (anatomical or functional solitary kidney)
ņ relative (functioning opposite kidney that is affected 
b y a condition that mig ht impair renal f u nction in the 
future) 
ņ elective (localized unilateral RCC with a healthy 
contralateral kidney)
Relative indications also include patients with 
hereditary forms of RCC, who are at high risk of 
deve loping  a tu mou r in the contralateral ki dney 
in the future [47]. Since more SRMs are detected 
now, elective PN has been adopted more frequently 
f or the treatment of  su ch tu mou rs. D u ring  the last 
decade elective PN has become the gold standard 
for the treatment of T1a tumours ( 4 cm) in patients 
with a normal contralateral kidney [48,49]. When 
PN is performed in carefully selected patients in 
specialize d centres, indications can b e exp anded 
to include T1b tumours (4-7 cm) [50-61]. ( fi g . 9 , 1 0 )  
Also multifocal tumours can be dealt with ( fi g . 
1 1 ) as well as centrally located tumours that can 
need intraoperative  u ltrasou nd to localize  tu mou rs 
completely cove red b y healthy parenchym a. ( fi g . 
1 2 )
c)  O ncol ogical  outcome
Lee et al compared RN and OPN for tumours  4 
cm and found equivalent oncological results at 5-
years (disease-free survival of 96) with no local 
recu rrences [ 4 8 ] . T a b l e  1 presents the oncolog ic 
ou tcome of  larg e series of  nephron- sparing  su rg ery 
[48-50,58,62-73].  PN for RCC  4 cm (T1a) is now 
established standard. More recently, PN is being 
proposed for T1b RCC (4-7 cm). Several recent 
studies indicate that elective PN can achieve similar 
oncological outcomes as RN for select T1b tumours 
[50,54,55,57,59,61]. T a b l e  2 presents stu dies 
assessing the oncologic outcome following NSS in 
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Fig.  7 c: Cl osure w ith singl e approx imating sutures
Fig.  7 a: W edge resection after bul l dog cl amping of 
both artery and v ein
Fig.  7 b: O v ersew ing of smal l  arteries and v eins
T abl e 1.  O ncol ogic outcomes of l arge series of N SS 
Au thor No . of 
patients
Mean tumour 
size (cm)
5-yr CSS 
()
10 - yr  
CSS ()
L ocal 
recu rrence 
()
Mean
follow-up (mo)
Steinbach et al (62) 121 5.5 9 0 - 4 .1 4 0
Moll et al (63) 14 2 4.5 9 8 - 1.4 35
Lerner et al (64) 185 4 .1 8 9 7 7 5.9 4 4
Belldegrun et al (65) 14 6 3.6 9 3 - 2.7 7 4
Herr et al (66) 7 0 3.0 - 9 7 1.4 120
Hafez et al (119) 485 3.4 9 2 - 3.2 4 7
Lee et al (48) 7 9 2.5 95 - 0 4 0
Lau et al (67) 16 4 3.3 9 8 - 3 4 1
Filipas et al (68) 18 0 3.3 9 8 - 1.6 56
Delakas et al (69) 118 3.4 9 7 .3 9 6 .4 3.9 10 2
Patard et al (50) 314 2.5 9 7 .8 - 0 .8 62.5
Fergany et al (70) 4 0 0 ° 4 .2 8 9 8 23.5 4 4
Becker et al (58) 24 1 3.7 9 7 .8 95.8 1.4 6 6
Pahernik et al (71) 715 3.0 98.5 9 6 .7 3.3 8 1
Pahernik et al (72) 10 3° 4 .2 8 9 .6 7 6 0 .1 9 6
Van Poppel et al (73) 51 3.0 9 8 .0 - 0 .0 7 8
°  solitary ki dneys  
CSS: cancer-specific survival
Reprinted from Van Poppel H. Efficacy and safety of nephron-sparing surgery. Int. J Urol, 2010;17(4):314-26.
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Fig.  9 a: E x posure of RCC at renal  hil us Fig.  9 b: Reconstruction of the k idney after 
midpol ar tumorectomy
Fig.  9 c: Reconstruction after midpol ar resection
Fig.  10 a: U pperpol e RCC w ith en bl oc 
adrenal ectomy w ith smal l  metastasis
Fig.  10 b: A fter upper pol e amputation and adrenal --
ectomy and l ymph node dissection for T 3 a RCC
Fig.  8 a: O pen enucl eoresection of a smal l  RCC w ith 
a rim of heal thy parenchyma
Fig.  8 b: A ppl ication of hemostatic adhesiv e agent 
( T achosil )
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Fig.  11a: O ne l arge and mul tipl e smal l  papil l ary 
type I  RCC’ s
Fig.  11b: A fter resection of the l arger,  and thermo-
abl ation of the smal l er l esions
Fig.  12 a: I ntra- operativ e ul trasound for intra- renal  
RCC
Fig.  12 b: I ntra- operativ e ul trasound to detect an 
intraparenchymal  tumor
Fig.  12 c: U S l ocal iza tion of the intra- renal  tumor Fig.  12 d: Resection of ov erl ying renal  cortex
Fig.  12 e: E nucl eation of deep intrarenal  mass
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relation to tumour size ! 4 cm or  4 cm [8,50,54,
55,57,58,60,74). Pahernik et al recently compared 
PN for pT1a ( 4 cm) and pT1b tumours (4-7 cm) 
in 474 PN procedures; estimated CSS was 97.9 
and 95.8 at 5 years, and 94.9 and 95.8 at 10 
years. This study failed to demonstrate statistical 
significant differences in terms of CSS after PN for 
T1a and T1b tumours [75]. This was also observed 
in a recent multicentre study of Patard et al [56]. 
Crispen et al recently reported durable cancer control 
in 798 patients undergoing PN for T1 renal tumours 
( 7 cm). They found that overall, CSS, metastasis-
free and local recurrence-free survival significantly 
decreased with each 1 cm increase in size in all 
tumours treated and in those with pathologically 
confirmed RCC [76]. A recent multi-institutional 
study revealed cancer control equivalence between 
RN and PN in patients with high-grade Fuhrman III- 
IV or with pT3a histology. Conversely, CSS after PN 
is statistically less than that after RN in patients with 
tumours ! 7 cm. It has to be noted that only 29 of 925 
patients (3.1) with tumour size ! 7 cm were treated 
with PN at 1 of 13 participating centres. Larger 
cohorts are required to confirm the results [77].
A recent study analysed the data of 1205 T1N0M0 
RCC patients treated with NSS. Despite the 
su g g ested more ag g ressive  phenotyp e of  the 
papillary histolog ic su b typ e, the au thors f ou nd no 
statistically significant differences in cancer-specific 
mortality among  the papillary , chromophob e, and 
clear cell va riants [ 7 8 ] . 
d)  Compl ications
When performed in appropriate patients and in 
centres with sufficient expertise, OPN can offer for 
small renal tumours a perioperative morbidity profile 
similar to that of ORN. The rate of postoperative 
complications was 13.7 in a recent multicentre 
comparative study by Gill et al including 1029 patients 
with renal tumours ( 7 cm) that underwent OPN. 
The rate of postoperative hemorrhages and urologic 
complications was 1.6 and 5.0, respectively. [28]. 
The best available evidence on this subMect is the 
prospective randomised EORTC phase III trial which 
compared the complications of elective PN and RN 
in patients with renal tumours  5 cm. In this study 
reported by Van Poppel, PN was associated with 
higher risk of severe perioperative bleeding (3.1 
vs. 1.2), reoperation due to side effects (4.4 vs. 
2.4) and having an abnormal postoperative CT 
scan (4.4 vs. 2.0).  The rate of urinary fistulas 
was 4.4 [42]. In a retrospective multicentre study, 
Patard et al demonstrated in 730 elective OPN 
procedu res that perioperative  morb idity as measu red 
by blood loss, urinary fistula rate, and need for blood 
transfusion was significantly increased for tumours 
! 4 cm in diameter. They concluded that expanding 
the indications of elective OPN to larger tumours 
is associated with an increased but acceptable 
morbidity [56].  In addition, a recent study including 
1117 PN revealed that 4.5  of patients developed 
postoperative urinary fistula. Patients with tumours ! 
2.5 cm were 2-fold more likely to develop a urinary 
fistula compared to patients with tumours  2.5 cm 
(P    0.04) [79]. 
Renal failure is another complication of PN. A 
recent study analysed the data of 166 patients with 
pathological T1-3 N0M0 RCC treated with PN. The 
investigators identified perioperative blood loss, hilar 
clamp time and preoperative GFR as independent 
predictors of renal failure (decrease in GFR of !25). 
I t is possib le that su rg ical exp erience cou ld minimize  
the rate of renal failure especially in patients with 
pre- exi sting  renal f u nction impairment [ 8 0 ] .
The risk of a significant complication may increase 
with the technical complexity of the case such as 
larger tumours or centrally located tumours. However, 
most complications can b e manag ed conserva tive ly 
and usually resolve without significant morbidity. 
O ve r the last ye ars, su rg ical techniqu es have  b een 
improvi ng  and complication rates f u rther decreasing  
with increasing surgical experience. 
e)  Comparison betw een P N  and RN  
McKiernan et al conducted a 10-year prospective 
study to compare 173 patients who underwent 
Table 2.  Studies assessing oncologic outcome following 1SS in relation to tumour size ! 4 or  4 cm
Au thor No . of patients  
and pT stage
5-yr  
CSS  
()
10 - yr  
CSS 
()
L ocal 
recu rrence 
()
Metastasis
()
Mean  
F U   
(mo)
Patard et al (50) 314 (pT1a)
65 (pT1b)
9 7 .8
9 3.8
-
-
0 .8
3.6
2.4
7 .1
51
62.5
Leibovich et al (55) 91 (30 pT1a, 60 pT1b, 1 pT3a) 9 8 .3 - 5.5 4 .4 10 6  
Mitchell et al (74) 33 (21 pT1b, 12 pT3) 9 6 .2 - 2.3 - 34
Carini et al (8) 71 (30 pT1a, 31 pT1b, 10 pT3) 85.1 - 4.5 14 .9 7 4
Dash et al (57) 45 (41 pT1b and 4 pT3) 8 0  - 2.2 - 14
Becker et al (58) 69 (62 pT1b, 4 pT2, 3 pT3a) 10 0 10 0 5.8 5.8 7 4
Peycelon et al (60) 61 (42pT1b, 12pT2, 6 pT3a, 1 pT3b) 8 1 7 8 9 .8 19 .7 7 0 .7
Joniau et al (54) 67 (13 pT1a, 49 pT1b, 1 pT2, 4 pT3a) 9 9 - 4 .0 6 .0 4 0 .1
Reprinted from Van Poppel H. Efficacy and safety of nephron-sparing surgery. Int. J Urol, 2010;17(4):314-26.  
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RN with 117 patients who underwent PN for renal 
tumours  4 cm and a normal contralateral kidney. 
The incidence of risk factors for renal insufficiency did 
not differ between the two groups. After controlling 
f or perioperative  risk f actors f or renal f ailu re, patients 
undergoing RN were at a greater risk of chronic renal 
insufficiency (creatinine  2.0 mg/dL) than a similar 
cohort of patients undergoing PN [81]. Moreover, in 
D ash et al prospective  comparison of  19 6  patients 
undergoing PN and RN for T1b tumours, serum 
creatinine level at 3 months post-operative was 
significantly lower in the PN cohort [57].
Patard et al performed a retrospective analysis of 1454 
patients undergoing PN or RN for T1N0M0 tumours. 
In patients treated by PN, the cancer death rate was 
higher for T1b tumours compared to T1a tumours 
(6.2 vs. 2.2, respectively). However, in the group 
of T1b tumours, there was no significant difference 
in the rate of cancer specific deaths whether treated 
with PN or RN (6.2 vs. 9, respectively). This study 
su g g ests that it is saf e to exp and the indications of  
PN to include patients with T1N0M0 tumours up to 
7 cm [50].  Likewise, Leibovich et al performed a 
retrospective analysis of 932 patients undergoing PN 
or RN for T1b renal tumours. Their study included 
control groups of T1a tumours for each procedure. 
There was no statistically significant difference in 
survival at 5 years between patients treated with PN 
and RN after adMusting for important pathological 
features. This study also shows that PN for T1b (4 
to 7 cm) RCC can result in excellent outcomes when 
performed in appropriately selected patients [55]. A 
recent study confirmed these results and suggested 
designing a prospective study to compare RN and 
PN in the management of RCC up to 7 cm [59]. 
Thompson et al combined data from the Mayo Clinic 
and Memorial Sloan Kettering Cancer Center of 
patients with 4 to 7 cm renal masses treated with 
RN (873) vs. PN   (286). They suggest that OS and 
CSS are not compromised when PN is compared 
with RN for tumours up to 7 cm. This study adds 
considerable evidence supporting PN use when 
technically f easib le [ 6 1] . A recent stu dy represents 
the larg est and the only popu lation- b ased analyse s 
of cancer control efficacy of NSS vs. RN in T1bN0M0 
RCC. It used Surveillance, Epidemiology, and End 
Results (SEER) data where 275 NSS were matched 
with 1100 RN for T1bN0M0 RCC. It indicates that 
NSS does provide equivalent cancer control relative 
to RN. NSS should be considered equally effective 
to RN for T1bN0M0 RCC [82]. None of these studies 
were randomised like the EORTC 30904 trial 
comparing PN to RN for patients with RCC up to 5 
cm of which the results are pending [42]. 
A recent analysis of the SEER-9 database revealed 
that relative to PN, RN predisposes to a rise in overall 
mortality and non- cancer related mortality rate in 
patients with T1aN0M0 RCC [83]. Convincing data 
show equivalence of PN and RN for cancer control 
and superiority of PN in terms of preserving renal 
function, preventing CKD and subsequent long-
term cardiac morb idity and mortality and improve d 
overall survival [53,84]. Therefore, patients with 
T1 renal tumours should undergo PN whenever 
technically feasible. The expanding role of PN is the 
topic of a recent paper of European Urology [85]. 
A comparative  popu lation- b ased stu dy analyze d 
the rate of PN vs. RN for clinically localized RCC 
(SEER data 1989-2004). Of 19,733 assessable 
patients, 2,614 (13.2) had PN and 17,119 (86.8) 
had RN.  The use of PN decreased with increasing 
tumour size and increasing age and increased with 
more contemporary years of surgery (all P  0.001). 
Although the rate of PN use increased over time, 
unexplained variability remained. Regional and 
gender differences in PN rates represent findings 
that need to b e u rg ently addressed and corrected. 
The PN rate was 16.4 in San Francisco-Oakland, 
vs. 7.6 in New Mexico (P  0.001). Women were 
10 less likely to have a PN than men. The study has 
several limitations.  There was no information about 
surgical approach (open vs. laparoscopic vs. robotic) 
of PN or RN that was performed, tumour location, 
nu mb er of  renal u nits and renal f u nction. I nf ormation 
on comorbidity status, hospital type (academic vs. 
community), surgical training and expertise (years in 
practice) was also unavailable [86]. 
4 . lA P A RosCoP IC P ART IA l neP H ReCT oM Y
a)  I ntroduction 
O ve r the last decade, laparoscopic partial 
nephrectomy (LPN) has gained acceptance as an 
alternative to the open procedure. Given its more 
recent development most LPN series understandably 
have shorter follow-up compared to most OPN 
series. The preferred choice of access for LPN is the 
transperitoneal approach. Retroperitoneal access is 
reserve d f or posterior and particu larly posteromedial 
tumours [87]. In the largest LPN series to date, Gill 
et al reported LPN in 1000 patients over a period of 
9 years. Of these, 800 LPNs performed by a single 
surgeon were stratified according to consecutive 
time periods (era I (1999-2003), era II (2004-2006) 
and era III (2007-2008). 
Tumours in the most recent era were larger, more 
commonly ! 4  cm, central and hilar, and less of ten 
peripheral  4 cm. Despite increasing tumour 
complexity, warm ischemia times were shorter, 
complication rates (overall, post-operative, urologic) 
were significantly lower, positive surgical margin 
rate was only 0.6, and renal functional outcomes 
were superior in the most recent era, In patients 
with pathologically-confirmed cancer, 5-year overall, 
cancer-specific, and recurrence-free survival was 
90, 99, and 97, respectively [88]. 
If a LPN encounters difficulties, the committee 
recommends that the optimal surgical plan would be 
to convert to OPN with LRN being performed in the 
rare case.
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b)  I ndications
The initial experience with LPN was limited to small 
( 4 cm), low stage, single, peripheral and exophytic 
lesions. These indications have also been expanded 
to inclu de more challeng ing  masses:  central tu mou rs, 
hilar tu mou rs, cyst ic tu mou rs,  mu ltiple ipsilateral 
tu mou rs, tu mou r in a solitary ki dneys , larg er tu mou rs 
(T1b and T2 or greater), and intraparenchymal 
tumours [89]. With regard to the tumour location, 
during a surgeon¶s initial LPN experience, exophytic 
tu mou rs and non- central tu mou rs not ext ending  into 
the renal sinus may be excised more easily, with a 
lower incidence of complications [90] ( fi g . 1 3 a  –  f ). 
A new anatomical classification has been recently 
proposed to categ orize  dif f erent locations of  renal 
tumours that could correlate with surgical ease and 
oncological safety of the PN [45]. A comprehensive 
standardize d sys tem f or qu antitating  renal tu mou r 
siz e, location and depth is the recently deve loped 
R.E.N.A.L. nephrometry score [46].
lP n f o r  c e n t r a l  a n d  h i l a r  t u m o u r s
I n the past, central location of  the tu mou r or contact of  
the tumour with a maMor renal vessel (hilar tumour) on 
preoperative cross-sectional imaging was considered 
to be a contraindication for LPN. The reason was the 
perceived difficulty in achieving negative surgical 
margins, while preserving adequate blood supply 
to the renal remnant. However, a prospective study 
demonstrated that the thickn ess of  the su rg ical 
marg ins has no ef f ect on the risk of  local recu rrence 
and a g ood prog nosis can b e exp ected as long  as 
the definitive margins are free of cancer [91]. Data 
on LPN for centrally located and hilar tumours are 
limited and definitions on central and hilar tumour 
are not u nif orm maki ng  comparison of  resu lts among  
different studies difficult. 
Venkatesh and co-workers reported that 
complications of LPN for 123 renal tumours were 
associated with location of the tumour in the kidney 
with lower complication rates for exophytic (10) 
than for endophytic (47) and hilar tumours (50) 
[ 9 2] .
Two studies performed in centres with adequate 
laparoscopic expertise reported that LPN in central 
tumours was associated with comparable outcome 
as LPN in peripheral tumours. However, long-term 
follow-up is needed and a longer ischemia time may 
ensu e f or central/ hilar tu mou rs [ 12,9 3] . F rank et al 
compared LPN for central (n 154) and peripheral 
(n 209) tumours. Although the blood loss was 
similar (median 150 mL) more early postoperative 
complications occu rred in the central tu mou r g rou p 
(6 vs. 2). In addition, central tumours required 
longer WIT (median 33.5 vs. 30 minutes, p  0.001) 
[12].  Nadu et al also compared LPN for central 
tumours (n 53 including 12 hilar tumours) and 
peripheral tumours (n 159). Four patients (7.5) 
had delayed hemorrhage (arterial pseudoaneurysm) 
with late onset hematuria; these 4 patients required 
ang iog raphic emb oliza tion. O nly one patient had 
a urine leak (1.9) after LPN for central tumours. 
Mean WIT in the central tumour group was longer 
than in the peripheral tumour group (37 vs. 28 
minu tes, P  0.05) but the median WIT was similar 
(30 vs. 29 minutes, P ! 0.05) [93]. Two recent smaller 
studies reported that in experienced hands LPN for 
hilar tumours is feasible and safe while short-term 
oncologic results are promising [94,95].
lP n f o r  t u m o u r  i n  s o l i t a r y  k i d n e y
A recent study from Lane et al compared 169 OPN 
and 30 LPN for stage T1 tumours in a solitary 
functioning kidney. By 3 months after OPN or LPN, 
the ave rag e loss of  postoperativ e renal f u nction 
was similar. LPN compared to OPN was associated 
with a longer WIT (mean difference of 9 minutes; P 
 0.0001), a 2.54-fold higher risk of postoperative 
complications (P  0.05) and a higher rate of 
postoperative dialysis (10 vs. 0.6, respectively, P  =  
0.01). Of note, the T1 tumours in this study were not 
sub-dived into cT1a ( 4 cm) and T1b (4-7 cm) sub-
categories. Although LPN is technically feasible for 
a tumour in a solitary kidney, at this time OPN may 
b e considered the pref erred treatment approach f or 
these patients who are at high risk for CKD [96]. 
This was recently confirmed in a study including 84 
patients with solitary kidney [1].
c)  O ncol ogical  outcome 
T a b l e  3 presents oncolog ic ou tcomes of  laparoscopic 
partial nephrectomy [ 13,37 ,9 7 - 9 9 ] . O ncolog ical 
outcomes are similar when comparing LPN and 
OPN for localized RCC. A comparison of  LPN and 
OPN performed in 1800 patients with a single renal 
tumour ( 7 cm) at maMor centres with greatest 
expertise showed  a similar oncological outcome (3-
year CSS: 99.3 vs. 99.2, respectively) [28]. Lane 
and Gill reported intermediate-term outcomes of 
LPN in 56 patients, with an OS and CSS of 86 and 
100, respectively, at 5 years [13]. A retrospective 
matched-pair comparison of LPN and OPN in 200 
pT1 patients showed a 5-year OS of 96 and 
85, respectively. The 5-year local recurrence-
free survival was 97 after LPN and 98 after 
OPN [100]. Most recently, Lane and Gill compared 
7-year outcomes of LPN (n 77) with OPN (n 310) 
for single clinical stage T1 (7cm). Cancer recurred 
inf requ ently , and only rarely cau sed mortality , af ter 
either LPN or OPN. At 7 years, metastasis-free 
survival was 97.5 and 97.3 (p 0.47) after LPN 
and OPN, respectively. On multivariate analysis, 
predictors of  all- cau se mortality inclu ded adva ncing  
age (p0.0001), co-morbidity (p0.0001), pre-
operative renal dysfunction (p 0.0001), but not 
tumour size (p 0.6) or operative approach (LPN vs. 
OPN, p 0.06). The authors concluded that LPN and 
OPN provide similarly excellent long-term overall 
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and cancer-specific survival, with the vast maMority 
(97) of patients experiencing metastasis-free 
su rvi va l [ 10 1] .
d)  Compl ications
Porpig lia et al recently reported the incidence of  
complications in recent LPN series from centres 
with adequate expertise with a total number of 
1062 patients. The overall complication rate was 
21.4 (range 9 to 33).  There was a 5.1 rate of 
hemorrhagic complications (range 1.5 - 10.0),  a 
4.2 rate of urine leakage (range 1.4 - 13) and a 
0.7  rate of renal failure (range 0.5 - 2.0) [102].
Turna et al reported a large series focusing on 
complications after 507 LPNs performed by a 
single surgeon. Of the 107 complications 49 (46) 
were urologic. Of total complications, 22 (20.6) 
were grade I, 48 (45) grade II, 32 (30) grade 
III, 5 (4.7) grade IV and none were grade V. 
Complications were compared for LPNs performed 
between 1999 to 2002 and 2003 to 2006. Despite 
the increase in the nu mb er of  total and complex 
procedures, there was a decrease in the rate of 
overall complications (29.6 vs. 16.9, P    0.001), 
urological complications (13.6 vs. 7.7, P   0.03) 
and nonurological complications (16 vs. 9.2, P 
  0.02). Urine leakage rate decreased from 4.7 to 
1.2 (P   0.01), while the postoperative hemorrhage 
rates did not show statistical difference (5.9 vs. 
5.6), likely due to the increased number of complex 
procedures [44]. Recently, a detailed single-centre 
review was reported of 144 consecutive LPN (4 
surgeons) conducted from November 2002 to 
January 2008. Standardized grading criteria were 
used which allows comparison to the series of Turna 
el al. A total of 39 complications occurred in 29 (20) 
patients. Of these, 20 (51) were urologic. Of total 
complications 6 (15.4) were grade I, 19 (48.7) 
grade II, 11 (28.2) grade III and 3 (7.7) grade 
IV and none were grade V. Overall results appear 
consistent with those of other contemporary series 
of LPN or OPN. Increased American Society of 
Anesthesiologists (ASA) score and ischemic time 
are associated with complication risk. Hospital 
readmission and reintervention was required in 15 
(10.4) and 9 (6.2) patients, respectively [103].
With the use of more sophisticated laparoscopic 
techniqu es and the increased exp erience of  
laparoscopic surgeons the complication rate of LPN 
has significantly decreased and now appears similar 
to that of OPN [34,44,104].
e)  Comparison betw een L P N  and O P N
Gill et al¶s recent combined study from 3 maMor centres 
with greatest expertise compared 1800 patients with 
a single tumour ( 7 cm) undergoing either LPN or 
OPN. Advantages of LPN were less operative time, 
decreased operative  b lood loss and shorter hospital 
stay. On the other hand, LPN was associated with 
a 10 minute longer WIT (31 vs. 20 min) and more 
postoperative complications (18.6 vs. 13.7) than 
OPN, particularly postoperative hemorrhage (4.2 
vs. 1.6) and urologic complications (9.2 vs. 5.0). 
Importantly, LPN and OPN were similar with regard 
to intra-operative complications (1.8 vs. 1). 
Shorter operative times and less blood loss with 
LPN than with OPN, but higher rates of urological 
complications parallel the findings of a recent meta-
analysi s of  the American U rolog ical Association 
(AUA) [105].  Oncological outcomes (CSS: 99.3 vs. 
99.2 at 3 years), renal function outcomes (97.9 vs. 
99.6 at 3 months) and positive surgical margins 
(1.6 vs. 1) were similar between LPN and OPN. 
Local (1.4 vs. 1.5) and distant (0.9 vs. 2.1) 
recurrences were also equivalent. Conversion to 
open surgery occurred in 2.1 of LPN cases [28]. 
A retrospective matched-pair comparison of LPN 
and OPN was recently performed in 200 patients 
with pT1 RCC. The authors concluded that in 
experienced hands LPN provides similar oncologic 
and functional outcomes compared to OPN at a 
mean follow-up of 3.6 years. Decrease in GFR at 
last follow-up, positive surgical margin rates, blood 
loss, and complication rates were comparable for 
b oth g rou ps.  O perative  time, ischemia time and 
hospitalization time were shorter in the LPN group 
and conversion rate to open surgery was 2 [100]. 
How often a conversion to LRN was done is not 
reported. In addition, studies show that LPN has 
protective  ef f ects on the long - term renal f u nction 
when compared with LRN [106,107]. 
T abl e 3 .  O ncol ogic outcomes of l aparoscopic partial  nephrectomy
Au thor No. of 
patients
Mean 
tu mou r size  
(cm)
CSS () Positive  
su rg ical 
margins ()
L ocal recu rrence 
()
Mean  
follow-up (mo)
Porpiglia et al (97)   34 3.2 10 0  2.9 0 .0 16
Gill et al (98) 4 30 3.6 100 (3-yr) 0 .0 0 .0 30
Permpongkosol et al (99)   85 2.4   9 1.4 2.4 2.4 4 0
Bollens et al (37)   39 3.2 10 0  2.6 0 .0 15
Lane et al (13)   58 2.9 100 (5-yr) 1.7 1.7  6 8
CSS: Cancer-specific survival
Reprinted from Van Poppel H. Efficacy and safety of nephron-sparing surgery. Int. J Urol, 2010;17(4):314-26. 
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Fig.  13 a: M RI  show ing a l arge angiomyol ipoma 
of the l eft k idney.
Fig.  13 b: T he l eft l ow er 
pol e is being remov ed in 
w arm ischemia using col d 
scissors.  T he central  part of 
the angiomyol ipoma can be 
seen cl earl y
Fig.  13 c: The first running 
suture incl udes the v essel s 
of the interstitial  tissue as 
w el l  as the col l ecting system.  
T his suture is secured on 
both ends w ith a l apra- tyR 
cl ip.
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Fig.  13 d: A  suture through the ful l  thick ness of the 
renal  parenchyma hel ps to approx imate the cut 
edges and prov ides haemostasis.  
Fig.  13 e: T he parenchymal  suture is secured 
w ith l arge hem- o- l okR cl ips w hich al l ow  to appl y 
pressure on the renal  parenchyma thereby 
prov iding optimal  haemostasis.  A  rol l  of 
tabotampR is pl aced underneath this suture to 
improv e haemostasis.
Fig.  13 f: Final l y,  as prev entiv e measure to av oid 
del ayed hemorrhage,  the repair is cov ered w ith 
fibrin blue and a strip of tabotampR.
Fig.  13 g: T he ex cised l ow er pol e w ith the tumour 
is pl aced w ith an organ bag for safe remov al .  
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f)  Contemporary outcomes of L P N : T he State-
of - the- A rt
With increasing LPN experience and standardization 
of  ou r early u nclamping  techniqu e, contemporary 
LPN outcomes have improved significantly. 
Specifically, the two remaining above-mentioned 
concerns with LPN have now been addressed, 
leading  to decreased ischemia times and redu ced 
hemorrhag e rates. 
Gill et al reported a single-surgeon series of 800 
LPN cases encompassing a 9-year period (1999-
2008) [88]. The authors divided the entire cohort 
into 3 chronologic eras: Era I: 1999–2003 (n 276), 
Era II: 2004–2006 (n 289), and Era III: 2007–2008 
(n 235). On comparing eras I, II and III, tumours in 
the most recent era were larger, more commonly 
! 4  cm, central and hilar, and less of ten peripheral 
and  4 cm (p-value significant for all). Despite such 
increasing tumour complexity, mean warm ischemia 
times were shorter in the most recent era: 32 min, 32 
min and 14 min (p0.0001). Overall, post-operative 
and urologic complications were significantly lower in 
the most recent era. I n the most recent era, positive  
su rg ical marg in rate, and incidence of  conve rsion to 
OPN or RN were 0.6, 0 and 2.1, respectively. 
Renal functional outcomes were superior in era III, 
as reÀected by lesser percent decrease in estimated 
GFR (18, 20 and 11, respectively). In patients 
with pathologically-confirmed malignancy (n 744), 
5-year overall, cancer-specific, and recurrence-free 
survival was 90, 99, and 97, respectively. The 
au thors conclu ded that ove r this 9 - y ear exp erience 
with 800 consecutive LPNs, tumour characteristics 
and LPN outcomes had evolved significantly. Despite 
increasing  tu mou r complexi ty in contemporary 
practice, the 3 key outcomes of LPN (ischemia time, 
complications, and renal function) have improved 
significantly. As a result, the authors routinely offer 
LPN for the maMority of tumours hitherto reserved for 
open NSS [88].
A recent stu dy f rom K avo u ssi’ s g rou p compared 
µoff-clamp¶ LPN with traditional µon-clamp¶ LPN. 
Significant differences (p  0.05) in the µoff-clamp¶ 
g rou p relative  to the ‘ on- clamp’  g rou p inclu ded 
shorter operative time (132 vs. 146 min), a higher 
proportion of exophytic lesions (51 vs. 28), 
smaller tumour volume (26 vs. 41cm3) and less 
hilar tumours (15 vs. 29).  Short term elevation 
in serum creatinine was significantly less (6 vs. 
29) although long term significance of this finding 
is unknown. There were no significant differences 
in b lood loss, transf u sion rate, or complications. As 
experience improves, an increasing number of LPNs 
may b e perf ormed ‘ of f - clamp.
Finally, Kamoi 	 Gill compared 150 contemporary 
patients undergoing OPN (2006–2008) with 150 
contemporary patients undergoing LPN (2007–
2008). Notably, all OPNs were performed by one 
xperienced open surgeon (Andrew C. Novick, MD), 
and all LPNs were performed by one experienced 
laparoscopic surgeon (Inderbir S. Gill, MD). LPN 
patients had shorter ischemia time (21 versus 13 
minutes, p0.0001), with more LPN patients having 
ischemia time  20 min (52 vs. 97). Post-operative 
complications were fewer in the LPN group (19 
vs. 8.7; p 0.01), including hemorrhage (3.3 vs. 
2.7; p ns) and urine leak (7.3 vs. 1.3; p 0.02). 
Patients undergoing elective PN had similar, and 
those undergoing imperative PN or PN in solitary 
ki dney had su perior renal f u nctional ou tcomes in the 
LPN cohort, likely a result of the reduced ischemia 
time during LPN. Of note, OPN patients had 
somewhat larger tumours, more solitary kidneys, 
and a higher incidence of baseline renal dysfunction; 
however, after adMusting for each of these baseline 
demographic differences, LPN outcomes were, at 
a minimum, equivalent to OPN outcomes in each 
parameter eva lu ated.
These emerging new data indicate that, in 
experienced hands, LPN is now similar to OPN as 
reg ards the ke y ou tcomes of  ischemia time, u rolog ic 
complications and renal functional outcomes. This 
improvement in LPN outcomes has occurred despite 
increasing  tu mou r complexi ty . As a resu lt, seve ral 
centres now routinely offer LPN for the maMority of 
technically- challeng ing  small tu mou rs su ch as hilar, 
central completely intra-renal, larger (4-7 cm, pT1b) 
tu mou rs or tu mou rs located in a solitary ki dney [ 8 9 ] .
A recent sing le- centre stu dy b y L if shitz et al compared 
th  technique and outcome between the early (group 
1: 50) and recent (group 2: 50) LPN experience 
between October 2002 and August 2008. Group 2 
had larger tumours (3 cm vs. 2.4 cm, P 0.002) and 
significantly more central tumours (52 vs. 12, 
P 0.001). In group 2 the authors stopped the use 
of  u reteral catheters and b olster renorrhaphy , and 
routinely clamped the renal hilum. The WIT (30 and 
27  minu tes, respective ly , P 0.3) and complication 
rates were similar in group 1 and 2. Overall, patients 
with tumours sized ! 4 cm had more complications 
(P 0.042). In group 2, the estimated blood loss (243 
vs.  14 0  ml, P 0.01) and hospital stay (2.5 vs. 1.4 
days,  P  0.001) decreased and the readmission 
rate was only 5.4. With growing experience and 
technical modifications LPN is now performed for 
patients with larger and more central tumours [108].
5 . RoB oT IC P ART IA l neP H ReCT oM Y
Shapiro et al reported excellent oncologic outcomes 
in their recent review of initial experience with robotic 
PN (n 211). Estimated blood loss, postoperative 
renal f u nction, su rg ery time and hospital stay 
seemed to be equivalent to LPN. Mean WIT ranged 
f rom 21 to 32 minu tes. H ilar clamping  continu es to 
be a difficult aspect of the procedure [109]. Rogers et 
al reported that robotic PN is safe and feasible in 14 
select patients with complex renal tumours including 
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hilar, endophytic, and multiple tumours [110].  They 
also evaluated 11 patients from 2 institutions who 
underwent robotic PN for renal hilar tumours [111]. A 
recent sing le- su rg eon analysi s of  consecu tive  rob otic 
PN (n 40) and LPN (n 62) procedures revealed that 
robotic PN can produce results comparable to LPN. 
In the specific author¶s hands mean WIT (19 vs. 25 
minu tes, P   0.03), total operative time (140 vs. 156 
minu tes, P   0.04), and length of hospital stay (2.5 
vs . 2.9  days,  P  0.03) were shorter for robotic PN 
than for LPN [112]. The sliding-clip renorrhaphy, a 
techniqu e adopted b y most hig her vo lu me su rg eons, 
and the learning  cu rve  are b oth responsib le f or 
a significant reduction in overall operative time 
and WIT [113]. Recently, Ho et al reported 1 year 
ou tcomes in 20  patients u nderg oing  rob otic- assisted 
LPN for tumours  7 cm. There were no late surgical 
complications, no local recu rrence or impairment of  
renal function [114]. Benway et al reported the largest 
comparison of robotic partial nephrectomy (n 129) 
to LPN (n 118) to date, with oncological outcomes 
and morbidity equivalent to those of LPN. This study 
comb ines data f rom seve ral smaller series that have  
been updated. Robotic PN appears to offer the 
advantages of a significant reduction in intraoperative 
blood loss (155 vs. 196 ml, P   0.03), WIT (19.7 vs. 
28 .4  min, P  0.0001) and hospital stay (2.4 vs. 
2.7  days , P 0.0001) [115]. Very recently, Scoll et 
al reported the patholog ic, perioperative , and renal 
functional outcomes from the first 100 robot-assisted 
partial nephrectomy (RAPN) operations performed 
at their institution during a 21-month period. They 
included an obMective renal mass scoring system 
(nephrometry) to grade anatomical complexity of 
the renal tumours resected. Nephrectomy scores 
of resected lesions were low in 47.9 of patients, 
medium in 45.7, and high in 6.4 of patients. 
Forty-seven percent of patients had tumours ! 
50 intraparenchymal, and 61.7 had tumours 
located less than 7 mm away from the renal sinus 
or collecting system. In 17 of patients, the tumours 
were touching a first-order vessel in the renal 
hilum. Mean WIT was 25.5 minutes. Mean change 
in postoperative GFR improved 6.32 mL/min/1.73 
m2. Histology was RCC in 81 of tumours. Positive 
margin rate was 5.7. MaMor and minor complication 
rates were 6 and 5, repectively. There were 2 
conversions to open surgery. RAPN seems to be 
a saf e and technically f easib le minimally inva sive  
approach to NSS even in more complex cases, with 
acceptab le patholog ic and renal f u nction ou tcomes 
comparable to open and laparoscopic PN [116].
Althou g h long - term ou tcome data are cu rrently 
lacking, early results with robotic PN demonstrate 
that it is clinically comparable to LPN. Large 
prospective , randomised stu dies are needed to 
validate preliminary results of robotic PN and 
compare with current methods.
6 .  folloW - uP  A fT eR P ART IA l 
neP H ReCT oM Y
There is currently no consensus on follow-up 
strategies after surgical extirpation for patients with 
RCC. Recently, Kassouf et al published the Canadian 
g u idelines f or su rve illance af ter nephrectomy f or 
nonmetastatic RCC, based on pathological stage 
[117]. Grades of recommendations were given 
using the modified Oxford Centre for Evidenced-
based Medicine scheme. Patients undergoing PN 
for pT1 tumours can be followed according to the 
same surveillance protocol as those undergoing RN 
since the local recu rrence rates in this popu lation 
are similar to RN (Grade B). Recommended 
surveillance will include medical history and physical 
examination, blood screen, and chest ;-ray every 
year. Abdominal CT will be recommended at 24 and 
60 months (Grade C). For patients treated with PN, 
abdominal CT at 3 months to evaluate the residual 
renal appearance and annu al ab dominal u ltrasou nd 
are optional (Grade D) [117].
A recently presented subtype-specific multifactorial 
protocol can be used to efficiently adapt postoperative 
imag ing  to the indivi du al patient [ 118 ] .
7 . ConClusIons
I n patients w ith a cl inical  T 1 renal  tumour,  P N  
prov ides eq uiv al ent l ocal  tumour control  as RN ,  
w hil e minimizi ng dev el opment of new - onset CK D  
or w orsening of ex isting CK D  ( G rade B ) .   A s such,  
P N  is the establ ished treatment for T 1a tumours 
( <  4  cm)  and an emerging standard treatment 
for T 1b tumours ( 4  to 7  cm)  prov ided that the 
operation is technical l y feasibl e and the tumour 
can be entirel y and adeq uatel y remov ed ( G rade 
B ) .  A ny tumour- free surgical  margin fol l ow ing 
P1 appears sufficient to prevent local recurrence 
and disease progression from RCC ( G rade B ) . 
In balancing the therapeutic decision between PN 
and RN, the individual patient¶s performance status, 
comorb idities and renal f u nction shou ld b e caref u lly 
weighed.
Over the years, OPN has been the reference standard 
nephron-sparing procedure. Today, at centres 
lacking advanced laparoscopic expertise, OPN 
remains the first nephron-sparing treatment option. 
However, at centres with the requisite minimally 
invasive expertise, LPN is now a routine procedure, 
with similar peri-operative and long-term outcomes 
as OPN, albeit with significantly decreased patient 
complication profile. As such, current indications 
for LPN have been expanded to include most renal 
tu mou rs hitherto reserve d f or open su rg ery . L arg er 
LPN series with longer follow-up, possibly in a 
prospective  randomised f ashion, are necessary . 
Robotic techniques may increase penetrance of 
minimally invasive PN into the community. 
F u tu re research shou ld f ocu s on decreasing  the 
1 29
technical complexity of LPN and finding newer 
techniqu es of  eliminating  or redu cing  ischemia. I n 
the u ltimate analysi s, savi ng  nephrons is the more 
important goal, which supersedes its technical 
approach, open or laparoscopic. Non-availability 
of  minimally inva sive  exp ertise mu st prompt open 
partial, not laparoscopic radical nephrectomy .
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VI. eneRG Y  A BlA T IVe T H eRA P Ies 
foR loCA lIZ eD  RCC
1 . T H eRM A l A BlA T IVe T H eRA P Ies
a)  I ntroduction
Ab lation of  renal tu mou rs is emerg ing  as a 
vi ab le minimally inva sive  alternative  to resection 
f or local control of  caref u lly selected tu mou rs. 
Potential adva ntag es of  ab lative  procedu res are 
redu ced morb idity , shorter hospitaliza tion, f aster 
convalescence, preservation of renal function, lower 
costs and the ability to treat patients who are at 
hig h- risk f or su rg ery [ 1] . O n the other hand, patients 
shou ld accept the need f or long - term radiog raphic 
su rve illance af ter treatment and shou ld b e clearly 
informed about the non-validated treatment efficacy 
of  ab lative  therapies [ 2] . Estab lished ab lative  
modalities inclu de cryo ab lation and radiof requ ency 
ablation (RFA), both of which can be performed 
open, laparoscopically, or percutaneously. The 
laparoscopic approach is pref erred in anterior 
tumours and when mobilization away from the 
adMacent organs is required to avoid damage.  The 
percu taneou s approach is typ ically reserve d f or 
posterior tu mou rs and f or patients at increased risk f or 
su rg ery or anesthesia [ 3] . All pu b lished series u sing  
ab lative  techniqu es are retrospective  ob serva tional 
stu dies. D espite seve ral concerns, resu lts of  thermal 
ab lative  procedu res in small renal tu mou rs are 
encou rag ing . F or anatomically u ncomplicated small 
renal masses conve ntional su rg ery has shif ted to 
less inva sive  ab lative  modalities at some institu tions. 
More complex renal tumours are still treated by 
PN when technically feasible [4]. Careful patient 
selection and patient cou nseling  are of  paramou nt 
importance in the complex decision- maki ng  process 
f or the manag ement of  renal tu mou rs. B iopsies prior 
to therapy are strongly encouraged [5].
b)  I ndications
Ab lative  therapy is indicated f or the manag ement 
of  small, incidentally f ou nd renal cortical lesions in 
elderly patients, patients with genetic predisposition 
to multiple tumours, patients with a solitary kidney, or 
bilateral tumours [6]. However, as more experience 
is gained, it may be extended to the SRM in younger 
patients and those with a normal contralateral kidney, 
a similar evolution seen with partial nephrectomy. It 
has to b e noted that at this time, there is no literatu re 
to support this. Contraindications include a limited 
life expectancy of  1 year or difficulty for successful 
ou tcome du e to size  or location of  the tu mou r. I n 
general, tumours ! 4 cm or tumours in the hilum, close 
to the proxi mal u reter or central collecting  syst em 
are not typ ically recommended f or ab lation. Ab solu te 
contraindications are irreve rsib le coag u lopathies 
or seve re medical instab ility , su ch as sepsis [ 6 ] . 
Thermal ablation may be best suited for high surgical 
risk candidates with multiple comorbidities who have 
small, exophytic renal tumours [7,8]. Nevertheless, it 
is possible that patients at high risk for surgery who 
u nderg o thermal ab lation su f f er complications that 
might necessitate surgery. There is no consensus 
on the maximum tumour size for ablation. Some 
authors find 3 cm appropriate as maximum tumour 
size for cryoablation [9] and RFA [10], others suggest 
a limitation of 3.5 cm [7] or 4 cm [8] above which 
su ccess rates su b stantially f all.  
c)  Concerns w ith the use of thermal  abl ativ e 
therapies
A primary concern in relation to thermal ab lative  
therapies is the higher local recurrence rate with 
cryoablation and RFA when compared to surgical 
excision in recent meta-analyses (4.6, 7.9, 2.7  
and relative rates of 7.45, 18.23, and 1.0, respectively) 
[ 11,12] . A second concern is the controve rsy ove r the 
validity of the radiographic definition of postablative 
success. Recent data showed that  46.2 patients 
(6 of 13 patients)  that showed no enhancement on 
radiographic imaging after RFA demonstrated viable 
tu mou r cells at a 6 - month post- ab lation  b iopsy [ 13] . 
Another weakness is the absence of histopathologial 
confirmation of complete tumour destruction and 
neg ative  su rg ical marg ins [ 7 ] . F inally , ab lative  
procedu res may preclu de or complicate su b sequ ent 
surgical salvage due to perinephric fibrosis [7]. 
Long-term oncologic efficacy of ablative procedures 
remains to be demonstrated. These concerns 
u nderscore the need f or meticu lou s selection of  
patients who today may be potential candidates for 
thermal ab lation. 
2 . CRY oA B lA T Ion
a)  I ntroduction
Cryoablation causes tumour destruction by rapid 
freeze and thaw cycles. A recent meta-analysis 
included 496 localized renal tumours that were 
treated with cryoablation. Mean weighted follow-
up after cryoablation was 18.3 months with the 
procedu re selective ly perf ormed in older patients 
with smaller tumours (mean weighted age 65.7 
years and mean weighted tumour size 2.56 cm) [12]. 
One purported advantage of cryoablation over RFA 
is the ab ility to perf orm continu ou s intraoperative  
u ltrasou nd monitoring  of  the ice b all althou g h 
surgeons experienced with RFA rely on thermal 
measures at the periphery with similar results. A 
recent su rve y of  B andi et al to determine the cu rrent 
practice patterns in the u se of  ab lative  modalities 
f or the manag ement of  small renal masses at 112 
academic centres in the United States revealed that 
cryoablation (79) was more frequently used than 
RFA (55) [14] ( fi g . 1 3 ,  1 4 , 1 5 ).
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b) Choice of surgical access – recent findings
At present, ! 75 of the reported renal cryoablation 
treatments has b een applied throu g h an open 
or laparoscopic approach. Percu taneou s imag e-
g u ided techniqu es have  b een u sed mu ch less 
frequently [15]. Recently, Finley et al retrospectively 
reviewed 18 patients (19 tumours) who underwent 
percutaneous cryoablation and 19 patients (24 
tumours) who had laparoscopic cryoablation. 
Percutaneous cryoablation was associated with a 
statistically significant decrease in operative time, 
hospital stay and narcotic use and a trend towards 
fewer complications. The overall complication rate 
was lower after percutaneous cryoablation (22.2 
vs. 40). The authors considered percutaneous 
cryo ab lation the treatment of  choice f or posterior, 
lateral and select anterior renal lesions of  3 cm or 
smaller [ 16 ] .  B andi et al condu cted a telephone 
su rve y to eva lu ate analg esic requ irements, 
conva lescence and patient satisf action af ter 
probe ablative procedures. They also found faster 
conva lescence f or the percu taneou s approach, 
but did not find a difference in the median opioid 
analg esic requ irement, and patient satisf action [ 17 ] . 
I n a recent comparative  stu dy , percu taneou s renal 
cryo ab lation has b een deemed saf e and ef f ective  
and associated with lower hospital charges than 
laparoscopic cryoablation [18]. Recently, single-
port laparoscopic and natural orifice transluminal 
endoscopic su rg ery approaches have  also b een 
u sed f or renal cryo ab lation [ 19 ,20 ] . V ery recently , 
a prospective pilot study showed that stereotactic 
percu taneou s cry oab lation f or renal tu mou rs of f ers 
the potential f or saf e, precise cryo prob e placement 
[ 21] .
c)  O ncol ogical  outcome
Current 3-year laparoscopic cryoablation data offer 
CSS rates of 98 [22,23] and 100 [24] and an OS 
of 89 [22]. Davol et al reported a 5-year CSS rate 
of 100. The cancer-free survival rate after a single 
cryoablation procedure was 87.5 and improved 
to 97.5 after a repeat procedure [25]. Mean renal 
tumour size in these studies was less than 2.7 cm. 
Three and 5-year survival data are promising and 
indicate that renal cryo ab lation cou ld b e a g ood 
alternative in appropriately selected patients who are 
considered unsuitable for PN or active surveillance. 
I n a recent sing le- centre stu dy laparoscopic renal 
cryoablation (n 52) and percutaneous renal 
cryoablation (n 20) achieved good cancer control 
with minimal morbidity at a mean follow-up of 30 
months in a patient cohort with numerous comorbid 
conditions. Percu taneou s renal cryo ab lation had a 
significantly higher primary treatment failure rate 
[5] than laparoscopic renal cryoablation [2], but re-
treatment offered salvage cancer control with no 
significant complications. Overall CSS and cancer-
free survival were 100 and 97, respectively [26]. 
T a b l e  4 presents the oncolog ic ou tcome in selected 
studies of cryoablation [22,23,25,27-30]. Very 
recently , Aron et al presented long - term oncolog ical 
outcomes in patients treated with laparoscopic renal 
cryoablation by a single surgeon. They report on 
80 patients with a minimum 5-year follow-up after 
cryoablation for a small renal mass, including 92 
5-year disease specific survival and 84 overall 
survival in the 55 patients with biopsy proven RCC. Of 
these 55 patients 11 (14) had recurrence, including 
local recurrence in 5, locoregional recurrence with 
metastasis in 2 and distant metastasis without 
locoregional recurrence in 4. Median follow-up was 
93 months (range 60 to 132). Mean tumour size 
was 2.3 cm (range 0.9 to 5.0 cm), median ASA 
score was 3 and mean BMI was 28 kg/m2. A disease 
specific survival rate of 83 at 10 years is possible. 
The authors recommend cryoablation as the initial 
Fig.  14 : D raw ing of a cryoneedl e being inserted 
transcutaneousl y into a right l ow er pol e anterior 
renal  tumor.  A  templ ate can be pl aced on the sk in 
to be used as a traj ectory guide.
Fig.  15 : D raw ing of a transabdominal  l aparoscopic 
v iew  of a cryoneedl e being percutaneousl y inserted 
into an ex ophytic,  pol ar tumor.  O ne or sev eral  
needles can be placed to provide sufficient ice 
to achiev e cel l ul ar k il l  of the tumor al ong w ith a 
surrounding margin of parenchyma.  
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treatment in patients with a small renal mass who 
are not suitable candidates for PN [31].
d)  I mpact on renal  function
I n a recent retrospective  analysi s of  123 patients, 
laparoscopic renal cryo ab lation appears to have  
minimal impact on renal f u nction, as measu red b y 
seru m creatinine and creatinine clearance leve ls. 
I t can b e pref ormed reg ardless of  the preoperative  
renal function [32]. The recent study by Aron et al 
also shows that cryoablation has minimal impact on 
renal function. The eGFR before vs. after treatment 
was 66 vs. 59 ml per minute per 1.73 m2 [ 31] .
e)  Compl ications
A multi-institutional review by Johnson et al 
demonstrated that cryoablation has a low 
complication profile when used to treat small renal 
tumours (13.7; minor 12.2, maMor 1.4) [33]. The 
most common complication was pain or paraesthesia 
at the probe insertion site (7.2). 
Recently, it has been shown that laparoscopic 
cryoablation of larger renal masses ( 3 cm) may be 
associated with increased morbidity and therefore 
should be reserved for tumours with diameter  3 
cm [ 9 ] . O n the other hand, in another recent stu dy , 
percu taneou s cryo ab lation of  anteriorly located 
tumours and tumours ! 4 cm in diameter was 
found technically feasible and relatively safe when 
perf ormed in an exp erienced centre [ 34 ] . L imitations 
of these studies were the retrospective design and 
the short follow-up. 
More recently, Laguna et al prospectively collected 
mu lti- institu tional data on laparoscopic renal 
cryoablation with ultrathin probes in 144 patients. 
Perioperative  neg ative  ou tcomes inclu ding  
conversion occurred in 17 of cases. Complications 
according to the Clavien system occurred in 15.5 of 
the cases; however most of the complications were 
Clavien grade 1 or 2. Increasing tumour size, the 
presence of  cardiac conditions and f emale g ender 
were associated with a higher risk of developing a 
complication. The authors confirmed the tumour 
size  cu t- of f  of  3.4  cm as an adequ ate predictor of  
negative outcomes. This study confirms the relative 
safety of laparoscopic cryoablation [35].
f)  M ul tipl e renal  tumours
A recent study shows that synchronous cryoablation 
is relatively safe and feasible for patients with 
mu ltiple ipsilateral renal lesions that cou ld b e ve ry 
challenging to address with an extirpative approach. 
F ive  patients had ab lation of  2 renal lesions, 1 had 
3 lesions, and 1 had 4 lesions. The mean greatest 
diameter of any single tumour was 2.0 cm (range 
0.7 – 7.5 cm).  Cryoablation of the 17 lesions 
was associated with few complications and with 
a median follow-up of 23,3 months (range 7-28 
months), serum creatinine in most patients had not 
significantly changed.  No tumour recurrences have 
b een detected on postoperative  imag ing  [ 36 ] .
T abl e 4  : Sel ected studies of cryoabl ation
PC: percutaneous; lap: laparoscopic; CSS: cancer-specific survival; RCC: renal cell carcinoma
Reprinted from Heuer R. et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance 
for kidney cancer. Eur Urol 2010; 57(2) : 223-32  with permission of Elsevier.
Study
Approach No.  
tu mou rs
Median 
tu mou r 
size  
(cm)
Follow-up 
(mo)
CSS 
()
Tumour 
recu rrence af ter 
one ablation ()
Gill et al (22) lap 56 (36 proven RCCs) 2.3 36  (mean) 9 8 3.6
Schwartz et al (27) lap/ open 85 (50 proven RCCs) 2.6 10 (mean) B 2.4
Davol et al (25) lap/ open 48 (38 proven RCCs) 2.6 64 (median) 10 0 12.5, 2.5
Hegarty et al (23) lap 179 (No. of RCC not 
given)
2.5 36 (median) 9 8 1.7
Cestari et al (28) lap 37  (29 proven RCCs) 2.6  
(mean)
20.5 (mean) B 5.7
Silverman et al (29) PC 26 (24 proven RCCs) 2.6 14 (mean) B 13
Aron et al (30) lap 88 (No. of RCC not 
given)
2.3 83 (median)
(range: 60-120)
95: at 
5-yr 22:  at  
5 years
1 36
g)  I ncreased risk  of rel apse after cryoabl ation 
–  w hich l esions fail ?
A recent study analyzed 163 patients who underwent 
laparoscopic cryoablation (LCA) between 2001 and 
2008 with at least 6 months of follow-up. Median 
tumour size was 2.4 cm (range 0.5-5.0). LCA showed 
good tumour control over a 5-year follow-up, with an 
acceptab le recu rrence rate. F or each 1 cm increase 
in tumour size there was a 4-fold increase in the 
prob ab ility of  local recu rrence. Endophyt ic tu mou rs 
(in 22.8 patients) were 11 times more likely to 
recur in this series. Larger tumours and those with 
endophytic growth pattern may be at increased risk 
of relapse after LCA [37].
Another recent stu dy analyze d 4 7  renal lesions 
that underwent LCA. Median tumour size was 2.7 
cm (range  1.2-5.4) and median follow-up was 13 
months. Treatment failure was noted in 8 of 47 
lesions (17), 7 of which (87.5 of failed lesions) 
had broad-based contact with the renal sinus. 
Lesions with broad-based contact with the renal 
sinus were successfully treated in 53.3 of the time 
whereas lesions not in contact with the renal sinus 
were successfully treated in 96.9 (P0.01) of the 
time. The authors suggest that renal lesions which 
make broad-based contact with the renal sinus are 
at a significantly higher risk of failure of LCA [38].
3 . RA D IofReQ uenCY  A BlA T Ion
a)  I ntroduction
RFA causes tumour coagulation by converting the 
radiofrequency waves to heat, resulting in thermal 
tissue damage [1]. RFA is one of the most recently 
developed treatment modalities for localized RCC 
and a standard techniqu e is still lacki ng  in the 
cu rrent literatu re.  A recent meta- analysi s inclu ded 
607 localized renal tumours that were treated with 
RFA. Mean weighted follow-up after RFA was 16.4 
months. RFA was selectively performed in older 
patients with smaller tumours (mean weighted age 
67.2 years and mean weighted tumour size 2.69 
cm) and is considered a viable treatment option [12]. 
Patient demographics and selection criteria for RFA 
are similar as f or cryo ab lation treatment, mainly f or 
older and high surgical risk patients and tumours with 
diameter  3 cm. Gervais et al treated 100 tumours 
in 85 patients by percutaneous RFA and showed that 
small-sized tumours ( 3 cm) and exophytic tumours 
were predictive factors for complete coagulation 
[10]. A study including 16 patients (20 tumours) with 
a minimum of 4 years follow-up revealed that RFA 
treatment of exophytic RCC ( 5 cm) is effective in 
destroyi ng  the tu mou r and comparab le to su rg ical 
ex cision at 4  ye ars [ 39 ] .  A meta- analysi s b y K u nkl e 
and Uzzo demonstrated that patients treated with 
RFA may require re-ablation more frequently than 
those treated with cryoablation (8.5 vs. 1.3, 
respectively) [15].  Compared with cryoablation, a 
large proportion of tumours managed with RFA had 
unknown or indeterminate pathology (42.8 vs. 
17.7) [12] which could lead to an overestimation 
of the actuarial specific CSS rates for RCC. Both 
phenomena may b e attrib u tab le to the f act that the 
maMority of RFA cases are performed percutaneously. 
B iopsy is not consistently perf ormed and re- ab lation 
rates are significantly higher when a percutaneous 
approach is used. Re-ablation rates seem to correlate 
with surgeon specialty (interventional radiologist or 
urologist) [40].  Difficulty of reoperation after ablation 
also depends on the location of  the prior ab lation. 
b)  Choice of surgical  access –  nav igational  
tool s and real - time monitoring systems for 
RFA
RFA can be performed percutaneously or 
laparoscopically under ultrasound, CT- or MRI- 
guidance. Currently, about 94 of the reported renal 
RFA treatments have been performed through the 
percutaneous approach [15], mostly under CT-scan 
guidance [41]. Only a few centres have used the 
laparoscopic approach for RFA ablation. To date, no 
randomised controlled trials have  b een condu cted to 
compare laparoscopic and percutaneous RFA or to 
compare RFA and cryoablation. Data in the literature 
reve aled that althou g h the percu taneou s approach 
is less invasive, RFA and cryoablation re-ablation 
rates are significantly higher when a percutaneous 
approach is used  and seemed to correlate with 
su rg eon speciality (interventional radiologist or 
urologist) [40]. Recently, sophisticated navigational 
tools and real-time monitoring systems for RFA are 
being investigated. Carey and Leveillee reported 
the u se of  non- condu cting  temperatu re prob es, 
independent of the RFA electrode, in order to achieve 
real- time temperatu re monitoring  of  the ab lation 
zone.  Ablations were continued until the peripheral 
and deep temperature probes registered 60 C for 
at least 15 seconds. All 37 renal tumours between 
3 and 5 cm in 36 patients could be successfully 
ablated in one session. There were two radiographic 
f ailu res at 9  and 30  months that requ ired second 
treatment (95 radiographic success rate). This 
techniqu e redu ces the need f or retreatment sessions, 
decreases the incidence of  ove rtreatment of  the 
normal parenchym a and preve nts collateral damag e 
of the adMacent organs [42].  Moreover, a recent study 
has demonstrated that RFA with peripheral fiberoptic 
real- time temperatu re monitoring  is ab le to improve  
the su ccess rate f or endophyt ic or centrally located 
renal tumours. In total, 37 of 41 (90.2) endophytic, 
hilar, or central tumours were treated successfully 
in one session [ 4 3] . U ki mu ra et al describ ed the 
use of real-time virtual ultrasonography (RVS) as a 
new and promising alternative imaging method for 
percutaneous RFA of solid RCC.  All 10 patients with 
13 RCC were treated successfully in one session 
and none of  them had a local tu mou r recu rrence 
during the follow-up period [44].
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c)  O ncol ogical  outcome
T a b l e  5 presents the oncolog ic ou tcome in selected 
studies of RFA [23,39,45,46]. Af ter laparoscopic or 
percutaneous RFA with a mean follow-up period of 25 
months recurrence-free survival, CSS and OS were 
96.8, 98.5, and 92.3 (68 were RCC). Mean 
renal tumour size was 2.4 cm [46]. L ong - term data 
after 34 percutaneous RFA procedures for small renal 
masses (mean size 2.0 cm) were recently reported. 
The overall recurrence-free survival was 90.3 
at a mean follow-up of 61.6 months and 79.9 for 
pathologically confirmed RCC at a mean follow-up 
of 57.4 months [47]. A recent multi-institutional study 
that u sed g eneral anesthesia- assisted, contrast-
enhanced CT-guided percutaneous RFA to treat 
163 masses in 151 patients demonstrated excellent 
intermediate- term ou tcomes and a hig h initial 
ablation success rate. However, endophytic and 
interpolar lesions were at higher risk for recurrence. 
The median follow-up was 18 months (range, 1.5-
7 0 ] . O ve rall 1-  and 3- ye ar recu rrence- f ree su rvi va l 
was 97 and 92, respectively [48]. Further studies 
of large numbers of patients with long-term follow-up 
are needed. 
d)  T umour size  and success of RFA  treatment
Z ag oria et al demonstrated in a larg e series 
of percutaneous RFA a significant correlation 
between the size of the renal mass and success 
of RFA treatment.  They reported that CT-guided 
percutaneous RFA can accurately destroy RCCs 
smaller than 3.7 cm. Of the 125 treated and biopsy-
proven RCC¶s in 104 patients, 116 (93) were 
completely ablated (109 after one session, 7 of the 
16 failures after a second session). RFA achieved 
complete ablation after one session in all 95 RCCs 
smaller than 3.7 cm and in only 14/30 RCCs larger 
than 3.7 cm [45].
e)  I mpact on renal  function
Several authors have sought to better define the 
renal impact of RFA on renal function. Lucas et al 
concluded that patients with small renal masses 
  4 cm undergoing RN or PN were 34.3 and 10.9 
times more like ly , respective ly , to deve lop stag e 3 
CKD compared with those who were treated with 
RFA [49]. Two studies focused on RFA for solitary 
ki dneys.  I n the small stu dy b y Jacob sohn et al 
creatinine clearance declined by 13.3 one week 
after ablation and by 9.1 at a mean follow-up 
of 15.3 months [50]. In the study by Raman et al 
GFR declined by 7.5, 6 weeks after ablation and 
remained stable up to 18 months and later [51]. 
In a more recent study Raman et al analyzed the 
outcomes from 89 patients with renal masses in 
a solitary kidney including 47 RFAs and 42 OPNs 
at a median follow-up of 18.1 and 30.0 months, 
respectively (P    0.02). Compared to RFA, patients 
treated with OPN using cold ischemia had a greater 
decline in GFR at all times evaluated, including soon 
after the procedure (15.8 vs. 7.1), 12 months after 
surgery (24.5 vs. 10.4) and at the last follow-up 
(28.6 vs. 11.4; all P  0.001). Median age (65.9 
vs. 59.6 years, P   0.03) and ASA score (3.0 vs. 2.0, 
P   0.01) were both higher in patients treated with 
RFA. The median tumour size (3.9 vs. 2.8 cm, P =  
0.001) was greater for tumours treated by OPN while 
the median preoperative GFR was lower in te RFA 
group (46.5 vs. 55.9 ml/min/1.73 m2 for OPN, P =  
0.04). The authors concluded that RFA might be an 
attractive  option f or manag ing  tu mou rs in a solitary 
kidney at risk of declining function [52]. In a recent 
retrospective analysis of 63 healthy patients with 
small renal cortical tumours, RFA appears to have 
minimal impact on renal f u nction, as measu red b y 
changes in GFR. The median GFR before and after 
ablation was 76.3 and 74.3 mL/min/m2 [53]. 
T abl e 5  : Sel ected studies of RFA
Approach No. tumours Median 
tu mou r size  
(cm)
Follow-up 
(mo)
CSS 
()
Tumour recurrence after 
one ab lation 
()
=agoria et al (45) PC 125 (125 RCCs) 2.7 13.8  
(mean)
9 8 13*
McDougal et al 
(39)
PC 20 (all RCCs) 3.2 55.2 
(median)
9 4 5
Hegarty et al (23) PC 82 (No. of RCC not 
given)
2.5 12 (median) 10 0 11.1
Park et al (46) PC/lap 94 (65 RCCs) 2.4 (mean) 25  
(mean)
98.5
3.2
CSS: cancer-specific survival; RCC: renal cell carcinoma; PC: percutaneous; lap: laparoscopic.  All tumours recurring 
were ! 3.7 cm.
Reprinted from Heuer R. et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance 
for kidney cancer. Eur Urol 2010; 57(2) : 223-32  with permission of Elsevier.
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f)  Compl ications
A multi-institutional review of Johnson et al 
demonstrated that RFA has a low complication 
profile when used to treat small renal tumours (8.3; 
minor 6.0, maMor 2.2)  [33]. The most common 
complication was pain or paraesthesia at the prob e 
insertion site (3.0). Two recent RFA studies failed 
to find a significant association between tumour 
size and likelihood of complications [45,54]. Veltri 
et al found that exophytic growth of the tumour is 
associated with a decreased risk of complications (P 
 0.0380) [54]. Weizer et al recommend restricting 
percutaneous RFA to exophytic, posterior and 
polar lesions or tumours  3 cm in diameter. Their 
experience with percutaneous RFA in 24 patients 
inclu ding  32 tu mou rs reve aled that thermal 
complications might be more likely with anteriorly or 
centrally located tu mou rs, mu ltiple tu mou rs treated 
in the same setting and in patients with prior PN [55]. 
In a recent review paper Park et al discuss the most 
common maMor and minor complications resulting 
from image-guided RFA of RCC with an emphasis on 
cau ses, possib le preve ntion strateg ies and imag ing  
features. Similar to cryotherapy, maMor complications 
include bowel inMury, ureteral inMury, massive 
bleeding and residual or recurrent tumour. Minor 
complications inclu de pain, hematoma, hematu ria, 
neuromuscular inMury, pneumothorax, infarction 
and inÀammatory tract mass. The most common 
cau se of  complications is the close proxi mity of  the 
tu mou r to neig hb ou ring organs (bowel, ureter). Non-
inva sive  methods to preve nt these ab lation- related 
complications inclu de chang ing  the patient’ s position 
and using the RF electrode as a lever [56]. Invasive 
methods to avoid bowel inMury involve instillation of 
Àuid or CO2 between the tumour and the bowel [57-
59]. After introduction of a 20- to 22-gauge fine needle 
under imaging guidance, dextrose in water is instilled 
into the space between the tumour and the adMacent 
bowel to increase the distance between the organs 
and reduce thermal conduction [57].  Dextrose in 
water is preferred for hydrodisplacement to normal 
saline b ecau se of  its non- ionic and iso- osmolar 
nature [60]. In addition, collecting system and bowel 
inMuries associated with RFA or cryoablation can be 
av oided b y b etter patient selection b ased on the 
patient and tumour characteristics. Care must be 
take n to avo id damag e to the collecting  syst em that 
may resu lt in loss of  the ki dney . 
g)  Comparison betw een techniq ues
There are currently no prospective studies comparing 
cryoablation to RFA or to other forms of nephron-
sparing  su rg ery . L ong - term resu lts comparing  
conventional OPN to cryoablation are expected. 
h)  Comparison of l aparoscopic P N  w ith 
l aparoscopic renal  cryoabl ation 
D esai et al reported that compared to cryo ab lation, 
LPN was associated with greater blood loss 
and significantly higher incidence of delayed 
complications after hospital discharge. The overall 
complication rate (intraoperative, postoperative and 
late complications) was 5-fold higher (32 vs. 6.7) 
with LPN compared with cryoablation. Both groups 
were comparable with regards to operative time, 
hospital stay , conva lescence and postoperative  
renal function. Local recurrence was detected over 
a mean follow-up time of 5.8 months (0.6) after 
LPN and 24.6 months (3 ) after cryoablation 
[ 6 1] . A more recent matched- cohort comparison 
between LPN and laparoscopic cryoablation in 
elderly patients showed that LPN had a higher mean 
estimated b lood loss, a long er operative  time and 
higher relative risk of open conversion. However in 
this small retrospective  eva lu ation of  laparoscopic 
cryoablation and LPN, the overall clinical outcome 
was similar in terms of morbidity, length of hospital 
stay and chang es in creatinine and hematocrit 
after surgery. No recurrences were observed in 
either group, with a similar follow-up of 9.8 and 11.9 
months, respective ly [ 6 2] . 
Several groups  have shown the ultimate 3-year and 
5-year CSS after laparoscopic cryoablation to be 
98 to 100  [22,24-26,28,63] which is equivalent 
to the 5-year CSS (100) after LPN of small clinically 
localized renal masses presented by Lane and Gill 
[ 6 4 ] .
i)  Comparison of cryoabl ation and RFA
Currently, CSS rates of cryoablation [22,24,25,28] 
and RFA [39,45,46] are relatively similar (97 - 98, 
respectively) [41]. A recent meta-analysis by Kunkle 
and U zzo  compared the ou tcome of  cryo ab lation 
(n 600; 65 laparoscopically) and RFA (n 775; 
94 percutaneously). Cryoablation was associated 
with a lower re-ablation rate (1.3 vs. 8.5), lower 
local tumour progression rate (5.2 vs. 12.9) and 
less metastases (1.0 vs. 2.5, P   0.06) than RFA. 
Pretreatment biopsy was performed more frequently 
in the cryoablation group (82.3 vs. 62.2) [15]. In 
another meta- analysi s b y K u nkl e et al cryo ab lation 
was also associated with lower rates of local 
recurrence and metastatic progression (4.6 vs. 
11.7 and 1.2 vs. 2.3) compared with RFA [12]. 
The meta-analyses were Àawed in that they consisted 
of retrospective series each with their own selection 
biases [65,66].  Furthermore, RFA was primarily 
performed percutaneously (compared to laparoscopic 
cryoablation) where incomplete treatment and re-
ab lation is more commonly acceptab le since re-
treatment is easier to perf orm. H eg arty et al f ou nd 
in their retrospective comparative analysis a CSS of 
98 after 3-years of follow-up in the laparoscopic 
cryoablation group (n 164) and 100 after 1-year 
follow-up in the percutaneous RFA group (n 82). 
The rate of radiologic relapse of tumour was 1.8 
in the cryoablation group versus 11 in the RFA 
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group. Overall complication rates were low for both 
groups [23]. The problem in comparing the efficacy 
of ablative techniques is that especially studies with 
percu taneou s approach tend to g ive  ove rall resu lts 
in terms of CSS without stating the number of repeat 
procedures needed. Primary efficacy is an important 
endpoint. I n a recent meta- analysi s b y H u i et al, the 
primary efficacy rate was 87 after a percutaneous 
approach and 94 after an open or laparoscopic 
approach (p  0.05) with a mean follow-up of 
only 15  8 months. The secondary efficacy (after 
repeated treatments) in the percutaneous treatment 
group (92) was not significantly different from that 
in the laparoscopic or open treatment group. The 
percutaneous approach was safer than the surgical 
approach (complication rate 3 vs. 7) and was 
equally effective but more than one procedure was 
requ ired to treat the tu mou r completely [ 6 7 ] . I n a 
multi-institutional review, Johnson et al analyzed 
complications associated with cryoablation and 
RFA performed laparoscopically or percutaneously. 
Complication rates for cryoablation and RFA were 
13.7, (minor 12.2, and maMor 1.4) and 8.3 
(minor 6, maMor 2.2) respectively. The most 
common complication was pain or paresthesia at the 
probe insertion site. Complications can be attributed 
to the approach as well as to the ablation alone [33]. 
Several studies have demonstrated minimal impact 
on renal function following cryoablation [22,32,68] 
or RFA [49-51,53]. At this time, there is insufficient 
long-term data available to show efficacy of ablative 
therapies to make comparisons between the ablative 
techniqu es. 
j )  Comparison betw een P N  and RFA
Stern et al recently reported in a retrospective study 
that at intermediate follow-up (mean 30 months) RFA 
(14 laparoscopic/26 percutaneous) for patients with 
cT1a renal tumours has comparable intermediate 
oncological outcome to PN (30 open/7 laparoscopic). 
The 3-year recurrence-free survival rate for all 
patients was 93.4 and 95.8 for the RFA and PN 
groups, respectively [69]. However, longer term data 
are needed. 
k )  Fol l ow - up after thermal  abl ativ e therapies
Because follow-up after ablative therapy lacks 
histopathological confirmation of tumour destruction, 
some centres pref er to add post- ab lation b iopsies 
to radiographic imaging [22]. Current imaging 
techniqu es are limited to monitor recu rrences 
and post-ablation biopsies are encouraged when 
recu rrence or incomplete ab lation is su spected or 
as routine in all cases [13]. Existing follow-up criteria 
are not well-defined and should be more precise and 
standardize d b ased on radiolog ical and histolog ical 
f actors. I n radiolog ical terms, a su ccessf u lly ab lated 
lesion shows absence of enhancement after contrast 
inMection and shrinkage within time. A blanco CT or 
MRI have to be systematically performed before 
contrast inMection to rule out calcifications secondary 
to small hemorrhag es du ring  the procedu re. Af ter 
cryoablation a CT scan tiny enhancement rim may 
show up in up to 20 of the cryolesions. This rim 
prog ressive ly disappears du ring  the 9  months 
following cryoablation [70]. Weight et al tried to 
determine a correlation between imaging findings 
and histopatholog y  af ter prob e ab lative  procedu res. 
They demonstrated a poor correlation between 
post-RFA radiographic imaging and post-RFA 
biopsy results and an excellent correlation between 
the radiographic findings after cryoablation and 
su b sequ ent percu taneou s b iopsy of  the treated 
lesions. In this study, 6 of 13 patients (46.2) that 
showed no enhancement on radiographic imaging 
after RFA demonstrated viable tumour cells at 
a 6-month post-RFA biopsy. The 6-month post-
ablation biopsy reduced the success rate of RFA 
from 85 to 64.8 [13]. Raman et al recently 
su g g ested that presence of  tu mou r architectu re 
on early ( 12 months) biopsy following RFA may 
be unreliable. They showed that  no viable tumour 
was present in lesions that were biopsied more 
than 1 year following RFA [71]. A multi-institutional 
stu dy reve aled that in most cases initial treatment 
failure following ablation was detected within the 
first 3 months. Results support a minimum of 3 to 
4 abdominal imaging studies in the first year after 
ablative therapy at months 1, 3, 6 (optional) and 12 
[2]. There is no consensus on the optimal follow-up 
of thermal ablative therapies. Some experts find that 
this statement does only pertain to RFA because the 
re- ab lation rate is mu ch hig her and does not pertain 
to cryo ab lation. A recent laparoscopic cryo ab lation 
study demonstrated  that of the 5 (15.6) ablation 
sites that showed enhancement at 3 months three 
persisted b y 6  months, b u t only one displaye d 
enhancement by 9 months. This patient with 
persisted enhancement by 9 months underwent 
PN that demonstrated no recurrent cancer [72]. 
Currently, computed tomography (CT) and magnetic 
resonance imaging (MRI) are usually performed  to 
evaluate residual or recurrent disease after RFA and 
cryo ab lation of  a renal tu mou r [ 7 3] .  
4 .  noVel T ReA T M enT  M oD A lIT Ies of 
RenA l M A sses
O ther minimally inva sive  techniqu es su ch as H ig h 
Intensity Focused Ultrasound (HIFU), Radiosurgery, 
Microwave Thermotherapy (MWT), Laser Interstitial 
Thermal Therapy (LITT), and Pulsed Cavitational 
Ultrasound (PCU) should at this time be considered 
experimental. Clinical series are small and no long-
term follow-up data have been reported.
a)  H igh I ntensity Focused U l trasound
H I F U  is attractive  as non- inva sive  therapy of  
malig nancies, b ecau se there is no need to pu nctu re 
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the tu mou r and theref ore no risk of  hemorrhag e or 
tumour spillage [74]. However, limited clinical data 
on extracorporeal HIFU of renal tumours show 
insufficient results [75-78]. The technique is found 
to be well tolerated with no serious perioperative 
complications b u t the eradication of  the tu mou r is 
inadequ ate, mainly du e to acou stic complexi ty of  
interve ning  stru ctu res and the respiratory move ments 
of  the ki dney [ 7 9 ] . An additional disadva ntag e  is the 
inab ility to monitor treatment prog ression in real time 
[ 7 9 ] .
Problems with respiratory movements of the kidney 
and acou stical interphases of  the ab dominal/
thoracic wall and tissue inhomogeneities within the 
kidney are avoided when the transducer is brought 
directly to the targ et b y laparoscopic H I F U  [ 7 4 ,7 9 ] . 
A phase I  stu dy b y K ling ler et al u sing  laparoscopic 
H I F U  ab lated 10  renal tu mou rs less than 3 cm in 
diameter. No HIFU-specific complications were 
ob serve d in the stu dy . L aparoscopic H I F U  is a nove l 
approach that may achieve  a g reater rate of  tu mou r 
destruction but further studies to refine the technique 
are needed [80]. To date, HIFU has to be considered 
experimental. Honeck et al, recently showed in an ex 
vi v o model of  the isolated perf u sed porcine ki dney 
that magnetic resonance imaging (MRI) is potentially 
a g ood diag nostic tool f or vi su alizi ng  and monitoring  
the ef f ects of  H I F U  ab lation of  renal masses. 
B ef ore this imag ing  modality can b e u sed u nder 
clinical conditions, f u rther technical deve lopment 
is essential, especially with regard to reducing the 
measuring times [81]. A recent 3-year follow-up study 
evaluated the safety, feasibility and efficacy of HIFU 
in 17 patients with radiologically suspicious renal 
tumours (mean tumour size 2.5 cm). Renal HIFU 
achieved stable lesions in two-thirds of patients, 
with minimal morbidity, and might be appropriate in 
selected cases [ 8 2] .
b)  Radiosurgery ( Cyberk nife)
The Cyberknife is a frameless image-guided 
radiosurgery device. The 2 main elements are the 
radiation produ ced b y a small linear accelerator and 
a robotic arm that allows the energy to be directed 
at any part of the body from any direction. The 
Cyberknife divides the high-dose radiation necessary 
to ab late the lesion completely into u p to 120 0  
separate radiation beams. The individual dose of 
each radiation b eam indu ces ve ry  little ef f ect on the 
surrounding tissue. However, high radiation doses 
are delive red to the f ocal point, destroyi ng  tu mou r 
tissu e and minimizi ng  collateral damag e [ 8 3] .
Ponsky et al reported a phase I  stu dy invo lvi ng  3 
patients with a renal tumour of  4 cm who underwent 
radiosurgery followed by a PN after 8 weeks. The 
patients were treated with a radiation dose of 4 Gy 
per fraction for 4 fractions. No acute toxicities and no 
changes in renal function were noted, with a mean 
follow-up of 12 months. One patient had a necrotic 
tumour while two others had pathologic evidence 
of viable RCC [84]. The results were promising 
considering that in animal models, ablation was not 
observed until a target of 40 Gy was obtained [83]. 
Preclinical data showed that radiosurgery (single 
doses of 24-40 Gy) for predetermined lesions in 
16 porcine kidneys with sequential histological 
evaluations at 4, 6 and 8 weeks achieved complete 
fibrosis after 8 weeks [83].
I n a prospective  stu dy inclu ding  30  patients, the 
safety and local efficacy of radiosurgery in metastatic 
or inoperable primary RCC was evaluated. In total, 
82 lesions were treated with high-dose fraction 
stereotactic radiotherapy . D ose/ f ractionation 
schedu les va ried depending  on targ et location and 
size (8 Gy x 4, 10 Gy x 4, 15 Gy x 2 or 14 Gy x 3) 
[85]. Radiosurgery is a promising new technology as 
it resulted in a high local control rate with generally 
low toxicity.  However, radiosurgery is currently an 
experimental modality and the first human studies 
in patients with localized RCC are underway.  At 
present, the role of  radiosu rg ery f or the manag ement 
of  renal tu mou rs is u nclear and f u rther stu dies are 
needed to address its oncolog ical and f u nctional 
resu lts.
c)  O ther modal ities
1.  MI CRO W A V E TH RM O T H E RA P Y
In MWT, microwave energy is delivered through an 
antenna inserted directly into the lesion cau sing  an 
electromagnetic field, which leads to ion oscillation 
and increase in kinetic energy which is converted to 
heat, resulting in coagulative necrosis. MWT may 
generate heat 100 times faster than RFA and may 
b e less su sceptib le to the heat sink phenomenon. 
MWT did not appear to be effective for destruction 
of experimental V;-2 renal tumours in rabbits [8]. 
MWT followed by nephrectomy has been evaluated 
in a single phase I study in which it could safely 
and qu ickl y g enerate larg e ab lation lesions of  renal 
neoplasms. No skip areas were observed within 
the ab lation zo nes [ 8 6 ] . I n a recent pilot stu dy of  12 
patients with pathologically proven RCC (1.3 to 3.8 
cm in diameter) ultrasound guided percutaneous 
microwave ablation appears to be safe and effective. 
Complete necrosis was induced in a single session 
in all tumours. No complications were observed, 
perhaps in part du e to the excl u sion of  tu mou rs 
adMacent to the bowel and ureter. No residual tumour 
or recurrence was observed at a median follow-up 
of 11 months (range 4 to 20). The ablation zone was 
well defined on contrast enhanced CT and contrast 
enhanced ultrasound, and it gradually shrank with 
time. Additional experience with this technique 
should be required before its widespread clinical use 
[ 8 7 ] .
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2 .  LA SE R IN T E RST I T I A L H E RM A L TH E RA P Y
LITT also known as Laser Thermal Ablation (LTA) 
delive rs energ y throu g h insertion of  laser fibres 
into the tumour, followed by coagulative necrosis 
by raising the tissue temperatures to ! 55C (1,88]. 
I n a pilot stu dy of  9  patients u nsu itab le f or su rg ery , 
MRI-guided LTA of renal tumours was proven 
safe, feasible (being well tolerated by the patient) 
and significantly reduced the mean percentage 
enhancement ( of approximate tumour volume that 
is viable) from 73.7 before to 29.5 after ablation. 
However, the clinical implications of this finding are 
not clear [ 8 9 ,9 0 ] .
3 .  PU L SE D CA V IT A T I O N A L UL TRA SO U N D
A limitation of  thermal ab lation is that the thermal 
zo ne of  destru ction cannot b e precisely predicted 
du e to su b tile dif f erences in tissu e character, tissu e 
heterog eneity and va riations in b lood perf u sion 
[91]. The transcutaneous, nonthermal, mechanical 
effects of US waves (cavitation) were thought to 
have  an adva ntag e ove r temperatu re- b ased ab lation 
systems.  PCU utilizes cavitational effects to destroy 
the tumour by varying acoustic parameters. The 
delive ry of  transcu taneou s hig h intensity u ltrasou nd 
to indu ce cavi tational tissu e ab lation is termed 
histotripsy. Cavitation is a phenomenon by which 
alternating  zo nes of  compression and raref action 
induce microbubble formation, which leads to 
subcellular tissue fragmentation [91]. With this 
approach no thermal collateral damag e is cau sed 
to adMacent tissues, structures or collecting system. 
Data about PCU are limited to two preclinal studies 
invo lvi ng  an i n  vi tr o porcine model [ 9 1]  and an i  vi vo 
stu dy in rab b its [ 9 2] .  Additional research is needed to 
optimize  the parameters f or in vi vo  cavi tational tissu e 
ab lation, inclu ding  the impact of  tissu e perf u sion and 
to elucidate any relationship between metastasis 
and histotripsy treatment [ 9 1] .
5 . ConClusIons
Cryosurgery and RFA by open, laparoscopic or 
percu taneou s approaches are promising  minimally 
inva sive  nephron- sparing  treatment options f or 
localized RCC for most small (mainly  3.0 cm), 
low grade renal tumours in patients who are at high 
surgical risk. However, no randomised comparisons 
have been performed between the outcome of 
ablative techniques and RN or PN.  Cryoablation 
and RFA are associated with acceptable short and 
intermediate survival results and low morbidity. 
However, long-term oncological outcome remains 
to be established. Retrospective, non-controlled 
stu dies su g g est that cryo ab lation may b e associated 
with a lower re-ablation rate and local recurrence rate 
compared with RFA. However, variables as surgical 
approach (laparoscopic versus percutaneous), renal 
parenchyma reserve, anesthesia (general versus 
sedation) and physician performing the procedure 
(surgeon versus radiologist) can strongly inÀuence 
these rates. B oth ab lative  procedu res appear to have  
minimal impact on renal f u nction. Perf ect assessment 
of  the ab lated tu mou rs at postprocedu ral imag ing  is 
cru cial f or eva lu ating  the adequ acy  of  treatment and 
guiding further management. There is an urgent need 
f or pre-  and postoperative  alg orithms, strong , u nif orm 
and exp licit indications and a standard consensu s f or 
follow-up schedules in the use of ablative therapies, 
which is nonexistent at this moment. 
At this time, there is insufficient long-term data 
av ail abl e to mak e adeq uate comparisons betw een 
abl ativ e techniq ues.  T herefore abl ativ e therapies 
shoul d be reserv ed for careful l y sel ected high 
surgical  risk  patients w ith SRM s <  4  cm ( G rade 
C) .  The alternative option in many patients is active 
surveillance, which at the present seems to have a 
similar outcome (with all limitations of poor data) at 
clearly lower invasiveness and complications. This is 
also qu ite apparent in the meta- analysi s u sed f or the 
2008 AUA Guidelines on SRMs [93,94]. 
To date, the use of other minimally invasive 
techniques, such as HIFU, radiosurgery, microwave 
thermotherapy , laser interstitial thermal therapy and 
pu lsed cavi tational u ltrasou nd shou ld b e considered 
exp erimental. F u rther stu dies are requ ired to 
determine their oncolog ical and f u nctional role in the 
management of localized RCC.
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VII. ConClusIons -  lIM IT A T Ions 
of T H e lIT eRA T uRe
The recent meta-analysis of Kunkle et al including 
9 9  stu dies representing  6 4 7 1 tu mou rs illu strates 
that PN, cryoablation, RFA and active surveillance 
are vi ab le approaches to the manag ement of  
SRMs. Although long-term data have demonstrated 
excellent outcomes for PN, extended oncological 
efficacy remains to be established for thermal 
ablation and active surveillance. Compared with 
PN, current data demonstrate a significantly 
hig her incidence of  local tu mou r recu rrence 
following cryoablation and RFA with cryoablation 
predominantly perf ormed laparoscopically resu lting  
in less local tumour progression than RFA generally 
performed percutaneously (RR 1.00, 7.45, 18.23, 
respectively). However, no statistical differences 
were detected in progression to metastatic RCC 
regardless of treatment option (PN, cryoablation or 
RFA) or absence of treatment (active surveillance) 
(RR 1.00, 1.24, 3.21, 0.11, respectively).  These 
data raises concern ove r a possib le ove rtreatment 
bias for SRMs [1]. Delayed intervention for SRMs 
appears to b e a saf e treatment strateg y in selected 
patients [2]. Currently, no hard recommendations 
can b e made ag ainst a g ive n treatment modality f or 
localized, SRMs because of the limitations of the 
cu rrent stu dies.
We identified the most important limitations of the 
exi sting  literatu re on manag ement of  localize d renal 
cell carcinoma. The main limitation seen across all 
treatment options was the lack of well-designed 
prospective or randomised studies. Selection bias (i.e. 
differences in patient age, tumour size and follow-up 
durations) is clear across interventions. For example 
active  su rve illance and ab lative  therapies g enerally 
have  b een perf ormed selective ly in older patients 
with smaller tumours and favourable radiographic 
findings. Other weaknesses include the absence of 
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transparent selection criteria, standardize d technical 
application of the interventions, clear definitions of 
su ccess and standardize d methodical reporting  of  
complications and other outcomes. Renal function 
was usually reported as pre- and posttreatment 
creatinine levels or as estimated glomerular filtration 
rate (eGFR) or creatinine clearance measurements 
f rom 24 - hou r u rine collection. F u rthermore, the lack of  
pathologic data in ablative and expectantly followed 
series remains a confounding factor when attempting 
to compare outcomes for renal lesions treated with 
other interventions. The category of tumours with 
unknown pathology certainly includes a number of 
b enig n tu mou rs and thu s, measu res of  treatment 
efficacy may be overestimated. Limited clinical 
follow-up of some studies may make their oncologic 
outcomes subMect to follow-up bias. For example, 
some series of  ab lated lesions tend to inclu de shorter 
post-treatment follow-up compared with published 
series of surgically managed or expectantly followed 
tumours.  Reporting and publication biases probably 
also exist; studies with higher complication or 
recu rrence rates or other poor ou tcomes tend not to 
be published. For example, few data regarding the 
morbidity of RN were published until the introduction 
of LRN. In addition, there is the problem of technique 
b ias in the interpretation of  the resu lts. F or exa mple, 
percutaneous therapy is repeated without difficulty 
whereas laparoscopic therapy is not. This certainly 
inÀuences the behaviour of the treating physician at 
the time of  therapy . 
In conclusion, the findings reported here must be 
interpreted within the context of the limitations 
outlined above. In order to allow better comparisons 
between treatment options for localized renal 
cell carcinoma, f u tu re research attempts shou ld 
minimize  these limitations b y promoting  prospective  
randomize d eva lu ations. 
VIII. eA u A nD  A uA  sT A T eM enT s 
foR T ReA T M enT  of loCA lIZ eD  
RCC
1 . eA u sT A T eM enT s ( uP D A T e 2 0 0 9 ) [ 3 ]
Surgical therapy is the only curative approach for 
the treatment of RCC. Routine extended lymph node 
dissection in patients without detectable lymph nodes 
does not improve  su rvi va l and can b e restricted to 
staging purposes (Grade A). Adrenalectomy, together 
with nephrectomy, except in the case of large upper 
pole tumours where direct invasion of the adrenal 
gland is likely, can be spared in most patients (Grade 
B). Embolisation as a palliative approach can be 
beneficial in patients unfit for surgery with massive 
hematuria or profound local pain (Grade C).
NSS  is an established curative approach for the 
treatment of RCC (Grade B). NSS for tumours  
4 - 7  cm maxi mu m diameter can b e perf ormed in 
centres with expertise in selected patients (Grade 
B). A minimal tumour-free surgical margin following 
partial resection of RCC appears appropriate to 
avoid the increased risk of local recurrence (Grade 
B). If tumours of larger size are treated with NSS, 
follow-up should be intensified due to increased risk 
of intrarenal recurrence (Grade B). 
L aparoscopic tu mou r nephrectomy shou ld b e 
performed in centres with laparoscopic expertise 
(Grade B). Laparoscopic tumour nephrectomy is 
likely to become a widely distributed treatment 
option. I t can b e promoted in specialised centres 
treating kidney tumours (Grade B).
OPN currently remains the standard of care (Grade 
C). LPN should be limited to experienced centres 
(Grade C).
Currently, patients not suitable for OPN due to poor 
performance status with smaller peripheral tumours 
shou ld b e considered f or non- su rg ical alternative  
techniques (Grade B).
These techniques include image-guided 
percu taneou s and minimally inva sive  techniqu es, 
e.g. percutaneous RFA, cryoablation, microwave 
ab lation, laser ab lation and hig h- intensity f ocu sed 
ultrasound ablation (grade B). 
2 . A uA  sT A T eM enT s 2 0 0 8 [ 4 ]
The statements are graded with respect to the 
degree of Àexibility in application. A ³standard´ is 
the most rigid treatment policy. A ³recommendation´ 
has significantly less rigidity, and an ³option´ has the 
largest amount of Àexibility. 
F o r  a l l  p a ti en ts
Standard: high quality cross-sectional imaging (CT 
or MRI) with and without contrast.
Standard: discuss the current understanding of the 
natu ral history of  clinical stag e 1 renal masses, the 
relative  risks of  b enig n vs.  malig nant patholog y and 
the potential role of  active  su rve illance.
Standard: percutaneous renal mass core biopsy 
with or without fine needle aspiration in all patients 
u nderg oing  thermal ab lation and in patients f or 
whom, it might impact management, particularly 
patients with radiographic findings suggestive of 
lym phoma, ab scess or metastasis.
Standard: review the available treatment options and 
the attendant benefits and risks, including oncologic 
considerations, renal f u nctional considerations and 
potential morb idities.
Standard: counsel patients about potential 
advantages of NSS in imperative and elective 
settings (avoidance of the need for dialysis, reduced 
risk of developing CKD with attendant morbidity and 
mortality .
1 46
$ healthy patient with a clinical 7a   cm 
enhancing renal mass
Standard: PN
Alternate standard: RN when PN is not technically 
f easib le
O ption:  thermal ab lation b u t hig her risk f or 
recu rrence
O ption:  active  su rve illance b u t small non- neg lig ib le 
risk f or tu mou r prog ression
$n elderly patient with maMor comorEidities and a 
clinical 7a   cm enhancing renal mass
Standard: PN with increased surgical risk
Standard: RN with increased surgical risk
Recommendation: thermal ablation because less 
inva sive  in this hig h- risk patient
Recommendation: active surveillance with delayed 
interve ntion in this hig h- risk patient
$ healthy patient with a clinical 7E . to . cm 
enhancing renal mass
Standard: RN for patients with normal contralateral 
ki dney
Standard: PN, particularly when there is need to 
preserve  renal f u nction
O ption:  thermal ab lation b u t hig her risk f or 
recu rrence
Option: active surveillance with delayed intervention 
b u t small non- neg lig ib le risk f or tu mou r prog ression
$n elderly patient with maMor comorEidities and a 
7E . to . cm enhancing renal mass
Standard: RN for patients with a normal contralateral 
ki dney , b u t increased su rg ical risk and increased risk 
of CKD
Recommendation: PN when there is need to preserve 
renal f u nction althou g h increased u rolog ic morb idity
O ption:  thermal ab lation b ecau se less inva sive  
in this hig h- risk patient b u t clearly hig her risk f or 
recu rrence
Recommendation: active surveillance in this high-
risk patient
IX . Consensus ReG A RD InG  
T ReA T M enT  oP T Ions foR 
loCA lIZ eD  RCC
1 . A CT IVe suRVeIllA nCe
Active  su rve illance is an acceptab le option f or the 
treatment of SRMs that should be discussed with 
all patients. Active surveillance should be a first 
treatment option for SRMs  4 cm in unfit patients 
or those w ith l imited l ife ex pectancy ( G rade 
C) .  D el ayed interv ention shoul d be undertak en 
in tumours that show  fast grow th during 
activ e surv eil l ance ( G rade C) . Patients shou ld 
b e cou nselled ab ou t the small b u t non- neg lig ib le 
risk of  tu mou r prog ression du ring  the ob serva tion 
period, possib le loss of  the opportu nity f or nephron-
sparing  su rg ery , lack of  cu rative  salva g e therapies 
if  metastatic disease deve lops, limitations of  renal 
mass b iopsy , lack of  long - term data on su rve illance, 
close follow-up imaging and required compliance. 
A significant number of SRMs ( 4 cm) are actually 
benign tumours (20). No more than about 20 to 25 
of SRMs have potentially aggressive characteristics. 
Several studies have shown increased aggressive 
potential of renal masses with a diameter ! 3 cm. 
Data of surveillance series reveal that the maMority 
of untreated localized renal tumours grow slowly and 
have little tendency to metastasize, at least in the first 
few years. Delayed intervention should be restricted 
to tumours that show fast growth during observation 
and have  a hig her risk of  prog ression to metastatic 
disease. Renal mass biopsy enhanced by molecular 
profiling holds promise for assessing aggressive 
potential. Further research will be required to define 
the u tility and limitations of  this approach to improve  
the selection of  patients f or active  su rve illance. 
Larger tumours beyond a diameter of 3 or 4 cm, with 
agg essive behaviour and rapid growth are at risk 
of  prog ression to metastatic disease and shou ld b e 
treated proactive ly .
2 . P A RT IA l A nD  RA D ICA l neP H ReCT oM Y
Nephron-sparing surgery should be a primary 
consideration in all patients with localized SRMs. 
This is based on the information that PN of small 
renal tu mou rs preserve s as mu ch normal renal 
parenchym a as possib le, provi des equ iva lent 
adequate oncologic outcomes as RN and is 
associated with a reduced risk of developing CKD 
compared with RN. Data have demonstrated that RN 
can result in a higher risk of CKD which is associated 
with increased risk of cardiovascular events and 
mortality . Partial nephrectomy is the ref erence 
standard for the treatment of SRMs, whether for 
imperative or elective indications. At present, PN is 
seriously underutilized while it is often feasible even 
f or a centrally located tu mou r or a tu mou r in the renal 
hilum when performed by an experienced surgeon. 
Laparoscopic PN can provide faster convalescence, 
but initial LPN reports were associated with 
somewhat longer ischemia times and increased risk 
of postoperative hemorrhage compared to OPN. 
However the more recent data presented in this 
chapter demonstrates that these concerns are no 
longer valid, and that contemporary LPN outcomes 
are similar to contemporary OPN outcomes, given 
adequ ate minimally inva sive  exp ertise. 
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I n patients w ith a cl inical  T 1 renal  tumour,  P N  
prov ides eq uiv al ent l ocal  tumour control  as RN ,  
w hil e minimizi ng dev el opment of new - onset 
CK D  or w orsening of ex isting CK D  ( G rade B ) .   
A s such,  P N  is the establ ished treatment for 
T 1a tumours ( <  4  cm)  and an emerging standard 
treatment for T 1b tumours ( 4  to 7  cm)  prov ided 
that the operation is technical l y feasibl e and the 
tumour can be entirel y and adeq uatel y remov ed 
( G rade B ) .  A ny tumour- free surgical  margin 
following P1 appears sufficient to prevent local 
recurrence and disease progression from RCC 
( G rade B ) .
RN remains a viable option in cases when PN is not 
technically f easib le b ased on tu mou r size , location 
or radiog raphic appearance as determined b y the 
urologic surgeon. When RN is required, laparoscopic 
RN should be considered as it is a recognized 
standard now. It is associated with low morbidity 
and f aster retu rn to normal activi ties, g ive n adequ ate 
su rg eon exp ertise. T herefore,  L RN  shoul d be the 
standard of care for T 1 and T 2  tumours,  prov ided 
that it is performed in an adv anced l aparoscopic 
centre by an ex perienced surgeon and N SS is 
not appl icabl e ( G rade B ) .Robotic-assisted partial 
nephrectomy is rapidly emerg ing  as an alternative  to 
LPN for the treatment of renal malignancy.
3 . T H eRM A l A BlA T Ion
Cryoablation and RFA are reasonab le minimally 
invasive treatment options for most small (mainly 
 3 cm) low grade renal tumours in patients who 
are at high surgical risk, who are not candidates 
for active surveillance and who accept the need for 
long - term radiog raphic su rve illance af ter ab lation. 
Percutaneous tumour core biopsy with or without 
fine needle aspiration should always be performed 
prior to ablation to define histology. Posttreatment 
biopsies may be necessary when recurrence or 
incomplete ablation is suspected. When deciding 
on thermal ab lation, it is important to cou nsel 
patients reg arding  the slig htly increased risk of  local 
recu rrence and the potential need f or retreatment 
when compared to surgical excision.  Counselling 
ab ou t thermal ab lation shou ld f u rther inclu de the 
ab sence of  estab lished radiog raphic measu res 
of post-ablative success, the potential for difficult 
surgical salvage therapy due to perinephric fibrosis 
if  tu mou r prog ression deve loped, and the su b stantial 
limitations of  the exi sting  literatu re on thermal 
ab lation. L arg er tu mou rs b eyo nd a diameter of  3 
or 4  cm and those with irregular form or infiltrative 
growth pattern may be associated with increased 
risk of recurrence when treated with thermal ablative 
therapies.
At this time there is insufficient long-term data 
av ail abl e to mak e adeq uate comparisons betw een 
abl ativ e techniq ues.  T herefore abl ativ e therapies 
shoul d be reserv ed for careful l y sel ected high 
surgical  risk  patients w ith SRM s <  4  cm ( G rade 
C) .
X . neW  ReseA RCH  –  fuT uRe 
D IReCT Ions
To allow comparison of the different treatment 
options for localized RCC, future studies should 
b e prospective ly desig ned, have  identical selection 
criteria, standardize d treatment protocols and 
consistent follow-up strategies using markers of 
clinical su ccess and ideally b e condu cted in a 
randomised way [5]. In addition, as newer treatment 
options b ecome ava ilab le, f u tu re stu dies shou ld 
include quality of life (4OL) and cost-efficacy 
ou tcomes [ 6 ] .
The most widely used system to provide prognostic 
information for RCC is currently the tumour, nodes, 
metastasis (TNM) staging system. The recent 
detection of  molecu lar tu mou r b iomarke rs is 
expected to refine the staging and prognostication 
of RCC. There is already evidence that gene 
expression profiles obtained with high throughput 
microarray technolog y can identif y histolog ical 
subtypes of RCC and predict clinical outcomes of 
the disease. Biomarkers will eventually improve our 
ab ility to predict the malig nant potential of  a tu mou r 
and to stratif y patients into more sophisticated risk 
categories [7].  Further active surveillance series with 
long-term follow-up are required to determine the 
real risks associated with this approach. Molecular 
profiling of SRMs is now possible but the available 
data on molecu lar marke rs are not ye t va lid enou g h 
for general use in clinical practice. Research will be 
required to define the utility and limitations of renal 
mass biopsy enhanced by molecular profiling [8,9]. 
F u rther endeavo u rs are requ ired to clarif y the 
long - term metab olic consequ ences of  a decreased 
number of functioning nephrons following RN for 
RCC. This may result in a better understanding of 
the pleiotropic effects of CKD in patients treated 
with RN, and may offer a further rationale for the 
implementation of  nephron- sparing  strateg ies f or 
the treatment of localized RCC. Moreover, novel 
protective  measu res to minimize  ischemic renal 
damage (pharmacologic, immunologic) should be 
f u rther exa mined in order to improve  the f easib ility 
and saf ety of  nephron- sparing  su rg ery [ 10 ] .
The use of the DaVinci Robot for robotic-assisted 
LPN is currently being evaluated at specialized 
laparoscopic centres [11,12]. Since 2004, four centres 
have reported their experience with robotic-assisted 
LPN.  Robotic-assisted LPN may potentially enable 
more urologists to perform LPN, thereby allowing 
wider dissemination of minimally invasive nephron-
sparing surgery [12). In addition, new developments 
su ch as sing le- port access laparoscopic su rg ery 
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and natural-orifice translumenal endoscopic surgery 
(NOTES) have received increased attention from 
the urological community. These techniques will 
continu e to evo lve  and mig ht lead to more adva nced 
therapeu tic options f or minimally- inva sive  renal 
surgery [13,14]. Novel surgical image-navigation 
sy stem has also b een emerg ed recently .  I mag e-
guided surgery is a new field in which visualization of 
the surgical anatomy beyond the surgical view helps 
the su rg eon to enab le percu taneou s, laparoscopic, 
or robotic surgery more precisely and safely.  Recent 
reports describ ed the nove l clinical capab ility of  
image-fusion system of ultrasonography (US) with 
computed tomography (CT) or Magnetic Resonance 
Imaging (MRI), real-time 3-dimensional US (3D 
US) navigation system, MRI-compatible navigation 
system, and augmented reality technology [15-18]. 
D ig ital- imag e- b ased compu terize d control of  the 
su rg ical procedu res has g reat potential to improve  
precision of tumour ablation/removal with maximizing 
of  preserva tion of  the renal f u nction and su rrou nding  
healthy anatomy .
MaMor advances in the understanding of the molecular 
biology of RCC have led to the development of 
several new therapies that target ligands at the 
molecular level, so-called ³targeted therapies´. The 
molecular targets important in clear cell RCC include 
vascular endothelial growth factor (VEGF) receptors, 
the mammalian target of rapamycin, and the VEGF 
molecule itself.  The small molecule tyrosine kinase 
inhib itors su nitinib  and soraf enib , the mammalian 
targ et of  rapamyci n inhib itor temsirolimu s and 
the comb ination of  the monoclonal antib ody 
bevacizumab with interferon-alpha are currently 
approved for treatment of metastatic RCC [19]. 
These new agents improve quality of life and seem 
ab le to stab ilise metastatic RCC for a prolonged 
period of time [20]. Recently-reported and ongoing 
studies compare combination therapies with single 
agents and determine the efficacy of single agents as 
adMuvant therapy for higher-risk localized and locally-
advanced disease. However, there is currently no 
role f or targ eted molecu lar therapy in the treatment 
of localized RCC outside of a clinical trial.
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D espite the increased detection of  small, 
asym ptomatic renal masses throu g h the increased 
use of abdominal imaging for non-specific complaints 
or f or non- renal malig nancy stag ing  eva lu ation, there 
remains a significant subset of patients that present 
w ith locally adva nced and/ or metastatic renal cell 
carcinoma (R C C ).  R eg arding  locally adva nced 
R C C , these inclu de patients w ith ve nou s thromb i, 
ex tra- capsu lar and adj acent org an invo lve ment, 
as w ell as nodal disease.  L ocally recu rrent R C C  
after definitive surgical therapy should also be 
inclu ded in this g rou p of  patients.  T he su rg ical 
manag ement of  these patients can b e ext remely 
dau nting  and complex,  and despite exp ert su rg ical 
manag ement, many are destined to su f f er relapse, 
either locally , distantly , or b oth[ 1] .  I n concert w ith 
su rg ical manag ement of  these locally adva nced 
tu mors, clinical research ef f orts have  f ocu sed 
on the deve lopment of  ef f ective  adj u va nt and/ or 
neoadj u va nt therapy that can ef f ective ly redu ce 
the risk of  disease recu rrence f ollow ing  su rg ical 
ex tirpation.  Sadly , ef f ective  adj u va nt/ neoadj u va nt 
therapy does not exi st f or renal cell carcinoma in the 
ye ar 20 10 , despite the condu ct of  many phase I I I  
clinical trials testing  ag ents that have  show n promise 
in the setting  of  metastatic disease[ 2, 3] .  C u rrently , 
the new  targ eted therapies are b eing  tested in b oth 
the adj u va nt and neoadj u va nt setting  f or locally 
adva nced renal cell carcinoma, and w e anxi ou sly 
aw ait the resu lts of  these important ong oing  clinical 
trials.
I n this article, w e w ill discu ss the manag ement 
and ou tcomes f or patients w ho present w ith 
locally advanced RCC, focusing specifically on the 
manag ement of  renal ve in and inf erior ve na cava  
thromb i, the role of  lym ph node dissection and the 
manag ement of  nodal metastases, the manag ement 
of  adj acent org an inva sion, the manag ement of  local 
recu rrences in the ab sence of  metastatic disease, 
and the role of  adj u va nt and neoadj u va nt therapy . 
W e w ill present leve ls of  evi dence f or each of  ou r 
findings, and a consensus statement derived from 
f u rther delib eration b y committee memb ers.
II. Venous InVAsIon
Approxi mately 10 %  of  patients w ith R C C  have  
ve nou s tu mor thromb u s in the renal ve in (R V ) or 
inf erior ve na cav a (I V C ) w ith approxi mately 1%  
havi ng  tu mor thromb u s ext ending  u p to the rig ht 
atriu m.[ 4 ]  ( fi g .1 ) V enou s tu mor thromb u s patients 
requ ire more exp editiou s care than many other 
R C C  patients secondary to the associated risks and 
complications inclu ding  ve nou s cong estion, emb olic 
eve nts, and the possib ility of  thromb osis w ith b land 
b lood clot.  F u rthermore, proxi mal prog ression of  
tu mor thromb u s secondary to delay in manag ement 
in reases complexi ty and potential morb idity of  
su rg ical resection.[ 5 , 6 ]
1 . eVA luA TIon
Appropriate manag ement of  R C C  w ith tu mor 
thromb u s requ ires accu rate stag ing .  Enhanced 
mag netic resonance imag ing  (M R I ) has b een 
determined to b e the most reliab le method of  
imag ing  tu mor thromb u s ext ent, invo lve ment of  ve in 
trib u taries, detection and dif f erentiation of  tu mor 
thromb u s ve rsu s b lood clot, and assessing  f or ve ssel 
occlu sion.[ 7 ]   R ecently , mu ltidetector compu terize d 
tomog raphy (C T ) has b een show n to correlate 
well with intraoperative findings including extent of 
thrombus as well as pathological findings at the time 
I. InT RoD uCT Ion
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of  resection of  R C C  w ith tu mor thromb ectomy . [ 8 ]  
D u e to possib le rapid prog ression of  tu mor thromb u s, 
operative  manag ement shou ld b e preceeded b y 
ve ry recent imag ing . Stag ing  f or b ony , ab dominal, 
thoracic, and intracranial metastatic invo lve ment 
shou ld f ollow  standard protocols.  
2 . M A nA G eM enT
C ase reports of  tu mor thromb u s dow nstag ing  w ith 
targ eted ag ents indicate that neoadj u va nt therapy 
may b ecome a vi ab le approach,[ 9 - 11]  how eve r, 
u ntil f u rther data is ava ilab le this practice shou ld b e 
limited to clinical trials. (l e v e l  o f  e v i d e n c e :  4) U ntil 
su ch data are ava ilab le, therapy f or the patient w ith 
tu mor thromb u s is b ased u pon su rg ical resection of  
the primary tu mor along  w ith the entire b u rden of  
intrava scu lar tu mor thromb u s.  Some data f rom case 
cohort series indicate that su rg ical manag ement 
of  R C C  w ith tu mor thromb u s may provi de su perior 
su rvi va l to non- su rg ical manag ement (median of  
19 .8  ve rsu s 6 .9  months, respective ly) .[ 12]   H ow eve r, 
the cohorts were significantly different with higher 
tu mor b u rden in the non- su rg ical g rou p.
A recent retrospective  revi ew  of  a larg e case series 
provi des an exce llent g u ide to manag ement b ased 
on tu mor thromb u s leve l.[ 5 ]  (l e v e l  o f  e v i d e n c e :  
3 b)  O perative  manag ement is dictated primarily b y 
the ext ent of  the tu mor thromb u s.  I solation of  the 
va scu lar stru ctu res is the initial step in dissection. 
Ligation of the ipsilateral renal artery is the first step 
and is b est accomplished b y approaching  the aorta 
directly f or b oth lef t and rig ht tu mors.  Preoperative  
ang ioemb oliza iton is not recommended and w as 
show n to of f er no adva ntag e in a larg e case 
control series and w as associated w ith increased 
complications.[ 13]   Af ter arterial lig ation the next  
step is ve nou s control and ext raction of  thromb u s. 
L ig ation of  minor trib u taries to the I V C  inclu ding  
some lu mb ar and minor hepatic b ranches may b e 
necessary to provi de adequ ate hemostasis and tu mor 
vi su aliza tion du ring  tu mor ext raction.[ 5 ]   H ow eve r, 
in cases of  complete or near complete occlu sion, 
meticu lou s dissection of  all collateral ve ins is to b e 
avo ided as these represent the maj ority of  ve nou s 
retu rn and are needed to maintain preload u ntil the 
I V C  can b e cleared.  M inimal manipu lation of  the 
ki dney and tu mor redu ce the risk of  emb oliza tion 
and theref ore the nephrectomy is completed af ter 
ext raction of  the thromb u s.
For thrombus that is confined to the renal vein or 
j u st entering  the I V C  (w hich can b e retracted b ack 
into the renal vein) minimal modification to standard 
approaches to open radical nephrectomy are 
requ ired to assu re complete remova l of  thromb u s 
w ith neg ative  marg ins.[ 5 ]  Sev eral reports of  
su ccessf u l minimally inva sive  approaches to su ch 
low  leve l thomb u s have  b een pu b lished.[ 14 - 16 ]
T hromb u s that is ab ove  the renal ve in ostiu m and 
b elow  the hepatic ve ins can b e manag ed w ith 
occlu sion of  the ve na cava  ab ove  and b elow  the 
thromb u s as w ell as occlu sion of  the contralateral 
renal ve in. Su ch cases rarely requ ire b yp ass. 
Ext raction of  the thromb u s en b loc w ith the ipsilateral 
renal ve in and tu mor is accomplished vi a a ve na 
cavo tomy on the anterior I V C  and inclu ding  the 
ostiu m of  the ipsilateral renal ve in.  T he interior of  
the IVC should be Àushed and inspected to assure 
complete clearance of  tu mor.[ 5 ]
T hromb u s at the leve l of  the hepatic ve ins and 
Level I 39  (41%)
Level II 28  (29%)
Level III 7    (7%)
Level IV 14  (16%)
Fig. 1: Level of Tumor Thrombus
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b elow  the diaphrag m may requ ired b yp ass b u t 
can b e perf ormed w ith simple occlu sive  measu res 
in many cases.[ 5 ]  T he u se of  intraoperative  
transesophag eal sonog raphy can b e ve ry helpf u l 
f or monitoring  hemodyn amics and assessing  the 
thromb u s.  Ext raction of  thromb u s is accomplished 
with occlusion of the inÀow to the liver (Pringle 
manu ve r) along  w ith control of  the I V C  b elow  the 
thromb u s as w ell as ab ove  the liv er and control of  
the contralateral renal ve in w ith a ve na cavo tomy 
w hich ends inf rahepatically .  Af ter ext raction of  the 
thromb u s, the I V C  can b e clamped inf rahepatic and 
the su prahepatic clamp can b e released to allow  
restoration of Àow to the liver.
T hromb u s ab ove  the diaphrag m necessitates 
opening  the rig ht atriu m w ith silmu taneou s 
manipu lation of  thromb u s f rom ab ove  and vi a 
an inf rahepatic ve na cavo tomy b elow  to assu re 
complete clearance.  Seve ral case series su pport 
the u se of  b yp ass techniqu es inclu ding  ve no- ve no 
b y pass and cardiopu lmonary b yp ass w ith or w ithou t 
circu latory arrest.[ 17 - 20 ]   T he decision to u se b yp ass 
is dependent u pon the ext ent of  occlu sion of  the 
I V C  preoperative ly as w ell as hemodyn amics u pon 
clamping  the va scu lar stru ctu res intraoperative ly .  A 
recent larg e case series reported the u se of  some 
b y pass techniqu e in 10 0 %  of  cases of  thromb u s 
ab ove  the diaphrag m, 29 %  of  cases b elow  the 
diaphrag m and w ithin the intrahepatic I V C , and in 
only 2%  of  I V C  thromb u s cases that w ere b elow  
the live r.[ 5 ]   I n all cases invo lvi ng  the I V C  complete 
clearance of  adherent or inva sive  tu mor thromb u s 
may requ ire complete or partial resection of  the 
ve na cav a and reconstru ction w ith a patch or g raf t. 
Preve ntion of  emb oliza tion of  distal b lood clot may 
requ ire interru ption of  the ve na cava , or placement 
of an IVC filter.[21]
3 . onColoG IC ouT CoM es
The prognostic significance of the level of tumor 
thromb u s has b een eva lu ated ext ensive ly .[ 5 , 22-
31]  (l e v e l  o f  e v i d e n c e :  3 b)  M ost of  these case 
series do not find a difference in survival based on 
leve l of  tu mor thromb u s w ithin the I V C . A recent 
retrospective  revi ew  of  4 22 patients w ith pT 3b  R C C  
evaluated the cancer specific survival based on 
leve l of  tu mor thromb u s.[ 24 ]  Patients w ith I V C  tu mor 
thrombus were significantly more likely to die from 
R C C  compared w ith patients w ith tu mor thromb u s 
confined to the renal vein even after adMusting 
f or reg ional lym ph node invo lve ment and distant 
metastases.[ 24 ]   T he presence of  renal ve in ostial 
w all inva sion b y tu mor thromb u s has b een reported 
to b e associated w ith poor prog nosis relative  to 
patients w ithou t w all inva sion.[ 30 ]
Tumor specific features that are associated with 
diminished su rvi va l are similar to R C C  w ithou t 
ve nou s invo lve ment and inclu de presence of  f at 
inva sion, lym ph node invo lve ment, metastases, 
hi tolog ic tu mor necrosis, sarcomatoid f eatu res, 
and hig h tu mor g rade.[ 5 ]   M edian su rvi va l among  
5 0 3 patients w ith clear cell renal cell carcinoma 
treated w ith su rg ery and no adj u va nt therapy in a 
larg e retrospective  revi ew  w as 3.1 ye ars w ith 5  ye ar 
su rvi va l of  5 9 %  f or patients w ithou t metastases and 
neg ative  lym ph nodes.[ 5 ]
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of noD A l M eT AsT Ases
The potential therapeutic benefits of lymph node 
dissecton (L N D ) at the time of  radical nephrectomy 
(R N ) are tw o- f old. F irst, the remova l of  reg ional 
nodal metastases can provi de cu re in patients 
whose disease is confined to the retroperitoneum, 
concu rrently allow ing  appropriate selection of  these 
hig h- risk patients to receive  adj u va nt syst emic 
targ eted therapy  in the context  of  a clinical trial. 
Alternative ly , reg ional L N D  in patients w ith syst emic 
micro-  and macro- metastatic disease may provi de 
sufficient cytoreduction to improve therapeutic 
efficacy and tolerability of post-surgical systemic 
treatments.  
1 . loCA llY  A D VA nCeD  RCC
Seve ral contemporary series, demonstrate that 
ag g ressive  remova l of  reg ional nodal metastases 
translates into improved cancer specific survival and 
provides long term cures in a significant number of 
patien s.[ 32- 34 ]  (l e v e l  o f  e v i d e n c e :  3 a). Pantu ck 
et al, f ou nd that 4 3 R C C  patients w ith clinically 
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su spected nodal invo lve ment, w ithou t distant 
metastases, w ho u nderw ent some f orm of  L N D , 
demonstrated a 5  month improve ment in median 
su rvi va l, compared to patients in w hom clinically 
positive  L N s w ere lef t in situ  at the time of  R N .[ 32]  
M oreove r, L N D  dissection w as an independent 
predictor of  su rvi va l in their mu ltiva riab le analysi s. 
I nve stig ators f rom M . D . Anderson C ancer C enter 
reported ou tcomes of  4 0  patients w ith reg ional nodal 
invo lve ment w ithou t evi dence of  syst emic metastatic 
disease, all of  w hom u nderw ent complete ext ended 
L N D .[ 33]   O nly cases in w hich all g ross disease w as 
completely remove d w ere considered su ccessf u l 
resections and included in the final analysis. Median 
cancer specific survival was 20.3 months and 30 
of  patients had no evi dence of  disease at a median 
f ollow - u p of  18  months.[ 33]
I n contrast to the data presented ab ove  in the setting  
of  clinically positive  L N ’ s, nu merou s retrospective  
studies have found no therapeutic benefit of 
rou tine L N D  in the setting  of  the lack of  clinically 
su spiciou s lym phadenopathy .  T he only randomize d 
prospective  clinical stu dy to eva lu ate the role of  
rou tine lym phadenectomy at the time of  R N  f or 
R C C  w as condu cted b y Eu ropean O rg aniza tion 
f or R esearch and T reatment of  C ancer (EO R T C  
30 8 8 1).[ 35 ]   I n this trial, 7 7 2 patients w ith clinical 
T 1- 3N 0 M 0  R C C  w ere randomize d to R N  only or 
R N  and lym ph node dissection.  R N  w as perf ormed 
w ith or w ithou t remova l of  retroperitoneal tissu e f rom 
the cru s of  the diaphrag m to the b if u rcation of  the 
aorta.  Althou g h proponents of  L N D  arg u e that the 
stu dy has not reached matu rity , preliminary resu lts 
f rom the randomize d trial f ailed to demonstrate any 
significant differences in cancer-specific survival 
b etw een the stu dy g rou ps (l e v e l  o f  e v i d e n c e :  1 b). 
D u e to hig h preva lence of  low  risk R C C , this stu dy 
was significantly underpowered to detect a survival 
adva ntag e af f orded b y L N D .  N ot su rprising ly , only 
3%  of  patients w ho u nderw ent lym ph node dissection 
at the time of  R N  had lym ph node metastases, and 
ve ry f ew  patients (17 % ) prog ressed or died f rom 
RCC, thus making it extremely difficult to draw 
conclusions about the therapeutic efficacy of lymph 
node dissection in R C C .[ 35 ] ( fi g . 2 , 3 )   
2 . M eT AsT A TIC RCC
Stu dies that have  eva lu ated the role of  L N D  at the 
time of  cyt oredu ctive  R N  f or metastatic R C C  also 
su pport ag g ressive  deb u lki ng  of  reg ional nodal 
disesase in addition to cyt oredu ctive  R N  (l e v e l  
o f  e v i d e n c e :  3 a). V asselli nd colleag u es, at the 
N ational C ancer I nstitu te. eva lu ated a cohort of  
patients treated w ith cyt oredu ctive  R N  and I L - 2 
immu notherapy and compared 8 2 patholog ically 
node neg ative  patients w ith 7 2 similar patients w ho 
had pathologically confirmed involvement of regional 
L N s.[ 36 ]  N ot su rprising ly , these au thors f ou nd a 
median su rvi va l of  14 .7  months and 8 .5  months, in 
node neg ative  and positive  g rou ps, respective ly (P  =  
.0 0 0 4 ). T here w as no statistical dif f erence in su rvi va l 
b etw een patients w ith node positive  disease w ho 
u nderw ent complete nodal dissection and patients 
w ith pN 0  disease. Similarly , in a report describ ing  
the U C L A exp erience w ith 129  patients w ith g rossly 
positive  lym ph nodes and syst emic metastases, 
the median su rvi va l af ter I L - 2 immu notherapy w as 
pproxi mately 5  months long er f or patients w ho 
u nderw ent L N D  compared to those w ho did not.[ 32]   
3 .  P A TIenT  seleCT Ion foR 
lY M P H A D eneCT oM Y
R ealizi ng  the limitations of  cu rrent radiolog ic imag ing  
techniques, a rational approach for identification 
of  patients at hig h risk of  harb oring  su b - clinical 
L N  metastases w as reported b y the M ayo  C linic 
g rou p.[ 37 ]   T heir analysi s of  more than 1,6 0 0  patients 
with clear cell renal cell carcinoma identified five 
histolog ical f eatu res that placed patients at increased 
risk f or reg ional lym ph nodes metastases:  hig h 
stag e, hig h nu clear g rade, larg e size , a sarcomatoid 
component, and presence of  histolog ical tu mor 
necrosis. I n their protocol, the au thors estab lished 
a ” risk cu t point”  of  tw o f eatu res as a threshold f or 
placing a patient at significant risk of regional lymph 
node invo lve ment, if  present ( T a b l e  1 ). Similarly , a 
pre- su rg ical prog nostic nomog ram f or prediction of  
reg ional nodal metastases w as deve loped b ased on 
139  (2.9 % ) node positive  patients ou t of  the 4 ,8 4 4  
patients w ho u nderw ent R N  at the M ayo  C linic and 
M emorial Sloan K ettering  C ancer C enter.[ 38 ]  T he 
nomog ram u tilize d ag e, g ender, perf ormance statu s, 
co- morb idity index,  sym ptoms at presentation, 
radiolog ic lym phadenopathy , tu mor size  and location, 
presence of  necrosis, pre- operative  hemog lob in, 
and history of  hematu ria to predict the prob ab ility 
of  patholog ically positive  L N  w ith an accu racy of  
7 6 .1% .[ 38 ]   I f  va lidated in ext ernal patient cohorts, 
these predictive  tools cou ld serve  as a va lu ab le 
g u ide to selective ly  targ et patients f or ext ended L N D  
at the time of  R N . 
T o date, there are no u nif ormly accepted g u idelines 
on the ext ent or anatomic b ou ndaries of  L N D  w hen 
perf ormed as an adj u nct to R N  f or R C C . Ava ilab le 
data, how eve r, su g g ests that a more thorou g h 
LND pr vides a significant improvement in staging 
accur cy.[39, 40]  Based on these findings and the 
kn ow ledg e g ained f rom the classic renal lym ph 
node mapping  stu dies, para- aortic dissection f rom 
the cru s of  the diaphrag m to the b if u rcation of  the 
aorta is perf ormed f or the lef t sided tu mors;  how eve r, 
f or the rig ht sided tu mors b oth para- cava l and 
inter- aortocava l dissection f rom the diaphrag matic 
cru s to the b if u rcation of  the g reat ve ssels is 
recommended.[ 4 1]  (l e v e l  o f  e v i d e n c e :  4)  
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T A B L E  1.   T he M ayo Cl inic risk  factors for prediction of regional  nodal  metastases in RCC. [ 3 7 ]
fe a t u r e oR ( 9 5 %  CI) p
G r a d e  3  +  4  5 .2 5  ( 1 .9 9 - 1 3 .8 2 )  < 0 .0 0 1
sa r c o m a t o i d  c o m p o n e n t  4 .1 1  ( 2 .0 8 - 8 .1 2 )  < 0 .0 0 1
T u m o r  1 0  c m  o r  g r e a t e r  2 .1 7  ( 1 .2 7 - 3 .7 0 )  0 .0 0 5  
P r i m a r y  s t a g e  p T 3  +  p T 4  2 .0 0  ( 1 .1 3 - 3 .5 5 )  0 .0 1 7  
H i s t o l o g i c a l  t u m o r  n e c r o s i s  1 .8 6  ( 1 .0 0 - 3 .4 8 )  0 .0 5 1  
no . fe a t u r e s no . p n0 / p nx  ( % ) no . p n1 / p n2  ( % )
    0  7 2 6  ( 9 9 .6 )  3  ( 0 .4 )  
    1  2 9 9  ( 9 9 .0 )  3  ( 1 .0 )
    2  2 6 4  ( 9 5 .7 )  1 2  ( 4 .4 )
    3  1 8 3  ( 8 7 .6 )  2 6  ( 1 2 .4 )  
    4  1 0 5  ( 8 6 .8 )  1 6  ( 1 3 .2 )  
    5  7  ( 4 6 .7 )  8  ( 5 3 .3 )  
Randomized phase III trial of RN alone or with complete 
lymph node (LN) dissection showed no benefit of 
dissection
Blom JH et al. Eur Urol. 1999;36:570.
Group N Metastasis Rate 
Within Group
All patients 772 3.3%
Patients in LN dissection 
arm without palpable LN
299 1%
Patients in LN dissection 
arm with palpable LN
43 16%
Patients in RN-only arm 
with palpable LN at surgery
29 21%
Fig. 2: Result of the EORTC 30881: Lymph Node Dissection in Localized RCCWithout
lymph-
node
dissection
(n=389)
With
complete
lymph-node
dissection
(n=383)
Hazard
ratio
95%
confidence
interval
p
value
Death 135 (35%) 137 (36%) 1.02 0.80-1.29 0.87
Local regional 
progression 34 (9%) 26 (7%) 0.77 0.46-1.28 0.31
Distant
progression 58 (15%) 60 (16%) 1.05 0.73-1.50 0.81
Local or distant 
progression 93 (24%) 87 (23%) 0.95 0.71-1.27 0.70
Progression or 
death 156 (40%) 159 (42%) 1.02 0.82-1.28 0.84
Second primary 45 (12%) 36 (9%) 0.79 0.51-1.22 0.28
Fig. 3: Result EORTC 30881: Lymph Node Dissection in Localized RCC
Blom et al., Eur Urol, 2008
Without lymph-
node
dissection
With complete 
lymph-node
dissection
% n %
1 4 1
5 21 6
T2 230 pTcategory n 63
T3 96 T0 5 29
T4 2 T1 19 1
TX 2 1 3 1
Fig. 2: Result 
of the EORTC 
30881: Lymph 
Node Dissection 
in Localized 
RCC
Fig. 3: Result 
EORTC 30881: 
Lymph Node 
Dissection in 
Localized RCC
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IV. AD J A CenT  oRG A n InVAsIon
R C C  may rarely present w ith locally adva nced 
disease, in the ab sence of  distant metastatic 
disease, w ith reported preva lence of  approxi mately 
1- 1.5 %  at centers su ch as M SK C C  and M D AC C , 
as w ell as the SEER  reg istry .[ 4 2- 4 4 ]   T he incidence 
of  adva nced tu mors has increased ove r time.[ 4 5 ]  
AJC C  stag ing  of  k idney cancer describ es T 4  R C C  as 
that w hich has penetrated b eyo nd G erota’ s f ascia to 
ascending  colon or du odenu m f rom the rig ht ki dney , 
descending  colon f rom the lef t ki dney , diaphrag m, 
peritoneu m, tail of  pancreas, psoas mu scle, rib s, 
liv er, spleen, stomach, aorta, or contralateral ki dney , 
adrenal g land, or u reter, and is Stag e I V  disease. 
Earlier reports in the literatu re w ere rou tinely 
pessimistic ab ou t the va lu e of  su rg ical resection f or 
su ch adva nced disease, b u t this important issu e has 
b een recently revi sited in seve ral pu b lications.  I t is 
important to note that all su ch stu dies are case series 
or retrospective  cohort stu dies (l e v e l  o f  e v i d e n c e  4  
a n d  2 b ,  r e s p e c t i v e l y).  
The first modern data on this patient population is 
f rom M D AC C .[ 4 2]   30  patients ou t of  an institu tional 
datab ase of  ove r 30 0 0  patients ove r a 15  ye ar 
accrual period, were identified as having T4NxM0 
R C C  and u nderw ent complete resection of  the 
primary tu mor, w ith adj acent org an resection, all w ith 
neg ative  su rg ical marg ins.  T he most common sites 
of  resection w ere colon, pancreas and diaphrag m, 
althou g h live r, spleen and b ow el mesentery 
inva sion w ere also seen.  N o reliab le preoperative  
predictors of invasion were identified. Of the 
important messag es in this report, perhaps the most 
important, w as that 6 0 %  of  patients thou g ht to have  
T 4  disease w ere dow nstag ed to < pT 4  disease, 
inclu ding  2 patients w ho w ere f ou nd to only have  pT 2 
disease.  O n mu ltiva riate C ox reg ression analysi s 
the only predictors of  su rvi va l w as the presence 
of pT 4  disease and most importantly , lym ph node 
metastases (R R  17 , p= .0 0 2) w ith 3 ye ar ove rall 
su rvi va l of  6 6 %  in L N  neg ative  patients ve rsu s 12%  
in lym ph node positive  patients, w hich comprised a 
third of  patients. T his report conclu ded that actu al 
patholog ical invo lve ment f rom R C C  is rare, and not 
reliab ly predicted f rom preoperative  or intraoperative  
findings.  Most patients are clinically overstaged. 
T hese su rg eries are possib le to perf orm w ith 
acceptab le patient morb idity (mean leng th of  stay 9  
days,  rang e 4 - 22) and no perioperative  deaths. 
Another va lu ab le stu dy on this rare patient su b set 
w as f rom M SK C C .  I nstead of  looki ng  at patients 
w ith clinically su spected locally adva nced renal 
cancer inva ding  other org ans, this g rou p looke d 
at 38  patients ou t of  a total of  approxi mately 25 0 0  
patient  w ho had patholog ical T 3 or T 4  disease 
w ith resection of  adj acent org ans or stru ctu res. 
Approxi mately one qu arter had positiv e lym ph nodes. 
M ost patients had neg ative  patholog ic marg ins, b u t 
36 %  had a positiv e marg in.  Presence of  a positive  
margin was significantly associated with decreased 
su rvi va l (p =  .0 0 6 ).  8 9 %  of  patients died w ith a 
median survival of 11.7 months (range 5-29).  A final 
stu dy f rom Sou th Asia stu died 18  patients w ith R C C  
su spiciou s f or adj acent org an invo lve ment.  Similar 
to the report f rom M D AC C , althou g h less f requ ent, 
3/ 18  patients did not have  tru e org an inva sion on 
the final resection specimen.  Interestingly, while 15 
patients died at a median du ration of  7 .5  months, 
3 patients w ere still alive  at a median of  13,16  and 
25 months. There were no differences identified 
in terms of  patient, tu mor and lab oratory va riab les 
b etw een those patients w ho live d and those w ho 
died.  L acki ng  f rom this particu lar series w as any 
description of  nodal patholog y .
I n an ef f ort to u nderstand the important issu e is 
w hether the resu lts of  radical nephrectomy f or 
T 4  renal cancer comb ined w ith adj acent org an or 
structure extirpation is confined only to true centers 
of  exp ertise, and the important qu estion of  w hat 
happens to patients if  su rg ery is not perf ormed. 
C apitanio exa mined 310  patients w ith clinical T 4 N 0 -
2 R C C  in the SEER  reg istry , w hich is thou g ht to b e 
representative  of  the U S popu lation, w ho u nderw ent 
resection (24 6 ) or no su rg ery (6 4 ). T hose w ho 
u nderw ent su rg ery had a median su rvi va l of  4 8  
months compared to only 6  months f or those w ho 
u nderw ent no su rg ery (H aza rd ratio of  2.2). T he ef f ect 
of  su rg ery f or those patients (125 ) w ho had T 4 N 0  
disease w as eve n strong er, w ith a haza rd ratio of  
3.7, with a cancer specific mortality of approximately 
4 0 %  at 10  ye ars, eve n af ter controlling  f or other 
c u se mortality , w hich mig ht b e exp ected (M I , stroke ) 
after this kind of extensive surgery. No benefit was 
seen in those patients w ith node- positive  disease. 
As an important cave at f or the commu nity u rolog ic 
su rg eon, the stu dy  w as conf ou nded b y only stu dyi ng  
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9  SEER  reg ions (ou t of  17 ), and f ou r of  these reg ions 
contained academic medical centers with significant 
u rolog ic oncolog y exp ertise.
T hu s, it may b e pru dent f or patients w ith this ki nd 
of  disease to b e cared f or in centers w here a tru e 
mu ltidisciplinary team of  su rg eons f amiliar w ith this 
ki nd of  resection, and of  su b sequ ent reconstru ction 
(hepatob iliary , pancreatic, colorectal, va scu lar, 
b ody w all) may b e present. I n su mmary , in patients 
fit to undergo surgery with no clinical evidence of 
metastatic disease, and no evi dence of  patholog ical 
retroperitoneal adenopathy , rather than deeming  
patients w ith clinical T 4  not cu rab le or u nresectab le, 
and of f ering  palliative  treatment only , su rg ery is like ly 
to be of benefit.
U nansw ered qu estions remain w hich concern patient 
selection b ef ore committing  a patient to ext ensive  
su rg ery , particu larly the role of  preoperative /
postoperative  prog nostic f actors, inclu ding  seru m 
b iomarke rs, and of  the role of  neoadj u va nt targ eted 
ag ent chemotherapy .[ 4 6 ]   I t is possib le that the u se 
of  these new er chemotherapeu tic ag ents b e u sed 
in conj u nction w ith su rg ical ext irpation of  localize d 
disease.  M u lti- institu tional reg istries may b e of  va lu e 
in tryi ng  to eva lu ate su ch ou tcomes.
Re c o m m e n d a t i o n s                           G r a d e
•	A d j a c e n t  o r g a n  i n v a s i o n  b y  RCC i s            C
n o t  r e l i a b l y  p r e d i c t e d  b y  p r e o p e r a t i v e  
r a d i o l o g i c  i m a g i n g  o r  i n t r a o p e r a t i v e  
finGinJs                          
•	A p p r o p r i a t e  s u r g i c a l  c a n d i d a t e s          C
s h o u l d  b e  m a n a g e d  w i t h  r a d i c a l  
n e p h r e c t o m y  a n d  e n - b l o c  r e m o v a l  
o f  a d j a c e n t  t i s s u e  o r  o r g a n s  i f  d i r e c t  
i n v a s i o n  i s  s u s p e c t e d
V. AD J uVAnT / neoA D J uVAnT
( P Re- suRG ICA l)  T H eRA P Y  foR 
RenA l Cell CA RCInoM A
1 . AD J uVAnT  T H eRA P Y
W hile su rg ery remains the cu rative  f or the va st 
maj ority of  patients w ith locally adva nced renal cell 
carcinoma, there remains a significant population of 
patients that remain at hig h risk f or disease relapse, 
both locally and distantly, after definitive surgical 
therapy .  A larg e f ocu s of  clinical research in renal cell 
carcinoma has b een the deve lopment of  an ef f ective  
adj u va nt therapy to decrease risk of  recu rrence and 
improve  su rvi va l in patients at hig h risk f or relapse 
af ter su rg ery . L og ically , therapeu tic deve lopment in 
the adj u va nt setting  has f ocu sed on therapy w ith 
some evi dence of  activi ty in the setting  of  metastatic 
disease.  T o date, in the ye ar 20 10 , ef f ective  adj u va nt 
therapy does not exi st f or renal cell carcinoma.
I nitial phase I I I  randomize d clinical trials f ocu sed on 
hormonal therapy su ch as medroxyp rog esterone 
acetate in the adj u va nt setting . T hese stu dies 
demonstrated significant toxicity associated with 
adj u va nt therapy and no recu rrence f ree or ove rall 
survival benefit for the treatment arm[47, 48]. (l e v e l  
o f  e v i d e n c e :  1 b) I n addition, adj u va nt radiation 
therapy has b een stu died and may decrease the 
risk of  local recu rrence b u t had no impact on the 
occu rrence of  distant metastases or su rvi va l[ 4 9 ] . 
(l e v e l  o f  e v i d e n c e :  3 a) W ith the deve lopment and 
implementation of  immu notherapy f or the treatment 
of  metastatic renal cell carcinoma, clinical research 
f ocu sed on the u tility of  this treatment modality in the 
adj u va nt setting . N u merou s phase I I I  clinical trials 
have  stu died interf eron and interleu ki n 2, either alone 
or in comb ination w ith va riou s chemotherapeu tics, 
in the adj u va nt setting . T o date, none have  
demonstrated a benefit regarding recurrence free 
or ove rall su rvi va l f or patients[ 2, 3, 5 0 - 5 5 ] . (l e v e l  
o f  e v i d e n c e :  1 a)  I mmu notherapeu tic strateg ies in 
the adj u va nt setting  have  also f ocu sed on va riou s 
va ccine f ormu lations. T he attraction of  va ccines in 
this setting  is that they are relative ly non- toxi c and 
rely on a competent host immu ne syst em f or their 
anti- tu moral activi ty .  W hile some, su ch as vi tespen, 
have  show n evi dence of  activi ty in su b set analyse s 
focused on specific patient populations, none of 
the clinical research perf ormed w ith a w ide va riety 
of  va ccine f ormu lations in the adj u va nt setting  can 
su pport their implementation into clinical practice 
at the cu rrent time[ 5 6 - 6 1] . (l e v e l  o f  e v i d e n c e :  1 a) 
T he antiang iog enic ag ent thalidomide has also 
b een eva lu ated in the adj u va nt setting  f or renal cell 
carcinoma, b u t like  all other ag ents that demonstrated 
some modicu m of  activi ty in the metastatic setting , no 
benefit was seen in the adMuvant setting[62]. (l e v e l  o f  
e v i d e n c e :  1 b)  A phase I I I  clinical trial exa mining  the 
role of  the antib ody G 25 0  (AR I SER ), w hich targ ets 
the carb onic anhyd rase I X  protein and indu ces 
antib ody dependent cellu lar cyt otoxi city , has recently 
completed accru al b u t the resu lts of  this stu dy have  
not b een reported in the literatu re to date[ 2] .
W ith the introdu ction of  small molecu le targ eted 
therapy , su ch as the tyr osine ki nase inhib itors su nitinib  
and soraf enib , in the treatment of  metastatic renal cell 
carcinoma, there has b een g reat exci tement ab ou t 
the potential activi ty of  these ag ents in the adj u va nt 
setting .  C u rrently , there are three larg e phase I I I  
randomize d placeb o controlled trials exa mining  the 
activi ty of  these ag ents in the adj u va nt setting  ( T a b l e  
2 ). T hese inclu de the ASSU R E trial (EC O G  28 0 5 ), 
w here patients are randomize d to 1 ye ar of  soraf enib  
or su nitinib  ve rsu s placeb o, the S- T R AC  trial, w here 
patients are randomize d to 1 ye ar of  su nitinib  ve rsu s 
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placeb o, and the SO R C E trial, w here patients are 
randomize d to 3 ye ars of  soraf enib  or 1 ye ar of  
soraf enib  ve rsu s placeb o[ 3, 6 3, 6 4 ] . W hile these 
trials remain ong oing  at present, there have  b een 
significant concerns raised regarding the toxicity 
of  these ag ents in the adj u va nt setting .  I n f act, 
several modifications and amendments have been 
made to these trials, inclu ding  dose redu ctions and 
increases in accru al g oals, to help accou nt f or the 
not insignificant patient dropout rates related to drug 
intolerab ility[ 2, 6 5 ] .
2 . neoA D J uVAnT  T H eRA P Y
T here have  b een no randomiz ed clinical trials 
ex amining  the role of  neoadj u va nt therapy in 
the treatment of  renal cell carcinoma. I n f act, 
u ntil ve ry recently , the only modality stu died in 
the neoadj u va nt setting  has b een the issu e of  
preoperative  emb oliza tion prior to nephrectomy[ 6 6 , 
6 7 ] .  ( l e v e l  o f  e v i d e n c e :  3 a )  I n these retrospective  
non- randomize d stu dies, there is a su g g estion that 
patients w ho had renal artery emb oliza tion prior to 
nephrectomy had a b etter ove rall su rvi va l relative  
to those that u nderw ent nephrectomy alone. T hese 
findings have not been confirmed prospectively.  
Prior to the dev elopment of  targ eted therapy , an 
ax iom in the manag ement of  patients w ith renal 
cell carcinoma w as the f act that the primary tu mor 
rarely , if  eve r, demonstrates a reliab le response 
to syst emic therapy[ 6 8 , 6 9 ] . (l e v e l  o f  e v i d e n c e :  
4) T his, in part, serve d as the impetu s to perf orm 
cy toredu ctive  nephrectomy in the manag ement of  
metastatic disease. W ith the increased u tiliza tion 
of  targ eted therapy in the setting  of  metastatic renal 
cell carcinoma, anecdotal case reports and small 
sing le institu tional series of  patients treated w ith their 
primary tu mor in place, demonstrating  impressive  
responses in the primary tu mor, b eg an to appear in 
the literatu re[ 11, 4 6 , 7 0 ] .  (l e v e l  o f  e v i d e n c e :  4) T hese 
impressive  responses have  prompted a revi siting  of  
the concept of  neoadj u va nt or presu rg ical therapy 
in b oth locally adva nced and metastatic renal cell 
carcinoma.  I n an initial report of  17  patients treated 
w ith su nitinib  w ith their primary tu mor in place, V an 
der V eldt and colleag u es reported that 23%  of  patients 
had a response as defined by RECIST criteria, and 
the mean vo lu me of  tu mor redu ction in the primary 
tu mor w as 31% . Su b sequ ently , how eve r, initial 
phase I I  stu dies su g g est that pre- su rg ical targ eted 
therapy is safe, but reliable and significant primary 
tu mor dow nstag ing  or dow nsizi ng  is u ncommon 
w ith the cu rrent g eneration of  targ eted ag ents[ 4 6 , 
7 1- 7 5 ] . (l e v e l  o f  e v i d e n c e :  2 b)  I n the maj ority of  
these stu dies, the primary tu mor demonstrated little 
if  any response to syst emic therapy prior to su rg ery . 
D ramatic redu ctions in tu mor siz e, and thankf u lly , 
dramatic prog ressions in disease, w ere rare eve nts. 
C u rrently , phase I I  and I I I  stu dies are planned to 
f u rther eva lu ate the role of  targ eted ag ents in the 
neoadj u va nt setting  f or b oth locally adva nced and 
metastatic renal cell carcinoma ( T a b l e  2 ). ( fi g . 4 , 5 )
Re c o m m e n d a t i o n s                           G r a d e
•	ne o a d j u v a n t  o r  a d j u v a n t  t h e r a p y                A
f o r  RCC r e m a i n s  e x p e r i m e n t a l  
•	ne o a d j u v a n t  t a r g e t e d  t h e r a p y  p r i o r            B
t o  s u r g e r y  i s  s a f e ,  h o w e v e r  d e g r e e  
o f  c y t o r e d u c t i o n  i s  u n p r e d i c t a b l e  
anG oncoOoJic eIficac\ is not 
e s t a b l i s h e d
VI. M A nA G eM enT  of loCA l 
ReCuRRenCe
L ocal recu rrences w ithin the renal f ossa can 
represent recu rrent disease w ithin the adrenal g land, 
the retroperitoneal lym ph nodes, or the sof t tissu e 
tissu es in the area of  the prior renal tu mor. W hile 
recu rrence w ithin the adrenal or retroperitoneal 
lym ph nodes represent metastatic prog ression, 
recu rrence in the sof t tissu es may represent a locally 
aggressive tumor but may also reÀect the results of 
a su rg ical mishap w ith tu mor vi olation at the orig inal 
nephrectomy . I solated local recu rrence w ithou t 
evi dence of  distant metastases is a rare eve nt, 
w ith a reported incidence of  1- 2%  f ollow ing  radical 
nephrectomy w ith cu rative  intent[ 7 6 - 7 9 ] . As su ch, 
the leve ls of  evi dence reg arding  natu ral history and 
methods of  manag ement are L eve l 4  at b est.
O ve rall, the manag ement of  renal f ossa recu rrence 
is predominately su rg ical. All of  the case series 
reported in the literatu re advo cate ag g ressive  su rg ical 
resection f or a local recu rrence in the ab sence of  
metastatic disease[ 7 6 - 7 9 ] . (l e v e l  o f  e v i d e n c e :  4) 
Esrig  et al. reported on 10  patients w ho u nderw ent 
su rg ical resection of  locally recu rrent renal cell 
carcinoma in the ab sence of  metastatic disease[ 7 7 ] . 
I n this series, 4  of  10  patients achieve d du rab le 
disease f ree su rvi va l f ollow ing  su rg ical resection, 
w ith one patient w ithou t evi dence of  disease 18  ye ars 
af ter su rg ery . I n the series b y T ang u ay et al., 15  of  
16  patients u nderw ent complete su rg ical resection 
of  locally recu rrent disease, w ith 3 patients havi ng  
positive  su rg ical marg ins[ 7 8 ] . T he au thors f ou nd 
that those patients treated w ith neoadj u va nt and/ or 
adj u va nt interf eron therapy w ere tw ice as like ly to 
re ain w ithou t evi dence of  disease f ollow ing  su rg ery . 
I tano et al. reported on 30  patients in the M ayo  C linic 
exp erience w ith local recu rrence[ 7 9 ] . O f  these 9  
w ere treated w ith ob serva tion, 11 w ere treated w ith 
therapy other than su rg ery , and 10  w ere treated w ith 
su rg ery alone or in comb ination w ith other therapies. 
W ith a median f ollow u p of  3.3 ye ars, the au thors 
f ou nd that patients w ho u nderw ent ag g ressive  
surgical resection had a 5-year cause specific 
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T A B L E  2 .   O ngoing cl inical  trial s of neoadj uv ant and adj uv ant systemic therapy in patients w ith l ocal l y
adv anced RCC.
T r i a l / In s t i t u t i o n D e s i g n T h e r a p y
N eoadj uv ant
U T  M D  Anderson Phase I I Axi tinib
U T  Sou thw estern Phase I I Eve rolimu s
A dj uv ant
AR I SER Phase I I I mAb  G 25 0  vs.  Placeb o
ASSU R E Phase I I I Su nitinib  vs.  Soraf enib  vs.  Placeb o
S- T R AC Phase I I I Su nitinib  vs.  Placeb o
SO R C E Phase I I I Soraf enib  vs.  Placeb o
T A B L E  3 .  Features predictiv e of systemic disease rel apse after surgical  resection of l ocal  RCC recurrence. [ 7 6 ]
fe a t u r e oR 9 5 %  CI p
P o s i t i v e  s u r g i c a l  m a r g i n  a f t e r  r e s e c t i o n  o f  l o c a l  r e c u r r e n c e3.20 7 1.0 6 5 - 9 .6 5 4 0 .0 38
si ze  o f  r e c u r r e n t  t u m o r 1.34 0 1.17 5 - 1.5 29 0 .0 0 1
P r e s e n c e  o f  s a r c o m a t o i d  f e a t u r e s  i n  r e c u r r e n c e  s p e c i m e n11.6 4 8 4 .0 0 0 - 33.9 21 0 .0 0 1
A b n o r m a l  s e r u m  a l k a l i n e  p h o s p h a t a s e  a t  t h e  t i m e  o f  
r e c u r r e n c e
13.7 5 4 3.0 6 6 - 6 1.6 9 4 0 .0 0 1
A b n o r m a l  s e r u m  l a c t a t e  d e h y d r o g e n a s e  a t  t h e  t i m e  o f  
r e c u r r e n c e
17 .0 8 9 4 .14 4 - 7 0 .4 7 9 0 .0 0 1
Fig. 4: Possible complication in wound healing by pre-surgical targeted therapy
Fig 5. : Impact of Targeted Therapy On The Primary Tumor
N %
sunitinib 57 39.9
bevicizumab 26 18.2
bevicizumab/
erlotinib 26 18.2
sorafenib 17 11.9
temsirolimus 10 7
bevicizumab/
chemo 5 3.5
erlotinib 2 1.4
Total 143 100
Sunitinib
Bevacizumab
Bevacizumab + Erlotinib
Sorafenib
Temsirolimus
Bevacizumab + Chemotherapy
Erlotinib
Abel et al. ASCO GU 2010
 Fig 5. : Impact of Targeted
 Therapy On The Primary
Tumor
Fig. 4: Possible complicat
 tion in wound healing
 by pretsurgical targeted
therapy
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su rvi va l of  5 1% , as compared to 18 %  w ith therapy 
other than su rg ery , and 13%  w ith ob serva tion alone. 
F inally , M arg u lis et al reported on 5 4  patients w ith 
renal f ossa recu rrence treated w ith su rg ery , w hich 
represents the larg est sing le institu tional series in the 
literatu re[ 7 6 ] . O f  these, 6 9 %  u nderw ent perioperative  
adMunctive systemic therapy. The authors identified 
5  f actors associated w ith a w orse prog nosis af ter 
su rg ical resection, inclu ding  size  g reater than 5  cm, 
the presence of  sarcomatoid dedif f erentiation, a 
positive  su rg ical resection marg in, eleva ted alka line 
phosphatase, and eleva ted lactate dehyd rog enase 
( T a b l e  3 ). Patients w ith none of  these risk f actors 
demonstrated a cancer specific survival of 111 
months, w hereas patients w ith more than one of  
these risk factors had a cancer specific survival of 
only 8  months.
I n the ab sence of  metastatic disease, ag g ressive  
su rg ical resection, either alone or in comb ination 
w ith perioperative  (neoadj u va nt + / -  adj u va nt) 
sy stemic therapy appears to provi de the b est 
ou tcomes f or locally recu rrent renal cell carcinoma. 
Limited data are available on the efficacy of the new 
targ eted ag ents in this setting , shou ld b e considered 
preoperatively if any of the adverse features identified 
b y  M arg u lis et al. exi st.
Re c o m m e n d a t i o n s                           G r a d e
•	su r g i c a l  e x t i r p a t i o n  r e m a i n s  t h e          C
s t a n d a r d  o f  c a r e  f o r  p a t i e n t s  w i t h  
i s o l a t e d  l o c a l  r e c u r r e n c e  o f  RCC
•	Cl i n i c a l  p r o g n o s t i c  f a c t o r s  c a n  b e          C
u t i l i ze d  f o r  e x p e r i m e n t a l  i n t e g r a t i o n  
o f  p e r i o p e r a t i v e  s y s t e m i c  t h e r a p i e s  
i n  p a t i e n t s  a t  h i g h  r i s k  o f  d i s e a s e  
r e l a p s e  a f t e r  s u r g e r y
  
VII. suM M ARY
T he manag ement of  locally adva nced R C C  remains 
a dau nting , su rg ically demanding  endeavo r b u t 
can b e associated w ith exce llent ou tcomes.  W ith 
the exce ption of  the role of  lym ph node dissection 
and adj u va nt therapy in patient manag ement, the 
va st maj ority of  treatment recommendations are 
made b ased on leve l 3 and leve l 4  evi dence. I n f act, 
despite leve l 1 evi dence to the contrary , the au thors 
w ou ld still advo cate lym ph node dissection, eve n in 
the presence of  clinically neg ative  ly mph nodes, to 
provi de more accu rate stag ing  inf ormation and the 
potiential to eliminate micro- metastatic disease.  T he 
deve lopment of  ef f ective  adj u va nt and neoadj u va nt 
therapy remains the sing le g reatest challeng e 
in improvi ng  the ou tcome of  patients w ith locally 
adva nced disease.  
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R enal cell carcinoma (R C C ) accou nts f or 2%  of  all 
cancers. I n Eu rope, 4 0 ,0 0 0  patients are diag nosed 
w ith R C C  each ye ar, leading  to 20 ,0 0 0  deaths [ 1] . 
O ne- third of  patients are initially diag nosed w ith locally 
inva sive  or stag e I V  disease. R ecu rrence occu rs in 
ab ou t 25 %  of  patients havi ng  su rg ical resection f or 
localize d disease eve n thou g h it w as considered 
as cu rative . T he prog nosis f or patients w ith distant 
disease w as g enerally poor, w ith a 5 - ye ar su rvi va l 
rate not exce eding  10 %  [ 2] . U ntil the past 4  ye ars, 
sy stemic treatments in patients w ith metastatic R C C  
(mR C C ) have  prove n larg ely inef f ective . R eg arding  
chemotherapy or hormonal therapy , no sing le 
ag ent has b een reported to achieve  a consistent 
response rate in more than 10 %  of  patients [ 3] . 
O nly a ve ry small percentag e of  patients are like ly 
to deve lop long - term disease- f ree su rvi va l f ollow ing  
interf eron-α (I F N ) and/ or interleu ki ne- 2 (I L - 2) b ased 
therapy [ 4 - 5 ] . At M emorial Sloan K ettering  C ancer 
C enter (M SK C C ), the ove rall median su rvi va l in 6 7 0  
patients w ho w ere treated w ith chemotherapy or 
immu notherapy in 24  consecu tive  clinical trials f rom 
19 7 5  to 19 9 6  w as 10  months [ 6 ] .
T w o ke y pathw ays are essential to the pathophysi olog y 
of  the clear cell R C C  su b typ e:  the hyp oxi a response 
pathw ay associated w ith inactiva tion of  the vo n 
H ippel- L indau  (V H L ) tu mou r su ppressor g ene 
and the mT O R  (mammalian targ et of  rapamyci n) 
sig naling  pathw ay  [ 7 ] . Seve ral therapies, targ eting  
these tw o pathw ays inclu ding  su nitinib , soraf enib , 
temsirolimu s, b eva cizu mab  and eve rolimu s are 
av ailab le f or clinical u se and have  revo lu tionize d the 
treatment of  mR C C  [ 8 ] . T his article revi ew s cu rrent 
targeted treatment approaches in the first- and 
second-line mRCC settings, as well as modifications 
to exi sting  treatment alg orithms, b ased on recently 
ava ilab le data.
II. eVID enCe ACQ uIsIT Ion
M edical literatu re w as retrieve d f rom Pu b M ed u p 
u ntil D ecemb er 20 0 9 . Additional releva nt articles 
and ab stract revi ew s w ere inclu ded f rom the 
b ib liog raphies of  the retrieve d literatu re. All data w as 
reviewed and final statements were approved by 
experts in the field.
III. eVID enCe sY nT H esIs
1 .  CuRRenT  T ReA T M enT A P P RoACH es 
uT IlIZ InG  noVel T A RG eT eD A G nT s
At present, treatment f or m clear cell R C C  w ith 
molecu larly targ eted ag ents can b e b roadly 
divi ded into the f ollow ing  categ ories:  previ ou sly 
u ntreated patients, those ref ractory or intolerant to 
immu notherapy , and those w ho have  f ailed treatment 
w ith V EG F - targ eted therapy [ 2] . An important 
consideration that inÀuences treatment decisions 
is the M emorial Sloan- K ettering  C ancer C enter 
(MSKCC) prognostic risk stratification system, 
which is widely used to define patient profiles and 
provi des an indication of  ove rall su rvi va l (O S) [ 6 ] . 
I n this syst em, derive d f rom patients treated w ith 
interf eron- b ased therapy on six prospective  clinical 
trials at a single center in the US, five prognostic 
f actors are u sed to categ orize  patients w ith mR C C  
into three risk g rou ps:  f avo u rab le (ze ro risk f actors), 
intermediate (1– 2 risk f actors) and poor (t3 risk 
f actors). M edian O S times f or patients w ith g ood risk 
is 30  months,  intermediate risk is 14  months and 
poor risk is 5  months [ 8 ] .  
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2 . T ReA T M enT - nA Ï Ve P A T IenT s
a)  T reatment- naï v e patients w ith fav ourabl e or 
intermediate prognosis
Su nitinib  is a mu lti- ki nase inhib itor (T K I ) that acts 
mainly on the V EG F  receptor (V EG F R ) and platelet-
derive d g row th f actor receptor (PD G F R ). I n a 
Phase I I I  trial of  su nitinib  ve rsu s interf eron alpha 
(IFN-α) in untreated patients with mRCC, sunitinib 
demonstrated significant improvements in obMective 
response rate (O R R ;  independent revi ew , 31%  
vs  6 % ;  p  <  0 .0 0 0 0 0 1), median prog ression- f ree 
su rvi va l (PF S;  11 mo vs 5 mo;  p <  0 .0 0 1) and ove rall 
su rvi va l (O S;  26 .4 mo vs 21.8 mo;  haza rd ratio [ H R ] , 
0 .8 21;  p =  0 .0 5 1 ) [ 9 - 10 ] . T hese data have  led to 
sunitinib being recommended as a first-line therapy 
f or patients w ith mR C C  [ 11]  (fiJure ). 
B eva cizu mab , a monoclonal antib ody targ eting  the 
VEGF ligand directly, in combination with IFN-α, 
has shown efficacy in two Phase III trials in patients 
w ith previ ou sly u ntreated mR C C  [ 12- 15 ] . I n the 
first of these studies, median PFS was 10.4 mo 
for bevacizumab plus IFN-α compared with 5.5 mo 
for IFN-α alone (p  0.0001) [12]. No significant 
dif f erence in ove rall su rvi va l w as ob serve d (23.3 mo 
vs  21.3 mo;  p =  0 .129 1) [ 16 ] . C onsistent resu lts w ere 
seen in the second stu dy , perf ormed b y the C ancer 
and L eu k emia G rou p B , w ith median PF S of  8 .4 mo 
and 4 .9 mo, respective ly (p <  0 .0 0 0 1) [ 13] . Ag ain, 
no significant difference in OS was observed (18.3 
mo vs 17 .4  mo;  p  0.069) [17]. The PFS benefits 
seen in these trials are similar to those ob tained w ith 
su nitinib  in therapy- naï ve  patients w ith adva nced 
RCC [9], and supports bevacizumab plus IFN-α as 
another acceptable and effective therapy in the first-
line setting  [ 11]  (fiJure ).
Pazo panib  has a similar b road spectru m of  ki nase 
inhib ition, inclu ding  V EG F R 1– 3, PD G F R - A and - B , 
and c- K it [ 18 ]. The resu lts of  a phase 3 trial ve rsu s 
placeb o in patients w ho either receive d no prior 
therapy or w ho f ailed on prior therapy w ith cyt oki nes 
or b eva cizu mab  has recently b een reported [ 19 ] . 
Four hundred thirty-five therapy naive and cytokine-
pretreated mR C C  patients w ere randomize d to 
oral pazo panib  or placeb o (randomisation 2: 1 f or 
pazo panib ), w ith PF S as the primary endpoint. I n 
b oth treatment naï ve  and pretreated patients there 
was a significant benefit in PFS.  The median PFS 
f or pazo panib  as compared to placeb o  w as 9 .2 vs 
4 .2 months and in treatment naï ve  patients, 11.1 vs 
2.8  months, respective ly (p < 0 .0 0 0 0 0 0 1). D ata are 
immatu re w ith reg ards to O S. T his data have  led to 
pazo panib  receivi ng  F D A approva l in the U S (fiJure 
1).
b)  T reatment- naï v e patients w ith poor prognosis
T emsirolimu s is an intrave nou sly administered 
inhib itor of  mT O R . A randomize d, Phase I I I  trial 
compared monotherapy w ith temsirolimu s ve rsu s 
I F N -α ve rsu s temsirolimu s plu s I F N -α as first-line 
treatment in patients w ith mR C C  and poor prog nosis 
[ 20 ] . Patients w ere requ ired to have  at least three 
of  six predictors of  a poor prog nosis and su rvi va l 
according to a prognostic factor scheme modified 
f rom the M SK C C  model. Patients w ho receive d 
temsirolimu s alone, compared w ith those w ho 
Figure 1. Treatment schematic for patients with metastatic clear-cell renal cell carcinoma in the first-
l ine setting
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receive d I F N -α alone or the comb ination had g reater 
PF S (5 .5  vs 3.1 vs 4 .7 mo, respective ly) , O S (10 .9  vs 
7 .3 vs 8 .4 mo) and O R R  (8 .6 %  vs 4 .8 %  vs 8 .1% ). T he 
results of this trial Mustify mTOR as a target for renal 
cancer treatment and recent Eu ropean g u idelines 
recommend that temsirolimus be considered as first-
line treatment in poor- risk patients [ 11]  (fiJure ).
3 . CY T oK Ine- RefRA CToRY  P AT IenT s
Soraf enib  is a small- molecu le mu ltiki nase inhib itor of  
V EG F R  and related receptors, and also inhib its the 
intracellu lar sig nalling  of  R af  ki nase. I n a placeb o-
controlled, Phase I I I  trial invo lvi ng  patients w ith 
mR C C  w ho had f ailed previ ou s cyt oki ne therapy , 
a PF S adva ntag e f or soraf enib  of  5 .5 mo ve rsu s 
2.8  mo (p <  0 .0 0 1) w as ob serve d [ 21- 22] . Partial 
responses w ere reported as the b est response in 
10 %  of  patients receivi ng  soraf enib  and in 2%  of  
placeb o recipients (p <  0 .0 0 1). D isease control rate 
w as hig her f or soraf enib  than placeb o (6 2%  vs 37 % ;  
p <  0 .0 0 1) [ 21] . An improve d O S w ith soraf enib  w as 
ob serve d af ter censoring  placeb o patients w ho had 
crossed ove r to soraf enib  (17 .8 mo vs 14 .3 mo;  
p =  0 .0 28 7 ) [ 22] . B ased on the resu lts of  this trial, 
soraf enib  is recommended as a second- line ag ent in 
cy toki ne- ref ractory patients [ 11]  (fiJure ).
The efficacy of sunitinib in a total of 169 patients with 
mR C C  w ho prog ressed on prior cyt oki ne therapy w as 
demonstrated in tw o Phase I I  trials [ 23- 24 ] .  Across 
the tw o trials, partial responses w ere reported in 34 –
4 0 %  of  patients and a median PF S of  8 .3– 8 .7 mo 
w as ob serve d.
T ake n tog ether, these data indicate that either 
soraf enib  or su nitinib  may b e va lid second- line 
treatment options f or patients w ho have  f ailed prior 
cyt oki ne- b ased therapies.
Pazo panib , in the recently reported phase I I I  trial 
comparing its efficacy over placebo in nawve and 
cyt oki ne ref ractory patients also demonstrated a 
PF S adva ntag e in the latest g rou p (median PF S 7 .4  
vs 4 .2 months, p va lu e <  0 .0 0 1) [ 19 ] . T his has lead to 
pazo panib ’ s approva l b y the F D A in the second line 
setting  af ter cyt oki ne f ailu re (fiJure ) and is u nder 
eva lu ation b y the EM EA. 
4 .  VeG f- T A RG eT eD  T H eRA P Y - RefRA CToR  
P AT IenTs A nD  seQ uenT IA l T H eRA P Y  
ConCeP T .
Substantial clinical benefit has been obtained 
f rom retrospective  or phase I I  trials b y nove l T K I s, 
inclu ding  su nitinib , soraf enib  and axi tinib , in patients 
w ith mR C C  f ailing  a V EG F - targ eted therapy [ 25 - 29 ] . 
T he R EC O R D - 1 trial has exp lored the possib ility to 
sw itch to an ag ent w ith a dif f erent mechanism of  
ction and molecu lar targ et, i.e. an mT O R  inhib itor 
su ch as eve rolimu s [ 30 ] . I n this Phase I I I  trial, patients 
receivi ng  eve rolimu s (10 mg  once daily;  n =  27 2) 
had significantly prolonged PFS versus those on 
placeb o (n =  138 ;  4 .0 mo vs 1.9 mo;  H R , 0 .30 ;  
p <  0 .0 0 0 1). T he end of  the dou b le- b lind analysi s 
f rom this trial indicated a f u rther improve ment in 
PF S w ith eve rolimu s treatment (4 .9 0 mo [n =  27 7 ]  
ve rsu s 1.8 7 mo [n =  139 ] ;  H R , 0 .33;  p <  0 .0 0 1). T he 
PFS benefit following treatment with everolimus was 
maintained across patients w ith f avo u rab le (n = 120 ), 
intermediate (n =  235 ) or poor (n =  6 1) M SK C C  
prog nosis. At the end of  the dou b le- b lind analysi s, 
median O S w as 14 .7 8  mo in the eve rolimu s g rou p 
Figure 2 .  T reatment schematic for patients w ith metastatic cl ear- cel l  renal  cel l  carcinoma in the 
second- l ine setting
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and 14 .39  mo in the placeb o g rou p. C rossove r f rom 
placeb o to the active  treatment arm w as allow ed 
af ter disease prog ression, potentially conf ou nding  
O S;  8 1%  of  placeb o recipients w ho prog ressed 
crossed ove r to eve rolimu s treatment. 
T w o other randomize d phase I I I  trials are cu rrently 
recru iting  to look f or the position of  temsirolimu s 
and axi tinib  as second line options. T he AX I S trial 
is testing  axi tinib  ve rsu s soraf enib  in patients f ailing  
any of the first line regimens such as sunitinib, 
b eva cizu mab + interf eron, temsirolimu s or cyt oki nes. 
T he second trial is a prospective  randomize d phase 
I I I  trial of  temsirolimu s ve rsu s soraf enib  as second 
line therapy in patients who have failed first line 
su nitinib  option. I n b oth trials, PF S is the primary 
endpoint.
O ther trials are ong oing  to determine the optimal 
T K I s/ T K I s or T K I ss/ mT O R  inhib itors dru g  sequ ence. 
B ased on seve ral retrospective  reports show ing  that 
the sequ ence of  soraf enib  g ive n prior to su nitinib  
may b e su perior w hen compared to the reve rse 
sequ ence, an ong oing  phase 3 trial (SW I T C H  trial) 
has been designed  to define the best sequence of 
T K I s. Another trial is the R EC O R D - 3 stu dy . T his is 
an open- lab el, mu lticenter phase I I  stu dy to compare 
first-line everolimus followed by second-line sunitinib 
versus the opposite sequence (first-line sunitinib 
f ollow ed b y second- line eve rolimu s) in the treatment 
of  patients w ith mR C C  (N C T 0 0 9 0 317 5 ).
5 . D RuG  CoM B InA T Ion
T he concept of  anti- ang iog enic dru g  comb ination is 
to enhance drug monotherapy efficacy by vertical 
or horizo ntal b locka de. T he inhib ition of  seve ral 
steps of  the same pathw ay (H I F - V EG F R - V EG F R ) 
is a “ ve rtical”  b locka de w hile targ eting  in parallel 2 
separate pathw ay s w ith dif f erent f u nctions (PD G F R , 
V EG F R , EG F R ) is considered as an horizo ntal 
“ b locka de”  [ 31] .
T he comb ination of  b eva cizu mab  and su nitinib  has 
b een ex plored in a phase I  stu dy [ 32] . N ineteen 
patients w ith mR C C  receive d escalating  doses of  
sunitinib from 25 to 50 mg daily with fixed- dose 
b eva cizu mab  (10  mg / kg  I V ). D ose- limiting  toxi city 
(D L T ) w as g rade 4  haemorrhag e in one patient in 
each of  the hig her doses and one f atal myo cardial 
inf arction at the hig hest dose. All leve ls of  treatment 
indu ced a 37 %  PR . T he toxi city seen w ith these 
tw o ag ents preclu ded f u rther deve lopment of  the 
comb ination.
T he comb ination of  b eva cizu mab  and soraf enib  
has b een exp lored in a phase I  trial [ 33] . Sixt een 
patients w ere inclu ded f or a dose- escalation. G rade 
3 proteinu ria and u ncontrolled g rade 3 hyp ertension 
w ere the D L T s at the hig hest lev el, corresponding  
to the maxi mu m tolerated dose (M T D ). T he 
recommended dose w as soraf enib  at 20 0  mg  tw ice 
daily (B I D ) and b eva cizu mab  at 5 mg / kg . I nteresting  
syn erg istic antitu mor activi ty w as ob serve d w ith this 
comb ination.
O ther phase I  trials have  exp lored the comb ination 
of  T K I s inhib itors w ith I F N . I n these trials, patients 
receive d su nitinib  or soraf enib  and I F N -α w ith D L T s 
that inclu ded f atig u e and mye losu ppression. O nly 
inf erior dosag es of  b oth su nitinib  or soraf enib  and 
I F N -α, compared to optimal dosag es in monotherapy , 
w ere manag eab le. Phase I I  stu dies have  eva lu ated 
the comb ination of  soraf enib  and I F N -α at standard 
or low dose without clear superior benefit for the 
comb ination [ 34 - 37 ] .  
T emsirolimu s and b eva cizu mab  w ere comb ined in a 
phase I  stu dy du ring  w hich the recommended w eekl y 
dose of  temsirolimu s  25  mg / kg  I V  and b eva cizu mab  
at a dose of  10  mg / kg / 2 w eeks w ere u tilize d. 
D L T s encou ntered w ere g rade 3 stomatitis and 
hyp ertryg lyce ridemia. Among  12 eva lu ab le patients, 
8  PR  w ere reported. B ased on the preliminary resu lts 
r ported, a randomize d phase I I I  trial (I N T O R AC T ) is 
ong oing  comparing  temsirolimu s/ b eva cizu mab  w ith 
b eva cizu mab / I F N .  
T he temsirolimu s and soraf enib  comb ination has 
also b een eva lu ated [ 38 ] . Patients w ere treated 
w ith escalating  continu ou s oral doses of  soraf enib  
(20 0  and 4 0 0  mg  B I D ) and w eekl y I V  temsirolimu s 
(15  mg , 25  mg ).  T hirty- three eva lu ab le patients 
show ed D L T s inclu ding  g rade 3 hand- f oot syn drome, 
mu cositis, rash, thromb ocyt openia, neu tropenia and 
creatinine eleva tion. T he f u ll recommended dose of  
b oth dru g s appeared u nachieva b le mainly du e to 
mu cositis. 
B eva cizu mab  in comb ination w ith the oral mT or 
inhib itor eve rolimu s is a promising  comb ination 
in first and second line settings [39]. Presently, a 
randomize d phase I I  trial is ong oing  comparing  
b eva cizu mab / eve rolimu s w ith b eva cizu mab / I F N  
(R EC O R D - 2).
O ther randomize d phase I I  or I I I  trials are b eing  
condu cted. T he B eST  trial is a 4  arms randomize d 
EC O G  phase 2 trial (E28 0 4 ) exa mining  f ront line 
therapy w ith b eva cizu mab  vs.  temsirolimu s and 
b eva cizu mab  vs soraf enib  and  b eva cizu mab  vs.  
temsirolimu s and soraf enib . T he T O R AV A trial is a 
phase I I  trial comparing  b eva cizu mab  plu s interf eron 
vs b eva cizu mab  plu s temsirolimu s vs su nitinib . 
Enrolment is closed and resu lts shou ld b e ava ilab le 
shortly [ 31] . T he cu rrent opinion of  most inve stig ators 
reg arding  comb ination therapy is that u ntil it has 
clearly show n to b e su perior to monotherapy , it 
shou ld not b e u sed ou tside the context  of  clinical 
trials. R esu lts of  ong oing  trials are eag erly aw aited.
6 .  TH e Role foR neP H ReCT oM Y  In T H e 
eRA  of T A RG eT eD  T H eRA P Ies
T w o randomize d stu dies have  demonstrated that 
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nephrectomy is associated w ith a su rvi va l adva ntag e 
in selected I F N  treated mR C C  patients [ 4 0 - 4 1] . 
B ased on these resu lts, primary tu mou r remova l 
is cu rrently part of  the standard of  care in mR C C . 
H ow eve r, no equ iva lent evi dence has b een ob tained 
w ith anti- ang iog enic dru g s so f ar eve n thou g h 
it remains reasonab le to remove  larg e tu mou rs 
that are like ly to cau se local complications u nder 
treatment. B y contrast to cyt oki ne b ased therapy , 
TKIs are indeed able to cause significant responses 
w ithin the primary ki dney tu mou r [ 4 2] . T heref ore, 
TKIs could be used in the neo-adMuvant setting for 
selecting  those g ood and  intermediate risk patients 
who may benefit from nephrectomy [43]. In several 
phase I I  trials presu rg ical su nitinib  or b eva cizu mab  
has demonstrated sufficient safety and efficacy [44-
4 6 ] . 
A su b g rou p analysi s f rom the phase I I I  trial 
comparing  temsirolimu s w ith I F N  in poor risk 
patients demonstrated similar survival benefit for 
temsirolimu s reg ardless of  patient nephrectomy 
statu s, thu s su g g esting  that nephrectomy may have  
a limited role in poor risk patients [ 4 7 ] . 
T w o phase I I I  randomize d stu dies, addressing  
respective ly the qu estions of  the role of  u pf ront 
therapy and of  the timing  of  nephrectomy , are 
cu rrently ong oing  in Eu rope [ 4 8 ] . T he C AR M EN A 
trial is a phase I I I  randomize d stu dy comparing  
nephrectomy plu s su nitinib  vs su nitinib  w ithou t 
nephrectomy in first-line metastatic RCC. Primary 
end point is ove rall su rvi va l. T he EO R T C  trial 
(SU R T I M E trial) is a randomize d phase I I I  trial 
comparing  su nitinib  f ollow ed b y nephrectomy in case 
of  non- prog ressive  metastases f ollow ed b y su nitinib  
vs  nephrectomy f ollow ed b y su nitinib  in patients w ith 
sy nchronou s metastatic renal cell carcinoma. T he 
primary endpoint is prog ression f ree su rvi va l.
7 . T H e Role of M eT A sT A seCT oMY .
F ive  ye ars su rvi va l rate f or patients u nderg oing  
R C C  metastases resection rang es f rom 35  to 6 0 %  
[ 4 9 ] . I nterva l f rom R C C  diag nosis to occu rrence of  
metastases su perior to 1 ye ar, a u niqu e metastatic 
site and age inferior to 60 years have been identified 
as f avo rab le su rvi va l predictive  f actors f ollow ing  R C C  
metastases resection [ 5 0 ] . I n case of  pu lmonary 
resection, delay f rom R C C  diag nosis to metastases 
occu rrence, complete resection, nu mb er of  nodu les 
to remove, metastatic nodule size  appear as maMor 
prog nostic f actors [ 5 1- 5 4 ] . F ive  ye ars su rvi va l rate 
seems to b e su perior in case of  pu lmonary resection 
(5 4 % ) than in case of  b rain resection (18 % ) [ 5 0 ] . 
Pancreatic metastases are like ly to occu r late in 
the natu ral history  of  the metastatic disease and 
seem to have  a g ood prog nosis w hen a su rg ical 
resection is f easib le [ 5 5 ] . D u e to the emerg ence of  
ef f ective  targ eted therapies, the concept of  tu mou r 
metastasectomy needs to b e revi sited f or potentially 
rendering  patients f ree of  disease f ollow ing  comb ined 
su rg ical and medical treatments [ 4 9 - 5 6 ] . 
IV.  P A nel Consensus 
ReCoM M enD A T Ions.
1. Su nitinib  monotherapy and b eva cizu mab  in 
comb ination w ith I F N -α may be considered first-
line treatment options in patients w ith metastatic 
or u nresectab le clear- cell R C C  and f avo u rab le 
or intermediate prog nosis according  to M SK C C  
criteria (G rade A).
2. In the first line setting, temsirolimus is 
recommended in patients w ith poor prog nostic 
features according to modified MSKCC criteria 
(G rade A).
3. I n the second- line setting , soraf enib  treatment is 
recommended f or patients w ith mR C C  ref ractory to 
cyt oki nes (G rade A). 
4 . I n the second- line setting , eve rolimu s treatment 
is recommended f or patients ref ractory to V EG F -
targ eted therapy (G rade A).
5. Pazopanib is a new therapeutic option in first line 
setting  or in cyt oki ne ref ractory patients (G rade A).
6 . C yt oki nes, inclu ding  hig h- dose interleu ki n- 2 
remain an option for first-line treatment of highly-
selected patients w ith m clear cell R C C  and g ood 
prog nosis (G rade B ).
7 . Su nitinib  is a possib le alternative  to temsirolimu s 
as first-line treatment in patients with poor prognosis 
and also as an alternative  to soraf enib  as a second-
line treatment af ter cyt oki nes (G rade B ).
8 . F or patients ref ractory to mT O R  inhib itors, 
enrolment in clinical trials is advi sed (G rade C ).
9 . Anti- ang iog enic dru g  comb inations are still 
inve stig ational (G rade B ).
10 . T he sequ ential therapy concept is va lidated 
b y phase I I  and I I I  trials. F u rther trials are needed 
to determine the optimal intra or inter dru g  class 
sequ encing  (G rade B ).
11. B ased on previ ou s randomize d stu dies 
w ith I F N , u pf ront nephrectomy is advi sed in 
appropriately selected patients. H ow eve r, f u rther 
phase I I I  clinical trials shou ld clarif y its exa ct role 
in the cu rrent therapeu tic era. N ephrectomy is not 
like ly to b e u sef u l in poor risk patients according  to 
M SK C C  criteria (G rade B ).
12. Su rg ical R esection of  a u niqu e metastasis 
shou ld b e considered as a va lu ab le therapeu tic 
option, particu larly in cases of  delay b etw een R C C  
diag nosis and occu rrence of  metastasis exce eding  
1 ye ar, yo u ng  ag e or f avo u rab le prog nostic f eatu res 
and w hen a complete resection is exp ected. T he 
concept of  tu mou r metastases resection shou ld b e 
revi sited in the era of  targ eted therapy (G rade C ).
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